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Abstract 
Influenza A virus adaptation to humans is a rare but recurrent event that can result in a 
pandemic. The influenza polymerase, composed of the viral proteins PB1, PB2 and PA, is 
responsible for transcription and replication of the viral genome. Typical avian-origin 
influenza polymerases are restricted in human cells and polymerase subunit PB2 is 
particularly involved in this restriction. Residue 627 of PB2 is a glutamic acid in almost all 
avian influenza viruses, and mutation to a lysine is a potent enhancer of avian polymerase 
function in human cells. However, the underlying molecular mechanism and the cellular 
factors modulating avian-origin influenza replication in mammals are not known.  
Using a cell based replication assay in heterokaryons formed between avian and human 
cells, we concluded that the restriction is not due to a dominant human inhibitory factor. 
We also showed that supply of avian factors to human cells stimulated the activity of an 
avian-origin influenza polymerase and a functional screen was set up to attempt to isolate 
such chicken co-factor(s). We hypothesised that PB2 E627K mutation enhances the viral 
polymerase activity by optimizing an interaction with a human co-factor. A biochemical 
approach was used to try to identify this factor. 
Pigs are thought to be more susceptible to avian influenza than other mammalian species 
and are a supposed “mixing vessel” for influenza A viruses. To compare the replicative 
capacity of different influenza polymerases in pig, human and avian cells, an influenza 
polymerase assay in pig cells was set up. This assay was also used to study the impact in pig 
cells of known PB2 mammalian adaptive mutations. No obvious difference in the capacity of 
pig and human cells to support influenza polymerase activity was found, questioning the 
suggested susceptibility of pigs to influenza.  
Viruses from the avian H9N2 G1 lineage have been responsible for some human infections. 
Despite having none of the known mammalian signatures, we found the H9N2 G1 
polymerase was active in human and pig cells. This study identified H9N2 G1 PA protein as 
being particularly mammalian adapted, highlighting the role of PA in influenza mammalian 
adaptation. 
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Chapter 1. Introduction 
Based on clinical descriptions made over the centuries, we can reasonably assume 
that human and avian influenza viruses have been with us for a very long time. Influenza 
viruses were possibly responsible for diseases reported during antiquity resulting in 
concomitant deaths of humans and birds in 1200 BC, in 412 BC ("Athens plague" described 
by Hippocrates), in 218 BC, in 43 BC (described by Virgil) or massive mortality of fowl and 
birds in Great Britain in 671 AD, in Austria in 1286, across Europe in 1830-1831, 1841 and 
between 1880 and 1900. Those early descriptions highlight the relation between avian and 
human species in influenza ecology. Influenza has also been recorded in horses for centuries 
and in pigs since the early years of the 20th century. The viral nature of influenza was 
discovered by Centanni and Savonuzzi in 1901, when for the first time the aetiological agent 
responsible for a disease called "fowl plague" was isolated from poultry and shown to be 
able to pass through a Chamberlain filter, which has pores too small for bacteria to pass 
through. The fowl plague virus was identified as being influenza virus more than half a 
century later, in 1955. The first human influenza viruses were isolated in the UK in 1933 and 
shown to reproduce the disease when inoculated into ferrets (Smith et al, 1933). Three 
years earlier the first ever influenza viruses to be isolated were from pigs (Shope, 1931). 
Influenza A virus reproduces rapidly, mutates frequently and occasionally crosses species 
barriers. Transmission of influenza from birds or another species to humans may result in a 
pandemic. Pandemics are caused by viruses that contain a haemagglutinin (HA) surface 
glycoprotein to which human population is immunologically naive. Influenza has proven to 
be a significant health threat with three major human pandemics having occurred over the 
20th century. All three are thought to have emerged from avian reservoirs that gave rise to 
novel haemagglutinin proteins and resulted in widespread mortality. The 1918-1919 
Influenza A pandemic (H1N1), the "Spanish flu", remains unsurpassed in its severity, killing 
an estimated 40 to 50 million people. Other pandemics occurred in 1957 (Asian influenza, 
H2N2) and 1968 (Hong Kong influenza, H3N2) causing 2 million and 1 million deaths 
respectively. More recently, a new pandemic started in April 2009, resulting in the first 
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influenza pandemic of the 21st century, highlighting again that the influenza virus is a very 
significant pathogen with characteristics to cause recurrent pandemics. 
However, avian influenza viruses are usually not capable of replication in humans. 
Although progress has been made recently to try to understand the mechanisms 
responsible for influenza virus host range barriers, our current knowledge is still limited. This 
introduction mainly focuses on influenza A viruses and seeks to present the virus, its natural 
hosts and some of the factors involved in its life-cycle, in particular during the 
transcription/replication step. 
 
1.1 Classification 
Influenza, commonly referred to as “flu”, is caused by a RNA virus. Viruses are the 
only known forms of life that can have RNA genomes. The word “virus” means poisonous 
liquid in classical Latin. 
Influenza viruses belong to the Orthomyxoviridae family (ortho meaning true or 
normal; myxo meaning mucus), defined by a segmented single stranded RNA genome of 
negative polarity. Some of the most widespread and/or deadly human diseases are caused 
by viruses with negative strand RNA genomes (measles, rabies, Ebola hemorrhagic fever, 
Lassa fever). Negative sense (or antisense) genomes cannot be translated into protein 
directly upon entering the host cell but must first be transcribed into a complementary copy 
that codes for the viral proteins. 
There are five genera in the Orthomyxoviridae family: the influenza A, B and C 
viruses, Thogotovirus and Infectious Salmon Anaemia virus (ISA virus). Each genus contains 
only one species of virus, except Thogotovirus, which consists of Thogoto virus and Dhori 
virus (Pringle, 1996). The division of the influenza viruses into A, B and C is based on the 
serological reactivity of their nucleocapsid (NP) and matrix (M) proteins. Influenza A viruses 
are further divided into subtypes based on the antigenic relationships of their 
haemagglutinin (HA) and neuraminidase (NA) surface glycoproteins. Influenza A HA and NA 
genes are extremely variable in sequence, and less than 30% of the amino acids are 
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conserved among all the subtypes. A total of 16 different HA subtypes (H1-H16) and 9 
different NA subtypes (N1-N9) have been identified so far (Fouchier et al, 2005). Additional 
HA or NA are expected to be recognized in the future as more extensive surveillance is being 
conducted on various wild bird species in geographically different locations. 
Genome organisation and structural features suggest that influenza A, B, and C 
viruses share the same common ancestor, which is distinct from other negative sense RNA 
viruses (Desselberger et al, 1980; Webster et al, 1992). Protein homology and genome 
organisation are more similar between influenza A and B viruses, compared to influenza C, 
suggesting that the latter diverged before the split between influenza A and B viruses (Smith 
& Palese, 1989) (see Figure 4, page - 29 -). 
Only influenza A viruses are established in different animal species including 
humans, horses, swine, and a wide variety of domesticated and wild birds. Influenza B and C 
are circulating in humans only, although influenza B viruses have been isolated from seals 
(Osterhaus et al, 2000) and influenza C viruses have been isolated from pigs and dogs. 
During a long period of human adaptation, influenza B and C viruses accumulated so many 
mutations that they are now not capable of reassortment with influenza A viruses or with 
each other. Only influenza A and B cause significant disease in humans. Influenza C viruses 
infect primarily young children and are usually responsible for only mild respiratory illness 
(Gatherer, 2010; Katagiri et al, 1983; O'Callaghan et al, 1980) and is not included in the 
seasonal influenza vaccine. Influenza B viruses infect also primarily children. Although 
influenza type B is said to cause milder symptoms than influenza type A, influenza B viruses 
are the predominant circulating influenza viruses approximately one in every three years 
(Lin et al, 2004). Similarly, those most at risk from influenza A virus infection are children 
and the elderly.  
Different influenza virus strains are named according to several factors in the 
following order: their genus (type), the species from which the virus was isolated (omitted if 
human or for influenza B), the geographical location of isolate, the number of the isolate, 
the year of isolation, and in the case of the influenza A viruses, the haemagglutinin (H) and 
neuraminidase (N) subtypes. For example, an H5N1 subtype virus isolated from a turkey in 
England in 1991 is designated: influenza A/turkey/England/50-92/91 (H5N1) virus.  
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1.2 Genome organisation 
All A and B type influenza viruses have genomes of eight separate RNA segments, 
whereas influenza C viruses only have seven RNAs. The eight RNA segments of influenza A 
virus encode up to 13 separate proteins, (shown in table I), including the recently discovered 
PA-X (Jagger et al, 2012) and PB1-N40 (Wise et al, 2009). PB1-N40 is an N-terminal 
truncated variant of polymerase basic protein 1 (PB1). However, little is known about this 
new polypeptide. In some strains, the PB1 segment also encodes for PB1-F2 protein, from a 
different reading frame (Chen et al, 2001). Two of the 10 influenza viral protein-coding 
mRNAs are processed by the cellular splicing machinery. M and NS genes give rise to spliced 
mRNA encoding the M2 and NEP/NS2 proteins respectively. PA-X is expressed by ribosomal 
frameshifting from the PA mRNA and contains the PA endonuclease domain. PA-X seems to 
modulate the host response to infection. 
 
Table 1: Influenza A viral genome segments and their encoded proteins. RNA segment and 
proteins sizes correspond to A/Puerto Rico/8/34 strain (adapted from (Lamb & Krug, 1996)). 
vRNA 
segment 
RNA length 
(nucleotides) 
Protein(s) encoded Function Protein length 
(amino acids) 
1 2341 Polymerase basic 
protein 2 (PB2) 
Cap-binding, part of the 
polymerase complex 
759 
2 2341 Polymerase basic 
protein 1 (PB1) 
 
Polymerase PB1-F2 
 
N40 
RNA-dependent RNA polymerase, 
part of the polymerase complex 
 
Pro apoptotic, virulence factor 
 
Interaction with the polymerase 
complex, role unclear 
757 
 
 
87 
 
719 
3 2233 Polymerase acidic 
protein (PA) 
 
PA-X 
Endonuclease, part of the 
polymerase complex 
 
? 
716 
 
 
232 or 252 
4 1778 Haemagglutinin 
(HA) 
Binds sialic acid on cell surface to 
facilitate endocytosis and 
membrane fusion 
566 
5 1565 Nucleoprotein (NP) Coat the vRNA, required for 
transcription and replication 
498 
6 1413 Neuraminidase (NA) Cleaves progeny virions from cell 
surface by removing sialic acid 
454 
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7 1027 Matrix protein (M1) 
 
 
Matrix protein (M2) 
Structural component of the 
virion, viral budding 
 
Ion channel, viral budding 
252 
 
 
97 
8 890 Non structural 
protein NS1 
 
 
 
Non structural 
protein 2 / Nuclear 
Export Protein 
(NS2/NEP) 
Multifunctional protein. IFN 
antagonist, inhibits cellular mRNA 
export, increases viral mRNA 
translation 
 
vRNP nuclear export 
 
230 
 
 
 
 
121 
  
All the genomic RNA segments present a central coding region, flanked by relatively 
short non-coding regions. The segment extremities constitute the viral promoter for 
transcription and replication. They are highly conserved between segments and between all 
influenza strains and show partial complementarity. The promoter sequences are the viral 
polymerase binding site. 
 
1.3 Viral structure 
The influenza A virus particle is 80-120 nm in size. However, virions can exhibit a 
variety of shapes and sizes ranging from spherical particles to elongated filamentous forms 
depending on the virus strain, passage history and on M1 (Matrix protein 1) amino acid 
sequence (Elleman & Barclay, 2004). If propagated in eggs or cell culture, viruses have a 
regular spherical appearance (Figure 1, panel A). In contrast, on initial isolation from 
humans or animals, influenza A viruses are often pleomorphic, as it is the case for the 2009 
swine flu (Neumann et al, 2009), (Figure 1, panel B). 
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Figure 1: Different shapes of influenza A viruses. A. Rod-like structures (Noda et al, 2006). B. 
Filamentous structures (Neumann et al, 2009). 
  
All negative-strand RNA viruses that infect vertebrates are enveloped. The viral 
envelope of influenza viruses consists of a lipid bilayer and is obtained upon budding from 
host cell membranes. Three transmembrane viral proteins are present on this envelope: HA, 
NA and a minor amount of M2 (Matrix protein 2). HA and NA are glycoproteins that project 
from the surface of the virion or infected cells and display rod and mushroom shapes 
respectively (Figure 2). HA exists as a homotrimer possessing important roles in receptor 
binding and membrane fusion, while NA is a homotetramer with the capacity to hydrolyse 
sialic acid (SA) groups present on host membranes. M2 is also a homotetramer and is also 
inserted into the viral membrane but at fewer copies than HA or NA and hardly projecting 
from the virus surface. It acts as an ion channel allowing positive ions to enter the viral 
particle interior resulting in acidification, an essential event during the uncoating process.  
Beneath the membrane envelope lays a layer of M1 proteins, a major structural 
component of the virion, which is thought to form a capsid-like shell rather than fill the 
whole virus particle as a matrix. M1 is intimately positioned to interact with both envelope 
proteins and the underlying ribonucleoprotein (RNP) complexes. 
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Figure 2: Schematic diagram of an influenza A virus particle and its eight viral ribonucleo-
proteins (vRNPS), adapted from (Neumann et al, 2009). The three transmembrane proteins 
(HA, NA and M2) are anchored in a lipid bilayer derived from the host cell. Underneath the 
lipid bilayer are found M1 proteins which surround the viral core composed of the eight 
vRNPs. Each vRNP is constituted of a negative strand RNA segment coated with NP proteins 
and bound to the three polymerase proteins (PB1, PB2 and PA). 
 
The eight influenza genomic viral RNA (vRNA) molecules never exist as naked RNA 
but are associated with four viral proteins to form the vRNP. The major viral protein in the 
RNP complex is the nucleocapsid protein (NP), which coats the viral RNA that forms a strand 
that is folded back on itself to form a hairpin-like structure. NP binds single-strand RNA with 
no sequence specificity. The RNA within the influenza virus RNP remains sensitive to 
digestion with RNAse, supporting the model that the RNA is wrapped around the outside of 
NP with its bases exposed so that they can be accessed by the polymerase without 
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disrupting the RNP structure (Baudin et al, 1994). It is estimated that one NP molecule binds 
to every 24 nucleotides (Ortega et al, 2000).  
Whereas multiple copies of NP are associated with the vRNA, only a single copy of 
the polymerase is bound per genomic RNA segment (Figure 3). The influenza RNA 
dependent RNA polymerase is composed of three viral proteins: polymerase basic protein 1 
(PB1), polymerase basic protein 2 (PB2) and polymerase acid protein (PA) (Braam et al, 
1983; Detjen et al, 1987). The structure of NP has been solved (Ng et al, 2008; Ye et al, 
2006). However, the influenza polymerase structure has been remarkably difficult to 
determine. A three-dimensional image of the polymerase complex bound with a short vRNA 
segment and NP molecules derived from tomography of images obtained at high resolution 
electron microscopy or high resolution cryo-electron microscopy (Area et al, 2004; Coloma 
et al, 2009; Martin-Benito et al, 2001) indicates that the three subunits are tightly 
associated to form a compact structure (Figure 3). Over the last few years, a series of high 
resolution structures of some influenza polymerase domains have been determined and are 
summarised in Table 2 (reviewed in (Boivin et al, 2010; Ruigrok et al, 2010)). 
 
Table 2: Available structures for influenza polymerase subunits. 
Protein Structure available 
(residues) 
Domain name/function References 
PB1 1-15  
1-25  
685-757 (end) 
PA interacting peptide  
PA interacting peptide  
PB2 interacting domain 
(Obayashi et al, 2008) 
(He et al, 2008) 
(Sugiyama et al, 2009) 
PB2 1-35 PB1 binding domain (Sugiyama et al, 2009) 
 320-483 Cap binding site (Guilligay et al, 2008) 
 528-678 
539-753 
535-742 
627 domain 
627-NLS domain 
627-NLS domain 
(Tarendeau et al, 2008) 
(Tarendeau et al, 2008) 
(Kuzuhara et al, 2009) 
 692-759 (end) NLS domain (Tarendeau et al, 2007) 
PA 1-197 Endonuclease domain (Yuan et al, 2009) 
 1-209 Endonuclease domain (Dias et al, 2009) 
 257-716 (end) PB1 binding domain (Obayashi et al, 2008), (He et al, 
2008) 
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Figure 3: Structural organisation of influenza vRNPs. Schematic model (top) and 3D 
reconstruction model (bottom) from electron microscopy images of purified polymerase 
complex co-expressed with nucleoprotein and a short viral-like RNA segment (Coloma et al, 
2009; Martin-Benito et al, 2001). The coloured areas indicate the localisation of the 3 
subunits using monoclonal antibodies (Area et al, 2004), (adapted from (Portela & Digard, 
2002)). 
 
The polymerase complex binds the vRNA promoter that is formed by the partially 
complementary 5' and 3'-terminal sequences of vRNA, which are highly conserved between 
all eight segments and in all influenza A strains (Desselberger et al, 1980; Skehel & Hay, 
1978).  
Minor quantities of NEP (Nuclear Export Protein, formerly known as NS2) are also 
present in the virion complex (Richardson & Akkina, 1991). Other proteins encoded by the 
influenza genome include NS1, which is absent from the final virion and in some strains, 
PB1-F2, which is also excluded from the virion and is not essential for virus replication (Chen 
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et al, 2001). Finally, some host cell proteins have been detected in influenza virions (Shaw et 
al, 2008). It is likely that among the 36 proteins identified in this study by proteomic 
techniques, some play a role in particular stages of the virus life-cycle. 
 
1.4 The hosts of influenza viruses 
Influenza A viruses remain a persistent health risk for humans and animals, causing 
annual epidemics, economic loss and, occasionally, serious pandemics. However, it was only 
after the 1957 human pandemic that researcher paid more attention to animal influenza 
and a possible link to human influenza. The notion of an animal reservoir for influenza A 
emerged relatively recently and the role of avian species as potential reservoir resulted from 
an increasing number of isolation of influenza viruses from various avian species during the 
60’s (Easterday, 2003). Since then, there have been many reports of influenza A viruses 
transmitting from the avian reservoir to other species (Van Reeth, 2007), but only rarely do 
such zoonoses spark an outbreak of human transmissible virus. Influenza A viruses have 
been isolated from a variety of hosts, including humans, pigs, horses, birds, whales, seals, 
minks, cattle, chicken, and even cats, tigers and dogs. Importantly, isolation of a virus does 
not necessarily indicate that the species is a natural host or reservoir for the virus. Some 
subtypes are more predominant in some species than others (H1 and H3 in swine, H3 and 
H7 in horses, and H5, H7 and H9 in chickens) but there is no clear correlation between host 
restriction and HA subtype.  
 
1.4.1 Birds 
1.4.1.1. Wild aquatic birds 
The native hosts of influenza A virus are wild waterfowl and ducks, where typically 
infection occurs asymptomatically, indicating that the virus has achieved an optimal level of 
adaptation in those animals. It was not until the mid-1970s that a survey organised by the 
WHO revealed the enormous pools of influenza viruses present in the wild bird population 
(Alexander, 2007; Easterday, 2003). Surveillance also revealed that non-pathogenic avian 
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influenza is commonly found in aquatic birds (Alexander, 2000; Webster et al, 1992) and 
that all the known HA (H1-H16) and NA (N1-N9) subtypes that have been identified 
(Fouchier et al, 2005) are maintained in aquatic bird population, especially ducks, shorebirds 
and gulls. However, some subtypes are more common in some avian species than others. 
For example, H3, H4 and H6 subtypes are more commonly found in ducks in North America 
(Ito et al, 1995). Few strains induce systemic infection in birds and are always members of 
the H5 or H7 subtypes. In wild aquatic birds, influenza infection occurs by the oral route and 
replication takes place in the intestinal tract where the temperature is estimated to be 
around 41°C. Viruses are excreted in high concentration in the faeces (Webster et al, 1978). 
In absence of symptoms, some migratory wild bird species have the capability to spread 
viruses over great distances or even continents. Thus, aquatic bird populations provide a 
vast reservoir for maintenance, persistence and spread of the virus in nature. As a 
consequence, they play a unique and important role in influenza virus ecology. 
 
1.4.1.2. Domestic poultry 
Avian influenza virus is an important pathogen for the poultry industry worldwide. 
The clinical outcome of avian influenza infection can be dramatically different in wild birds 
or in domestic birds. Influenza viruses infecting domestic poultry such as chickens or 
turkeys, can be classified into two different groups, based on the outcome of infection in 
chickens. So far, the highly pathogenic avian influenza (HPAI) viruses have been restricted to 
H5 and H7 subtypes, although not all H5 or H7 viruses are highly pathogenic. HPAI viruses 
cause up to 100% mortality in poultry within 36-48 hours postinoculation (Spackman, 2008). 
All other viruses are low pathogenic (LP) with a subclinical outcome most of the time in 
chickens or turkeys. Interestingly, generation of HPAI appears to be associated with 
adaptation of LPAI viruses to chicken or turkeys. HPAI viruses usually do not cause disease in 
wild birds such as ducks (Spackman, 2008). However, since 2001, HPAI H5N1 viruses isolated 
in Asia can cause severe disease in ducks and other waterfowl and even death (Sturm-
Ramirez et al, 2004). A HPAI H5N1 virus was isolated from dead wild waterfowl around 
Qinghai Lake in China in 2005 (Chen et al, 2005; Liu et al, 2005). The HA molecule plays a 
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major role in the pathogenicity of influenza viruses. The proteolytic cleavage site sequence 
in the HA precursor protein determines whether infection will be systemic (HP) or not (LP), 
based on the protease required for the cleavage (Rott, 1992) (see also paragraph 1.5.7, page 
- 57 -).  
 
1.4.2 Humans 
The range of severity of diseases caused by influenza in humans is extremely wide. 
Common symptoms include acute respiratory inflammation, high fever, cough, nasal 
congestion, body aches, headaches, muscle pain and fatigue. These symptoms usually last 
for several days. However, influenza infection can sometimes be associated with significant 
morbidity amongst the general population and mortality particularly amid risk groups, such 
as the elderly, immunocompromised and the very young. Patients with certain chronic 
medical conditions and pregnant women are at higher risk from a severe outcome. 
According to the World Health Organisation, seasonal influenza affects 5 to 15 % of the 
worldwide population every year, causing an estimated 500,000 deaths annually. 
Influenza A viruses circulating in humans have, since the end of the 19th century, only 
been limited to few subtypes. Detection of antibodies in the sera of elderly people and 
virological evidence suggest that there has been a cyclical appearance of only three HA 
subtypes: H1, H2 and H3. H3 viruses emerged around 1890, H1 in 1918, then H2 in 1957, H3 
in 1968, and H1 in 2009 (Smith et al, 2009; Webster et al, 1992) (Figure 4). The 
reintroduction of H1 in 1977 is not considered to have been by a natural event. This 
observation raises the question of whether the 13 other HA subtypes have the potential to 
ever generate a pandemic. 
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Figure 4: Evolution of human influenza viruses and human infection events caused by 
influenza A viruses (adapted from (Webster et al, 1992)). Based on genetic and antigenic 
data, and historical records, the main human influenza lineages and some notable human 
infection events are represented in chronological order. The avian virus reservoir, placed in 
the middle, indicates the source of the viruses or the source of some gene segments. 
 
The H1N1 subtype was responsible for the deadly “Spanish flu” pandemic in 1918. 
This exceptionally severe pandemic replaced the circulating H3N8 subtype and circulated 
among humans for many years, undergoing antigenic drift and finally disappearing around 
1957, when it was displaced by the incoming H2N2 pandemic virus. It is estimated that one 
third of the world’s population were infected and had clinical symptoms during the 1918-
1919 pandemic (Taubenberger et al, 2001). The virus was responsible for an estimated 20-
50 million deaths associated with acute pulmonary haemorrhage and oedema 
(Taubenberger et al, 2001). As no antibiotics were available, the majority of the deaths may 
have been due to secondary bacterial infection that caused severe pneumonia (Morens et 
al, 2008). After a second lethal wave in the autumn of 1918, the susceptible host population 
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and thus the numbers of new cases fell and the strain became the seasonal influenza strain 
until the end of the 50’s. The reason for the apparent drop in virulence at this time is not 
clear but may be attributed to the reduction of the proportion of naïve population or to 
mutations accumulation in the virus which decreased its virulence. It is believed that the 
virus appeared in the United States and was brought to Europe by U.S. troops in 1918 
(Crosby, 1989). Genetic analysis suggests that the 1918 H1N1 virus originated from direct 
transfer of a whole avian strain into humans, suggesting that a small number of adaptive 
mutations were the cause of its capacity to infect and spread among humans (Reid et al, 
2004; Taubenberger et al, 2005; Tumpey et al, 2005). However, its origin remains puzzling 
and identification of pre-1918 human influenza RNA samples would help understand about 
the origin of this virus. In contrast, the two following pandemics occurred by reassortment 
between the circulating human strain and avian influenza viruses. 
 
In 1957, the “Asian” H2N2 strain obtained its HA, NA, and PB1 genes from an avian 
influenza virus (Figure 5). The remaining five genes were from the human H1N1 strain 
circulating at the time (Kawaoka et al, 1989). Because the human population had not 
experienced infection with a virus of H2 antigenic type, the entire world was susceptible and 
during the spring of 1957, the virus spread rapidly. The Asian flu virus killed between 1 
million and 4 million people. 
The H3N2 subtype was introduced in humans in 1968 as a reassortant virus 
comprising HA subtype H3 and PB1 gene segments of avian origin and the remaining six 
segments from previously circulating human H2N2 strain (Scholtissek et al, 1978b) (Figure 
5). The so-called “Hong Kong” pandemic replaced the H2N2 subtype and was later found in 
pigs, cattle, chickens, dogs and other species worldwide and claimed around 2 million 
human lives. 
In 1977, an influenza outbreak occurred in Northern China and subsequently spread 
around the world. Serological and genetic analysis indicated that the virus responsible for 
what was later called the “Russian flu” was identical in all genes to the H1N1 virus 
circulating in humans in 1950 (Nakajima et al, 1978). The most likely explanation for the 
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reappearance of a virus 27 years after its disappearance is an accidental release from a 
frozen source. 
 
Figure 5: Evolution and reassortment of the influenza A viruses circulating in humans during 
the 20th century (adapted from (Webster et al, 1992) and (Miotto et al, 2008)). A whole 
H1N1 avian virus transmitted to humans and originated the “Spanish flu” pandemic in 1918. 
In 1957, three genes (PB1, HA, and NA) from duck origin influenza virus reassorted with the 
circulating human H1N1 generating the Asian flu (H2N2). H2N2 replaced the circulating 
H1N1. In 1968, H2N2 human influenza reasserted by acquisition of PB1 and HA from the 
duck reservoir, generating the currently circulating H3N2 lineage and replacing H2N2. The 
Russian pandemic of 1977 was caused by the release of 27 year old frozen H1N1 virus. 
 
During the course of my PhD studies, a new pandemic strain emerged. Pandemic 
2009 H1N1 (pH1N1, also called “swine flu”) is a complicated reassortant whose combination 
of genomic segments is unique but all segments of the virus were most recently present in 
viruses found in swine (Dawood et al, 2009; Garten et al, 2009; Smith et al, 2009). The origin 
of the virus was initially thought to be in pig farms in Mexico but where and when the 
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reassortment that gave rise to the virus occurred is currently unclear. Reports suggest that 
the new strain might have arisen in Asia and then travelled to North America by an infected 
human, although this hypothesis remains controversial (Lam et al, 2011). The virus exhibited 
a remarkable transmissibility between humans most of whom who had very little pre-
existing immunity against this novel strain, despite the fact that it was of the H1 subtype 
and H1 viruses had already been circulating in humans since their reintroduction in 1977.  
The NA and M segments were derived from influenza viruses circulating in pigs in 
Eurasia. The swine Eurasian H1N1 lineage had been established after a wholly avian 
influenza strain crossed into pigs in 1979 (see paragraph 1.4.3, page - 33 -). Intriguingly, this 
lineage, named “avian-like” swine H1N1, is prevalent in European pigs but has never been 
reported in North America. The six remaining segments of the pandemic virus were derived 
from swine viruses isolated in North-America and known as “triple reassortant” viruses 
(Figure 6, see also paragraph 1.4.3, page - 33 -). The polymerase and NP genes of pH1N1 are 
from the triple reassortant internal gene (TRIG) cassette which has circulated in pigs in 
North American since 1998 (Karasin et al, 2000). In this cassette, PB1 segment comes from 
the H3N2 human strain, NP is from the classical H1N1 swine lineage. Interestingly, PB2 and 
PA genes are from North America avian origin and yet, pH1N1 PB2 and PA proteins are 
active in a human environment. Surprisingly, many of the previously known mammalian 
signatures are not present in the 2009 pH1N1 virus (Garten et al, 2009) and this suggests 
that other determinants are responsible for the capacity of this virus to replicate and 
propagate in humans. 
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Figure 6: The complicated origin of pandemic 2009 H1N1 influenza A virus, from (Garten et 
al, 2009). Pandemic 2009 H1N1 strain arose through a multiple-reassortment process 
combining avian-origin PB2 and PA, human PB1, classical swine HA, NP and NS and Eurasian 
swine NA and M segments. 
 
During the 2010/2011 season, 2009 pH1N1 virus circulated as a seasonal virus, 
having replaced the previously seasonal H1N1 viruses. The human H3N2 seasonal influenza 
viruses have not been displaced. However, currently (2011/2012 season), detection of 
pH1N1 among the population seems relatively low and the huge majority of isolated 
influenza A viruses in Europe are from the H3N2 subtype (98.7%, source WHO). After each 
of the three pandemics of the 20th century, the virus returned as a seasonal form. However, 
it is not yet known if 2009 pH1N1 virus will still be circulating in the future. 
 
1.4.3 Pigs 
Signs of disease in pigs are similar to what is observed in human (nasal discharge, 
coughing, fever, breathing difficulties and conjunctivis). Three influenza A subtypes have 
become established in pigs: H1N1, H3N2, and H1N2. Swine H1N1 and H3N2 viruses are 
antigenically and genetically different from their counterparts circulating in humans. In 
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contrast to human influenza, swine influenza subtypes have different origins in different 
parts of the world. H1N1 subtype includes the classical H1N1 and the “avian like” H1N1. 
Classical H1N1 was first observed in the USA in the fall of 1918 simultaneously with the 
second wave of the pandemic in humans (Koen, 1919), but also in Eastern Europe and China 
(Chun, 1919). The virus responsible for the disease in pigs and humans was closely related 
(Gorman et al, 1991; Kanegae et al, 1994; Reid et al, 1999) and it most probably spread from 
humans to pigs during the “Spanish flu”. Classical swine H1N1 was first isolated in 1930 in 
North America (Shope, 1931) in what was the first ever successful influenza A virus isolation 
and experimental infection. In 1979, “avian-like” H1N1 viruses were isolated from pigs in 
Europe (Pensaert et al, 1981; Scholtissek et al, 1983). This virus was distinguishable from the 
classical swine H1N1 viruses circulating worldwide at the time (Hinshaw et al, 1984; 
Scholtissek et al, 1983). Genetic analysis showed that the 8 gene segments were from avian 
origin, and were derived from H1N1 viruses isolated from wild ducks in North America and 
Germany in 1976-77 (Schultz et al, 1991) indicating that a whole avian virus crossed from 
birds to pigs, and successfully transmitted among the European pig population. “Avian-like” 
H1N1 viruses had a selective advantage over the classical swine H1N1 since they became 
the predominant H1N1 swine influenza strain in Europe, replacing the classical H1N1 viruses 
(Brown, 2000; Campitelli et al, 1997). An Asian sublineage of the Eurasian lineage has also 
became established from an independent introduction event (Guan et al, 1996). However, 
“avian-like” H1N1 viruses are not present among North American pigs. 
Another human pandemic that occurred in the 20th century and successfully 
established in pigs worldwide is the H3N2 virus. “Human-like” H3N2 viruses were isolated 
from pigs shortly after the Hong Kong pandemic (Kundin, 1970; Nerome et al, 1981) and, 
there is no evidence that pigs have been infected with H3N2 before the 1968 human 
pandemic (Kundin & Easterday, 1972). Thus, and similarly to the introduction of classical 
H1N1 virus in pigs, these observations suggest a potential transmission from humans to 
pigs. 
The presence of H1N2 subtype in pig population worldwide is the result of multiple 
introduction events (reviewed in (Brown, 2008)). Antigenic and genetic characteristics of 
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swine H1N2 viruses are diverse, reflecting their different origins. These viruses derived from 
co-infection with endemic H1N1 and H3N2 viruses circulating in pig populations. 
Since 1998, a new lineage of “triple reassortant” H3N2 viruses has been isolated 
from pigs in the USA. HA, NA, and PB1 genes were from human influenza origin H3N2 virus, 
NP, M and NS genes were from classical swine H1N1 virus origin, and PB2 and PA originated 
from a North America avian origin virus (Karasin et al, 2000; Zhou et al, 1999). Following the 
isolation of the triple reassortant H3N2 viruses, multiple reassortant events occurred, 
producing viruses with different combinations of HA and NA genes (H1N2, H1N1) (Webby et 
al, 2000). However, the unique internal genes constellation, known as the triple-reassortant 
internal gene (TRIG) cassette, was conserved. The TRIG cassette seems to confer a selective 
advantage to the viruses that spread through swine population in USA and other countries 
(Olsen et al, 2006b). In addition, these H3N2 viruses have also transmitted from swine to 
turkeys in 2003 and 2004 (Choi et al, 2004; Tang et al, 2005) and were responsible for 
sporadic human infections in Canada in 2005 (Olsen et al, 2006b) and 2006 (Robinson et al, 
2007). Finally, in 2009, a reassortant virus containing six gene segments (including the TRIG 
cassette) derived from a triple reassortant virus of H1 subtype and two genes from the 
Eurasian swine lineage (NA and M), gave rise to the first human influenza pandemic in 40 
years ((Dawood et al, 2009; Fraser et al, 2009; Garten et al, 2009; Smith et al, 2009), see also 
paragraph 1.4.2, page - 28 -). 
This brief summary of the history of swine influenza epidemiology exemplifies the 
complexity of swine influenza, and illustrates the fact that pigs are susceptible to infection 
by human and avian influenza viruses (see also (Gammelin et al, 1989)) and that many 
reassortment events occur in pigs. In addition, human and avian infection from pigs have 
been regularly reported (reviewed in (Myers et al, 2007; Van Reeth, 2007)). As a 
consequence, pigs have for many years been ‘accused’ of acting as intermediate hosts for 
the mammalian adaptation of avian influenza viruses or the generation of new reassortant 
viruses between avian and human influenza strains that can cause pandemics (Brown, 2000; 
Castrucci et al, 1993; Kida et al, 1988; Scholtissek et al, 1985; Webster et al, 1971; Yasuda et 
al, 1991). 
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1.4.4 Horses 
In 1872, an epidemic of equine influenza occurred near Toronto and spread across 
North America with consequences on the economy. Influenza A virus was isolated from 
horses in 1956 in Czechoslovakia (Sovinova et al, 1958). This equine H7N7 subtype was 
subsequently found in many parts of the world. In 1963, the H3N8 subtype was responsible 
for an epidemic of equine influenza in the United States and then spread throughout North 
and South America and Europe, creating massive outbreaks during the two following years. 
Whereas the equine H7N7 lineage probably died out, the H3N8 lineage is still present 
worldwide, showing a complex evolution pattern (Gibbs & Anderson, 2010). In contrast to 
the distinct geographical separation of different lineages of swine influenza, equine 
influenza seems to be more uniformly spread worldwide. Until 2004, the horse was 
considered a “dead-end” reservoir for influenza A viruses as no equine influenza 
transmission to other species had been reported. However, since 2004, equine H3N8 was 
isolated from pigs in China (Tu et al, 2009) and dogs in USA (Crawford et al, 2005). 
 
1.4.5 Other species 
Infection of dogs with equine H3N8 in 2004 resulted in sustained transmission 
between animals and H3N8 canine influenza is now endemic in the canine population of the 
USA. In 2007, transmission of an avian influenza virus to dogs was reported in South Korea. 
This avian virus, from H3N2 subtype, successfully transmits between dogs experimentally 
and naturally (Song et al, 2008; Song et al, 2009a). Other sporadic infection of dogs with 
influenza were reported and studies have demonstrated that dogs are susceptible to human 
influenza virus infection (reviewed in (Gibbs & Anderson, 2010)). It was also suggested that 
dogs may play a role in mammalian adaptation of HPAI H5N1 viruses. Thus, there are 
concerns that dogs may represent a source of novel influenza A strains for humans. It is 
interesting to note that the preferred cell line for growth of influenza virus in tissue culture 
is the canine cell line Madin Darby canine kidney (MDCK). 
Until recently, influenza virus was not known to infect wild felids. But in December 
2003 in a zoo in Thailand, two tigers and two leopards showed clinical signs, including high 
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fever and respiratory distress and died (Keawcharoen et al, 2004). In 2004, 45 tigers 
showing similar symptoms died in another zoo (Thanawongnuwech et al, 2005). The animals 
had been given chicken carcasses that retrospectively were identified as being infected with 
HPAI H5N1 viruses (see paragraph 1.6.1, page - 63 -), suggesting that high viral loads were 
required for wild felid infection with HPAI H5N1. Domestic cats are considered to be 
resistant to influenza virus infection (Hinshaw et al, 1981). However, cases of fatal infection 
of cats with H5N1 virus were reported and experimental infection of cats with HPAI H5N1 
virus resulted in clinical disease or death, with lung damage resembling that from human or 
nonprimates infected with H5N1 (Kuiken et al, 2004). The ferret is a natural host for 
influenza and is the best animal model to study influenza virus (reviewed in (Maher & 
DeStefano, 2004)). Mice are not a natural host for influenza but are commonly used by 
researchers. Their small size and low cost allows studies on a large scale. 
Intriguingly, it is not known why influenza virus is not circulating in animals such as 
cattle, sheep or goats. 
In conclusion, influenza is established in only few species other than birds, and in 
those species, influenza strains have evolved according to their hosts. 
 
 
1.5 Influenza A viral replication and host range barriers 
Most transmissions of whole avian influenza viruses from birds to humans or other 
species do not result in sustained circulation (Webster et al, 1992) indicating that, in order 
to be established into a new species, avian influenza viruses must overcome host range 
restriction. Host range is defined by the range of species in which the virus replicates and is 
transmitted efficiently. Viruses do not have their own metabolism and are obligatory 
intracellular parasites. For optimal viral multiplication in a new species, the virus needs to 
adapt to host-specific factors. 
This section seeks to introduce the different steps of influenza A virus life cycle. The 
known or potential host range barriers that can prevent an avian influenza virus to 
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successfully infect a non-natural organism such as humans will be highlighted in this section. 
Cellular factors playing a role in intracellular and intranuclear events are reviewed in more 
detail. 
 
1.5.1 Entering a new host 
Restriction of efficient infection by influenza A viruses might occur at various points 
in the virus infectious cycle. First of all, the virus that enters a new organism must overcome 
the mucus barriers secreted by airway cells that it must penetrate before it will reach the 
target tissues in which it will replicate. Host proteins present in the mucus and saliva, such 
as mucins, restrict the spread of influenza viruses by providing false receptors. The reason 
chimpanzees are relatively resistant to experimental respiratory exposure to human 
influenza viruses could be explained by their secreted mucins that can specifically bind 
viruses before they reach airway epithelial cells (Gagneux et al, 2003; Olofsson et al, 2005). 
 
1.5.2 Attachment 
If it reaches the correct tissues, the virus must recognize and bind to and enter cells 
in order to replicate. The first step of influenza infection and replication is attachment at the 
cell surface by viral HA glycoproteins. HA binds to sialic acid receptors (Gottschalk, 1959). 
Sialic acid is a highly abundant molecule found as the terminal carbohydrate moiety on 
many oligosaccharides that are bound to glycoproteins and glycolipids protruding from the 
cell membranes. This allows attachment to virtually any cell. Sialic acids exist in different 
isoforms that are characterized by their chemical linkage to galactose sugars and are 
denoted 2,6 or 2,3 -linked. Human viruses preferentially bind to sialic acid attached to 
galactose sugar by an 2,6 linkage whereas most avian viruses bind to sialic acid with an 
2,3 linkage (Matrosovich et al, 1997; Rogers & Paulson, 1983). In humans, 2,6 receptors 
are found throughout the airway (Baum & Paulson, 1990) especially on the surface of 
nonciliated, secretory cells (Thompson et al, 2006), whereas 2,3 receptors are found 
deeper in the lung, in the alveoli, and on the surface of ciliated cells (Shinya et al, 2006). In 
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avian species, influenza viruses replicate in the 2,3-linked rich area of the gut (Ito & 
Kawaoka, 2000). It is thought that replication of avian viruses deep in the lung limits human-
to-human transmission. 
Since virus binding is a prerequisite for infection, the presence or absence of an 
appropriate receptor is one of the most important factors determining which species and 
which cell types can be infected by a given virus. Thus, the conformation of sialic acid 
present on the cell surface (2,3-linked or 2,6-linked) is an important determinant of 
species-specific restriction. However, although 2,3 SA binding avian influenza viruses can 
infect people, they do not transmit without 2,6 SA preference adaptation (Tumpey et al, 
2007). Even if the predominance of 2,6 linked SA in the human trachea and the difference 
in receptor specificity seem to be major determinants of avian influenza host range 
restriction, they are not the only factors. 
Finally, several studies have demonstrated that the difference of temperature at the 
site of replication in different species is an important barrier. For example, avian influenza 
viruses are restricted at the low temperature of the human proximal airway. It was observed 
that the temperature affects the activity of avian influenza polymerase in mammalian cells 
(Hatta et al, 2007; Massin et al, 2001). In addition it was shown that avian haemagglutinin 
and neuraminidase have a reduced capacity to establish productive infection in primary 
cultures of human airway cells at the temperature of the human respiratory tract airway 
cells (Scull et al, 2009). 
 
1.5.3 Fusion and uncoating 
After binding to the target cell surface, the virus allows itself to be carried as cargo 
inside an endocytic vesicle into the endocytic pathway (Matlin et al, 1981). This vesicle 
ferries the virus particle through the cortical network of cytoskeletal fibres, which could 
otherwise constitute a major obstacle, and transports it away from the cell surface and 
toward the cell nucleus. Two pathways are used. The majority of the particles uses a 
clathrin-dependent pathway, and the rest are thought to use an unidentified pathway that 
is independent of both clathrin and caveolin (Rust et al, 2004). The low pH of the endosome 
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activates fusion of the viral membrane with that of the endosome (Stegmann et al, 1990). 
This fusion is induced by an irreversible structural change in the HA protein on the surface of 
the internalised virion (Skehel & Wiley, 2000), provided that the HA0 precursor molecule 
has been cleaved into two subunits, HA1 and HA2 (Lazarowitz & Choppin, 1975). Cleavage of 
HA is thus an absolute requirement for infectivity. Without proper HA cleavage, virions may 
bind to and enter the cell, but will remain in the endosome. The conformational change of 
several haemagglutinin molecules then opens up a pore that releases the content of the 
virion into the cytoplasm of the cell. M2 has been shown to possess ion channel activity and 
its major role is to conduct protons from the acidified endosomes into the interior of the 
virus to dissociate the RNP complex from the rest of the viral components, thus completing 
the uncoating process (Helenius, 1992; Martin & Helenius, 1991). However, genome 
molecules remain associated with nucleocapsid proteins and the polymerase complex. 
Amantadine and rimantadine have been shown to block the M2 ion channel activity and 
thus viral uncoating (Wang et al, 1993), see paragraph 1.5.9, page - 61 -. 
Once in the cell of a non-natural host, the vRNPs are confronted with important 
changes in the cellular microenvironment that might influence every step of the replication 
cycle. The absence of a cellular factor upon which the virus used to depend, the presence of 
an inhibiting factor that has to be circumvented, or a lower or higher concentration of, or 
affinity for, such a positive or a negative factor may alter the replication. 
Recently, the isomerase cyclophilin A (CypA) was identified as an M1 interactor and 
this interaction seems to affect the early stage of the viral replication. CypA is a peptidyl-
prolyl isomerise and overexpression of CypA inhibited the nuclear translocation of M1, 
resulting in a reduced infectivity whereas knockdown of CypA gene expression resulted in an 
increase of influenza virus infectivity (Liu et al, 2009). Interestingly, the presence of CypA 
has been detected in influenza virions (Shaw et al, 2008) and in the virions of other viruses 
such as HIV-1 (Franke et al, 1994) or VSV (Bose et al, 2003). Using a human genome-wide 
RNA interference (RNAi) screen strategy, König et al. identified PRSS35, SF3A1, F13A1 and 
PPP1R14D as influenza co-factors playing a role in early post-entry step but further 
characterisation is required (Konig et al, 2010). The interferon inducible Mx proteins have 
intrinsic antiviral activity (Horisberger et al, 1983; Lindenmann, 1964) and appear to detect 
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viral infection by sensing nucleocapsid-like structures that are then trapped and become 
unavailable for viral replication (reviewed in (Haller et al, 2007)). The exact mechanism of 
action has been studied for several viruses but is still incompletely understood. The block 
takes place at a very early step of the viral life cycle and affects primary transcription of the 
viral genome. Since the virus cannot transcribe and replicate its genome, generation of Mx 
escape mutants is virtually impossible. 
 
1.5.4 Nuclear import 
One of the characteristics of the influenza virus life cycle which is unusual for an RNA 
virus is its dependence on nuclear functions. The incoming virus must deliver its genome 
and necessary viral proteins to the nucleus which is the site of replication for influenza virus. 
Since new particles bud from the plasma membrane, influenza replication cycle involves a 
complex series of nuclear import and export events. At early times post infection, NP is 
localized predominantly to the nucleus whereas at later times it is found in the cytoplasm, 
which reflects the trafficking of RNPs during the virus life cycle. The trafficking of the viral 
genome into and out of it is a tightly regulated process (reviewed in (Cros & Palese, 2003)). 
The vRNP complexes are too large to allow passive diffusion into the nucleus. Proteins and 
large complexes that carry a NLS are transported into the nucleus by the importin-/β 
heterodimer. Importin- binds the NLS, while importin-β mediates translocation through 
the nuclear pore complex. After release in the cytoplasm, the influenza vRNPs interact with 
the importins. All proteins in the vRNP complex possess nuclear localization signals (NLS), 
which mediate their interaction with the nuclear import machinery. However, a NLS on NP 
has been shown to be both sufficient and necessary for the import of viral RNA (Cros et al, 
2005; O'Neill et al, 1995; O'Neill & Palese, 1995), through its interaction with importin  
(O'Neill & Palese, 1995).  
The role of importins in host range restriction and adaptation is the only molecular 
mechanism associated with adaptive mutations. It has been suggested that the avian virus 
polymerase PB2 protein and nucleoprotein NP may bind less efficiently to human importins 
than do the viral proteins of viruses already adapted for humans. Thus, slower accumulation 
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of the vRNPs inside the nucleus may account for the lower replication of avian viruses in 
human cells (Gabriel et al, 2008; Resa-Infante et al, 2008). On the other hand, Resa-Infante 
et al. have suggested that importin interaction may be required for the function of the 
polymerase inside the nucleus rather than just for import. A human genome-wide RNAi 
screen identified CSE1L (chromosome segregation 1-like (yeast)) as a novel factor required 
for influenza vRNPs and/or newly synthesized viral proteins nuclear import (Konig et al, 
2010). CSE1L binds to NLS-free importin- and this interaction is displaced by RanBP1 and 
RanGAP1 in the cytoplasm. RanBP1 binds to RanBP5, another influenza co-factor (see 
paragraph bellow). 
 
1.5.5 Replication 
Once in the nucleus, the viral genome must direct expression of viral proteins that 
will enable genome replication in the step know as primary transcription. 
The RNA of negative-strand viruses cannot be directly translated upon entry into the 
cell, but must first be transcribed into positive-sense messenger RNAs. Negative-strand RNA 
viruses face two problems as a result of their RNA genomes: 1) how to synthesize 
messenger RNAs from an RNA template, and 2) how to replicate their RNA genome. There is 
no cellular RNA-dependent RNA polymerase available for production of viral RNAs. 
Therefore, negative-strand RNA viruses must make their own RNA polymerase and package 
at least one copy of this enzyme within the virion. Influenza polymerase complex consists of 
three subunits: PB1, PB2 and PA, which in combination with NP replicates and transcribes 
the viral genome.  
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Figure 7: Transcription and replication of the viral genomic RNA is performed by the viral 
polymerase (PB1, PB2 and PA). Newly made vRNPs may serve for new transcription or 
replication rounds, or may exit the nucleus to be incorporated into new progeny virions. 
 
One polymerase complex is attached to the highly conserved extremities of each 
influenza genomic segment. These extremities constitute the promoter regions of each 
segment. These sequences are partially complementary and consist of the terminal 13 
nucleotides of the 5’-end and 12 nucleotides of the 3’-end of the vRNA. The promoter forms 
a secondary structure for both the vRNA and cRNA promoters (Bae et al, 2001; Park et al, 
2003). Among the three proposed promoter structures, the panhandle (Hsu et al, 1987), 
fork (Fodor et al, 1993; Kim et al, 1997), or corkscrew model (Flick & Hobom, 1999), the 
latter one is considered the current model of the secondary structures of both the vRNA and 
cRNA promoters (Azzeh et al, 2001; Crow et al, 2004) (see Figure 9, page - 47 -). However, it 
is possible that such structures are modified by interaction of the polymerase complex, NP, 
or host factor(s) to the RNA template during the transcription and replication processes. 
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1.5.5.1. Transcription of viral mRNA 
The incoming negative sense vRNAs are first transcribed into mRNAs by the viral 
polymerase complex that was introduced into the nucleus as part of the vRNPs (Air et al, 
1990; Scholtissek & Rott, 1970; Taylor et al, 1977). This primary transcription involves 
cutting of 5’ methylated mRNA cap-containing oligonucleotides from host cell pre-mRNAs. 
This “cap snatching” mechanism occurs in the nucleus and the 9-17 nucleotide long capped 
RNA fragments are used to “prime” mRNA transcription using viral genomic RNAs as a 
template. It is the PB2 component of the vRNP which binds the 5’ cap of nascent host pre-
mRNAs (Blaas et al, 1982; Braam et al, 1983; Ulmanen et al, 1981). The 5’ capped RNA 
primers are generated by cleavage of newly synthesised host polymerase II transcripts by an 
endonuclease activity which was recently shown to be present on the PA polymerase 
subunit (Dias et al, 2009; Yuan et al, 2009) and not on PB1 as previously thought (Li et al, 
2001). The cap-binding and endonuclease activities are only activated if the viral genomic 
RNA is bound. PA is essential for both transcription and replication (Braam et al, 1983; 
Horisberger, 1980; Nagata et al, 2008), is involved in vRNA and cRNA promoter binding 
(Hara et al, 2006), in elongation (Fodor et al, 2003) and in assembly of the virus particle 
(Regan et al, 2006). PA also posseses a proteolytic activity whose function is not fully 
understood. The PB1 protein is the “core” of the complex and is responsible for chain 
elongation. PB1 contains the conserved motifs characteristic of RNA polymerases to 
function as a polymerase catalytic subunit for the sequential addition of nucleotides to the 
nascent RNA chains (Argos, 1988; Biswas & Nayak, 1994; Braam et al, 1983; Poch et al, 
1989). PB1 binds to both PA and PB2, through its N- and C-terminal domains respectively 
(Boivin et al, 2010; Gonzalez et al, 1996; Ohtsu et al, 2002; Perales et al, 1996) and interacts 
with the terminal ends of both vRNA and cRNA. 
NP is not part of the polymerase but this arginine-rich protein coats the vRNA, 
preventing its degradation, and is required for both viral genomic transcription and 
replication (Honda et al, 1988; Huang et al, 1990), possibly by assembling functional vRNP 
complexes. Structural data also provide evidence that NP makes direct contact with the 
bound polymerase complex on the RNP (Coloma et al, 2009; Martin-Benito et al, 2001) and 
a recent publication has shown that residues R204, W207, and R208 of NP are required for 
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functional interaction with the viral polymerase (Marklund et al, 2012). Initiation of viral 
mRNA transcription is represented in Figure 8. 
 
Figure 8: Transcription of a viral genomic RNA into mRNA. PB2 subunit of the polymerase 
has a cap-binding function, PA is the endonuclease and PB1 catalyse mRNA synthesis. 
 
The vRNA is copied until the end of the coding sequence and then, the polymerase 
reaches a short (5 to 7 bases) U sequence 15 to 22 bases from the vRNA 5' end present on 
each viral segment. At this precise region, the polymerase is stopped, presumably because 
of steric hindrance caused by the polymerase bound to the 5’end of the vRNA (Beaton & 
Krug, 1986; Fodor et al, 1994; Tiley et al, 1994) and the reiterative copying of the U tract by 
“slipping” generates the poly-adenylated tail by adding more adenines to the 3’end of the 
mRNA. Thus, a poly-A tail is generated without the need of the cellular polyadenylation 
machinery. The resulting viral mRNAs are not complete copies of the vRNAs. The newly 
transcribed mRNA thus comprises a proper methylated 5’ cap and a poly-adenylated tail and 
is treated as a regular host-cell transcript. In the early stage of infection, the first translated 
viral proteins are predominantly NP and NS1 (Inglis & Mahy, 1979). 
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1.5.5.2. Viral replication 
This primary round of transcription is followed by the production by the viral 
polymerase of complementary RNAs (cRNAs). In contrast to viral mRNAs, cRNAs are full-
length, positive sense copies of the vRNAs. cRNAs are neither capped nor polyadenylated. 
New cRNAs are in turn used as a template to produce more vRNA transcripts which are 
subsequently used as the genomic constituents of new virions, or used as templates for 
more viral mRNAs. A vRNA or a cRNA molecule does not have 5’ or 3’ modifications. 
Initiation of cRNA synthesis occurs at the 3’ end of the vRNA template without a 
primer (Figure 9 A) and the product of the elongation reaction is a full length 
complementary copy of the vRNA. It has been proposed that one role of NP is to prevent 
termination at the U tract, thereby enabling the polymerase to read through the poly-U 
stretch and synthesise a complete copy of the vRNA template (Beaton & Krug, 1986). Thus, 
a cRNA molecule contains the complete antigenome sequence including the promoter that 
is required for vRNA synthesis. NP molecules or new polymerase package the newly 
synthesised cRNA and protect it from nuclear RNAses that recognise unmodified RNAs 
(Beaton & Krug, 1986; Vreede et al, 2004). 
In contrast, initiation of vRNA transcription is initiated few nucleotides inside of the 
3’ cRNA promoter region. After the synthesis of the two first nucleotides (pppApG), this 
short primer is realigned to the 3’end of the template (Figure 9 B) and elongation resumes 
and terminates at the end of the cRNA template (Deng et al, 2006b). vRNA are then 
incorporated into RNPs. 
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Figure 9: Initiation of cRNA and vRNA synthesis. The corkscrew models for the vRNA and 
cRNA promoters are shown at the top. Initiation on the vRNA promoter takes place directly 
on positions 1 and 2 whereas initiation on the cRNA promoter takes place few nucleotides 
inside of the 3’ cRNA promoter. The pppApG dinucleotide is then transferred to positions 1 
and 2 for elongation. 
 
Thus, the viral polymerase produces three main species of RNA (Figure 7) and 
initiates both transcription and replication from the vRNA promoter. How the polymerase 
switches between mRNA and cRNA synthesis is not well understood. It was initially thought 
that a conformational change in the polymerase could facilitate the functional switch 
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(Barrett et al, 1979; Hatada et al, 1989; Taylor et al, 1977). Protein synthesis inhibition in 
infected cells by cycloheximide prevents the switch from the initial transcription phase to 
the replication phase, indicating that de novo protein synthesis is required for replication 
and NP might be involved in regulation of the transcription/replication balance (Barrett et 
al, 1979; Beaton & Krug, 1986; Taylor et al, 1977). It was demonstrated that when viral 
polymerase and NP are pre-expressed before infection, both mRNA and cRNA are detected 
(Vreede et al, 2004) and recent evidence showed that virion-derived vRNPs can synthesise 
both cRNA and mRNA in vitro, in absence of added viral or cellular proteins (Vreede & 
Brownlee, 2007). However, in the model established by Jorba et al., transcription of the viral 
mRNA occurs in cis by the polymerase bound to the vRNA, but viral replication would occur 
in trans by a soluble polymerase complex different to the one that is attached with the 
vRNA template (Jorba et al, 2009). The current accepted model is that there is indeed no 
switch: cRNA is also synthesised early in infection but is degraded by cellular pathways and 
it is the accumulation of de novo expressed polymerase proteins and NP that mediates this 
switch by stabilising and protecting cRNAs from degradation (Vreede & Brownlee, 2007). In 
addition, cellular RNA polymerase II degradation or cell “shut off” (Vreede et al, 2010), 
reviewed in (Vreede & Fodor, 2010) and in the following paragraph, is also likely to play a 
role in the switch toward replication. There are increasing evidence that viral protein 
NS2/NEP also plays a role in the regulation of replication and transcription of influenza 
genome (Manz et al, 2012; Robb et al, 2009). 
Recently, the presence in infected cells of high levels of influenza derived small viral 
RNAs (svRNA), also named small viral leader RNAs (leRNAs), with sequences corresponding 
to the ends of the vRNA segments have been reported (Perez et al, 2010; Umbach et al, 
2010). These small RNAs may play a regulatory role in the switch from viral mRNA 
transcription to genomic replication. 
 
1.5.5.3. Cellular factors that modulate influenza replication 
Thus, the vRNPs must successfully hijack host cell processes to transcribe and 
replicate the eight viral genomic segments. The cellular DNA dependent RNA polymerase II 
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and its associated co-factors are probably among the key influenza polymerase cofactors. 
The RNA polymerase II is responsible for transcription of mRNA and small nuclear RNAs (U 
snRNAs) in eukaryotes. Influenza transcription is closely linked to cellular transcription since 
initiation of viral transcription requires capped RNA fragments that are derived from host 
mRNAs. It has been known for a long time that the influenza virus polymerase function is 
associated with the activities of the cellular RNA polymerase II (Lamb & Choppin, 1977; 
Mark et al, 1979). The C-terminal domain (CTD) of RNA polymerase II largest subunit (Rpb1) 
plays a central role in pre-mRNA processing by functioning as a loading platform for pre-
mRNA processing factors. It has been reported that the viral polymerase interacts with the 
cellular RNA polymerase II CTD when engaged in transcription initiation (Engelhardt et al, 
2005) and it is the PA subunit of the vRNP that interact with the RNA polymerase CTD 
(Tafforeau et al, 2011). Efficient interplay between the viral polymerase and the cellular RNA 
polymerase II complex is probably crucial for efficient cap-snatching reaction as PB2 needs 
to have access to methylated 5’ cap transcripts. Importantly, the interaction with the 
cellular RNA polymerase II is not impaired in human cells infected with an avian virus 
(Rameix-Welti et al, 2009). Export of viral mRNA is also dependent on polymerase II function 
(Amorim et al, 2007). Recent studies demonstrate that the host RNA polymerase II is 
inhibited in its elongation step and degraded during influenza infection (Chan et al, 2006; 
Rodriguez et al, 2007) and that the viral polymerase alone is responsible for this degradation 
or cell “shut off” (Vreede et al, 2010), reviewed in (Vreede & Fodor, 2010). Cellular RNA 
polymerase II degradation by influenza virus is somewhat surprising as this factor is one of 
the most important host factor involved in influenza life cycle, absolutely required for viral 
mRNA synthesis and processing. However, this observation is not incompatible with 
influenza requirement and is accommodated by the observed switch from viral transcription 
to viral replication. Following infection, a quick and robust viral mRNA production is 
observed while viral replication cannot be detected. Later, when viral mRNA synthesis is in 
decline, probably due to the host RNA polymerase II degradation, viral replication takes 
place, as this process does not require an RNA polymerase II activity. The stock of proteins 
produced early in infection might be sufficient for the formation of new particles. Host gene 
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shut-off would then be beneficial for viral spread by inhibiting the cellular antiviral response 
(Vreede & Fodor, 2010). 
A growing number of publications suggest that mRNA processing events like addition 
of the cap, splicing, addition of the poly(A) tail are performed cotranscriptionally (Bentley, 
2005; Proudfoot et al, 2002). The M2 and NEP/NS2 proteins are encoded by spliced mRNAs 
(from M and NS genes respectively). So influenza virus has to efficiently exploit the host 
cellular splicing machinery. In particular, the cellular nuclear SF2/ASF splicing factor binds 
the viral M1 mRNA to control the usage of the M2 5’ splice site. Thus, the virus must be able 
to correctly use the host factor SF2/ASF to regulate the production of the M2 ion-channel 
protein (Shih & Krug, 1996a). The splicing factor Proline-Glutamine Rich (SFPQ/PSF) was first 
identified as a host cell protein important for influenza using a proteomic approach with 
influenza polymerase as a bait (Jorba et al, 2008). This factor is involved in several cellular 
mechanisms such as regulation of transcription, splicing and polyadenylation of mRNA, and 
interacts with the polypyrimidine tract-binding protein (PTB) and the RNA polymerase II 
CTD. The role of SFPQ/PSF in influenza replication has just been investigated (Landeras-
Bueno et al, 2011). vRNA, cRNA, viral mRNA and viral protein levels were reduced in cells 
where SFPQ/PSF gene expression was silenced by siRNA. As a consequence, influenza gene 
expression was delayed and a significant reduction in viral replication was observed. 
However, viral splicing was not affected. Interestingly, knock down of SFPQ/PSF also reduces 
viral mRNA polyadenylation. Depletion in human cells of hCLE/C14orf166/CGI-99 protein, 
first identified in a yeast two-hybrid screen against PA (Huarte et al, 2001), decreases 
influenza replication. hCLE positively modulated influenza polymerase activity but the 
mechanism remains to be identified. hCLE also associates with the cellular RNA polymerase 
II and is thought to be an mRNA transcription modulator (Perez-Gonzalez et al, 2006). hCLE 
was also found in another yeast two-hybrid screen using PA as a bait (Tafforeau et al, 2011) 
and interaction with influenza polymerase was confirmed in infected cells (Rodriguez et al, 
2011). Silencing of hCLE did not prevent influenza polymerase complex assembly but viral 
transcription and replication were affected. However, a role for hCLE in transport of 
incoming vRNPs to the nucleus or in viral protein synthesis was not excluded (Rodriguez et 
al, 2011). Jorba et al. also identified other cellular partners of influenza polymerase that are 
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related to cellular mRNA synthesis or splicing (Jorba et al, 2008). Examples of these are: 
hnRNP M, also identified as an influenza polymerase interactor by Mayer et al. (Mayer et al, 
2007), that interacts with newly transcribed RNA polymerase II transcripts; hnRNPH1, a 
factor involved in mRNA splicing; and two DEAD-box RNA helicases: p68/DDX5 and DDX3. 
p68/DDX5 is a modulator of transcription that also has a role in spliceosome assembly. 
DDX3 navigates between the nucleus and the cytoplasm and interacts with CRM1, another 
important cellular co-factor for influenza life cycle (see below). Silencing of hnRNP M, 
hnRNPH1, p68/DDX5, or DDX3 expression reduce influenza polymerase activity and viral 
replication (Bortz et al, 2011). The cellular mRNA splicing factor RAF-2p48/NPI-
5/BAT1/UAP56 is involved in mRNA nuclear export and interacts with the N-terminus of NP 
and facilitates formation of NP-RNA complex, stimulating viral RNA synthesis (Momose et al, 
2001). RAF-2p48/NPI-5/BAT1/UAP56 was also found by Mayer et al in their study (Mayer et 
al, 2007). Silencing of this factor reduced viral replication and it was suggested that the host 
protein might act as a chaperone for NP (Kawaguchi et al, 2011). Influenza virus polymerase 
interacts with the P-TEFb complex (cyclin T1/CDK9), which phosphorylates the cellular RNA 
polymerase II CTD. Cyclin T1/CDK9 seems to function as an adaptator between RNA Pol II 
CTD and influenza vRNPs (Zhang et al, 2010). It was recently reported that export of all viral 
mRNA transcripts from the nucleus occurs to some different degree via the NXF1/TAP 
export pathway (Read & Digard, 2010). mRNA export via the NXF1 pathway is closely 
coupled to cellular RNA polymerase II transcription and pre-mRNA maturation, including 
capping, splicing and polyadenylation reactions. In summary, localisation of viral 
transcription in close proximity to cellular transcription allows the viral polymerase to have 
access to cellular factors it can exploit for viral RNA synthesis but also facilitates the 
subversion of cellular transcription, causing for example host cell shut-off.  
Influenza is a virus that replicates fast, so the virus must express its proteins rapidly 
and efficiently. Viral and cellular mRNAs are structurally identical. However, selective 
translation of viral mRNA occurs in infected cells whereas translation of cellular mRNAs is 
strongly inhibited (Garfinkel & Katze, 1993; Katze & Krug, 1984; Skehel, 1972). The exact 
molecular mechanisms involved in translation of viral mRNAs in favour of cellular mRNAs 
remain not fully understood. Influenza infection alters the phosphorylation state of 
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translation initiation factors (Feigenblum & Schneider, 1993). The conserved viral 5’ UTR 
mediates the selective and efficient translation of the viral mRNAs (Enami et al, 1994; 
Garfinkel & Katze, 1993). It has been demonstrated that the cellular factor guanine-rich 
sequence factor 1 (GRSF-1) interacts with a specific sequence (AGGGU) present on NP and 
NS1 5’UTR and stimulates translation of those viral mRNAs (Kash et al, 2002; Park et al, 
1999). In parallel, initiation and elongation of cellular mRNA translation are inhibited (Katze 
et al, 1986). In addition to host factors, the viral protein NS1 stimulates the translation of 
viral mRNAs but not cellular (de la Luna et al, 1995; Enami et al, 1994), and also plays a role 
in nuclear export and splicing of the viral mRNAs (Hale et al, 2008; Robb & Fodor, 2012). 
However, selective translation is still observed in delta NS1 mutant viruses (Salvatore et al, 
2002). It has also been shown that influenza polymerase can bind viral mRNAs in vitro 
through the cap structure and the conserved AGCAAAGCAGG sequence present in all viral 
mRNAs (Shih & Krug, 1996b) and participate in their translation by replacing the translation 
initiation factor eIF4E (Burgui et al, 2007; Yanguez et al, 2012). However, these results 
remain controversial as no binding between the viral polymerase and viral mRNA was 
observed in other studies (Vreede & Brownlee, 2007), and cellular factors such as the cap-
binding protein NCBP2/CBP20, poly(A)-binding protein 1 (PABP1), and the export factor-
binding protein REF/Aly that associate with cellular mRNAs also associate with viral mRNAs, 
suggesting that viral mRNAs exploit the normal pathways used by cellular mRNAs (Bier et al, 
2011). Finally, translation of influenza mRNAs requires a functional eIF4G and the eIF4A 
helicase (Yanguez et al, 2011). 
 
Influenza viral proteins such as those of the polymerase complex that are translated 
by free ribosomes in the cytoplasm must then accumulate in the nucleus to carry on with 
the RNA synthesis of new vRNAs. PB1 and PA are imported into the nucleus as a dimer 
associated with RanBP5 (also known as importin β3 or importin 5) (Deng et al, 2006a; Fodor 
& Smith, 2004). PB2 and NP are imported separately using the classical importin-α/β 
pathway (Gabriel et al, 2008; O'Neill & Palese, 1995; Resa-Infante et al, 2008).  
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A large number of human proteins that interact with the reconstituted viral 
polymerase have been identified biochemically in pull down experiments, by yeast two-
hybrid screen using human cDNA libraries and individual polymerase components as baits 
(Shapira et al, 2009; Tafforeau et al, 2011) or in large scale siRNA screens (Brass et al, 2009; 
Hao et al, 2008; Karlas et al, 2010; Konig et al, 2010; Shapira et al, 2009). However few of 
them have been characterised for their role in influenza replication so far. Here is a 
description of what is known about some cellular factors that can modulate influenza virus 
replication step. 
The minichromosome maintenance (MCM) complex is a helicase that has been 
shown to interact with the C-terminus of PA and stabilize replication elongation complexes 
through scaffolding between nascent cRNA and viral RNA polymerase (Kawaguchi & Nagata, 
2007). Tat-SF1 was found to interact with influenza NP and facilitate viral RNA synthesis 
(Naito et al, 2007a). Hsp90 was shown to interact with PB2 and enhance influenza vRNA 
synthesis (Momose et al, 2002), to play a role in nuclear import of influenza polymerase 
subunits and may act as a chaperone for the formation of the polymerase complex (Naito et 
al, 2007b). Moreover, upon influenza infection, Hsp90 is relocalised in the nucleus (Naito et 
al, 2007b) and inhibitors of Hsp90 reduce by two log the viral titre, probably by reducing the 
viral RNP assembly (Chase et al, 2008). It was recently reported that the human chaperonin 
containing TCP-1 complex (CCT) binds monomeric PB2 in the cytoplasm and because CCT 
interaction is lost when PB2 is associated with PB1 and PA, CCT might also act as a 
chaperone for PB2 (Fislova et al, 2010). Another potential chaperone is nucleophosmin 
(NPM) which might facilitate influenza vRNPs assembly (Mayer et al, 2007). Silencing of 
NPM expression reduces influenza polymerase activity and viral replication (Bortz et al, 
2011). Depletion of the calcium/calmodulin-dependent protein kinase type II beta chain 
(CAMK2B) was shown to affect influenza polymerase activity in a minigenome assay (Konig 
et al, 2010).  
Some host proteins show inhibitory activity for influenza replication. Wang and 
colleague reported an interaction between influenza NP and the double-stranded RNA-
binding protein NF90. NF90 may act as a negative regulator during the early stage of 
influenza virus replication (Bortz et al, 2011; Wang et al, 2009b). Ebp1 (ErbB3-binding 
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protein) was identified as a PB1 interactor and found to selectively interfere with in vitro 
RNA synthesis by influenza RNA polymerase (Honda, 2008; Honda et al, 2007). A functional 
screen identified RuvB-Like Protein 2 (RBL2) as an inhibitor of influenza polymerase activity, 
probably by interfering with NP oligomerization, leading to a reduction in viral replication 
(Kakugawa et al, 2009). RBL proteins are members of a helicase family and play a role in 
many cellular activities such as chromatin remodeling, DNA replication and repair, signaling, 
apoptosis, rRNA and snRNA processing. RBL2 was also identified in a coimmunoprecipitation 
study using influenza vRNP as a bait (Mayer et al, 2007) and knock-down of the Drsosophila 
homologue of RBL2 in a large scale siRNA screen was responsible for an increase in influenza 
virus transcription (Hao et al, 2008). NXP2 (KIAA0136), a protein involved in cellular 
transcription repression, interacts and colocalizes with influenza polymerase (Jorba et al, 
2008). Silencing of NXP2 increased influenza polymerase activity in a minigenome assay 
(Bortz et al, 2011). Very recently, cyclophilin E (CypE) was also identified as an influenza 
restriction factor (Wang et al, 2011). CypE interacts with NP and inhibits the transcription 
and replication of influenza virus by impairing the formation of vRNP. However, for these 
given examples, there has been no evidence that the interactions vary between species.  
A summary of the cellular factor described in this section is presented in Table 3.  
Table 3: Summary of some cellular factors modulating influenza replication. 
Positive factors Viral partner Role Reference(s) 
RNA polymerase II CTD 3P (PA) Viral transcription (Engelhardt et al, 2005) 
SF2/ASF M1 mRNA Viral splicing (Shih & Krug, 1996a) 
SFPQ/PSF 3P ? (Jorba et al, 2008) 
hnRNP M 3P Viral RNA synthesis? (Jorba et al, 2008; Mayer et al, 
2007) 
hnRNPH1 3P Viral RNA synthesis? (Jorba et al, 2008) 
P68/DDX5 3P Viral RNA synthesis? (Jorba et al, 2008) 
DDX3 3P Viral RNA synthesis? (Jorba et al, 2008) 
NXF1/TAP Viral mRNAs Nuclear export (Read & Digard, 2010) 
Cyclin T1/CDK9 PB1, PB2, PA Promote association 
between vRNPs and 
RNA Pol II 
(Zhang et al, 2010) 
GRSF-1 Viral 5’UTR Translation (Park et al, 1999) 
RANBP5 (importin 5) Dimer PB1-PA Nuclear import (Deng et al, 2006a) 
Importin α PB2, NP Nuclear import (Gabriel et al, 2008) 
MCM PA Viral replication (Kawaguchi & Nagata, 2007) 
RAF-2p48/NPI-
5/BAT1/UAP56 
NP Viral RNA synthesis. 
Chaperone? 
(Mayer et al, 2007; Momose et 
al, 2001) 
Tat-SF1 NP Viral RNA synthesis (Naito et al, 2007a) 
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Hsp90 PB2 Viral RNA synthesis. 
Chaperone? 
(Momose et al, 2002) 
CCT PB2 Chaperone? (Fislova et al, 2010) 
NPM 3P Chaperone? (Mayer et al, 2007) 
CAMK2B ? Viral 
transcription/replicatio
n 
(Konig et al, 2010) 
hCLE/C14orf166/CGI-9 PA Viral transcription/ 
replication 
(Huarte et al, 2001) 
CSLE1L vRNP or 
individual  3P 
proteins or NP 
Nuclear import (Konig et al, 2010) 
 
 
   
Negative factors Viral partner Role Reference(s) 
NF90 NP ? (Wang et al, 2009b) 
Ebp1 PB1 Viral 
transcription/replicatio
n 
(Honda et al, 2007) 
RBL2 NP? Inhibits NP 
oligomerisation? 
(Kakugawa et al, 2009) 
NXP2 3P ? (Jorba et al, 2008) 
CypE NP Inhibits vRNPs 
formation 
(Wang et al, 2011) 
Mx NP Sensing of NP  (Haller et al, 2007) 
3P: influenza polymerase complex (PB1, PB2, PA). 
 
1.5.6 Nuclear export of ribonucleoproteins 
Following replication, newly formed vRNPs are assembled in the nucleus and are 
exported into the cytoplasm. The late viral proteins M1 and the nuclear export protein 
(NEP/NS2) are involved in this process. M1 associates with vRNPs in the nucleus and might 
be responsible for the dissociation of vRNPs from the nuclear matrix. NEP/NS2 associates 
with the C-terminus of M1 but also with the cellular export machinery, and thus directing 
nuclear export of the complex vRNP-M1, according to the current model (reviewed in (Cros 
& Palese, 2003)). Newly synthesized vRNPs use the export receptor CRM1 (chromosome 
region maintenance 1 protein homologue or exportin 1) (Boulo et al, 2007; Elton et al, 2001; 
Neumann et al, 2000). CRM1 is the major nuclear export receptor for cellular proteins and 
mediate the nuclear export of proteins containing a nuclear export signal (NES). CRM1 is an 
interesting example of a species-specific factor required for efficient nucleocytoplasmic 
transport of Rev-dependent HIV-1 intron-containing RNAs (Sherer et al, 2011). Influenza 
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protein NS2/NEP was shown to interact with nucleoporins, a constituent of the nuclear pore 
complex through a NES (O'Neill et al, 1998) and alteration of the NS2/NEP NES abolished 
this interaction (Neumann et al, 2000). Deletion of NS2/NEP or mutation of the NES 
abolished the nuclear export of NP and abrogated the generation of viral particles. Thus 
interaction between NS2/NEP and host cellular factor CRM1 is essential for vRNP nuclear 
export and virion formation. A proposed nuclear export model is an interaction vRNPs-M1-
NS2/NEP-CRM1. However, NP binds CRM1 in vitro and it was suggested that NP also 
participate in the nuclear export of vRNPs by directly interacting with CRM1 (Elton et al, 
2001), questioning the exact role of NS2/NEP in nuclear export. Transport of some 
complexes across the nuclear envelope is regulated by the transient interaction between 
transporter molecules and nuclear pore complex (NPC) components. Recently, human 
nucleoporin 98 (hNup98), a component of the NPC, was identified as an NS2/NEP-binding 
protein using yeast two-hybrid screening of a human cDNA library (Chen et al, 2010). 
Nup98, which is interferon-inducible, was also identified in three of the large scale siRNA 
screens as a human protein whose knockdown affected influenza replication (Brass et al, 
2009; Hao et al, 2008; Karlas et al, 2010). Another NPC protein, Nup153 was also identified 
in two of the genome wide screens (Hao et al, 2008; Konig et al, 2010). The exact role in 
influenza infection of both Nup98 and Nup153 remains to be defined. Thus, the detailed 
mechanism by which influenza A vRNPs exit the nucleus is still not clear. Host protein Hsp70 
interacts with vRNPs and was shown to prevent viral protein M1 from binding to vRNP, 
which would result in M1 inhibiting vRNP nuclear export (Hirayama et al, 2004; Li et al, 
2011). 
After nuclear export, it is thought that interaction between tubulins, actin 
cytoskeleton and influenza virus vRNPs are responsible for the long-distance transport from 
the nucleus to the cell membrane, prior to virion formation and budding (Avalos et al, 1997; 
Bucher et al, 1989; Digard et al, 1999; Jorba et al, 2008; Mayer et al, 2007). NS2/NEP 
interacts with the cellular human immunodeficiency virus (HIV) Rev-binding protein (HRB) 
and this interaction might facilitate the transfer of vRNPs from nuclear export complex to 
the cytoplasmic trafficking machinery (Eisfeld et al, 2011b). The Rab11 endosomal trafficking 
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pathway appears to play a indispensable role in both trafficking of influenza vRNPs and viral 
budding (Bruce et al, 2010; Eisfeld et al, 2011a). 
 
1.5.7 Assembly and release of the new virions 
Once the vRNPs have reached the plasma membrane, they are packaged into virions. 
Progeny virions assemble and bud from the apical plasma membrane of polarized cells (i.e. 
lung or airway epithelial cells), taking a piece of the lipid membrane as the virus envelope.  
 
Figure 10: Packaging of influenza vRNPs into particles. A. Transverse section of a progeny 
virion showing a “star-like” organisation of the 8 vRNPs. The arrow represents associations 
between the vRNPs (Noda et al, 2012). B. Profile view of newly synthesised particles 
budding from the cellular membrane, from (Noda et al, 2006). 
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Viruses with fragmented genomes face the problem of ensuring that at least one 
copy of each genome segment is packaged into the virion. There is increasing evidence to 
support the selective incorporation model for packaging of the eight viral RNA segments, in 
opposition to the random incorporation model. Segment specific packaging is hypothesised 
to occur via specific RNA-protein or RNA-RNA interactions allowing each segment to be 
packaged selectively (Duhaut & Dimmock, 2002; Duhaut & McCauley, 1996; Noda et al, 
2006). Two recent studies confirmed the existence of a selective incorporation model in 
which the 8 vRNPs are held together by base pairing between packaging regions and by 
physical multi-interactions among the eight RNPs (Fournier et al, 2012; Noda et al, 2012). 
According to Fournier et al., the segment 4 (HA) is in the centre of the star-like structure 
(Figure 10 A) often observed by electron microscopy (Noda et al, 2006). However, Noda et 
al. concluded that the positioning of the eight vRNPs was not consistent. Specific packaging 
signals have been localised at the end of all eight vRNA segments in the non coding 
sequences and sometimes on terminal coding regions (reviewed in (Hutchinson et al, 2010)). 
However, incomplete or non-infectious particles may be formed. These particles called 
“defective interfering (DI)” are defined as particles without critical genomic material 
necessary for functionality. 
The assembly of influenza virions is one of the least well-understood steps of the 
viral life cycle. The M1 protein, as well as binding to the nuclear vRNP complex, can also 
associate with lipid membranes, suggesting that M1 plays a key role in assembly by 
recruiting newly synthesised genomes to the assembly site at the plasma membrane 
(Schmitt & Lamb, 2005). After synthesis, haemagglutinin and neuraminidase are 
glycosylated and transferred to the Golgi apparatus and eventually directed to the virus 
assembly site (Barman et al, 2001). It is thought that completed influenza virions selectively 
bud from lipid raft domains that serve as a virus assembly platform (Scheiffele et al, 1999). 
M1 protein was initially thought to be the driving force for viral budding. However, it 
has recently been suggested that haemagglutinin, neuraminidase and M2 are also critical in 
this process (Chen et al, 2007; Gomez-Puertas et al, 2000; Rossman et al, 2010). According 
to a recent model, M1 binds to the cytoplasmic tails of haemagglutinin and neuraminidase 
where it can then polymerize and form the interior structure of the virion. The interaction 
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between M1 and the cellular factor RACK1 (Reinhardt & Wolff, 2000) which involves proline 
16 of M1 is essential for influenza virus release and depletion of RACK1 inhibit virus release 
(Demirov et al, 2012). M1 would also serves as a docking site for the recruitment of the viral 
RNPs and may mediate the recruitment of M2 to the budding site. A possible role of M2 
would be to stabilize the budding site, possibly enabling the polymerization process of the 
matrix protein and the formation of virions. M2 also induces scission of the host cell 
membranes at the base of the virion which mark the end of the budding process (reviewed 
in (Rossman & Lamb, 2011)). 
 
Once formed, the virions leave the cell to find and infect new host cells and reinitiate 
the replication cycle. However, the new virions may re-attach to the cell because of 
interactions of their own haemagglutinins with cellular sialic acid receptors. The viral 
neuraminidase protein cleaves the terminal sialic acid molecules from the surrounding 
receptors to prevent the aggregation of virions at the surface of the cell and ensure proper 
release of the progeny virions. This activity is prevented by two approved drugs: Oseltamivir 
(Tamiflu) and zanamivir (see following paragraph). NA is also required for the cleavage of 
sialic acid from newly synthesised glycosylated HA molecules on progeny virions which 
would otherwise aggregate. As a consequence, a correct balance between HA and NA is 
required for these molecules to function together efficiently. 
Finally, cleavage of the haemagglutinin molecules by extracellular proteases is 
required for infectivity of viral particle. HA cleavage site usually contains one basic amino 
acid and cleavage occurs exclusively by trypsin-like host protease, restricting viral replication 
to sites where the protease is secreted (i.e. the epithelium of the respiratory tract). 
However, highly pathogenic strains such as HPAI H5N1 or H7N7 posses multiple basic 
amino-acids at their HA cleavage site which is recognised by furin-like proteases in the trans-
Golgi (Garten & Klenk, 1999), expanding the tropism of the virus to multiple organs.  
It is estimated that the virus requires about 8 to 10 hours to undergo one round of 
replication. 
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1.5.8 Pathogenicity of influenza and immune response 
The pathogenesis of influenza virus in humans depends on a combination of host 
and viral factors. Among the viral factors that contribute in virulence, the surface 
glycoproteins HA and NA, the polymerase complex, and the non-structural protein NS1 are 
particularly important (Neumann & Kawaoka, 2006). 
Following detection of pathogens, the host expresses antiviral factors such as 
inflammatory and antiviral mediators, known as cytokines, to defend against infection. 
Interferons (IFN) play an essential role in host defence against influenza virus. A large 
number of transcripts are induced after IFN stimulation. Mx expression is normally silent but 
rapidly induced by type I (/) or type III () interferons. Initially, Mx proteins were 
discovered in a mouse strain highly resistant to influenza A virus infection (Horisberger et al, 
1983; Lindenmann, 1964). Avian influenza strains have been shown to be more sensitive 
than human viruses, and this was influenced by the viral NP in vRNP reconstitution assays 
(Dittmann et al, 2008; Zimmermann et al, 2011). Thus, Mx proteins provide a barrier to 
avian-origin influenza to cross into humans. Recently, a new family of IFN induced restriction 
factors have been isolated in a large scale human siRNA screen performed against influenza 
replication. IFITM1, 2 and 3 proteins restrict influenza A viral replication at an early step, but 
are also able to restrict replication of other viruses such as dengue virus or West Nile virus 
(Brass et al, 2009; Everitt et al, 2012). 
However, viruses have evolved to deploy anti-interferon strategies. Influenza A NS1 
is a multifunctional protein whose major role is to inhibit activation of the cellular innate 
immune response (reviewed in (Hale et al, 2008)). Counteracting the host's innate immunity 
at an early phase of infection is probably an important step for the efficient replication of 
avian virus in human cells (Hayman et al, 2007) and a virus deleted for NS1 expression is 
non-pathogenic in an immune-competent host (Garcia-Sastre et al, 1998). 
Following infection and replication, a vigorous immune response is induced which 
usually results in the formation of neutralizing antibodies, mainly produced against the two 
viral surface proteins, HA and NA. Those antibodies are the major determinant for a 
protective immune response (Suarez & Schultz-Cherry, 2000). Host immune pressure is the 
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driving force in selecting mutant viruses with amino acid mutations in HA and NA, a process 
referred as "antigenic drift". 
 
1.5.9 Vaccines and drugs 
Since influenza virus causes major medical and veterinary problems, it is important 
that we have ways to control its spread within and between hosts. 
The most direct mean of preventing virus entry is to intercept the virus with 
neutralizing antibodies before it reaches the cell. Vaccines against influenza virus were 
developed during the 1930s and vaccination is recognised as one of the most important way 
to prevent and control influenza infection. The seasonal vaccine contains antigens of a 
circulating influenza A and B. Because influenza virus undergoes antigenic drift, the surface 
proteins HA and NA are highly variable and change yearly. This means that the composition 
of the vaccines directed against these variable surface antigens must be updated every year. 
In addition, vaccine production is a time consuming process and is not adapted to pandemic 
events. When the pandemic 2009 emerged, several months were necessary before a 
vaccine was produced and safety trials performed. This delay of several months from start 
of vaccine production to administration could have had devastating results but thanksfully 
the virus was not as virulent as initially feared. 
There is a great need for the development of compounds that have therapeutic 
efficacy in treating influenza disease, especially when caused by the highly pathogenic 
strains. 
So far, there are only four approved drugs used for the treatment of influenza illness. 
They are targeting viral proteins M2 or NA. Amantadine and rimantadine are two M2 ion-
channel inhibitors specific for influenza A virus. By blocking acidification of the incoming 
viruses, they prevent the release of the vRNPs into the cytoplasm (Pinto & Lamb, 1995). 
Oseltamivir (Tamiflu) or zanamivir (Relenza) prevent the release of the newly produced 
virions from the infected cell by targeting the neuraminidase activity. Oseltamivir and 
zanamivir are active against both influenza A and B viruses (Gubareva et al, 2000). In 2008-
2009, almost 100% of the seasonal influenza H1N1 viruses circulating in the United States 
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were resistant to oseltamivir, and all isolates of the H3N2 viruses were resistant to 
adamantanes (Lackenby et al, 2008; Moscona, 2009; Regoes & Bonhoeffer, 2006). The rapid 
spread of drug resistant strains is a major concern and highlights the urgent need for new 
antiviral drugs. 
The viral RNA polymerase represents a promising drug target due to its activities that 
are distinct from those of the host cell. Favipiravir, known as T-705, negatively affects the 
synthesis of influenza viral RNA, but not cellular DNA or RNA by acting as a pseudopurine or 
a pseudopurine nucleoside or nucleotide (Furuta et al, 2002). T-705 is effective against 
H1N1, H2N2, H3N2 influenza A, a mouse adapted H5N1 (Sidwell et al, 2007), and highly 
pathogenic H5N1 viruses in a murine model (Kiso et al, 2010). T-705 is also effective against, 
influenza B and C, and various RNA viruses in cultured cells and mammalian animal models.  
Very recently, a promising compound was identified. Nucleozin induces aggregation 
of NP and inhibits its nuclear accumulation. Viral replication is reduced in vitro and nucleozin 
protects mice against lethal doses of avian influenza H5N1 (Kao et al, 2010). This compound 
was also identified in another study published few months later (Su et al, 2010). More small 
compounds library screens identified interesting molecules. Among then, BPR3P0128 might 
target cellular factors involved in influenza polymerase cap snatching mechanism (Hsu et al, 
2011). Another study showed that compound BPR1P0034 might target the viral uncoating 
step or vRNP nuclear import (Shih et al, 2010). Very recently, an in silico screen identified 
potential inhibitors of influenza A PB1-PA interaction (Muratore et al, 2012) and inhibition 
of influenza B replication was also observed with one of the small molecule inhibitors. 
Discovery of new molecules effective against influenza infection is a very active field and 
new drugs will hopefully become available within the next years. 
 
1.6 Direct transmission of an avian influenza virus to humans 
As a consequence of the complex interplay between virus and host factors at various 
point of its life cycle, influenza A has evolved toward host specific mechanisms of infection 
leading to genetic divergence between avian and human strains. As a consequence, strict 
influenza species specificity is usually observed. One of the few notable exceptions is the 
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H5N1 HPAI avian strain that crosses the species barrier and can lead to deadly human 
infection. This paragraph will also focus on two other examples of avian influenza strains 
that can directly infect humans: H9N2 and H7N7. 
 
1.6.1 Avian H5N1 outbreaks 
Until 1997, there were only a handful of rare cases of direct human infection with 
avian influenza viruses, and as a consequence, avian influenza viruses were not considered a 
threat to human health. Instead, it was thought that avian influenza virus could only 
transform into viruses that infected humans after reassorting their genomes in an 
intermediate hosts such as the pig. However, antibodies to avian influenza viruses had been 
reported in humans in Southern China (Shortridge, 1988), suggesting the possibility of 
human exposure to avian influenza viruses in that part of the world which is regarded as an 
epicentre for the evolution of novel influenza viruses. 
But in 1997, precisely in Southern Asia, highly pathogenic avian influenza A viruses of 
the H5N1 subtype that circulated in chicken in Hong Kong since 1996 were responsible for 
18 human infections. Six of the affected patients died. The viruses isolated from humans 
and chickens were genetically similar (Claas et al, 1998; Suarez et al, 1998; Subbarao et al, 
1998) in all the eight segments which were clearly derived from avian influenza A viruses. 
This was the first identified example of an avian influenza virus capable of infecting humans 
that did not acquire genes from an already established human influenza virus. The receptor 
binding specificity of the H5N1 viruses isolated was characteristic of avian rather than 
human influenza viruses, indicating that receptor preference was not sufficient to prevent 
these avian influenza viruses from infecting human hosts (Matrosovich et al, 1999). Not only 
had H5N1 virus crossed the species barrier to humans but it was also highly lethal for 
humans. The mass culling of poultry in Hong Kong stopped the outbreak.  
However, H5N1 HPAI precursors continued to circulate in ducks and geese and were 
repeatedly isolated from poultry in Southern China and Vietnam. During the 2003-2004 
season, H5N1 viruses reemerged and new avian and human infections were reported almost 
simultaneously across Eastern and Southern Asia, expanding the geographic range of H5N1 
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viruses cases. As of April 2012, there have been 361 cases of human infection with a 
mortality rate of almost 60% (source WHO, April 2012). Since 2003, H5N1 viruses have 
evolved rapidly and formed 2 major clades and multiple subclades based on the HA 
sequence and antigenicity. In 2005, H5N1 caused the death of thousands of migratory 
waterfowl at Qinghai Lake nature reserve in China (Chen et al, 2005; Liu et al, 2005; Olsen et 
al, 2006a), suggesting that infected wild birds could spread the viruses. Between 2005 and 
2007, H5N1 was reported across Asia, Middle East, North and West Africa and Europe. Since 
then, outbreaks in poultry and human cases with high fatality rate have repeatedly been 
reported.  
The extreme virulence of H5N1 in humans has been associated with high virus 
replication in the lungs and a prolonged overproduction of cytokines by the host. 
Each HPAI H5N1 virus infection appeared to result from independent transmission of 
the virus from poultry to humans and the majority of human infections have occurred 
through close contact with infected animals. To date, human-to human transmission has 
been extremely rare (Butler, 2006; Ungchusak et al, 2005) and aerosol transmission of H5N1 
viruses in mammalian models such as pigs, ferrets or guinea-pigs has been for a long time 
inefficient (Choi et al, 2005; Maines et al, 2006; Steel et al, 2009; Yen et al, 2007). However, 
in 2012, two groups (R. Fouchier and Y. Kawaoka) independently reported successful aerosol 
transmission in ferrets of viruses harbouring HPAI H5 HA in two highly controversial 
publications (Herfst et al, 2012; Imai et al, 2012). Thus, it was demonstrated that acquisition 
of mutations can allow highly pathogenic avian H5 HA containing viruses to transmit 
between mammals which could potentially lead to a devastating pandemic.  
 
1.6.2 Another source of concern: H9N2 subtype 
However, H5N1 HPAI viruses are not the only source of concern. Avian influenza 
H9N2 subtype is a remarkable member of the influenza A viruses as it can infect and 
replicate not only in chicken, ducks or pigs but also in humans.  
In North America, where the first avian influenza H9N2 virus was isolated in 1966, 
this influenza subtype is now present in shorebirds and ducks. Outbreaks caused by H9N2 
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viruses occurred in several Asian countries but also across the Middle East and Europe 
(reviewed in (Alexander, 2007)). Various avian species have been affected such as domestic 
ducks, chicken, turkeys, pheasants, ostriches, or quail. H9N2 infections have now become 
endemic in poultry in many countries. Sporadic human infections by H9N2 occurred in South 
East China since 1998 but causing only mild disease illness (Butt et al, 2005; Cheng et al, 
2011; Gou et al, 2000; Guo et al, 1999; Guo et al, 2002; Lin et al, 2000; Peiris et al, 1999). In 
addition, serological studies suggest that more cases of H9N2 infection might have occurred 
in humans (Butt et al, 2005; Jia et al, 2009; Lu et al, 2008; Peiris et al, 1999; Wang et al, 
2009a). Infection of pigs by H9N2 subtypes have also been reported (Cong et al, 2007; Peiris 
et al, 2001; Shi et al, 2008; Xu et al, 2004; Yu et al, 2008) and mice experimentally infected 
with some H9N2 strains replicate efficiently without prior adaptation, resulting in severe 
disease (Hossain et al, 2008). Finally, H9N2 viruses from various avian origins can replicate in 
ferrets (Wan et al, 2008). No cases of human to human transmission were observed, but the 
possibility of limited human to human transmission cannot be absolutely excluded (Butt et 
al, 2005). However, experimental H9N2 transmission in ferrets by direct contact was 
observed for two out of the five isolates used by Wan and colleagues in their study (Wan et 
al, 2008). Human infection may be explained by the capacity of some H9N2 viruses to bind 
to receptors that are found on human upper respiratory tract (Matrosovich et al, 2001). The 
endemicity of H9N2 viruses in many avian species, their ability to replicate in human and 
their receptor specificity are making this strain as likely to cause a potential pandemic as 
avian H5N1 viruses if adaptive mutations occur. Thus, the WHO considers H9N2 viruses as a 
potential pandemic threat. 
 
1.6.3 H7N7 
Another avian influenza subtype that has been found in humans is H7N7. An HPAI 
H7N7 outbreak started in winter 2003 in poultry in The Netherlands. The huge majority (86 
out of 89) of humans infected by H7N7 had reported close contact with infected animals. 
Interestingly, H7N7 infection in humans caused predominantly conjunctivitis with fewer 
cases of influenza-like symptoms, suggesting that the tropism of this strain was the eyes 
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rather than the respiratory tract (Koopmans et al, 2004). H7N7 was responsible for one 
fatality in this outbreak. There was no evidence of person-to-person transmission of the 
virus and about 250 humans were exposed (Enserink, 2004). 
 
H5N1, H9N2 and H7N7 human infections demonstrated that some avian influenza 
viruses could infect humans and cause disease. Fortunately human-to-human transmission 
of these avian viruses has not yet been reported and such inter-species transmission is 
relatively infrequent as influenza viruses must overcome substantial host range restriction 
by mutation or reassortment with human adapted circulating viruses. 
 
1.7 Evolution of influenza viruses 
Influenza virus evolution and species jump is driven by two mechanisms: the 
reassortment of viral gene segments in a cell infected by two different influenza strains 
(antigenic shift) or the accumulation of point mutations in the viral genome (antigenic drift). 
When changes in the viral antigens HA and NA are sufficient in comparison with the 
previously circulating virus, a new pool of susceptible hosts can be infected with the new 
viral strain and this explains why epidemics occur yearly. Changes in many of the viral genes 
can also allow a strain to jump the species barrier. 
 
1.7.1 Genetic reassortment 
Since influenza A genetic material exists as separate segmented units, the viruses 
have the ability to reassort genes in cells infected with two different influenza viruses. If the 
genetic reassortment occurs with viruses from other species, it may result in the emergence 
of new pandemics. The 1957 Asian (H2N2), 1968 Hong Kong (H3N2) and 2009 "swine flu" 
(H1N1) pandemic viruses originated by reassortment. 
The mechanisms leading to genetic reassortment are not understood. In the pig 
trachea, epithelial cells contain both 2,3 and 2,6 linked sialic acid receptors, explaining 
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why pigs are susceptible to both human and avian viruses and are thought by some to be a 
"mixing vessel" for avian and human viruses, which might give rise to a pandemic strain (Ito 
et al, 1998). However, there is no evidence that the 1957 and 1968 pandemic viruses were 
generated in pigs.  
 
1.7.2 Adaptation 
The viral RNA-dependent-RNA-polymerase is notorious for its lack of proof-reading, 
resulting in errors in the produced genetic copies, facilitating high mutation rates and 
evasion of immune surveillance (Drake, 1993). The mutation rate for influenza A is 
estimated at one point mutation every 1.5x105 nucleotides (Buonagurio et al, 1986). 
Because of this mutation rate, virions produced after a round of replication represent a 
population of genomes (a quasispecies) rather than a homogenous population. Mutations 
that are detrimental to the virus are not propagated, but changes that confer an advantage 
to the virus over its parental strain can be selected for. This genetic diversity allows 
plasticity within the viral population, for example escape from immune pressure, emergence 
of drug-resistant virions or adaptation to a new host environment.  
However, while the rate of mutation observed on a nucleotide level is similar 
between both avian and human influenza strains, avian strains show more conservation on 
the amino acid level (Chen et al, 2006; Gorman et al, 1990), suggesting an optimal 
adaptation of influenza A in birds, whereas a selective pressure on the virus to adapt in 
mammals explains the accumulation over time of amino acid changes. 
Approaches to identify mutations important for host adaptation include: 
- Large scale computational approach and alignment of sequences for each gene, 
- Analysis of mutations which arise when a virus replicates sufficiently in humans to 
establish an infection, 
- Sequence analysis of genomes obtained after serially passaged viruses in animal 
models. 
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Several influenza virus genes are involved in mediating adaptation to a specific host 
but both the viral polymerase complex and NP are considered important determinants of 
host adaption. PB1, PB2, PA and NP all harbour amino acids that appear to be characteristic 
of the species in which the virus was isolated and thus might be involved in host adaptation 
(reviewed in (Naffakh et al, 2008)). A list of the most frequently identified host signatures 
that differ between avian and human viruses and residues selected during passage of 
influenza viruses in mammalian models is summarised in Chapter 9: Appendix, page - 224 -. 
 
1.7.2.1. PB2 627 
Many studies have identified the viral protein PB2 as a strong determinant of 
influenza host range in tissue culture and mice (Almond, 1977; Fouchier et al, 2004; Shinya 
et al, 2007), reviewed in (Naffakh et al, 2008). In 1977, Almond identified the PB2 segment 
as being responsible for the restriction of the avian influenza strain fowl plague virus 
Dobson (FPV-Dobson) in mammalian cells (Almond, 1977). A particularly remarkable host-
associated genetic signature is located at position 627 of PB2. With the notable exception of 
pandemic 2009 H1N1, influenza A viruses circulating in humans generally have a lysine 
residue (rarely an arginine), whereas avian viruses have a glutamic acid. In mammalian cells, 
a reassortant virus that derived its PB2 from an avian influenza strain and remaining genes 
from a human influenza strain was restricted in replication (Clements et al, 1992). By 
passage through mammalian cells, this restricted virus acquired the ability to replicate by 
acquisition of the PB2 E627K mutation (Subbarao et al, 1993). The 1918 pandemic virus had 
a lysine residue at position 627, although the PB2 gene was otherwise avian virus-like, 
suggesting that selection of this adaptive mutation may have occurred early in the 
emergence of the Spanish flu pandemic (Taubenberger et al, 2005). H5N1 viruses isolated 
from humans in Hong Kong in 1997 differed at this position, and there was a strong 
association of a lysine at position 627 with fatal outcome in mice (Gao et al, 1999; Hatta et 
al, 2001) whereby the presence of a lysine led to more aggressive viral replication in a 
variety of organs in the infected animals (Shinya et al, 2004). However, the correlation in the 
outcome of infection with H5N1 in human cases in 1997 and the nature of residue 627 was 
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less clear (Gao et al, 1999). The 627K residue was observed in the H5N1 virus isolate 
obtained from the two dead leopards (but not from the two dead tigers) infected in 
Thailand in 2003 (Keawcharoen et al, 2004) and from most of the H5N1 isolates that killed 
tigers in 2004 (Amonsin et al, 2006). 
However, the molecular mechanism by which the nature of residue 627 on PB2 
modulates replication of avian influenza viruses in human cells is not understood. The 
attenuated replication of avian influenza virus at cooler temperature (33°C) in a 
minigenome assay or in the context of infected cell culture was somewhat relieved by the 
E627K mutation (Hatta et al, 2007; Massin et al, 2001). In addition the formation of the RNP 
complexes from avian virus -derived polymerase was impaired in human cells but restored 
by the E627K mutation (Labadie et al, 2007; Mehle & Doudna, 2008; Rameix-Welti et al, 
2009). In particular, interaction between NP and PB2 within the vRNP was several times 
reported to depend on the nature of residue 627. A glutamic acid appears to decrease the 
association between PB2 and NP in mammalian cells but not in avian cells. However, it 
remains to be clarified if this observation is not simply a direct consequence of the 
polymerase activity: a less active polymerase will produce less vRNAs and as a consequence, 
less vRNPs can be formed. It was also proposed that the “627 domain” could be involved in 
RNA binding (Kuzuhara et al, 2009). 
The crystal structure of a domain of human-origin influenza PB2 containing residue 
627 revealed a previously unobserved fold, with residue 627 exposed at the surface of the 
domain, lying in the middle of a positively charged patch. Substitution K627E modifies the 
electrostatic surface potential of the 627-domain resulting in the disruption of the positive 
patch (Figure 11), possibly modulating interactions between PB2 and host factors. The 627 
substitution did not change the overall structure of the domain (Tarendeau et al, 2008). 
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            “Human” 627K               “Avian” 627E 
 
Figure 11: Effect of the 627 amino acid nature on the electrostatic surface potential of the 
PB2 627-domain. A Crystal structure of the PB2 domain (amino acids 538-693) harbouring 
the human signature (lysine 627), and B with the avian signature (glutamic acid 627). Red, 
blue and white indicate negative, positive and neutral potentials, respectively. The 
electrostatic surface reveals that the K627E substitution disrupts a prominent basic, 
positively-charged surface patch which also includes residues Lys586, Arg589, Arg597, 
Arg630 and Arg646, from (Tarendeau et al, 2008). 
 
However, the nature of residue PB2 627 (E or K) does not always correlate with the 
virulence of the virus in humans or in animal models. Several H5N1 isolates presenting a 
glutamic acid at position 627 were lethal for mice (Gao et al, 1999; Katz et al, 2000) or 
ferrets (Govorkova et al, 2005; Zitzow et al, 2002). In addition, several human H5N1 viruses 
such as A/Vietnam/1204/04 are highly pathogenic despite having a glutamic acid at position 
627 (Maines et al, 2005). With the exception of the virus isolated from the only fatal case, a 
glutamic acid was present in PB2 from the avian H7N7 strain responsible for the outbreak in 
the Netherland in 2003 (de Wit et al, 2010; Fouchier et al, 2004), and H9N2 viruses 
responsible for human infection in South East Asia have a glutamic acid at position 627. 
Finally, the 2009 swine origin pandemic H1N1 virus (pH1N1), which efficiently replicates and 
transmits in humans and pigs (Brookes et al, 2010) retains the avian signature E627 in PB2. 
Instead it appears that two other PB2 residues S590 and R591 are responsible for efficient 
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activity of the pandemic virus polymerase in human cells (Mehle & Doudna, 2009). Based on 
the crystal structure of PB2 domain 538-693, those residues lie very close to amino acid 627 
(Tarendeau et al, 2008). R or K at position 591 modify the surface charge of the domain that 
seems required for polymerase activity in human cells, and a K changes the shape of the 
domain (Mehle & Doudna, 2009; Yamada et al, 2010). Addition of the 627K mutation to a 
virus containing the SR polymorphism did not result in a significant replicative advantage, 
increased virulence or a greater polymerase activity in a polymerase assay suggesting that 
these residues work in the same way (Herfst et al, 2010; Jagger et al, 2010; Mehle & 
Doudna, 2009; Zhu et al, 2010). 
Interestingly, whilst it is apparent that E627K is strongly selected for when an avian 
virus replicates in mice or humans (de Jong et al, 2006; Hatta et al, 2001; Puthavathana et al, 
2005), in equine or swine viruses, 627K does not necessarily predominate (Shinya et al, 
2007), see also Chapter 5, page - 150 -. 
 
Cellular factors involved in PB2 627K mediated host adaptation and pathogenicity 
still remain poorly understood. Very recently, the DEAD box RNA helicase DDX17/p72, which 
has been identified among other polymerase interacting proteins (Mayer et al, 2007), was 
shown to specifically increase polymerase activity of 627K containing polymerase, facilitate 
627K virus transcription and replication in human cells (Bortz et al, 2011). However, the 
mechanism is unclear as DDX17/p72 interacts with both PB2 627K and 627E. Thus, 627-
dependent binding of any cellular component has yet to be demonstrated. 
 
1.7.2.2. PB2 701 
In several H5N1 viruses isolated from humans or other mammals, the PB2 gene 
contains 627E but has a different humanizing mutation, D701N. Interestingly this change 
was one of two mutations within the polymerase complex genes that emerged during 
adaptation of an avian H7 virus to mice. In contrast to its parental strain SC35 (HPAI H7N7), 
the mouse adapted SC35M replicates more efficiently in mammalian cells (Gabriel et al, 
2007; Gabriel et al, 2005). The adaptive mutations PB2 D701N have been demonstrated to 
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enhance nuclear import of PB2 by importin- in mammalian cells but not in avian cells 
(Gabriel et al, 2007; Gabriel et al, 2008). As influenza virus genome replication takes place in 
the host cell nucleus, it is essential that the viral ribonucleoprotein (RNP) complexes gain 
efficient entry through the nuclear pore complex by interacting with transport proteins such 
as the importins (Wang et al, 1997). Residue 701 lies in the NLS domain of PB2, which 
contains a classical bi-partite nuclear localisation sequence 736-RKRX12KRIR-755. Thus, PB2 
D701N mutation can adapt an avian virus to human cells likely by affecting the interactions 
between PB2 and human importin  (Gabriel et al, 2011; Tarendeau et al, 2007; Tarendeau 
et al, 2008) or by modulating influenza polymerase activity in a host-specific manner, 
independently of the role of importins in nuclear transport (Resa-Infante et al, 2008). 
Finally, 701N can compensate for the absence of 627K and restore transmissibility between 
guinea-pigs (Steel et al, 2009), expand the host range of avian H5N1 to mice and humans (de 
Jong et al, 2006; Li et al, 2005) and contributed to the efficient transmission of a duck-origin 
H5N1 strain in guinea pigs (Gao et al, 2009). 
 
1.7.2.3. Other mammalian adaptive mutations 
Other known mammalian adaptive mutations include the T271A mutation. While a 
threonine (T) is usually located at this position in avian influenza viruses, an alanine (A) is 
found in human viruses (Chen et al, 2006; Finkelstein et al, 2007; Miotto et al, 2008; Miotto 
et al, 2010). 271A, present in 2009 pH1N1 PB2, enhanced the function of an avian-origin 
influenza polymerase in human cells but not in avian cells, increased virus growth in human 
cells, and is in part responsible for the high polymerase activity of the 2009 pH1N1 virus 
polymerase (Bussey et al, 2010). The PB2 E158G mutation was obtained by passage of 2009 
pH1N1 virus in mice. Although 158G has never been reported in any PB2 sequences, the 
presence of this residue increased polymerase activity, virus titers, morbidity and mortality 
in a mouse model (Zhou et al, 2011). Introduction of the E158G mutation in an avian-origin 
polymerase increases the polymerase function to similar levels to what is seen with the 
E627K mutation in human cells and also increase polymerase activity in avian cells (A. 
Cauldwell, Barclay Lab, unpublished results) 
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Pandemic 2009 also lead to the identification of mammalian adaptive mutation on 
the PA subunit. I85, S186, and M336 enhanced the polymerase function of an avian 
influenza strain in human cells. In addition, I85 enhanced viral replication in human cells and 
M336 increased pathogenicity in mice (Bussey et al, 2011).  
 
1.8 Reverse genetics 
A number of systems to study influenza replication, transcription and expression of 
influenza RNAs have been developed since the end of the 90’s. The first report, from Luytjes 
et al. showed that in vitro reconstituted vRNP complexes made of synthetic influenza virus 
RNA containing a chloramphenicol acetyltransferase (CAT) gene and purified polymerase 
proteins and NP could produce CAT activity in cells infected with a helper virus (Luytjes et al, 
1989). It was then shown that functional vRNPs can be reconstituted in cells, providing that 
PB1, PB2, PA and NP are supplied in trans from expression plasmids, vaccinia virus, or simian 
SV40 recombinant viruses, and support the expression and replication of a transfected 
influenza RNA template previously transcribed in vitro (Biswas & Nayak, 1994; de la Luna et 
al, 1993; Huang et al, 1990; Kimura et al, 1992; Mena et al, 1994). The development of 
plasmid-based reverse genetics techniques has revolutionised the study of influenza and the 
virology field in general. The rescue of influenza virus entirely from cDNA proved to be 
challenging due to the fact that eight negative sense vRNA segments constitute the genome. 
In 1996, Pleschka et al. constructed a plasmid that contained the influenza A NA segment in 
a negative sense orientation flanked at the 5’ end by a human RNA polymerase I promoter 
and at the 3’ end by a ribozyme sequence. The human RNA polymerase I enzyme, which 
normally transcribes ribosomal RNAs, can direct synthesis of influenza vRNA because it 
produces molecules which are not capped and without poly(A) tail, features which are also 
absent from influenza vRNA. The promoter initiates transcription precisely at a defined 
sequence position and viral 3’ terminus is achieved with cleavage by the ribozyme to ensure 
exact 3’ ends to the vRNA. Authentic 5’ and 3’ vRNA ends are critical for transcription and 
replication. It was previously published that influenza vRNP is the minimal component 
required for transcription and replication of the vRNA segments (Huang et al, 1990). 293 
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cells were co-transfected with four plasmids encoding the three influenza polymerase 
proteins and NP, together with the NA reporter plasmid. The NA vRNA segment was 
transcribed by the cellular RNA polymerase I enzyme and a reconstituted active vRNP was 
formed. This was followed by infection with a helper influenza virus to provide structural 
proteins and progeny virions containing the recombinant NA gene were produced (Pleschka 
et al, 1996). 
Successful recovery of influenza A viruses entirely from plasmids was finally achieved 
three years later (Fodor et al, 1999; Neumann et al, 1999). Plasmids encoding each of the 
eight vRNA gene segments flanked by the human RNA polymerase I promoter and either a 
mouse RNA polymerase terminator (Neumann et al.) or the Hepatitis Delta Virus (HDV) 
ribozyme sequence (Fodor et al.) were co-transfected in 293-T cells (Neumann et al.) or 
Vero cells (Fodor et al.) with four plasmids expressing the viral polymerase and NP. The 
RNPs were transcribed and replicated resulting in the production of infectious progeny 
virions. This system allows one to engineer multiple mutations into any gene segments 
simultaneously and is a powerful tool to investigate influenza virus-encoded proteins but 
also promoters, non coding sequences or packaging signals. However, those studies could 
only been done in the context of cells of primate origin due to species specificity of the 
human RNA polymerase I promoter sequence. More recently, the avian polymerase I 
promoter was cloned, allowing the generation of recombinant influenza viruses in avian 
cells (Massin et al, 2005) and comparative studies of the molecular determinants involved in 
virus synthesis or polymerase activity in avian cells and in human cells (Labadie et al, 2007; 
Rameix-Welti et al, 2009). Similarly, RNA Pol I promoters have also been cloned and used to 
establish a reverse genetic system or to study influenza polymerase activity in canine (Wang 
& Duke, 2007) and mice cells (Zobel et al, 1993). Successful recovery of influenza B virus 
entirely from cDNA was published in 2002 (Hoffmann et al, 2002; Jackson et al, 2002). 
Investigation of influenza polymerase activity in cells, the role of each component of 
the vRNP, the consequences of host signatures or the impact of mutations in promoter or 
non coding sequences for example, have largely benefited from the development of the 
plasmid based influenza reverse genetic systems. Since expression of the viral polymerase 
proteins (PB1, PB2 and PA), NP and a negative sense influenza virus RNA in cells is sufficient 
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to support expression and replication of the influenza gene, this replication activity can be 
measured if the influenza gene is replaced by a reporter gene (i.e. CAT, luciferase, GFP). In 
this polymerase assay (or minigenome assay), minigenome refers to the negative sense 
viral-like RNA reporter that is transcribed by the cellular RNA polymerase I and contains the 
reporter gene sequence. An illustration of a polymerase assay is presented in Figure 12. 
 
Figure 12: Influenza polymerase assay. In an influenza polymerase assay, or minigenome 
assay, vRNP complexes are generated in situ in cells by expression of viral polymerase 
proteins (PB1, PB2 and PA) and vRNA coating protein NP together with a negative sense 
viral-like RNA reporter (named minigenome) that has been transcribed by the cellular RNA 
polymerase I from a species-specific RNA polymerase I promoter. The reporter coding 
sequence is flanked by the viral conserved noncoding sequences that are the minimal viral 
promoters required for transcription and replication of viral RNA and bound by the 
heterotrimeric polymerase. Viral replication and transcription of the negative-sense 
minigenome RNA take place in the nucleus and occur only in the presence of a reconstituted 
functional influenza virus polymerase (Pleschka et al, 1996). 
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1.9 Thesis aims 
The aim of this work was to give a better understanding of the molecular basis of the 
host-restriction mechanisms related to the low activity of avian-origin influenza polymerase 
in mammalian hosts. In contrast to HA and NA, the exact role of internal proteins and in 
particular the vRNPs in determining the host range is unclear. 
Many previous experimental and epidemiological observations as well as 
bioinformatic studies suggest that selection for a lysine at position 627 of PB2 is a strong 
determinant of influenza adaptation to humans. The molecular mechanisms responsible for 
the restriction of avian influenza viruses in humans and the reason why restriction is 
overcome by changing the nature of residue 627 on PB2 remain to be understood. In 
Chapter 2, avian-origin influenza polymerase restriction was investigated using a 
polymerase assay performed in heterokaryons formed between avian and human cells. One 
of the conclusions from Chapter 2 is that avian co-factor(s) for avian-origin influenza 
polymerase are absent, different or poorly expressed in human cells. Following this 
conclusion, a functional screen to try to identify avian co-factors for avian-origin influenza 
polymerase was set up and is described in Chapter 3. Little is known about the requirement 
for host cell factors during influenza virus transcription and replication. Identifying these 
host factors is therefore fundamental to understand influenza host range restriction and 
adaptation. The second main lesson from the heterokaryon assay (Chapter 2) is that the 
dramatic enhancement in polymerase activity observed in human cells when a lysine at 
position 627 of PB2 replaces a glutamic acid is probably the result of a stronger interaction 
with a human cellular factor. In Chapter 4, a biochemical approach was used in an attempt 
to isolate PB2 627K human cellular co-factor(s). 
As a supposed “mixing vessel”, pigs have a particular role in influenza ecology. 
Genetic reassortments among avian, human and/or swine influenza virus genomic segments 
have been frequently detected in swine, and thus, pigs are thought to be more susceptible 
to avian influenza infection than other mammals such as humans. Sequence analysis of 
swine influenza isolates reveals that either a lysine or a glutamic acid can be found at 
- 77 - 
 
position 627 of PB2 and influenza evolution in pigs indicates that there is no pressure in pigs 
to mutate position 627. In Chapter 5, a polymerase assay was set up in pig cells in order to 
investigate the ability of avian or human-origin influenza polymerases to support 
replication. The consequences of some known mammalian adaptive mutations on PB2 were 
also investigated in pig cells. 
Genetic and bioinformatics analysis have identified host associated signatures on 
several of the viral genes that are components of the vRNP (Chen et al, 2006; Finkelstein et 
al, 2007; Miotto et al, 2008; Miotto et al, 2010; Naffakh et al, 2008), see Chapter 9: 
Appendix, page - 224 -. The quail-origin influenza isolate A/Quail/Hong Kong/G1/97 (H9N2 
G1) shows all the known avian signatures on its polymerase and NP genes. However, G1 
polymerase can support a good level of expression and replication in mammalian cells, 
which correlates with the fact that viruses from the G1 lineage were responsible for some 
human infection cases. The aim of Chapter 6 was to use G1 polymerase as a model to 
identify new residues involved in mammalian adaptation. 
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Chapter 2. Use of a fusion assay between avian and human cells to 
investigate the avian influenza restriction mechanism in human 
cells 
 
2.1 Introduction 
As presented in Chapter 1, it is well accepted that typical avian influenza viruses do 
not replicate to their maximum capacity in most types of mammalian cells. In tissue culture 
this manifests as an inability to form plaques or to accumulate significant virus yield during 
multiple cycles of replication. To investigate the presence of a restriction factor in human 
cells or the absence of a co-factor to explain the human host range restriction of polymerase 
complexes derived from avian influenza viruses, a replication assay was performed in avian 
and human cell heterokaryons in which two different viral-like RNA reporters were used as 
minigenome for a viral polymerase complex reconstituted from expression plasmids. The 
reporter minigenomes were produced from species-specific polymerase I promoters active 
in the nuclei of the two different cell types. Thus, this assay allowed to simultaneously 
monitor of the ability of influenza polymerase to replicate and transcribe a vRNA molecule 
generated in both avian and human nuclei.  
 
2.2 Results 
2.2.1 Molecular cloning of new reporter plasmids 
In order to measure polymerase activity in human and avian nuclei, two sets of 
species-specific minigenome reporter plasmids were made. These plasmids can be used to 
monitor transcription and expression of firefly luciferase, Renilla luciferase, eGFP or DsRed 
reporter genes from viral-like RNA in avian or human cell. 
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pCk-PolI-Firefly (a gift from Dr L. Tiley) is a minigenome expressing plasmid 
containing the firefly luciferase gene in the negative orientation, flanked by the influenza A 
virus NS gene noncoding regions, a chicken RNA polymerase I promoter and the hepatitis 
delta virus (HDV) ribozyme sequence. The firefly luciferase coding sequence was replaced by 
Renilla luciferase, eGFP or DsRed coding sequences in pCk-PolI. Then, the chicken RNA 
polymerase I promoter sequence was removed and replaced by the human RNA polymerase 
I promoter sequence for each different reporter gene. It is important to note that for each 
minigenome reporter plasmid (firefly, Renilla, eGFP or DsRed), the viral-like minigenome 
segment expressed in avian or human cells is strictly the same. A diagram of the two set of 
minigenome plasmids (avian and human) is presented in Figure 13. 
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Figure 13: Representation of the sets of avian and human Pol I minigenome reporter 
plasmids. A. Coding sequences for Renilla luciferase, eGFP or DsRed were introduced into 
pCK-PolI-Firefly. The obtained plasmids (pCk-PolI-Renilla, pCk-PolI-eGFP, pCk-PolI-DsRed) 
were then digested to replace the avian polymerase I (Pol I) promoter sequence (Massin et 
al, 2005) shown in red, by the human polymerase I promoter sequence (Pleschka et al, 
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1996) shown in grey, to generate the set of human Pol I minigenome reporter plasmids. B. 
Representation of the RNA products synthesised by the cellular RNA polymerase I and by 
the influenza polymerase complex in a polymerase assay. 
 
All the reporter plasmids were tested and validated in a minigenome assay in avian 
(DF-1) or human (293T) cells (data not shown). 
 
2.2.2 Human cells do not support efficient replication of avian influenza polymerase 
complex. 
Activities of polymerase complexes from an avian or a human origin influenza A virus 
were compared in human (293T) cells. 50-92 is an H5N1 highly pathogenic avian virus (HPAI) 
isolated during an outbreak in domestic birds in Norfolk, England, in 1991 
(A/Turkey/England/50-92/91) (Wood et al, 1994). 50-92 is a typical avian influenza strain, 
and unlike modern genotype Z-like H5N1 viruses, there is no evidence that humans or other 
mammals were infected by the 50-92 virus or its derivatives during the HPAI outbreak. The 
polymerase activity of 50-92 virus was previously shown to be restricted in human cells 
(Howard et al, 2007). Victoria is a representative human H3N2 circulating strain isolated in 
Australia in 1975 (A/Victoria/3/75). Plasmids encoding the Victoria polymerase complex 
were originally obtained from Dr Thomas Zurcher and Professor Juan Ortin. As described in 
chapter 1.7.2.1, PB2 residue 627 plays a key role in influenza mammalian adaptation. Amino 
acid E627 on 50-92 PB2 was mutated into a lysine and conversely, K627 on Victoria PB2 was 
mutated into a glutamic acid. 
Human 293T cells were cotransfected with plasmids expressing PB1, PB2 (wt or 
mutated at position 627), PA, and NP from 50-92 or Victoria virus, together with the firefly 
luciferase minigenome plasmid pHuman-PolI-Firefly. Firefly luciferase activity was measured 
at different times post transfection (Figure 14). 
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Figure 14 : Viral transcription/replication of a firefly minigenome by avian origin (50-92) or 
human origin (Victoria) viral polymerase complexes in human cells (293T). Plasmids 
encoding the PB1, PB2, PA and NP proteins derived from 50-92 (squares) or Victoria 
(triangles) viruses were cotransfected together with reporter plasmid pHuman-PolI-Firefly in 
human 293T cells. Activity of 50-92 with “human” signature (627K) on PB2 and Victoria with 
the “avian” signature (627E) are represented with dotted lines. At various times post-
transfection, cells were lysed and firefly luciferase activity was measured. Results are 
expressed as the mean of duplicate samples from one experiment that is representative of 
two independent experiments. RLU: relative light units. 
 
The avian influenza virus-derived 50-92 polymerase complex did not replicate 
efficiently in human cells, but polymerase activity was dramatically increased (by 2 log10) 
when the “human” signature 627K was introduced into the PB2 protein. Conversely, the 
human virus-derived Victoria polymerase showed robust activity in human cells, but 
introduction of the “avian” signature 627E on PB2 resulted in a strong reduction in activity 
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(more than 1 log10). These results are in agreement with previous studies showing reduced 
activities of polymerase complexes from avian viruses in mammalian cells and the 
modulating role of PB2 amino acid 627 (Naffakh et al, 2000). This effect was previously 
shown not to be due to a lower expression or stability of PB2 627E protein (Labadie et al, 
2007; Mehle & Doudna, 2008; Rameix-Welti et al, 2009). 
 
The molecular basis for the low efficiency of avian polymerases (or the PB2 K627E 
mutated human polymerases) in mammalian cells is not yet clear. To determine if this is due 
to the presence of a restriction activity or to the absence of an essential cofactor, we aimed 
to fuse avian cells with human cells in order to monitor activity of the avian virus 
polymerase complex in the presence of factors from both cell types. 
 
2.2.3 Fusion of avian and human cells mediated by expression of measles virus glycoproteins 
To this end, we tested the ability of the Measles virus fusion protein (F) and 
haemagglutinin (H) to induce fusion between DF1 (avian) and 293T (human) cells. Plasmids 
encoding the F and H proteins (a gift from Dr M. Pizzato) were transfected into either 
human or avian cells while a plasmid encoding the eGFP was transfected into the other cell 
type to monitor cell fusion. As shown in Figure 15 (panel C), DF1 cells did not fuse together, 
which is likely explained by the absence of a receptor for Measles virus at the surface of 
avian cells (Escoffier & Gerlier, 1999). As a consequence, there was no fusion between 
human and avian cells when F and H proteins were expressed from human cells (panel F). 
However, when DF1 cells were expressing the two measles virus proteins, an efficient fusion 
with human cells was observed (panel I). Finally, 293T cells were very efficiently fused 
together when expressing F and H Measles proteins (panel L). 
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Figure 15: Efficient fusion between avian (DF1) and human (293T) cells was obtained with 
Measles F and H fusogenic proteins. Three hours after transfection of plasmids encoding 
Measles F and H proteins in one cell type and an eGFP expressing plasmid in the other cell 
type, cells were detached and mixed (ratio 1:1). 24 hours later, cell fusion was monitored 
visually using eGFP expression for the formation of syncitia with a magnification of X10. (A, 
D, G and J) cells transfected by Measles F and H expression plasmids. (B, E, H and K) cells 
transfected by the eGFP expression plasmid. (C) DF1 cells expressing eGFP were mixed with 
DF1 cells expressing Measles F and H proteins. (F) DF1 cells expressing eGFP were mixed 
with 293T cells expressing Measles F and H proteins. (I) 293T cells expressing eGFP were 
mixed with DF1 cells expressing Measles F and H proteins. (L) 293T cells expressing eGFP 
were mixed with 293T cells expressing Measles F and H proteins.  
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To form cell hybrids between DF1 and 293T cells, Measles glycoproteins F and H 
must be expressed from DF1 cells, as those cells do probably not express Measles receptors. 
Thus, Measles protein F and H can be use to produce heterokaryons between avian and 
human cells. 
 
2.2.4 A positive co-factor for avian influenza polymerase complex in avian cells can 
complement avian polymerase function in human cells 
A minigenome assay was performed in hybrid cells formed between DF1 and 293T 
cells using the avian-origin 50-92 polymerase complex. In this assay, both types of cells 
expressed a species-specific minigenome reporter (Figure 16). If a dominant negative factor 
present in human cells were responsible for the restriction of activity, the reporter signal 
from both human and avian nuclei should be inhibited in hybrid cells. Conversely, if a 
positive co-factor were present in avian cells but absent in human cells, the human specific 
reporter expression should increase.  
 
Figure 16: Strategy to monitor the activity of an avian polymerase (50-92) in fused human 
and avian cells. Human cells (restrictive to replication) were transfected with plasmids 
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encoding the 50-92 avian polymerase complex and NP and a plasmid expressing a viral-like 
minigenome containing the firefly luciferase gene (under the human polymerase I 
promoter). These cells, named “293T-Pol”, were fused with avian cells (permissive to 
replication) co-transfected with a second influenza minigenome reporter containing the 
Renilla luciferase gene (under the control of the avian polymerase I promoter) and with the 
Measles F and H proteins expression plasmids. 
 
Human 293T cells were transfected with plasmids encoding 50-92 PB1, PB2, PA and 
NP as well as the negative-sense firefly luciferase RNA minigenome expressing plasmid 
pHuman-PolI-Firefly. For simplicity, those cells will be referred as “293T-Pol” cells. Three 
hours after transfection, 293T-Pol cells were detached and mixed with increasing amounts 
of avian cells that were previously co-transfected with plasmids encoding Measles virus F 
and H proteins and a plasmid expressing a minigenome with negative-sense Renilla 
luciferase RNA under the control of an avian Pol I promoter (pCk-PolI-Renilla). These avian 
cells will be referred as “DF1-R”. Thus, firefly luciferase expression reflected activity of 50-92 
polymerase complex in the nucleus of human cells, whereas the Renilla luciferase signal was 
the result of 50-92 polymerase function in the avian cell nucleus.  
Results in Figure 17 show that firefly luciferase expression (the human reporter) 
driven by the 50-92 avian virus polymerase increased when the 293T-Pol cells were fused 
with increasing numbers of DF1-R cells (light blue bars, top panel). This increase was 
statistically significant. This implies that supplying an avian cellular factor enhanced the 
activity of the avian virus polymerase complex in the human nucleus. In parallel, the 
minigenome present in the avian cell nucleus (Renilla luciferase) was also expressed in a 
dose dependent manner, which proved that human and avian cells were successfully fused 
(see also Figure 18) and that 293T-expressed 50-92 polymerase complex could enter the 
avian nucleus and function there efficiently even though it had been exposed to human cell 
factors. This tends to indicate that there is no dominant inhibitory factor for avian 
polymerase in human cells. As a control, the same assay was performed in parallel but 
fusing 293T-Pol with 293T cells that were previously transfected with plasmids encoding 
Measles virus F and H proteins and a plasmid expressing a Renilla luciferase minigenome 
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RNA under the control of a human Pol I promoter (pHuman-PolI-Renilla). Those cells were 
named “293T-R”. Result of fusion between 293T-Pol and 293T-R are presented as dark blue 
bars in Figure 17. Expression of the firefly luciferase minigenome by 50-92 polymerase in 
293T-Pol was not altered after fusion with 293T-R cells (P value >0.05) (Figure 17, top graph, 
compare dark blue bars and white bar in absence of fusion). The Renilla luciferase signal 
produced in 293T-R cells (Figure 17, bottom graph, dark blue bars) was very low and 
corresponded to the minimal activity of 50-92 polymerase complex in human cells. This 
control experiment proved that it was the addition of factors from the avian cell, rather than 
the fusion event itself, that enabled the avian 50-92 polymerase activity to drive a better 
expression of the firefly luciferase reporter. 
DF1 cells are less transfectable than 293T cells (for instance, in Figure 15, compare 
the number of green cells when a GFP expressing plasmid is transfected in DF1 (pictures B or 
E) or in 293T cells (pictures H or K)). However, the Renilla signal expressed from DF1-R cells 
is about 7 times higher than the Renilla signal from 293T-R after fusion (Figure 17, bottom 
graph, ratio 7.5:1) indicating that avian nucleus is a suitable environment for 50-92 
polymerase to transcribe the minigenome despite having been exposed to human cellular 
factors. 
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Figure 17: Activity of avian 50-92 polymerase complex in fused 293T-DF1 or 293T-293T cells. 
50-92 polymerase complex was reconstituted in 293T cells expressing a firefly luciferase 
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minigenome (293T-Pol) and fused with increasing amount of DF1 cells or 293T cells 
transfected with a Pol I species-specific Renilla luciferase minigenome plasmid and Measles 
F and H expression plasmids (referred as DF1-R and 293T-R respectively). 16 hours after 
fusion, cells were lysed and firefly and Renilla activities were measured. The firefly signals 
(top graph) were normalized to the signal from 293T-Pol not fused (white bar in absence of 
fusion). The Renilla signals (bottom graph) correspond to the raw data. Result from fusion 
between 293T-Pol and DF1-R cells are presented as light blue bars and result from fusion 
between 293T-Pol and 293T-R cells are presented as dark blue bars. The same number of 
DF1-R and 293T-R was used. The number of 293T-Pol cells remained constant but the 
number of DF1-R or 293T-R was gradually increased from 1 DF1-R or 293T-R cell for 60 
293T-Pol cells (1:60) to 1 DF1-R or 293T-R cell for 7.5 293T-Pol cells (1:7.5). For the firefly 
signals, Student’s t-test was performed between 293T-Pol versus DF1-R or 293T-R cells 
(black stars) and between DF1-R versus 293T-R cells (blue stars) to determine the p-values 
(*, P<0.05; **, P<0.01). 
 
An example of cell fusion just before cell lysis and firefly and Renilla luciferase 
measurement is presented in Figure 18 and shows similar fusion efficiency between 293T-
Pol with DF1-R and between 293T-Pol with 293T-R cells. 
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Figure 18: Example of fusion between 293T-Pol and DF1-R cells or 293T-Pol and 293T-R cells 
during a minigenome assay. Increasing amount of DF1-R (top panel) or 293T-R cells (bottom 
panel) were added to 293T-Pol. Cell fusion was easily detected by the formation of syncitia 
(white arrows). The number of 293T-Pol cells remained constant but the number of DF1-R or 
293T-R was gradually increased from 1 DF1-R or 293T-R cell for 60 293T-Pol cells (1:60) to 1 
DF1-R or 293T-R cell for 7.5 293T-Pol cells (1:7.5). Pictures were taken 16 hours after co-
culture with a magnification of X10, just before cell lysis for measurement of firefly and 
Renilla activities. 
 
A control experiment was performed to verify that DF1 cells did not enhance 
expression of the minigenome reporter when mixed with human cells unless they were 
transfected with the two plasmids encoding the Measles fusogenic F and H proteins. Results 
are presented in Figure 19. 
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Figure 19: DF1 cells need to be fused to 293T in order to stimulate 50-92 polymerase 
activity. 50-92 polymerase was reconstituted in 293T (293T-Pol) and co-cultured with DF1 
cells previously transfected by plasmids expressing the Measles F and H proteins (light grey 
bars) or co-cultured with DF1 not transfected (dark grey bars). The number of 293T-Pol cells 
remained constant but the number of DF1 F+H or DF1 cells was gradually increased from 1 
DF1 F+H or DF1 cell for 60 293T-Pol cells (1:60) to 1 DF1 F+H or DF1 cell for 7.5 293T-Pol 
cells (1:7.5). 16 hours after co-culture, cells were lysed and firefly luminescence was 
measured. The firefly signals were normalized to the signal from 293T-Pol not fused (white 
bar). Student’s t-test was performed between 293T-Pol versus DF1 F+H or DF1 cells (black 
stars) and between DF1 F+H versus DF1 cells (blue stars) to determine the p-values (*, 
P<0.05; **, P<0.01). 
 
Another control experiment was performed to verify the species-specificity of the 
minigenome reporter plasmids used. Both avian and human firefly minigenomes expressing 
plasmids were used in a polymerase assay in avian or human cells. The polymerase complex 
used was Victoria, a very active polymerase. Results are presented in Figure 20. 
 
Figure 20: Species-specificity of the two minigenomes reporter plasmids used. A polymerase 
assay was performed in avian (A) or human (B) cells using the two species-specific 
minigenome reporter plasmids for avian (pCKPolI-Firefly) or human (pHumanPolI-Firefly) 
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species. Firefly expression was driven by Victoria polymerase. 20 hours after transfection, 
cells were lysed and firefly luminescence was measured. Results are expressed as the mean 
of duplicate samples. 
 
 Results presented in Figure 20 confirmed a previous observation that the cellular 
RNA polymerase I promoter sequence is species specific. Thus, results in Figure 17 can not 
be explained by cross-contamination by minigenome reporter plasmids (i.e. transcription by 
the avian polymerase I of the human influenza minigenome reporter firefly in fused 293T-
Pol-DF1-R). 
 
Taken together these results implied that avian-origin influenza polymerase 
restriction in human cells is not due to the presence of a dominant inhibitory activity. Rather 
there appears to be a positive cofactor present in avian cells that enhanced the avian viral 
polymerase activity. The next step was to test whether this factor was specific for avian 
viruses or would also enhance the activity of polymerases that were already adapted to 
human cell replication. 
 
2.2.5 The positive activity present in avian cells does not enhance viral 
transcription/replication of a human-derived influenza polymerase complex 
The same heterokaryon assay was performed using the polymerase complex and NP 
derived from the human influenza strain Victoria. In contrast to avian 50-92 virus 
polymerase, Victoria virus polymerase is not restricted in human cells (see Figure 14). 
Figure 21 shows that the function of reconstituted Victoria polymerase in human 
“293T-Pol” cells was marginally enhanced (P value >0.05) after fusion with either avian or 
human cells (up to around 2 fold, firefly luciferase signals). Polymerases from human 
influenza viruses are active in avian cells and as expected, the reporter present in avian 
“DF1-R” and human “293T-R” cells (Renilla luciferase) was expressed by the Victoria 
polymerase complex expressed from 293T-Pol cells. 
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Figure 21: Human-derived influenza polymerase complex Victoria is not stimulated by avian 
factors. Victoria polymerase complex was reconstituted in 293T cells expressing a firefly 
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luciferase minigenome (293T-Pol) and fused with increasing amount of DF1 cells or 293T 
cells transfected with a Pol I species-specific Renilla luciferase minigenome plasmid and 
Measles F and H expression plasmids (referred as DF1-R and 293T-R respectively). 16 hours 
after fusion, cells were lysed and firefly and Renilla activities were measured. The firefly 
signals (top graph) were normalized to the signal from 293T-Pol not fused (white bar in 
absence of fusion). The Renilla signals (bottom graph) correspond to the raw data. Result 
from fusion between 293T-Pol and DF1-R cells are presented as light blue bars and result 
from fusion between 293T-Pol and 293T-R cells are presented as dark blue bars. The same 
number of DF1-R and 293T-R was used. The number of 293T-Pol cells remained constant but 
the number of DF1-R or 293T-R was gradually increased from 1 DF1-R or 293T-R cell for 60 
293T-Pol cells (1:60) to 1 DF1-R or 293T-R cell for 7.5 293T-Pol cells (1:7.5). For the firefly 
signals, Student’s t-test was performed between 293T-Pol versus DF1-R or 293T-R cells and 
between DF1-R versus 293T-R cells. None of the p-values were stastisticaly significant. 
 
The fact that activity of the avian-origin influenza polymerase 50-92 but not the 
human virus-derived polymerase Victoria was enhanced upon fusion with avian cells 
suggests that the effect might depend on sequence differences between the two 
polymerase complexes. Residue PB2 627 is a key amino-acid in mammalian adaptation. 
Avian viruses have a glutamic acid, while until recently, most human viruses possessed a 
lysine. 
 
2.2.6 The enhancement in viral transcription/replication of avian-origin influenza 
polymerase complex by an avian factor is independent of the nature of amino acid 627 on 
PB2 
The experiment was repeated using the 50-92 influenza polymerase complex in 
which the human signature 627K was introduced in PB2. 50-92 polymerase complex with 
the PB2 mutation E627K is now very active in human cells (see Figure 14). However, after 
fusion with DF1-R cells, reconstituted 50-92 PB2 E627K polymerase was even more active in 
293T-Pol nucleus than after fusion with 293T-R cells (up to 9 fold, Figure 22, firefly signal, 
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light blue bars). The increase was statistically significant. Activity of the reconstituted 50-92 
PB2 E627K polymerase in human “293T-Pol” cells was slightly enhanced after fusion human 
293T-R cells (up to nearly 4 fold). As expected, the Renilla minigenome present in human 
293T-R cells and in DF1-R cells was expressed in a dose dependent manner (bottom graph, 
light blue bars and dark blue bars). 
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Figure 22: Activity of avian 50-92 polymerase harbouring the human signature 627K in 
heterokaryon assay. 50-92 polymerase complex harbouring the E627K mutation was 
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reconstituted in 293T cells expressing a firefly luciferase minigenome (293T-Pol) and fused 
with increasing amount of DF1 cells or 293T cells transfected with a Pol I species-specific 
Renilla luciferase minigenome plasmid and Measles F and H expression plasmids (referred 
as DF1-R and 293T-R respectively). 16 hours after fusion, cells were lysed and firefly and 
Renilla activities were measured. The firefly signals (top graph) were normalized to the 
signal from 293T-Pol not fused (white bar in absence of fusion). The Renilla signals (bottom 
graph) correspond to the raw data. Result from fusion between 293T-Pol and DF1-R cells are 
presented as light blue bars and result from fusion between 293T-Pol and 293T-R cells are 
presented as dark blue bars. The same number of DF1-R and 293T-R was used. The number 
of 293T-Pol cells remained constant but the number of DF1-R or 293T-R was gradually 
increased from 1 DF1-R or 293T-R cell for 60 293T-Pol cells (1:60) to 1 DF1-R or 293T-R cell 
for 7.5 293T-Pol cells (1:7.5). For the firefly signals, Student’s t-test was performed between 
293T-Pol versus DF1-R or 293T-R cells (black stars) and between DF1-R versus 293T-R cells 
(blue stars) to determine the p-values (*, P<0.05; **, P<0.01). 
 
When the activity of the human Victoria virus polymerase with the PB2 point 
mutation K627E was tested (Figure 23), again, only a marginal (but statistically significant) 
enhancement of polymerase function was detected in 293T-Pol cells after fusion with DF1-R 
(firefly signal, light blue bars). When 293T-Pol cells were fused with 293T-R cells, Victoria 
K627E polymerase was not enhanced (firefly signal, dark blue bars). Although the 
“avianized” version of Victoria polymerase was generated in 293T-Pol cells, the reporter 
present in DF1-R cells was expressed (Renilla signal, light blue bars), which should not be the 
case if a dominant inhibitory factor that targeted the 627E PB2 complex were present in the 
human cells. 
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Figure 23: Activity of Victoria polymerase harbouring the avian signature PB2 627E in 
heterokaryon assay. Human-origin influenza polymerase Victoria mutated in position 627 on 
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PB2 (K627E) was expressed in 293T cells as well as a firefly luciferase minigenome (293T-Pol) 
and fused with increasing increasing amount of DF1 cells or 293T cells transfected with a Pol 
I species-specific Renilla luciferase minigenome plasmid and Measles F and H expression 
plasmids (referred as DF1-R and 293T-R respectively). 16 hours after fusion, cells were lysed 
and firefly and Renilla activities were measured. The firefly signals (top graph) were 
normalized to the signal from 293T-Pol not fused (white bar in absence of fusion). The 
Renilla signals (bottom graph) correspond to the raw data. Result from fusion between 
293T-Pol and DF1-R cells are presented as light blue bars and result from fusion between 
293T-Pol and 293T-R cells are presented as dark blue bars. The same number of DF1-R and 
293T-R was used. The number of 293T-Pol cells remained constant but the number of DF1-R 
or 293T-R was gradually increased from 1 DF1-R or 293T-R cell for 60 293T-Pol cells (1:60) to 
1 DF1-R or 293T-R cell for 7.5 293T-Pol cells (1:7.5). For the firefly signals, Student’s t-test 
was performed between 293T-Pol versus DF1-R or 293T-R cells (black stars) and between 
DF1-R versus 293T-R cells (blue stars) to determine the p-values (*, P<0.05; **, P<0.01; ***, 
P<0.001). 
 
Thus, enhancement of avian influenza virus polymerase activity by avian host cell 
factor(s) did not rely on the nature of amino acid 627 on PB2. In addition, the results 
suggested the absence of any restriction activity in human cells targeting amino acid E627 
on influenza protein PB2.  
All these experiments were repeated by replacing the DF1 cells with chicken embryo 
fibroblasts cells (CEFs) and results were confirmed (data not shown). 
 
2.2.7 A lysine in position 627 on PB2 leads to an optimized replication in the presence of a 
human cofactor 
In order to confirm the absence of any restrictive activity expressed from 293T cells, 
the reciprocal experiment in which chicken cells expressing the 50-92 avian virus 
polymerase complex and a firefly luciferase minigenome (under control of an avian 
polymerase I promoter) were fused with increasing amount of human cells was carried out 
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(Figure 24 A). A dominant inhibitory activity present in 293T cells should reduce the avian 
polymerase activity and thus reduce firefly luciferase expression in a dose dependent 
manner. However, expression of the reporter was not inhibited by fusion with human cells. 
Rather, a moderate increase (not stastically significant) was observed (Figure 24 B pale grey 
bars). This increase in signal may be due to the 293T cells allowing mixing of several 
different partially transfected DF1 cells and increasing the chance that a complete 
polymerase complex might be present in the heterokaryons. The same experiment 
performed with the “avian-like” Victoria polymerase (PB2 K627E) gave similar results (Figure 
24 C, pale grey bars) and confirmed the absence of dominant restriction factor in 293T cells 
targeting residue PB2 627E. 
If the adaptive mutation E627K on PB2 is not a way to escape from a human 
restriction factor, it may alternatively be selected because it creates a positive interaction 
with a human factor that increases replication activity of the virus polymerase complex. To 
test the effect of human factors on PB2 627K-containing polymerases, 50-92 627K and 
Victoria polymerases were tested in this assay. When avian cells were fused with human 
cells, the increase in firefly expression driven by 50-92 polymerase complex harbouring the 
PB2 E627K mutation was much more dramatic and reached 15 fold when the ratio of 293T 
to DF1 was highest (Figure 24 B, column 4, dark bar). This enhancement was statistically 
significant when compared to DF1 cells not fused and when compared to 50-92 polymerase 
wt (pale grey bar). When the firefly expression was driven by Victoria polymerase complex, 
again an increase of polymerase activity in fused cells was observed when the PB2 627K was 
part of the complex (Victoria WT, dark bars in Figure 24 C), in comparison with Victoria 
polymerase with a PB2 harbouring the avian signature E627 (Figure 24 C, pale grey bars). 
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Figure 24: The presence of a lysine in position 627 on PB2 is an adaptive mutation that 
facilitates polymerase enhancement by a human co-factor. A. Diagram of the experiment. 
Polymerase complexes and NP were expressed from DF1 cells expressing a firefly 
minigenome and Measles fusogenic F and H proteins. Three hours after transfection, cells 
were incubated with increasing amount of 293T cells. 16 hours later, cells were lysed and 
firefly luciferase activity was measured. B. DF1 cells were expressing the avian 50-92 
polymerase complex wild type (PB2 627E, pale grey bars) or harbouring the human 
signature (PB2 627K, dark grey bars). C. DF1 cells were expressing the human Victoria 
polymerase complex wild type (PB2 627K dark grey bars) or mutated (PB2 627E, pale grey 
bars). For (B) and (C), 293T and DF1 cells were mixed in the ratio 1:60 column 1, 30:1 
column 2, 15:1 column 3 and 7.5:1 column 4. Results were normalized to firefly activity of 
the control DF1 cells not fused with 293T cells (shown in the column marked -). 
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2.2.8 Enhancement of influenza virus polymerase activity by avian host factors visualized at 
the level of individual transfected cells 
To assess the level of polymerase activity within an individual heterokaryon rather 
than within the whole cell population, the same approach was used but with two species 
specific influenza minigenomes that expressed fluorescent reporters: eGFP and DsRed. 293T 
cells transfected with a plasmid expressing a DsRed minigenome were mixed with either 
293T or DF1 cells transfected with 50-92 PB1, PB2, PA, NP, Measles F and H protein-
expressing plasmids and a plasmid expressing an eGFP minigenome under control of 
species-specific Pol I promoter (pHuman-PolI-eGFP or pCk-PolI-eGFP respectively). At 24 
hours after co-culture, cells were analysed for DsRed and eGFP expression (Figure 25). 
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Figure 25: Measurement of influenza polymerase activity in a fusion assay using two 
fluorescent reporters. 293T cells were transfected with a DsRed minigenome plasmid. 3 
hours after transfection, cells were detached and mixed (ratio 1:1) with 293T or DF1 cells 
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expressing 50-92 polymerase complex and NP, an eGFP minigenome and the two Measles F 
and H fusogenic proteins. Pictures were taken 24 hours after co-culture. A. 293T cells 
expressing a DsRed minigenome. B. 293T cells expressing the avian 50-92 polymerase and a 
GFP minigenome. C. DF1 cells expressing the avian 50-92 polymerase and a GFP 
minigenome. D. 293T cells expressing the DsRed minigenome were fused with 293T cells 
expressing the 50-92 polymerase and the GFP minigenome. E. 293T cells expressing the 
DsRed minigenome were fused with DF1 cells expressing 50-92 polymerase and the GFP 
minigenome (two different fields are shown). White arrows indicate syncytia in which the 
two minigenomes are expressed. 
 
No red signal was observed from the control 293T cells expressing only the DsRed 
minigenome (figure 22 panel A) as no influenza polymerase is present in these cells. 293T 
cells expressing 50-92 polymerase and eGFP minigenome gave a low GFP signal 
corresponding to the minimal activity of 50-92 polymerase complex in human cells (panel 
B). In contrast, bright green cells were observed from DF1 cells expressing 50-92 polymerase 
and eGFP minigenome (panel C). In fused 293T-DsRed/293T 50-92 Pol-eGFP cells, extensive 
syncytia formation was apparent by the DAPI staining and phase contrast images. However, 
the avian 50-92 polymerase complex drove only low expression of the eGFP minigenome 
reporter, and there was no red signal visible (panel D). In contrast, when 50-92 polymerase 
complex was expressed by DF1 cells, a robust eGFP signal was evident in the heterokaryons 
(panel E). Note that since DF1 cells were not able to fuse together (see Figure 15, panel C) 
and since 293T cells did not express the fusogenic proteins in this assay, syncytia were 
exclusively the result of fusion between DF1 and 293T cells. Moreover, after fusion of the 
human cells with avian cells, red fluorescence was observed, which was the result of viral 
transcription and expression of the DsRed minigenome reporter present in the human 
nucleus. Finally, in a proportion of the fused cells, simultaneous expression of the two 
reporters was observed (panel E, white arrows). Thus this result again confirms that there is 
no dominant restriction factor in human cells; otherwise eGFP expression would have been 
inhibited in avian cells that were fused, and the human-avian cell heterokaryons would not 
have supported expression of the dsRed minigenome by the avian polymerase. 
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2.3 Conclusions 
Typical avian influenza A viruses do not replicate efficiently in humans. A 
heterokaryon assay between avian and human cells was employed to investigate avian 
influenza polymerase restriction in human cells. The data obtained show that the host range 
restriction of avian RNPs in mammalian cells is not due to a restriction factor that 
specifically targets a glutamic acid in position 627 of PB2, the amino acid found in almost all 
avian influenza strains. In the presence of human cellular factors, the minigenome reporter 
present in avian nucleus was transcribed and expressed when any of the polymerases were 
used. In a dose-response assay, fusion of human with avian cells did not inhibit an avian or 
an ‘avianized’ polymerase (Figure 24). Moreover, an avian virus polymerase complex that 
was generated in heterokaryons and therefore exposed to human factors still became active 
if it gained access to the avian nucleus. The lack of inhibition of polymerase function by 
human cell factors was particularly obvious when fluorescent reporters were used (Figure 
25). Thus, restriction of typical avian-derived polymerase in human cells is likely the 
consequence of absence of or low affinity interaction with an essential co-factor. 
Another conclusion from this fusion assay is that a positive factor present in avian 
cells enhances replication/transcription of influenza vRNP from avian virus origin but not 
from human virus origin. The mechanism of action of this avian positive factor does not 
involve residue 627 of PB2 (Figure 22 and Figure 23). Thus, an important co-factor required 
for efficient function of avian influenza virus polymerase is missing, different or under-
expressed in human cells. Finally, the PB2 E627K mutation can compensate for the absence 
of the avian co-factor by creating an adaptive interaction with a co-factor present in human 
cells. This hypothesis was supported by the observation that 293T cells supplied a co-factor 
that specifically increased activity of a PB2 627K containing polymerase (Figure 24). Thus, 
the dramatic increase of avian influenza polymerase activity in human cells when residue 
E627 is mutated to a K (see Figure 14) is likely attributed to the ability of the ‘humanized’ 
PB2 protein to recruit a human positive factor. PB2 residues S590 and R591 are responsible 
for efficient activity of the 2009 H1N1 pandemic virus polymerase in human cells, which 
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retains the avian signature 627E (Mehle & Doudna, 2009). The structural resolution of the C-
terminal domain of the PB2 polymerase subunit has revealed that residue 627 lies very close 
to residues 590 and 591 (Tarendeau et al, 2008). It is then likely that they contact the same 
human co-factor as the PB2 containing lysine 627 to enhance the polymerase function. 
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Chapter 3.  Identification of avian genes required for influenza virus 
polymerase function 
 
3.1 Introduction 
One of the conclusions from the cell-fusion assay presented in Chapter 2 was that an 
avian factor that is lacking from human cells is required for the efficient function of an 
avian-origin influenza polymerase. We therefore reasoned that provision of avian host 
genes to mammalian cells should allow replication of a restricted avian influenza virus 
polymerase and that this could be a strategy to identify the unknown avian factor(s). 
A chicken cDNA library was made from chicken embryo mRNAs and cloned into a 
HIV-1 derived lentiviral expression system. A lentiviral expression system produces lentiviral 
particles (named lentiviral vectors or lentivectors) that contain a gene of choice (named 
transgene) in their genome. This system was chosen as it allows high level of transduction of 
many cell types, stable integration of the transgene in the target cell genome and high 
expression level of the transgene (Naldini et al, 1996). In addition, this system is safe and 
allows re-encapsidation of the transgene from the transduced cells into new lentivectors. 
A diagram of the functional screen strategy is presented in Figure 26. Briefly, 
lentiviral particles expressing the chicken cDNA library were produced and used to 
transduce human cells (293T). An avian-origin polymerase was reconstituted in the 
transduced 293T cells by co-transfection with plasmids encoding the 50-92 avian influenza 
polymerase subunits and NP. As demonstrated in Chapter 2, the polymerase from the 50-92 
avian influenza strain is poorly active in human cells. To isolate chicken genes able to 
increase the activity of the avian-origin 50-92 polymerase, an eGFP viral-like RNA 
minigenome reporter plasmid was used. Cells in which eGFP expression increased to 
detectable levels were sorted by flow cytometry. It is very likely that at that stage, a large 
proportion of the sorted cells contained false positive cDNAs. One way to increase the 
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proportion of positive genes and reduce the proportion of false positives is to repeat the 
selection process. After cell sorting, the chicken cDNA sequences can be re-encapsided into 
new lentiviral particles to generate a new sub-library. This sub-library could be used in a 
new round of selection and the number of cells containing chicken cDNAs of interest should 
be enriched after every iteration of the selection process. Finally, after several rounds of 
selection, chicken cDNAs present in the sorted cells should be sequenced. They may be 
coding for potential co-factors for avian influenza polymerase. 
 
Figure 26: Functional chicken cDNA library screening strategy to identify avian influenza 
polymerase co-factors. The chicken cDNA library is encapsidated into lentivectors produced 
from 293T cells (1). The lentivectors are then used to transduce human 293T cells (2). After 
expression of the chicken genes, an avian-origin influenza polymerase is reconstituted in the 
transduced human cells. An eGFP minigenome is used as a reporter of the influenza 
polymerase activity (3). Human cells are restrictive to avian influenza polymerase. As a 
consequence, a low level of GFP is produced. However, the presence of an avian co-factor 
for influenza polymerase should increase influenza polymerase activity and enhance 
expression of the eGFP minigenome. GFP positive cells are sorted by flow cytometry (4). The 
chicken genes are recovered from the sorted cells by remobilisation and re-encapsidation of 
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the lentiviral genome into new lentivectors (5) and a new round of selection can be 
performed. 
 
3.2 Results 
3.2.1 Previous work 
Dr Manuela Mura, a postdoc in the laboratory, initiated the construction of a chicken 
cDNA library in the Gateway "entry" donor plasmid pDONR222 from primary chicken 
embryo fibroblasts cells (CEFs). The Gateway cloning technology is based on 
recombination of double-strand DNA. Recombination occurs between specific (att) 
sequences. The different steps performed by Dr Mura and results obtained are summarised 
in Figure 27. After the size selection step of the double stranded chicken cDNA molecules, 
two different recombination reactions ("BP" reaction) were performed with a pool of 
elution fractions 5+6 or with elution fraction 7 (Figure 27) to introduce the cDNAs into 
pDONR222. 
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Figure 27: Chicken cDNA library construction (adapted from CloneMiner cDNA construction 
kit, Invitrogen). Total RNA was extracted from chicken embryo cells and mRNAs were 
purified using oligo d(T) primers. Double-stranded DNA products were obtained after 
synthesis of the first strand using the Superscript II reverse transcriptase and synthesis of 
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the second strand with E. coli polymerase I. Adapter sequence attB1 was ligated to the 5’ 
end of the products. The double stranded cDNA products containing recombination 
sequences attB1 and attB2 were separated by size exclusion chromatography. Fractions 
containing double-stranded chicken cDNA of larger size (pool of fraction 5 and 6 or fraction 
7) were introduced in the Gateway "donor" plasmid pDONR222 by recombination reaction 
(BP reaction) of attP1 and attP2 sequences present in pDONR222 with attB1 and attB2 
flanking the cDNA molecules. This reaction is catalysed by BP Clonase enzyme. All those 
steps were performed by Dr Manuela Mura. 
 
3.2.2 Transformation and characterisation of the two chicken cDNA libraries  
Electrocompetent cells E.coli DH10B were then transformed with the BP 
recombination reaction products “5+6” or “7” for amplification of the libraries. After growth 
in liquid media, plasmids were extracted and purified (Figure 28).  
 
Figure 28: Schematic representation of bacteria transformation and library amplification. 
Highly competent E. coli cells were transformed with BP reaction products “5+6” or “7”. 
After a rescue of 1 hour at 37°C in rich media, a sample was harvested and serial dilutions 
were plated in order to determine the complexity and the titre of each library. Bacteria 
suspensions were grown for 6 hours at 37°C for amplification. 10% of each library was 
frozen as a backup. A bacterial sample was harvested and serial dilutions were plated in 
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order to determine the number of cell division during the amplification step. Finally, 
plasmids were extracted by midipreparation. 
 
After the transformation and amplification steps, bacteria samples were plated for 
characterisation of the two libraries. Some clones were randomly picked and grown for 
minipreparation plasmid extraction. Restriction digest of the plasmid DNAs with BsrGI 
enzyme was used to determine the median size of the insert in each library. Results are 
presented in Figure 29. The details of the two libraries are presented in Table 4. 
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Figure 29: Characterisation of the chicken cDNA libraries "5+6" and "7". A sample of bacteria 
suspension was plated 1 hour after E.coli electroporation with the BP reaction products. 
Some colonies were used to grow minipreps. For each library, the median size of the chicken 
cDNA fragments was determined by restriction digest of the plasmid DNAs with BsrGI. 
 
Table 4: Characteristics of the chicken cDNA libraries “5+6” and “7” in the Gateway 
donor plasmid pDONR222. 
Library Complexity (total 
cfu)
a
 
Titre 
(cfu/µg DNA)
b
 
Number of cell 
division 
Median insert size 
(base pair) 
“5+6” 2.53 10
6
 1 10
7
 2 to 3 2350 
“7” 1.65 10
7
 8.27 10
7
 2 to 3 1640 
acfu: colony-forming unit 
b Titres are expressed as cfu per µg of insert DNA used in the BP reaction 
 
The complexity (number of different plasmids in the library) was lower for library 
“5+6” (2.53 106) than for library “7” (1.65 107). The chicken genome is estimated to be 
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composed of 2 x 104 to 2.3 x 104 genes (Hillier et al, 2004), thus in theory, each library covers 
the chicken genome. In accordance with the size exclusion chromatography results (Figure 
27), the median size of insert chicken cDNAs in library "5+6" was higher than the median 
insert size in library 7 (2350 base pair and 1640 base pair respectively). Finally, 12 clones out 
of 24 were sequenced for each library. Results confirmed that all the inserts were of chicken 
origin. Although the complexity of library “5+6” was lower than the complexity of library 
“7”, library “5+6” was more likely to contain more full-length chicken cDNAs than library 
“7”. Thus, the rest of the study was performed with library “5+6” only. 
 
3.2.3 Generation of new bicistronic plasmids to encode the 50-92 avian viral polymerase 
subunits and NP 
Four proteins (PB1, PB2, PA and NP) and the viral-like eGFP minigenome must be 
present in the same cell to reconstitute a functional avian-origin 50-92 vRNP (Figure 26, step 
(3)). In order to reach a high level of cells expressing all the vRNP components, expression 
plasmids were re-engineered in order to reduce their number.  
The Encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) was used 
to produce two proteins from the same bicistronic mRNA transcribed from one expression 
plasmid. Thus, 293T cells must receive only two plasmids in order to express the 50-92 avian 
polymerase and NP instead of four. pCAGGS-5092 NP-IRES-PB2 and pCAGGS-5092 PB1-IRES-
PA plasmids were generated.  
In order to validate that the proteins are expressed from the bicistronic plasmids, a 
polymerase assay was performed. However, as 5092 PB2 is restricted in human cells, the 
plasmid pCAGGS-5092 NP-IRES-PB2 E627K was also made and included as positive control. 
The minigenome assay was performed in human 293T cells but also in avian DF1 cells with a 
firefly minigenome reporter (Figure 30). 
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Figure 30: Validation of pCAGGS-5092NP-IRES-PB2 and pCAGGS-5092PB1-IRES-PA bicistronic 
plasmids in a minigenome assay. 293T and DF1 cells were seeded in a 24 well plate and 
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transfected with plasmids indicated in the table. Firefly activity was measured 20 hours after 
transfection. Results are presented as the mean of triplicate samples.  
 
The use of three plasmids (pCAGGS-5092NP-IRES-PB2, pCAGGS-5092PB1-IRES-PA 
and the firefly minigenome reporter) instead of five enhanced firefly expression in DF1 cells 
(up to 5 fold), probably due to a greater number of transfected cells. This assay also 
demonstrated that EMCV IRES is functional in avian DF1 cells. However, reduction of the 
number of plasmids from 5 to 3 only slightly increased firefly expression in 293T cells (1.3 
fold). The same polymerase assay was performed in 293T cells using a GFP reporter 
minigenome and the transfected cells were analysed by FACS. The percentage of GFP 
positive cells are presented in Table 5. 
Table 5: FACS quantification of GFP positive cells in a polymerase assay performed 
with 5 or 3 plasmids 
 Positive cells (%) 
5 plasmids PB2 WT 11.88 
3 plasmids PB2 WT 17.01 
5 plasmids PB2 627K 51.37 
3 plasmids PB2 627K 60.44 
Minigenome reporter alone 1.04 
Non transfected cells 0.37 
 
In conclusion, the two bicistronic plasmids were functional but conferred only a 
minor advantage in the number of polymerase active 293T cells. 
 
3.2.4 Transfer of the chicken cDNA library into an HIV-1 derived lentiviral expression vector 
In order to target a maximum of human 293T cells with the chicken cDNA library, a 
HIV-1 derived lentiviral expression system was chosen. Lentivectors allow efficient delivery, 
stable integration, expression and re-isolation of their genome from the transduced cells. 
Depending on the cell type targeted, the envelope present at the surface of the lentivectors 
and the length of the transgene, a transduction efficiency of nearly 100% can be achieved. 
The lentiviral expression vector pCH-GFPW was kindly provided by Dr M. Pizzato. A 
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schematic representation of the different elements present on pCH-GFPW plasmid and the 
modification made are presented in Figure 31. 
 
Figure 31: Schematic representation of the lentivector expression plasmids derived from 
pCH-GFPW. A. HIV-1 derived plasmid pCH-GFPW directs expression of eGFP under control of 
the cytomegalovirus (CMV) promoter. This plasmid contains all the cis-acting elements for 
production and packaging of the RNA genome into lentiviral particles. The eGFP coding 
sequence was replaced with the cassette A sequence from the Gateway cloning system 
(Invitrogen). B. The chicken cDNA library was then transferred from pDONR222 plasmid into 
the pCH-cassetteA plasmid by recombination (LR reaction). U3: unique 3’ sequence, R: 
repeated sequence, U5: unique 5’ sequence, cPPT-CTS: central polypurine tract – central 
termination sequence, RRE: Rev responsive element, eGFP: enhanced Green Fluorescent 
Protein, WPRE: Woodchuck hepatitis virus post-transcriptional regulatory element, UTR: 
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Untranslated region, attR1, attR2, attL1, attL2, attB1, attB2 are the different Gateway 
recombination sequences. 
 
pCH-GFPW plasmid was modified to allow recombination of the chicken cDNA library 
using the Gateway recombination system. The eGFP coding sequence present in pCH-
GFPW was removed and replaced with the "cassette A" sequence (Gateway cloning 
system). The “cassette A” sequence contains attR1 and attR2 recombination sequences.  
The chicken cDNA library “5+6” was then transferred from pDONR222 into pCH-
cassetteA plasmid (Figure 31 B). The LR Clonase catalyses in vitro the recombination of attR1 
and attR2 sequences with attL1 and attL2 recombination sequences flanking the chicken 
cDNA library in pDONR222 plasmid (Figure 31 B). After the transformation of 
electrocompetent E. coli cells with the LR reaction product (see paragraph 3.2.2.), chicken 
library “5+6” in pCH lentiviral plasmid was characterised. Details are presented in Table 6. 
 
Table 6: Characteristics of the chicken cDNA library in the pCH lentiviral plasmid 
(pCH-Lib 5+6). 
Complexity (total 
cfu)
a
 
Titre 
(cfu/µg DNA)
b
 
Number of cell 
division 
1.38 10
7
 4.6 10
7
 3 
acfu: colony-forming unit 
b Titres are expressed as cfu per µg of insert DNA used in the LR reaction 
 
Two controls were also introduced in the lentiviral plasmid: 50-92 PB2 wt and 50-92 
PB2 627K. Those controls were required to set-up the FACS cell sorting step. 50-92 PB2 wt 
should mimic a negative candidate and lentivectors containing 50-92 PB2 wt were used to 
determine the background level of GFP expressed by the reconstituted influenza 
polymerase. A lentivector expressing 50-92 PB2 627K was used as a positive control to 
validate the assay. 50-92 PB2 627K reproduced the effect of a positive factor by enhancing 
the avian influenza polymerase activity and thus the GFP expression level. 
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3.2.5 Lentivector production 
Four types of lentivectors (LVs) were produced: 
- Library 5+6 LVs, containing the chicken cDNA library, 
- 5092-PB2 WT LVs, expressing the negative control 5092 PB2, 
- 5092-PB2 627K LVs, expressing the positive control 5092 PB2 627K, 
- GFP LVs, expressing GFP. GFP LVs were used as a positive control of cell 
transduction but also to estimate the titre of the LVs. 
Lentivector particles (LVs) were generated by co-transfection of three different 
plasmids in 293T cells used as producer (Naldini et al, 1996):  
- A retroviral genomic plasmid carrying the transgene and all the cis-acting 
elements for packaging and expression of the lentiviral-derived genome (pCH-
Library 5+6, pCH-5092-PB2 WT, pCH-5092-PB2-627K, or pCH-GFPW), 
- A packaging plasmid expressing the virion packaging proteins Gag and Pol 
derived from HIV-1 (pCMV-Delta 8.91 (Salmon et al, 2000)),  
- A plasmid encoding an envelope protein. Vesicular stomatitis virus (VSV) protein 
G was chosen due to the high stability and broad tropism of this protein. 
 
An example of lentivector production and cell transduction with the GFP LVs is 
presented in Figure 32. 
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Figure 32: Example of production of GFP lentivectors (GFP LVs) and transduction of 293T 
cells. A. Producer 293T cells were transfected with pCH-GFPW plasmid, a plasmid encoding 
the VSV-G envelope protein and a plasmid encoding HIV-1 packaging proteins (Gag and Pol). 
24 hours after transfection, supernatant from producer 293T cells was harvested and 
various volumes were added to the media of 293T cells seeded in 6 well plates. B. GFP 
expression was observed less than 24 hours after 293T transduction. 
 
In this transduction assay, approximately 100% of the 293T target cells were 
expressing the GFP transgene when 150 µL of lentivector suspension was added in a well of 
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a 6 well plate. GFP LVs were then titrated on 293T cells. Based on the percentage of GFP 
positive cells determined by FACS analysis, GFP LVs preparation titre was estimated at 6.25 
106 pfu/mL (Figure 33).  
 
 
Figure 33: GFP lentivector (LV) titration. 293T cells were seeded in a 12 well plate (105 cells 
per well) and transduced with various amounts of GFP LVs (2 to 12 µL). 24 hours post 
transduction, 40 000 cells per well were analysed by FACS and the percentage of GFP 
expressing cells LVs was measured. 
It was assumed that titres of the other LV preparations (chicken cDNA library, 5092-
PB2 wt and 5092-PB2 627K) were similar to the titre of the GFP LVs. 
 
3.2.6 Selection of avian genes that increase avian-origin influenza polymerase function 
293T cells were transduced with the chicken cDNA library lentivectors with an 
estimated multiplicity of infection (MOI) of 1. In parallel, 293T cells were transduced with 
the control lentivectors 50-92 PB2 wt, 50-92 PB2 627K or GFP using the same MOI. 48 hours 
later, cells were transfected with bicictronic expression plasmids pCAGGS-5092-NP-IRES-PB2 
and pCAGGS-5092-PB1-IRES-PA and the minigenome reporter plasmid pHuman-PolI-eGFP in 
order to reconstitute avian 5092 vRNPs. 20 hours post transfection, cells were detached and 
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prepared for cell sorting. 293T cells not transduced and not transfected were used to 
determine cellular autofluoresence background (Figure 34 A). Analysis of cells not 
transduced but transfected with 50-92 polymerase and GFP minigenome indicated that the 
GFP background due to 50-92 polymerase activity in human cells was around 0.8% (Figure 
34 B), a figure that reached 2% when negative control 50-92 LVs were used to transduce 
293T cells (Figure 34 C). When cells transduced with the PB2 627K lentivectors (and then 
transfected) were analysed, a proportion of cells (15.5%) were present in the positive gate 
(Figure 34 D). Finally, cells transduced with the chicken cDNA library were sorted (Figure 34 
E). Three different cell sorting experiments were performed and a total of 3.108 cells were 
analysed. The 0.2% most fluorescent cells were sorted and collected (an example is shown 
in Figure 34 F), which represented a total of 6.105 cells. 
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Figure 34: Cell sorting analysis. A. Control 293T cells. B. 293T cells not transduced but 
transfected with the bicistronic plasmids expressing 50-92 PB1, PB2, PA and NP and with the 
Pol I plasmid expressing eGFP minigenome transcript pHuman-PolI-eGFP. C. 293T cells 
transduced with 50-92 WT LVs and transfected. D. 293T cells transduced with 50-92 E627K 
LVs and transfected. E and F. 293T cells transduced with the chicken cDNA library LVs and 
transfected. The purple gate indicates the percentage of GFP positive cells in panels A-E and 
in panel F represents the population of sorted cells (the top 0.2% GFP positive cells). Data 
are plotted Side scatter (SSC) versus GFP expression. 11 000 cells per sample were plotted. 
Panels E and F corresponded to the same sample. 
 
However, after cell sorting, the GFP positive cells never attached to the plastic plate, 
divided or grew. It was thus not possible to produce new lentivectors containing the 
selected chicken cDNA from those cells by transfection of the envelope and packaging 
expression plasmids (step 5 in Figure 26). An alternative approach was used (Figure 35). 
Genomic DNA was extracted from the sorted cells and chicken cDNA sequences were 
amplified by PCR using primers flanking the AttB1 and AttB2 recombination sequences. The 
pool of PCR products was then introduced into the pDONR221 Gateway entry plasmid 
using the BP clonase enzyme. The following steps (transfer of the candidate genes into the 
pCH-cassetteA plasmid, production of a new sub-library of lentivector and new rounds of 
selection, represented in Figure 35) have not been performed before the end of this thesis 
due to the short period of time left. 
- 125 - 
 
 
Figure 35: New strategy to recover chicken cDNAs from sorted cells. Genomic DNA was 
extracted from the collected GFP positive cells and chicken cDNAs were amplified by PCR. 
PCR products were introduced into a Gateway donor plasmid (pDONR221) in order to 
produce a new sub-library of chicken cDNAs (6). 
 
However, an estimated total of 3 104 cDNAs were recovered from the cell sorting 
and introduced into the Gateway donor plasmid pDONR221. A total of 16 plasmids were 
sequenced. They all contained chicken origin cDNAs.  
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Table 7: Chicken genes obtained from selected cells and sequence comparison 
between the avian and human homologues at the protein level. 
Clone Gene/EST cDNA size (bp) Protein conservation with 
human homologue (%) 
1 ChEST947h2 390 N/A 
2 40S ribosomal protein S16 (RPS16) 
(full length) 
520 98.7 (differs by 2 residues) 
3 26S protease regulatory subunit 
6B-like (full length) 
1400 87.6 
4 Thy-1 glycoprotein (3’UTR only) 720 N/A 
5 60S ribosomal protein L8 (PRL8) 
(full length) 
825 98.1 
6 NADH dehydrogenase (full length) 660 79.2 
7 40S ribosomal protein S13 (RPS13) 
(full length) 
570 100 
8 ChEST5c10 900 N/A 
9 GAPDH (full length) 1280 92.2 
10 rRNA 2’O methyltransferase 
fibrilarin-like (partial) 
470 90.6 
11 LOXL2 (3’UTR only) 400 N/A 
12 40S ribosomal protein S15 (RPS15) 
(full length) 
460 99.2 (differs by 1 residue) 
13 ChEST730e13 880 N/A 
14 Β-actin (partial, out of frame) 1250 100 
15 Tubulin α1A (full length) 840 99.2 (differs by 2 residues) 
16 Pro-α collagen (partial) 960 86.2 
 
Excluding one gene out of frame, two plasmids containing a 3’UTR and three genes 
without any known function, 4 out of the 10 remaining genes were ribosomal proteins. All 
were full length and are highly conserved between chicken and human. 
 
3.3 Conclusion 
A chicken cDNA library was made and screened using a functional assay in human 
cells. This assay was designed to select avian genes that would confer replication to an 
otherwise non-functional avian polymerase in human cells. The hypothesis was that an 
important cofactor required for the function of avian influenza virus polymerase is missing, 
different or underexpressed in human cells. Thus, the supply of such a factor to a human cell 
should restore, or at least increase activity of a reconstituted avian influenza-origin 
polymerase. 
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Functional cDNA screens are usually technically challenging. In this study, six 
components had to be delivered into the same cell: a chicken gene, plasmids expressing 
influenza proteins PB1, PB2, PA and NP, and the influenza minigenome reporter eGFP. The 
chicken cDNA library was delivered into human cells using lentiviral particles. This delivery 
system allows high transduction efficiency ((Naldini et al, 1996) and Figure 32). In order to 
increase the transfection efficiency of the polymerase subunits and NP genes, bicistronic 
plasmids were generated. A total of 3x108 cells were screened and 6.105 cells in which 
expression of the eGFP reporter minigenome was the highest (top 0.2% GFP positive cells) 
were collected. 
After cell sorting, it was not technically possible to re-encapsidate the chicken cDNAs 
into new lentivector particles from the sorted cells. An alternative approach was used but 
unfortunately, several successive rounds of selection have not been performed due to the 
short period of time left in my PhD. 
However, some candidate genes isolated from the screen were sequenced. Results 
confirmed that avian cDNAs could be recovered from the sorted cells. The size of the 
chicken cDNA isolated was small (from 390 to 1400 bp) in comparison to the average size of 
insert in the initial library which was of 2350 bp. This can indicate a bias in this system which 
favours the recovery of small genes. Lentivector production and transduction efficiency 
decrease when the size of the transgene increases. In addition, large DNA fragments are 
more difficult to amplify by PCR than small fragments so large inserts may have been lost at 
the recovery stage after selection. Those technical issues can explain why the chicken genes 
obtained are small. The low percentage of positive cells (15.5%) observed when the positive 
control PB2 627K LVs was used (Figure 34, panel D) might be explained by a low LV 
production efficiency. It was not technically possible to determine the exact titres of the 
different LV preparations (except for the GFP LV), so PB2 627K LVs titer could have been 
overestaimated. 
Several tools were developed during this study. The two chicken cDNA libraries 
generated from primary avian cells (“5+6” and “7”) showed a high complexity and contain 
some inserts of up to 6 Kb. Those libraries were introduced in the universal Gateway entry 
plasmid pDONR222 and can be used for various applications (Figure 36). Indeed they have 
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been supplied to Professor Jürgen Haas (The University of Edinburgh) for generation of a 
yeast two hybrid screen for influenza proteins that interact with avian host proteins. 
 
Figure 36: The Gateway technology is a simple and rapid route to multiple expression 
systems. The chicken cDNA libraries can easily be transferred into various expression 
systems and used for many genomic applications (adapted from Cloneminer, Invitrogen). 
 
The bicistronic plasmids engineered to express 50-92 PB1, PB2, PA and NP proteins 
are a valuable tool to study influenza polymerase function, especially in avian cells. DF-1 
cells and avian cell lines in general are known to be difficult to transfect, which sometimes 
imposes a limitation for the study of influenza polymerase (Labadie et al, 2007). Thus, 
reduction of the number of expression plasmids should allow assays such as pull-down and 
facilitate influenza vRNPs reconstitution assays in avian cells. 
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In conclusion, this screen needs to be repeated and co-factors for avian-origin 
influenza must be enriched following successive rounds of selection, which should be 
reflected by an increase of the percentage of GFP positive cells in each reiteration. 
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Chapter 4.  Identification of human factors associating specifically 
with PB2 627K 
 
4.1 Introduction 
Another conclusion from the heterokaryon assay presented in Chapter 2 was that a 
co-factor present in human cells specifically enhances the activity of influenza polymerase 
complex when a lysine is present at position 627 of influenza polymerase subunit PB2. This 
might be mediated by a specific interaction between the viral protein and a human host 
encoded protein. A proteomic-based approach was used to try to identify this human 
factor(s). 
The tandem-affinity purification (TAP) method employs two successive affinity 
chromatography steps to isolate protein complexes (Puig et al, 2001). The two steps 
enhance the specificity of the purification procedure and reduce the number of false 
positives. The conditions used are mild to preserve molecular complex integrity. Briefly, a 
bait protein (in this case PB2) is fused with a double tag (Tap-tag) and is expressed in cells 
that are then lysed under gentle conditions. The soluble fraction is first adsorbed on beads 
specific for one of the two tags and eluted. The elution product passes through beads that 
specifically interact with the second tag. The bait and its interacting partners are eluted, 
separated by SDS-PAGE and analysed by mass spectrometry. 
There are several reports of binding partners for influenza polymerase or for 
individual influenza polymerase components identified using the Tap-tag method (Fislova et 
al, 2010; Jorba et al, 2008; Mayer et al, 2007; Resa-Infante et al, 2008). However, 
identification of cellular factors that associate with the whole and functional influenza vRNP 
(PB1, PB2, PA, NP and a vRNA segment) reconstituted in cells is probably a more relevant 
approach. The most comprehensive study is from Mayer et al. in which human cellular 
interaction partners were co-purified with reconstituted vRNPs or with the influenza 
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polymerase complex alone. Using the WSN influenza strain, interactions with known 
influenza co-factors were confirmed and new partners were identified such as 
nucleophosmin (NPM), DNA damage-binding protein 1 (DDB1), Poly [ADP-ribose] 
polymerase 1 (PARP-1), or DDX17/p72 (Mayer et al, 2007).  
However, none of these studies compared cellular binding partners of an influenza 
polymerase complex harbouring PB2 627E or 627K residues. The aim of this chapter was to 
compare human interactors for avian-origin influenza vRNPs that only differ at position 627 
(E or K) of PB2 and identify human binding partner(s) specific for 627K residue. Identification 
of human cellular interaction partner(s) for PB2 627K might be easier when a polymerase 
complex from avian origin “humanized” at position 627 is used, rather than an influenza 
polymerase already adapter for mammalian replication. As shown in Figure 14, page - 82 - 
(Chapter 2), the single mutation E627K dramatically enhanced the function of an avian-
origin influenza polymerase in human cells. In contrast, introduction of a glutamic acid at 
position 627 of a human adapted polymerase complex such as Victoria reduced the 
polymerase function but the remaining activity was still high. It is likely that the presence of 
other adaptive mutations accumulated over time in polymerase genes of human strains of 
influenza are making those strains less dependent on PB2 627K, whereas an avian PB2 
humanized at position 627 is more likely to be dependent on this residue for enhanced 
activity. 
 
4.2 Results 
4.2.1 Tap-Tag sequence validation 
This study was performed with the avian influenza strain 5092 reconstituted in 
human cells (293T). The N-terminal part of PB2 is involved in direct interaction with the PB1 
polymerase subunit (Gonzalez et al, 1996; Perales et al, 1996) and it has been reported that 
the presence of a C-terminal Tap tag sequence on PB2 does not significantly alter its 
function and is commonly used (Engelhardt et al, 2005; Fislova et al, 2010; Fodor & Smith, 
2004). Thus 5092 PB2 wt and the mutant E627K were tagged on their C-terminus. Two 
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different tap tag sequences were tested. The first tap-tag sequence was a repetition of two 
strep-tags and two flag tags. Strep-tag is a small peptide sequence that specifically binds to 
strep-tactin, a derivate of streptavidin (Lichty et al, 2005). The flag tag is a short, hydrophilic 
8-amino acid peptide (DYKDDDDK) (Hopp et al, 1988) that exhibits excellent specificity and 
high affinity to a monoclonal antibody. The second tap-tag sequence tested was composed 
of the Streptavidin-Binding Peptide (SBP) followed by two Tobacco Etch Virus (TEV) protease 
cleavage sites and two immunoglobulin G (IgG) binding domains of Streptococcus protein G. 
SBP binds to streptavidin and this high affinity interaction can be disrupted with biotin. The 
TEV protease cleaves its recognition site with high specificity and is used to detach the tap-
tagged protein from the streptavidin beads. Protein G IgG binding domain binds to IgG 
coated beads. The two tap-tags will be referred as “Strep-Flag” tag and “SBP-ProtG” tag 
respectively. It was shown in Chapter 3 that expression from two bicistronic plasmids 
instead of four expression plasmids of 50-92 derived PB1, PB2, PA and NP allowed vRNP 
reconstitution in a larger number of cells (paragraph 3.2.3). Thus, the two different Tap-tag 
sequences were introduced in the bicistronic plasmids pCAGGS-5092-NP-IRES-PB2 WT and 
pCAGGS-NP-IRES-PB2 627K (Figure 37). 
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Figure 37: Details of the two tap-tag sequences used. A. Representation of the tap-tag 
bicistronic expression plasmids. B. “Strep-Flag” tag sequence. C. “SBP-ProtG” tag sequence. 
 
The tap-tag sequence should not disrupt PB2 function. To verify the biological 
activity of the tagged PB2 protein, a minigenome assay in which 50-92 PB2 (wt or 627K) with 
or without a tap-tag sequence was performed in human 293T cells. Results are presented in 
Figure 38. 
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Figure 38: Validation of the tap-tag bicistronic plasmids. A minigenome assay was 
performed in human 293T cells with reconstituted 50-92 vRNPs. Activities of PB2 subunits 
wt or E627K without a tap-tag sequence were compared with activities of the protein fused 
to SBP-ProtG or Strep-Flag tap-tag sequences. 20 hours after transfection, cells were lysed 
and firefly luminescence was measured. Results are from one experiment run in triplicate, 
representative of two independent experiments. 
 
Activities of 5092 PB2 (wt or 627K) Strep-Flag tagged fusion proteins were 
comparable to activities of the untagged proteins when tested in a polymerase assay. In 
contrast, activity of 5092 PB2 fused to the SBP-ProtG tag was compromised and showed 
only around one fifth the luciferase signal as compared to untagged PB2. This reduction 
might be explained by a steric hindrance caused by the SBP-ProtG tag which is a 20 KDa 
polypeptide (180 amino acids). In contrast, the Strep-Flag sequence is only 5.4 KDa (50 
amino acids). As a consequence, the rest of the study was performed with PB2 fused with 
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the Strep-Flag tag only. The eGFP coding sequence was introduced into pCAGGS-Strep-Flag 
tag plasmid and was used as negative control. 
 
4.2.2 Generation of a minigenome reporter plasmid for visualisation of cell nucleus lysis 
In a tap-tag experiment, cell lysis conditions are mild in order to preserve the 
integrity of molecular complexes. Reconstituted influenza vRNPs are present in the nucleus 
of the transfected cells. Thus, a balance had to be found between conditions that would 
achieve efficient nucleus lysis and preservation of protein-protein interactions. A Pol I 
reporter plasmid transcribing an influenza virus minigenome containing the DsRed 
fluorescent protein sequence fused with SV40 nuclear localisation sequence (NLS) was 
made. Thus, the NLS-DsRed protein was not only a reporter for influenza polymerase 
function but also an indicator of cell nuclear content release in the soluble fraction after cell 
lysis. It was important that vRNPs were formed in abundance in a maximum number of cells. 
The use of the mouse RNA polymerase I terminator sequence (Pol I term) was reported to 
be more efficient than the HDV ribozyme sequence in generating the desired 3’ end of the 
minigenome RNA molecule (Feng et al, 2009). Thus, the mouse RNA polymerase I 
terminator sequence was amplified from mouse genomic DNA and cloned into the NLS-
DsRed reporter constructs in order to optimise the minigenome RNA segment transcription 
termination. The obtained plasmid was named pHPOM1-NLS-DsRed. In parallel, a version 
without SV40 NLS was made (named pHPOM1-DsRed). 
pHPOM1-NLS-DsRed minigenome reporter plasmid was validated in 293T cells in a 
minigenome assay. 50-92 polymerase with the PB2 E627K mutation was used. Results are 
presented in Figure 39. DsRed localisation was compared between cells transfected with 
pHPOM1-NLS-DsRed (panel A) or pHPOM1-DsRed Pol I reporter plasmid (panel B); and 
reporter transcription efficiency was compared between cells transfected with pHumanPolI-
DsRed (containing the HDV ribozyme sequence instead of the mouse Pol I terminator 
sequence, panel C) and the two pHPOM1 plasmids (panels A and B).  
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Figure 39: Validation of pHPOM1-NLS-DsRED Pol I minigenome plasmid. Three different 
minigenomes plasmids containing the DsRed gene were compared in a polymerase assay 
performed in 293T cells using 50-92 PB2 E627K mutant polymerase. pHPOM1-NLS-DsRed 
plasmid contains the DsRed coding sequence fused to SV40 NLS and the mouse RNA 
polymerase I terminator sequence (Pol I term). pHPOM1-DsRed plasmid does not contain 
SV40 NLS sequence. pHuman-PolI-DsRed is identical to pHPOM1-DsRed but contains HDV 
ribozyme sequence in the 3’end of the minigenome instead of the Pol I term. Pictures were 
taken 24 hours post transfection. Magnifications are indicated on the right. 
 
As expected, NLS-DsRed protein was found in the nucleus of the transfected cells 
(panel A), whereas DsRed was localised in the cytoplasm (panel B). Use of the mouse RNA 
polymerase I terminator sequence to terminate transcription of the minigenome RNA 
transcript resulted in more cells expressing the DsRed reporter (compare pHPOM1-DsRed 
(panel B) with pHumanPolI-DsRed (panel C)) and higher expression level of the reporter 
protein (especially visible when panels B and C were compared with a 4X magnification), 
confirming the observation made by Feng et al. (Feng et al, 2009). 
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4.2.3 Influenza vRNPs purification 
Tap-tagged reconstituted 50-92 avian influenza vRNPs WT or PB2 E627K or the 
control GFP were purified from human 293T cells. Briefly, 10 x 10 cm Petri dishes (around 
108 cells) were transfected with a mixture of expression plasmids pCAGGS-5092-NP-IRES-
PB2 (WT or E627K)-Strep-flag tag, pCAGGS-5092-PB1-IRES-PA and the minigenome reporter 
plasmid pHPOM1-NLS-DsRed or with pCAGGS-eGFP-Strep-Flag-tag. 24 hours post-
transfection, expression of the DsRed reporter driven by 50-92 PB2 627K influenza 
polymerase was clearly visible under the microscope, whereas the red signal was only visible 
in few cells when 50-92 PB2 wt was part of the polymerase complex (Figure 40 A). Total cell 
extracts were prepared 40 hours after transfection. The difference in DsRed expression was 
clearly visible when cells were pelleted before the lysis step (Figure 40 B). Lysis conditions 
were adapted from a protocol from N. Peters, Imperial College London, and previous 
publications in which influenza vRNPs were purified such as Fodor et al. (Fodor & Smith, 
2004). Red coloration of the soluble fraction indicated that nuclear factors had been 
released (Figure 40 C). However, a proportion of DsRed protein was still present in residual 
intact nuclei or formed aggregates. 
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Figure 40: Indirect observation of influenza polymerase activity in 293T cells and nuclear 
content release after cell lysis using NLS-DsRed reporter protein. A. Pictures taken 24 hours 
post-transfection. The difference in NLS-DsRed expression driven by 50-92 influenza 
polymerase wt or with the PB2 E627K mutation was clearly visible. B. 40 hours post 
transfection, cells were detached and centrifugated. C. After cell lysis, NLS-DsRed protein 
was released in the supernatant, indicating that cell nuclei have been lysed. However, under 
the mild lysis condition used, a proportion of DsRed protein was still present in the insoluble 
fraction. 
 
Tagged GFP and influenza vRNPs were purified on Strep-tactin beads. Following this 
first purification step, tagged complexes were isolated on anti-flag M2 affinity gel and eluted 
by competition with an excess of free FLAG™ peptide. Eluted proteins were separated on 
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SDS-PAGE electrophoresis and stained with a Coomassie staining kit compatible with mass 
spectrometry analysis. Results of a purification experiment comparing proteins co-eluted 
with the control GFP-Strep-Flag tag or with 50-92 PB2 627K-Strep-Flag tag vRNPs are 
presented in Figure 41. 
 
Figure 41: Tandem affinity purification of influenza 627K containing vRNPs and associated 
proteins. A. Comparison of proteins that co-purified with the negative control Tap-tagged 
GFP or with Tap-tagged 50-92 627K vRNPs. Cell extracts of 293T cells transfected either with 
eGFP-Strep-Flag tag or 50-92 polymerase subunits and NP expression plasmids were purified 
with Strep-Tactin beads, eluted, adsorbed onto anti-Flag M2 affinity gel, and eluted with an 
excess of FLAG™ peptide. The samples were separated in a 4-12% acrylamide gradient SDS-
polyacrylamide gel, and the proteins were visualised by Colloidal Blue coomassie staining. 1: 
input (soluble fraction), 2: Strep-Tactin beads after the first elution, 3: final elution (from 
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anti-Flag M2 affinity gel), 4: proteins attached to the anti-Flag M2 affinity gel after the 
second elution. B. Detection by Western-blot of Tap-tagged GFP or PB2 using a monoclonal 
antibody against the Flag epitope sequence. 
 
Polymerase subunits PB1 (86.5 kDa), tap-tagged PB2 (91.8 kDa) and PA (82.5 kDa) 
were visible after Coomassie staining (Figure 41 A). Identity of Strep-Flag tagged PB2 and 
GFP were confirmed by Western-blot (Figure 41 B). A protein corresponding to NP (56 kDa) 
was also observed and confirmed by western-blot (results not shown). However, the 
amount of NP protein in the elution fraction was expected to be higher if native vRNPs 
complexes were efficiently purified as several NP molecules bind the vRNA (one NP protein 
is thought to bind every 24 nucleotides (Ortega et al, 2000)). Thus this result suggested that 
most of the vRNA and NP molecules were lost during the purification process. In addition, 
no specific bands were observed. The 40 kDa protein detected by coomassie (dashed arrow 
in Figure 41 A) was also present in the control GFP-Strep-Flag tag elution fraction (lane 3 in 
Figure 41 A) and thus corresponded to a non-specific interactor. Elution profiles for PB2 
627E or 627K containing vRNPs were identical using those purification conditions (data not 
shown). 
In conclusion, it seemed that the purification protocol was too stringent and most of 
the interacting partners for 50-92 vRNP were lost during the process. The experiment was 
repeated several times with similar results. Finally, protein complexes were isolated from a 
single step purification onto anti-Flag M2 affinity gel. 
Comparison of the proteins co-eluted with the control tap-tagged GFP, Tap-tagged 
50-92 vRNPs wt or with the PB2 E627K mutant after a single step purification are presented 
in Figure 42. 
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Figure 42: Single step purification of human cellular interaction partners of avian influenza 
vRNP harbouring PB2 residue 627 E or K. Control GFP or reconstituted 50-92 vRNPs wt or 
mutated at position 627 (E to K) were purified onto anti-Flag M2 affinity gel 40 hours after 
293T transfection. Bound tagged proteins were released from the anti-Flag M2 affinity gel 
with an excess of Flag peptide, separated on a denaturing 12% SDS-PAGE gel and visualized 
by Colloidal Blue coomassie staining. Positions of PB1, PB2, PA, NP and GFP are indicated. 1, 
2 and 3 indicate the 3 bands sent for mass spectrometry analysis. 
 
As expected, more proteins were eluted after a single step purification, most of 
them being probably non-specific binding partners. Again, PB1, PB2 and PA were detected 
by Coomassie staining. In addition, NP was easily detected, suggesting that native vRNP 
complexes were successfully maintained in the conditions used. The presence of NP was 
confirmed by western-blot (results not shown). Comparison between elution samples 
showed three bands of slightly stronger intensity for PB2 627K containing vRNP, compared 
to their PB2 627E counterpart (labelled 1, 2, and 3 in Figure 42). The three bands were 
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extracted from the gel as individual slices and sent to the Centre for Integrative Systems 
Biology (Imperial College London) for mass spectrometric protein identification. 
 
4.2.4 MS identification of copurified proteins with vRNPs  
Results from liquid chromatography–mass spectrometry (LC-Ms/Ms) analysis of 
proteins present in gel slices 1, 2 and 3 are presented in Table 8.  
Table 8: Summary of PB2 627K vRNPs associated proteins identified by LC-Ms/Ms.  
Band 
No 
Hits Acc. No. Unique 
pep. 
count 
% 
coverage 
Identification 
probability 
(%) 
% of 
total 
spectra 
Protein name Protein 
size (KDa) 
1 1 YBOX1_HUMAN 6 34 100 7.4 Nuclease-sensitive 
element-binding 
protein 1 
35.9* 
2 RL4_HUMAN 6 16 100 4.9 60S ribosomal 
protein L4 
47.7 
3 NCAP_I66A0 4 11 100 4.9 Nucleoprotein 
Influenza A virus 
56.2 
4 TRYP_PIG 3 21 100 3.7 Trypsin 24.4 
5 PABP2_HUMAN 2 4.7 100 2.5 Polyadenylate-
binding protein 2 
32.7* 
6 LA_HUMAN 2 4.9 98 1.2 Lupus La protein 46.8 
7 RL3_HUMAN 2 4.2 88 0.98 60S ribosomal 
protein L3 
46.1 
8 LYAR_HUMAN 1 4 88 1.2 Cell growth-
regulating nucleolar 
protein 
43.6 
9 HRNH1_HUMAN 1 3.8 75 1.2 Heterogeneous 
nuclear 
ribonucleoprotein H 
49.2 
10 IF4A3_HUMAN 1 4.6 65 1.2 Eukaryotic initiation 
factor 4A-III 
46.9 
2 1 YBOX1_HUMAN 5 30 100 6.5 Nuclease-sensitive 
element-binding 
protein 1 
35.9* 
2 NCAP_I66A0 4 11 100 6.5 Nucleoprotein 
Influenza A virus 
56.2 
3 TRYP_PIG 3 16 100 4.8 Trypsin 24.4 
4 LA_HUMAN 1 3.4 76 1.6 Lupus La protein 46.8 
5 PABP2_HUMAN 1 4.7 51 1.6 Polyadenylate-
binding protein 2 
32.7* 
3 1 RLA0_HUMAN 8 39 100 19 60S acidic ribosomal 
protein P0 
34.2 
2 RL6_HUMAN 6 25 100 16 60S ribosomal 
protein L6 
32.7 
3 NCAP_I01A0 3 8.6 100 3.2 Nucleoprotein 
Influenza A virus 
56.2 
4 TRYP_PIG 2 12 99 6.5 Trypsin 24.4 
* On SDS polyacrylamide gel electrophoresis, YBOX1 and PABP2 are known to 
possess a mobility corresponding to that of proteins with molecular mass of about 50 kDa 
(Eliseeva et al, 2011; Wahle et al, 1993). 
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Influenza NP was detected in all three bands. Contamination with NP was not 
surprising as this protein was very abundant in the elution fraction. Also detected in the 
three bands was the trypsin used to digest the proteins into peptides before mass 
spectrometry analysis. 
Nuclease-sensitive element binding protein 1 (NSEBP1, also known as YBOX1, YBX1 
or YB-1), was the best hit identified in gel slices 1 and 2. NSEBP1 was first described as a 
major component of messenger ribonucleoprotein (mRNP) from duck erythroblasts (Morel 
et al, 1973). NSEBP1 performs a wide variety of cellular functions, including transcriptional 
regulation, DNA repair, cell proliferation, and stress responses to extracellular signals 
(Kohno et al, 2003; Matsumoto & Bay, 2005). NSEBP1 also mediates pre-mRNA alternative 
splicing regulation, binds to splice sites in pre-mRNA and regulates splice site selection (Li et 
al, 2003; Raffetseder et al, 2003; Stickeler et al, 2001). In addition, NSEBP1 binds and 
stabilises cytoplasmic mRNA and contributes to translation regulation by modulating 
interactions between eukaryotic initiation factors and mRNAs (Evdokimova & Ovchinnikov, 
1999). NSEBP1 is mainly localised in the cytoplasm, in cytoplasmic mRNP granules 
containing untranslated mRNAs and shuttles between nucleus and cytoplasm (Kedersha & 
Anderson, 2007). Under stress conditions, NSEBP1 translocates from the cytoplasm to the 
nuclei. NSEBP1 is organised in three domains: a variable N-terminal domain rich in alanine 
and proline residues, the highly conserved cold shock domain which is also the nucleic-acid 
binding region, and a C-terminal tail domain though to be involved in protein-protein 
interactions (Eliseeva et al, 2011; Wolffe, 1994). Human and avian NSEBP1 protein 
sequences share 89.1% homology of amino acid sequences (see Table 9) and residues within 
the N-terminal domains are the less conserved. The molecular mass calculated from the 
amino acid sequence is 35.9 kDa, but NSEBP1 migrates as a protein with an apparent mass 
of about 50 kDa, and NSEBP1 was initially designated p50, p54/56 (reviewed in (Eliseeva et 
al, 2011)). 
Several potential cellular interaction partners for influenza PB2 627K vRNPs are 
components of the large (60S) ribosomal subunit: L4, L3, P0, and P6 proteins. Ribosomal 60S 
subunit is composed of around 49 proteins. Proteins that compose band number 3 are 
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mainly 60S ribosomal subunits, as peptides specific for P0 and P6 proteins represent 35% of 
the total spectra. 
PABP2 was identified in gel slices 1 and 2. PABP2 (also known as PABPN1) plays a 
role in various stages of mRNA metabolism, especially in the 3'-end formation of pre-mRNA. 
PABP2 stimulates the poly(A) tail elongation reaction, controls the poly(A) tail length and 
increases the affinity of poly(A) polymerase for RNA (Kuhn & Wahle, 2004). PABP2 binds to 
poly(A) with high affinity and may protect the poly(A) tail from degradation. PABP2 is also 
present at various stages of mRNA metabolism including nucleocytoplasmic trafficking and 
nonsense-mediated decay (NMD) of mRNA (Ishigaki et al, 2001; Mangus et al, 2003). NMD is 
a surveillance mechanism that specifically degrades damaged, not fully functional mRNA 
and mRNA with premature stop codons. Similarly to NSEBP1/YBX1, the molecular mass of 
PABP2 has been estimated as 50 kDa based on SDS gel electrophoresis, although its 
estimated size from sequence anaylsis is 32.7kDa, reflecting the typical aberrant migration 
properties of PABP2 (Nemeth et al, 1995; Wahle et al, 1993). 
Also identified in gel slices 1 and 2 was La autoantigen (Lupus La protein) which is an 
RNA-binding protein involved in initiation and termination of RNA polymerase III transcripts 
(Gottlieb & Steitz, 1989; Stefano, 1984; Wolin & Cedervall, 2002). Mainly localized in the 
nucleus, this protein is an RNA chaperone (Lin-Marq & Clarkson, 1998; Pannone et al, 1998). 
Heterogeneous nuclear ribonucleoprotein H (HRNH1 or hnRNP H) is a splice 
regulator (Chen et al, 1999; Chou et al, 1999) mainly localised in the nucleus (Honore et al, 
1999). Heterogeneous nuclear ribonucleoproteins (hnRNPs) are ubiquitously expressed. The 
hnRNPs are RNA binding proteins associated with pre-mRNAs in the nucleus and influence 
pre-mRNA processing and other aspects of mRNA metabolism and transport. Some hnRNPs 
shuttle between the nucleus and the cytoplasm. 
Little is known about LYAR (Ly1 antibody reactive homolog (mouse)) also known as 
cell growth-regulating nucleolar protein (Su et al, 1993). This zinc finger protein is localised 
in the nucleus and is suggested to function with NOP56, a protein required for 60S 
ribosomal subunit biogenesis. 
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Eukaryotic initiation factor 4A-III (EIF4A3), also known as DDX48, is an ATP-
dependent RNA helicase. Proteins of the DDX family (DEAD box) are defined by the presence 
of several motifs, in particular the DEAD sequence. In humans, there are three forms of 
EIF4A: EIF4A1 (DDX2A) and EIF4A2 (DDX2B), which are 90% identical and functionally 
equivalent (Hernandez & Vazquez-Pianzola, 2005), and EIF4A3 (DDX48), which is only 65% 
identical to EIF4A1 . EIF4A1 and 2 function in translation initiation, whereas EIF4A3 (DDX48) 
is a core element of the exon junction complex (EJC) (Chan et al, 2004; Tange et al, 2004) 
and as a consequence influences mRNA metabolism processes such as mRNA splicing, 
nuclear mRNA export, translation efficiency and NMD (Ferraiuolo et al, 2004; Palacios et al, 
2004; Shibuya et al, 2004). Thus, EIF4A3 is shuttling between the nucleus and the cytoplasm 
as part of the EJC bound to mRNA. EIF4A3 is involved in translational enhancement of 
spliced mRNAs after formation of the 80S ribosome complex.  
 
None of the candidates are 100% identical between humans and chickens at the 
protein level. The most conserved candidate is EIF4A3 (DDX48) with differences located 
exclusively in the first 18 residues of this protein of 411 amino acids. The most divergent is 
LYAR. 
Table 9: Protein sequence comparison of the candidates between human and 
chicken. 
Candidate Protein homology of amino 
acid sequences with chicken 
homologue (%) 
YBOX1/NSEBP1 89.1 
RL4 82.4 
PABP2 62.7 
La autoantigen 74.5 
RL3 95.8 
LYAR 52.2 
HRNH1 84.7 
IF4A3/DDX48 97.3 
RLA0 95.3 
RL6 78.3 
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4.3 Conclusion 
There is no doubt mammalian adaptation of avian influenza viruses requires 
optimised interactions of viral polymerase proteins with cellular factors. The well known 
mammalian adaptation PB2 E627K dramatically affects influenza virus replicative ability in 
mammalian cells but not in avian cells. It is thus believed that the PB2 627 residue interacts 
with a mammalian factor. Results obtained with the heterokaryon assay between human 
and avian cells (Chapter 2) suggest that a human co-factor interacts with a lysine at position 
627 and this factor is responsible for the increase in influenza polymerase function. Thus, 
comparison of binding partners of biologically active PB2 627E or 627K influenza vRNP using 
the tap-tag approach seemed an excellent strategy to identify this co-factor. 
Using this method, human proteins associated with reconstituted avian influenza 
virus strain 50-92 vRNPs harbouring a lysine or a glutamic acid in position 627 of tagged PB2 
were compared. Initial purification conditions used were too stringent and so a single step 
purification was performed in order to co-purify influenza vRNP interacting partners. Three 
bands of stronger intensities were observed on a stained SDS-PAGE gel when vRNPs 
containing PB2 627K was used as a bait, compared to 627E containing vRNPs. Results from 
mass spectrometry identified with high confidence several interesting proteins which can be 
classify into two categories: ribosomal proteins of the 60S subunit and RNA-binding 
proteins.  
Ribosomal proteins of the 60S and 40S subunits have also been identified in tap-tag 
studies that used reconstituted vRNPs (Mayer et al, 2007) or influenza polymerase alone 
(Jorba et al, 2008). In particular, 60S acidic ribosomal protein P0 (band number 3) was 
identified by Mayer et al. who also showed that ribosomal proteins were specific influenza 
vRNP partners, as they were not co-purified when other baits were used in their 
experiments. Indeed, the same result was observed with the GFP control (Figure 42), where 
no proteins of the size of the 60S subunits L3, L4, P0, or P6 were detected.  
Among the RNA-binding proteins, NSEBP1 (YBX1) was identified with high confidence 
and was the most abundant protein in bands 1 and 2 according to the percentage of the 
total spectra represented by this protein (Table 8). Very recently, NSEBP1 was shown to be a 
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novel interacting partner of HCV NS3/4A protein using the tap-tag approach and was shown 
to be involved in HCV RNA replication (Chatel-Chaix et al, 2011). NSEBP1 binds HCV 5′ and 3′ 
untranslated regions in vitro (Harris et al, 2006; Lu et al, 2004) but also the 3′ untranslated 
region of Dengue virus. In contrast to its positive function in HCV replication, NSEBP1 has a 
restrictive role in Dengue virus infection (Paranjape & Harris, 2007). 
EIF4A3 seems a promising candidate as this protein was also identified in a human 
genome-wide screen for influenza co-factors (Karlas et al, 2010). In this study, EIF4A3 was 
among a list of 287 hits having a role in influenza life cycle and silencing of this factor using 
siRNA significantly reduced replication of influenza strains from H1N1 or H5N1 subtypes in 
human cells. When more filters were applied to the list of 287 genes, 81 candidates were 
conserved and EIF4A3 is still present in this short list (A. Karlas, personal communication). 
EIF4A3 is a core component of the EJC. Interestingly, one of the EJC interacting partners is 
the cellular mRNA nuclear export factor NXF1, and it is a known influenza co-factor (see 
paragraph 1.5.5.3, page - 48 -).  
Interestingly, HRNH1 was also identify by Jorba et al. in their tap-tag study using 
influenza polymerase (but no vRNA) (Jorba et al, 2008). However, silencing of HRNH1 
reduced activity of both a PB2 627K or PB2 627E containing polymerase and thus HRNH1 
does not seem to be a specific co-factor for PB2 627K (Bortz et al, 2011). 
In addition to HRNH1, NSEBP1 and EIF4A3 are involved in splicing. Other factors 
related to mRNA splicing have been identified in tap-tag experiments using influenza 
polymerase as a bait: SFPQ (Splicing Factor Proline and Glutamine-rich)/PSF, and p68/DDX5 
(Jorba et al, 2008). hnRNP M was identified in both Jorba et al. and Mayer et al. (Mayer et 
al, 2007). The cellular mRNA splicing factor RAF-2p48/NPI-5/BAT1/UAP56, initially 
discovered in a yeast two-hybrid screen (Momose et al, 2001) was also found by Mayer et 
al. in their study. Splicing factors comprised the most or one of the most enriched cellular 
function in several large scale influenza RNAi screens (Brass et al, 2009; Karlas et al, 2010) 
and splicing function was ranked in fourth position when genes enrichment from the five 
genome wide RNAi screens performed against influenza were compared (Shaw, 2011). 
However, the virus-like vRNA minigenome used in this chapter was intronless. But it is now 
well established that splicing, as well as, capping, and addition of the poly(A) tail are 
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performed cotranscriptionally (Bentley, 2005; Proudfoot et al, 2002), suggesting that the 
splicing factors identified may represent components of a much larger complex associated 
with the cellular polymerase II machinery, maybe also containing PABP2.  
Very interestingly, La autoantigen was identified as a cellular factor that interacts 
with influenza 5’-UTR in vitro (Park & Katze, 1995). However, a biological significance to that 
interaction has not been attributed so far. La autoantigen binds several viral RNAs 
(poliovirus, human immunodeficiency virus, hepatitis C) and can enhance their translation in 
vitro (Ali & Siddiqui, 1997; Chang et al, 1994; Costa-Mattioli et al, 2004; Meerovitch et al, 
1993; Pudi et al, 2003; Svitkin et al, 1994). 
Apart from LYAR protein, whose function is not clearly known, all the non-ribosomal 
proteins identified are involved in mRNA metabolism. PABP2 and EIF4A3 are both involved 
in nucleocytoplasmic trafficking of mRNA and nonsense-mediated decay (NMD) (Ishigaki et 
al, 2001; Shibuya et al, 2004). 
 
It is now important to investigate if those factors preferentially interact with 
influenza PB2 627K than 627E. It is also essential to know if they are required for influenza 
polymerase function. A bias in this approach is that PB2 627K containing vRNPs are more 
active than PB2 627E vRNPs and thus more NP proteins are co-purified (as a result of a 
better interaction with PB2 627K or a direct consequence of the polymerase activity), which 
can be seen on Figure 42. NP binds RNA with no specificity and might be responsible for the 
co-purification of RNA-binding proteins. First of all, in order to determine the 627K 
specificity of the candidates, their detection by Western-blot will be performed in elution 
samples obtained after a single step purification of 627E or 627K containing vRNPs. Co-
immunoprecipitation experiments between the candidates and PB2 protein (627E or K) 
individually expressed or co-expressed with PB1 and PA will also be performed. The effect of 
siRNA-mediated knockdown polymerase activity of PB2 627E or 627K containing vRNPs will 
be performed. Co-immunoprecipitation and co-localisation studies in virus-infected cells will 
also be carried out. To assess the biological significance of the interactions in the influenza 
virus life cycle, the effect of siRNA-mediated knockdown on influenza type A (and type B) 
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virus replication will also be investigated. If knock-out mice are available, infection with 
627E or 627K containing viruses can be performed. It is expected from these experiments a 
reduction in replication for PB2 627K containing viruses but not form PB2 627E containing 
viruses. Differences in pathogenicity and cell tropism of PB2 627K viruses in wild-type versus 
knockout mice can be investigated. 
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Chapter 5. Investigation of influenza polymerase activity in pig cells 
 
5.1 Introduction 
As previously described, influenza viruses usually show a restricted host range with 
poor or no replication in species that are not the natural host. However, transmission of 
influenza viruses from one species to another can occur, particularly if the virus is mutated 
in host determining genes. This may result in an influenza pandemic and the establishment 
of a new lineage (Kilbourne, 2006). The causative agents of the 1957 (H2N2) or 1968 (H3N2) 
human pandemics were reassortant viruses containing gene segments from a human 
circulating strain combined with segments from avian viruses (Kawaoka et al, 1989; 
Scholtissek et al, 1978a) and it has been suggested, although there is no direct evidence to 
support the suggestion, that the reassortment events occurred in pigs (Scholtissek, 1994).  
Close interaction between humans, poultry, ducks and pigs in farms or markets 
offers an opportunity for interspecies influenza transmission. Swine influenza lineages often 
originated from avian or human influenza viruses (reviewed in (Brown, 2008; Van Reeth, 
2007)), implying that pigs are susceptible to infection with both types of influenza viruses. 
Indeed, Kida et al. showed that 33 of 38 avian influenza strains (including representatives of 
subtypes H1 to H13) used in their study, replicated in pigs (Kida et al, 1994). In contrast, 
human volunteers were largely refractory to infection with a panel of avian influenza viruses 
(Beare & Webster, 1991). In addition, genetic reassortment among avian, human and/or 
swine influenza genes has frequently occurred in pigs (Brown, 2008; Brown et al, 1994; 
Brown et al, 1998; Castrucci et al, 1993; Sugimura et al, 1980). Finally, there have been 
several reports and evidence of influenza transmission from pigs to humans worldwide 
(Brown, 2000; Gaydos et al, 2006; Myers et al, 2007; Rota et al, 1989; Van Reeth, 2007) and 
the genome segments of the 2009 pandemic H1N1 (pH1N1) strain were all previously found 
in swine influenza viruses (Dawood et al, 2009; Garten et al, 2009; Smith et al, 2009). As a 
consequence, pigs have for many years been ‘accused’ of acting as intermediate hosts for 
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the mammalian adaptation of avian influenza viruses or the generation of new reassortants 
between avian and human influenza strains that can cause pandemics (Brown, 2000; 
Castrucci et al, 1993; Ito et al, 1998; Kida et al, 1994; Kida et al, 1988; Ma et al, 2008; 
Scholtissek et al, 1985; Webster et al, 1971; Yasuda et al, 1991). 
The apparent susceptibility of pigs to both avian and human influenza may be 
explained by the presence of receptors for both types of viruses in the cells of the upper 
respiratory tract of pigs (Ito et al, 1998). However, more recent publications have challenged 
that notion (Nelli et al, 2010; Trebbien et al, 2011; Van Poucke et al, 2010). 
As presented in the introduction and illustrated in Chapter 2, most avian-origin 
influenza polymerases are poorly active in human or primate cells (Bussey et al, 2010; 
Foeglein et al, 2011; Gabriel et al, 2005; Labadie et al, 2007; Massin et al, 2001; Moncorge et 
al, 2010; Naffakh et al, 2000; Yao et al, 2001) but their activity in pig cells has never been 
studied in detail so far. PB2 residue 627 is a key residue in host range restriction, viral 
replication and pathogenicity of avian influenza in mice, guinea-pigs, ferrets or humans 
(Almond, 1977; Fornek et al, 2009; Fouchier et al, 2004; Gao et al, 1999; Hatta et al, 2001; 
Hatta et al, 2007; Munster et al, 2007; Naffakh et al, 2000; Naffakh et al, 2008; Salomon et 
al, 2006; Shinya et al, 2004; Shinya et al, 2007; Steel et al, 2009; Subbarao et al, 1993) but 
the majority of swine influenza viruses that originate from an avian source retain the avian 
signature 627E. For example residue 627E has been maintained in the predominant H1N1 
Eurasian swine lineage which originated from birds in 1979 (Pensaert et al, 1981; Scholtissek 
et al, 1983). This is in contrast with observations in mice where the E627K adaptation arises 
very quickly and often after a single passage when the animals are infected with an avian- or 
equine-origin influenza virus (Hossain et al, 2008; Li et al, 2009; Li et al, 2005; Mase et al, 
2006; Naffakh et al, 2008; Shinya et al, 2007).  
The PB2 701N residue is not present in human circulating influenza strains but this 
well known mammalian adaptive residue is present in the Eurasian swine H1N1 lineage. 
Interestingly, the SR polymorphism (PB2 590S-591R) appeared in North American pigs in 
1998 with the establishment of a lineage of viruses that contain the triple-reassortant 
internal gene (TRIG) cassette (Karasin et al, 2000; Mehle & Doudna, 2009; Zhou et al, 1999). 
PB2 present in the TRIG cassette also possesses the 271A mammalian adaptative mutation, 
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which is in part responsible for the high activity of the pH1N1 polymerase (Bussey et al, 
2010). A recent publication from Liu et al. concluded that 590S/591R or 271A on their own 
are insufficient to affect viral replication in mammals but do so when combined together 
(Liu et al, 2012). The consequences of PB2 mutations E627K, D701N, G590S/Q591R and 
T271A that enhance influenza polymerase activity in human cells have never been 
investigated in pig cells. 
Interestingly, some influenza subtypes seem not capable of efficient replication and 
transmission in pigs. Some examples are highly pathogenic avian influenza (HPAI) H5N1 
(Lipatov et al, 2008), and influenza B viruses (Brown et al, 1995).  
Despite the widespread geographical distribution of highly pathogenic avian 
influenza (HPAI) H5N1 virus in Asia, Africa and parts of Europe, reports describing natural 
infection of pigs with HPAI H5N1 viruses have been limited (Choi et al, 2005; Nidom et al, 
2010; Shi et al, 2008; Zhu et al, 2008). Indeed, during the peak of the HPAI H5N1 outbreak in 
Vietnam in 2004, only 0.25% of pigs were seropositive for HPAI H5N1 (Choi et al, 2005) and 
no seropositive pigs were detected during an H5N1 poultry outbreak in 2003 in Korea (Jung 
et al, 2007). In contrast to mouse and ferret animal models where H5N1 HPAI replicates 
extensively and often leads to systemic infection and high pathogenicity (Govorkova et al, 
2005; Hatta et al, 2007; Maines et al, 2005; Zitzow et al, 2002), the outcome of experimental 
infection of pigs or miniature pigs was limited disease signs, accompanied by only modest 
viral titres and no transmission to contact animals (Choi et al, 2005; Isoda et al, 2006; 
Shortridge et al, 1998). It is not known why the outcome of HPAI H5N1 virus infection in pigs 
is different from other mammals nor why HPAI H5N1 virus replication in pigs is so limited. 
In addition to influenza A, the Orthomyxoviridae family includes influenza virus type 
B. Interestingly, influenza B virus is only circulating in humans and has never been detected 
in pigs. Only limited evidence of pig seropositivity to influenza B has been reported (Brown 
et al, 1995; Kawano et al, 1978; Takatsy et al, 1967). Those studies suggest that transmission 
of influenza B from human to pigs is a random event and that the virus is not able to spread 
between pigs. In humans, influenza B viruses are the predominant circulating influenza 
viruses approximately one in every three years (Lin et al, 2004), creating many opportunities 
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for influenza B to cross from human to pigs, especially from farm workers. However, the 
establishment of an influenza B lineage never occurred in pigs. 
The aim of this Chapter was to develop the first minigenome assay in pig cells in 
order to compare activities of avian or human influenza-origin polymerases in pig, human 
and avian cells but also the consequences of some known mammalian host range 
determinants in pig cells. Finally, polymerase activities of influenza subtypes that seem not 
capable of efficient replication and transmission in pigs such as HPAI H5N1 or influenza B 
have been investigated using this system. 
 
5.2 Results 
5.2.1 Generation of an influenza A minigenome reporter construct driven by the swine RNA 
polymerase I promoter 
Because of the suggested role of pigs as a mixing vessel for influenza viruses and the 
apparent susceptibility of pigs to avian influenza, it is interesting to study influenza 
polymerase activity in pig cells. To this aim, the promoter sequence recognized by the swine 
RNA polymerase I (Ling & Arnheim, 1994) was amplified by PCR from genomic DNA 
extracted from newborn swine kidney (NSK) cells (Ferrari et al, 2003) and introduced into 
the previously described minigenome reporter plasmid pHPOM1-Firefly also containing the 
mouse RNA polymerase I terminator sequence. Three different constructs with different 5’ 
boundaries were made (Figure 43 A). 
Newborn pig trachea (NPTr) cells (Ferrari et al, 2003) were co-transfected with 
plasmids expressing A/England/195/09 (Eng195) PB1, PB2, PA and NP proteins together 
with pSPOM1-Firefly, pSPOM2-Firefly or pSPOM3-Firefly minigenome expressing plasmids. 
Although Eng195 is a representative of the swine origin pandemic 2009 H1N1 (pH1N1) 
isolated from a human patient, this virus, like many pH1N1 isolates, efficiently replicates 
and transmits between pigs (Brookes et al, 2010; Lange et al, 2009) and swine infection with 
pH1N1 was coincident with the 2009 pandemic (Brown, 2012; Pasma & Joseph, 2010). 
Therefore Eng195 polymerase was expected to support amplification and replication of the 
- 154 - 
 
minigenome in pig cells. Firefly luciferase activities obtained 20 hours after transfection are 
presented in Figure 43 B.  
 
Figure 43: Generation of an influenza polymerase assay in swine cells. A. The swine RNA 
polymerase I promoter sequence was cloned into an influenza A minigenome reporter 
plasmid. Three different constructs with different 5’ boundaries were made (-472, -387, or -
173 to +1 of transcription). The mouse RNA polymerase I terminator sequence is indicated 
by a white box. The grey boxes correspond to the influenza A NS segment non coding 
sequences. B. NPTr cells were transfected with four plasmids encoding PB1, PB2, PA and NP 
proteins derived from influenza virus A/England/195/09 (Eng195), together with a plasmid 
that directs expression of virus-like firefly reporter RNA minigenome under the control of 
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the swine RNA polymerase I promoter (pSPOM1-firefly, pSPOM2-firefly or pSPOM3-firefly). 
Control cells were transfected with the reporter RNA minigenome alone (C-). 20 hours post 
transfection, cells were lysed and firefly activity measured. The mean and standard 
deviation of duplicates are represented. Results are shown as raw data. Similar results were 
obtained in swine NSK cells (data not shown). 
 
The three constructs all gave a robust luminescent signal following vRNP 
reconstitution and almost no background was detected from the reporter plasmids alone. 
Similar results were obtained following transfection of the swine NSK cell line (data not 
shown). For the rest of the study, pSPOM2-firefly was used. 
 
The firefly luciferase coding sequence present in pSPOM2 reporter plasmid was 
replaced by Renilla luciferase, eGFP or DsRed coding sequences in order to make a set of 
different reporters. All the new swine minigenome reporter plasmids were tested and 
validated in a minigenome assay. Example of swine cells transfected with influenza 
polymerase and the GFP or DsRed minigenome plasmid is presented in Figure 44. 
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Figure 44: Validation of GFP and DsRed swine Pol I minigenome plasmid. Swine NPTr cells 
were transfected with plasmids expressing influenza polymerase and NP genes together 
with pSPOM2-GFP (left panels) or pSPOM2-DsRed (right panels). Pictures were taken 24 
hours post transfection.  
Figure 44 shows that a good level of transfection can be achieved in swine cells as in 
a minigenome assay, 5 different plasmids must be present in the same cell in order to 
express the fluorescent reporter. 
 
5.2.2 Comparison of activities of a panel of influenza polymerases in pig, human and avian 
cells  
A polymerase assay was performed in pig, human and avian cells using a panel of 
influenza polymerases from different origins. A/Turkey/England/50-92/91 (50-92) (H5N1) 
and A/Duck/Bavaria/1/77 (Bav) (H1N1) are two typical avian influenza strains. 50-92 has 
previously been described in this document and in the literature as a typical poultry-
adapted avian influenza virus whose polymerase displays host range restriction in 
mammalian cells (Foeglein et al, 2011; Howard et al, 2007; Moncorge et al, 2010). 
A/Duck/Bavaria/1/77 is considered to be an ancestor of the avian-origin H1N1 virus that 
crossed into pigs in 1979 to generate the Eurasian avian-like swine H1N1 lineage (Ottis & 
Bachmann, 1980; Pensaert et al, 1981). A/Quail/Hong Kong/G1/97 (G1) is a less typical avian 
influenza virus, representative of one of main prevalent avian H9N2 virus lineages 
circulating in Southern China (Guan et al, 1999). Viruses from the G1 lineage have been 
responsible for two human infections, causing mild illness (Butt et al, 2005; Cheng et al, 
2011; Peiris et al, 1999). Finally, two human strains were tested: a seasonal H3N2 strain 
frequently used in laboratory studies, A/Victoria/3/75 (Vic) and the already mentioned 
pH1N1 virus, Eng195. The capacity of this panel of influenza polymerases to replicate a 
minigenome in human 293T, swine NPTr, and avian DF-1 cells is presented in Figure 45 A, B 
and C respectively.  
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Figure 45: Activities of a panel of avian or human influenza-origin polymerases in human, 
pig, and avian cells. Plasmids encoding PB1, PB2, PA and NP proteins derived from influenza 
viruses A/England/195/09 (Eng195), A/Duck/Bavaria/1/77 (Bav), A/Turkey/England/50-
92/91 (50-92), A/Quail/Hong Kong/G1/97 (G1), or A/Victoria/3/75 (Vic) were transfected in 
human 293T (A), swine NPTr (B), and avian DF-1 (C) cells, together with a species-specific 
firefly minigenome reporter plasmid. 20 hours post transfection, cells were lysed and firefly 
activity measured. Data were normalised to cells transfected with reporter plasmid alone. 
Results shown are the averages with standard deviations from three independent 
experiments. 
 
The pattern of results was very similar in human and pig cells. In the two mammalian 
cell lines, the two typical avian strains 50-92 and Bav showed a low polymerase activity, in 
contrast to the human-origin H3N2 Vic polymerase which gave the strongest polymerase 
activity observed in both human and pig cells. G1 polymerase was more active than either 
Bav or 50-92 polymerases in human and pig cells, with an activity approaching that of 
Eng195. In avian cells, the differences between the influenza polymerase activities were not 
dramatic and the pattern was different. For example, H9N2 G1 polymerase was the most 
active, followed by Eng195 and Vic. The difference between 50-92 and Vic polymerase was 
only 3.3 fold in avian DF-1 cells, whereas a 50 and a 98 fold difference was observed in 
swine NPTr cells and in human 293T cells respectively. Taken together these data imply that 
a host range barrier at the level of polymerase activity for typical avian influenza viruses 
exists in pig cells just as it does in human cells.  
 
5.2.3 Known human adaptive mutations also increase influenza polymerase activity in pig 
cells 
In order to gain some insights into the nature of the genetic changes required for 
efficient replication of a typical avian-origin influenza polymerase in swine, the 
consequences in pig cells of some known influenza polymerase adaptive mutations on PB2 
was tested. The mechanism whereby PB2 627K enhances influenza polymerase activity in 
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human and other mammalian cells is not known. Interestingly, analysis of swine influenza 
virus sequences indicates that viruses that adapt directly to pigs from an avian source 
without an intermediate human host retain 627E. More than 30 years after introduction of 
the Eurasian H1N1 lineage in pigs, the PB2 E627K mutation has not been naturally selected. 
Similarly, 627E is found in PB2 sequences from swine influenza viruses that have the TRIG 
cassette in which PB2 and PA originated from a North America avian origin virus 14 years 
ago (Karasin et al, 2000; Zhou et al, 1999). Thus it seems that there is not a strong selection 
pressure for 627K to emerge in pigs, in contrast to other mammalian species. This might be 
due to differences in the cellular factors that modulate influenza replication in swine cells. 
The E627K mutation was introduced in PB2 genes from the typical host restricted avian virus 
polymerases Bav and 5092. Activities of polymerase complexes containing PB2 WT or 
mutated at position 627 were compared in human, swine and avian cells (Figure 46 A and B 
C).  
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Figure 46: Polymerase activity of Bav and 50-92 complexes containing PB2 mutants. Human 
293T (A), swine NPTr (B) or avian DF-1 (C) cells were transfected with A/Duck/Bavaria/1/77 
(Bav) or A/Turkey/England/50-92/91 (50-92) NP, PB1, PA, and WT or mutant PB2 expressing 
plasmids, together with a species-specific firefly minigenome reporter plasmid. 20 hours 
post-transfection, cells were lysed and firefly luciferase activity was measured. Data were 
normalised to the activity of the WT polymerase. Results shown are the averages with 
standard deviations from three independent experiments. Student’s t-test was performed 
between wt and mutant polymerases to determine the p-values (*, P<0.05; **, P<0.01). 
 
As previously reported, introduction of 627K residue in avian-origin polymerases 
dramatically increased expression of the reporter gene in human cells (Bussey et al, 2010; 
Foeglein et al, 2011; Labadie et al, 2007; Massin et al, 2001; Moncorge et al, 2010; Naffakh 
et al, 2000). Interestingly, 627K also increased avian virus polymerase activity in pig cells. 
Compared to the respective WT polymerases, an increase of about 12 fold and 10 fold were 
observed for Bav E627K and 50-92 E627K polymerases respectively. Similarly to E627K, the 
D701N adaptive mutation has been reported when influenza viruses were passaged in 
animal models such as mice (Brown et al, 2001; Gabriel et al, 2005; Ping et al, 2010; Yao et 
al, 2001). Mutation D701N on PB2 is associated with enhanced polymerase activity in 
human cells (Foeglein et al, 2011; Gabriel et al, 2005; Herfst et al, 2010; Ping et al, 2010; 
Zhang et al, 2012). Interestingly, 701N is present in the PB2 genes of the first isolates of the 
Eurasian avian-like H1N1 swine viruses (for example A/swine/Germany/2/1981) but not on 
the PB2 from the supposed avian precursor A/Duck/Bavaria/1/77. The effect of this 
mutation on the activity of the two avian virus polymerases Bav and 50-92 was tested in 
human and pig cells (Figure 46 A and B respectively). In both cell types, D701N resulted in 
increased polymerase activity but to a much lesser extent than the E627K mutation. Thus in 
pig cells, luciferase signal from Bav D701N was only 2.7 fold higher than Bav wt. The D701N 
mutation increased 50-92 polymerase activity by 4.8 fold in pig cells. In avian cells neither 
the E627K nor the D701N mutation increased the polymerase activity of either of the avian 
viruses tested (Figure 46 C).  
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Residues PB2 627K or 701N are absent in 2009 pH1N1, which very likely originated in 
pigs. However, the G590S/Q591R and T271A mutations present in the 2009 pH1N1 PB2 
gene can compensate for this absence (Bussey et al, 2010; Mehle & Doudna, 2009). Those 
mutations might have been selected and maintained in pigs because they confer a specific 
replicative advantage in this species. G590S/Q591R, and T271A were introduced in 50-92 
PB2 gene and minigenome assays were performed to assess the consequence of these 
changes on polymerase activity in human, swine and avian cells (Figure 46 A, B and C). 
Results indicate that G590S/Q591R or T271A mutations increased the activity of avian-origin 
50-92 polymerase in both human and swine cells (4.5 and 3 fold in human cells, and 2.4 and 
2.2 fold in pig cells respectively). Once again, polymerase activities in DF-1 cells were not 
significantly affected by these mutations, in agreement with previous publications (Bussey 
et al, 2010; Mehle & Doudna, 2009). Thus, the four PB2 mutations tested (E627K, D701N, 
G590S/Q591R, and T271A) that adapt avian influenza polymerase for human cells also 
increase activity in pig cells but not in avian cells. 
 
5.2.4 HPAI H5N1 polymerase is active in pig cells 
The reasons why replication of highly pathogenic H5N1 influenza viruses is limited in 
pigs, in comparison to mice, ferrets, guinea-pigs or humans, are not understood. Lipatov et 
al. inoculated pigs with a panel of viruses representing different clades of circulating HPAI 
H5N1 viruses and showed viral replication was low, and limited to the respiratory tract of 
the animals and the infections were practically asymptomatic (Lipatov et al, 2008). We 
speculated that the poor viral titres obtained after pig infection with HPAI H5N1 influenza 
strains might be due to a low polymerase activity in this species. HPAI H5N1 
A/turkey/Turkey/1/2005 (Ty05) is a prototypic Eurasian lineage Z virus. However, the 
minigenome assay performed in swine cells revealed that expression of the firefly reporter 
gene by the polymerase derived from HPAI H5N1 Ty05 was stronger even than expression 
driven by Eng195 polymerase (Figure 47 B). Similar results were obtained when the swine 
NSK cell line was used (data not shown).  
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Figure 47: HPAI H5N1-origin influenza polymerase is active in pig cells. Plasmids encoding 
PB1, PB2, PA and NP proteins derived from influenza viruses A/England/195/09 (Eng195), 
A/Duck/Bavaria/1/77 (Bav), A/Turkey/England/50-92/91 (50-92), A/Quail/Hong Kong/G1/97 
(G1), A/Victoria/3/75 (Vic), or A/turkey/Turkey/1/2005 (Ty05) were transfected in human 
293T (A), swine NPTr (B), and avian DF-1 (C) cells, together with a species-specific firefly 
minigenome reporter plasmid. 20 hours post transfection, cells were lysed and firefly 
activity measured. Data were normalised to cells transfected with reporter plasmid alone. 
Results shown are the averages with standard deviations from three independent 
experiments. 
 
The ability of a virus with Ty05 polymerase to undergo efficient multicycle replication 
in pig cells was confirmed. A reassortant virus containing the surface genes HA and NA from 
the PR8 strain and internal genes from Ty/05 was generated by Jason Long in the lab. As a 
control, a reassortant virus containing PR8 HA and NA and internal genes from pH1N1 
Eng195 strain was used. Both viruses showed efficient plaque formation on MDCK or swine 
NPTr cells, (Figure 48). Similar results were obtained in swine NSK cells (data not shown).  
 
Figure 48: Characterisation of reassortant viruses containing HPAI H5N1 or Eng195 vRNPs in 
vitro. Plaque formation in MDCK and NPTr cells 3 days after infection with 10-fold serial 
dilutions of HPAI H5N1 or Eng195 polymerase containing reassortant viruses. Theorical 
number of pfu per well is indicated on the right panel. Remaining viable cells were stained 
with crystal violet 3 days after infection. 
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5.2.5 Influenza B polymerase is not restricted in pig cells 
Similarities between influenza A and B viruses suggest that the two types of viruses 
share a common ancestor. However, influenza type B viruses are only circulating in humans. 
It was then interesting to investigate the activity of a polymerase complex derived from 
influenza B in pig cells using the minigenome assay. A minigenome reporter plasmid 
expressing a negative strand firefly RNA flanked by influenza B HA segment promoters was 
made in the pSPOM2-firefly backbone plasmid (swine Pol I reporter) and in the pHPOM1-
firefly backbone plasmid (human Pol I reporter), generating pSFluB1-firefly and pFluB1-
firefly respectively. Minigenome assays were performed in human and swine cells using 
expression plasmids encoding influenza B PB1, PB2, PA and NP proteins. Results are 
presented in Figure 49. 
 
Figure 49: Influenza B polymerase is active in swine cells. Human 293T (A), or swine NPTr 
and NSK (B) cells were transfected with influenza B NP, PB1, PA, and PB2 expressing 
plasmids, together with a species-specific influenza B firefly minigenome reporter plasmid. 
20 hours post-transfection, cells were lysed and firefly luciferase activity was measured. 
Data were normalised to cells transfected with reporter plasmid alone. Results are from one 
experiment run in triplicate, representative of two independent experiments. AU: arbitrary 
units. 
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Expression of influenza B polymerase and NP genes resulted in a very robust 
expression of the firefly minigenome in swine NPTr or NSK cells. A strong polymerase 
activity was also detected in human 293T cells. Thus, similarly to HPAI H5N1 viruses, the 
absence of influenza B in pigs is not likely due to a defective polymerase activity in pig cells. 
The ability of influenza B virus to undergo efficient multicycle replication in pig cells 
was tested. Influenza B virus (B/Florida/04/06, rescued by J. Ashcroft in W. Barclay’s Lab) 
was used to infect swine NPTr or canine MDCK cells. In plaque formation assay performed 
on swine NPTr cells, influenza B virus was not able to form plaques whereas plaques were 
formed on canine MDCK cells (Figure 50 A). Similar results were obtained in swine NSK cells 
(data not shown). No plaques were formed when the concentration of trypsin in the media 
was changed from 1.6 to 0.2 µg/ml (data not shown). However, influenza B virus was able to 
enter and transcribe its genome in swine NPTr cells even more efficiently than in MDCK cells 
as shown by the production of NP proteins detected by immunostaining in a blue cell assay 
(Figure 50 B). Thus, there is no obvious block at the level of influenza B viral attachment, 
endocytosis, vRNPs nuclear import, or polymerase activity in swine cells. 
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Figure 50: Influenza B failed to form plaques in swine cells in vitro. A. Plaque formation in 
MDCK and NPTr cells 3 days after infection with 10-fold serial dilutions of influenza B 
(B/Florida/04/06) viruses. Theorical number of pfu per well is indicated on the right 
panel.Remaining viable cells were stained with crystal violet 3 days after infection. Influenza 
B virus was not capable of forming plaques in NPTr cells. B. immunostaining for influenza B 
NP expression (blue cell assay) indicated that the virus can enter NPTr cells and express its 
proteins. 
 
5.3 Conclusion 
Reassortant influenza viruses with combinations of avian, human and/or swine 
genomic segments have been frequently detected in pigs. As a consequence, pigs have been 
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accused of being a “mixing vessel” for influenza viruses. This implies that pig cells support 
transcription and replication of avian influenza viruses in contrast to human cells in which 
most avian influenza virus polymerases display limited activity. Influenza polymerase has 
been intensively studied using the plasmid driven minigenome assay in human cells since 
the late 1990’s and in 2005, an avian system was developed (Massin et al, 2005). Canine 
(Wang & Duke, 2007) and mouse (Zobel et al, 1993) RNA Pol I promoters have also been 
cloned and used to establish reverse genetic systems for recovery of recombinant influenza 
viruses or to study influenza polymerase activity in corresponding cell types. Here a 
minigenome assay to investigate influenza polymerase activity in pig cells was developed 
and used to compare the activity of six various viral polymerase complexes cloned from 
viruses isolated from different species (turkey, duck, quail, human). Surprisingly, there was 
no obvious difference in the capacity of pig or human cells to support activity of influenza 
polymerases from viruses of different hosts. Polymerase complexes from typical avian 
influenza viruses directed a level of replication much lower than those from mammalian 
adapted strain in both human and pig cells. Interestingly, H9N2 A/Quail/Hong Kong/G1/97 
(G1) polymerase showed a good activity in pig cells, but also in human cells (Figure 45). 
These results correlate with recent reports showing that H9N2 G1 virus replicates efficiently 
in human cells (Lee et al, 2010) and that a H9N2 virus grew to high titre in porcine 
differentiated respiratory epithelial cells precision-cut lung slice system (Punyadarsaniya et 
al, 2011). Although there are many opportunities for avian H9N2 viruses to cross into pigs, 
only few cases have been reported. Infection of pigs by H9N2 subtypes has been reported in 
South East Asia on several occasions since 1998 (Peiris et al, 2001; Xu et al, 2004; Yu et al, 
2008) where it sometimes caused significant morbidity and mortality but did not result in 
sustained circulation in pigs. 
PB2 mutations that enhanced avian-origin influenza polymerase function in human 
cells also increased activity in pig cells but not in avian cells. PB2 E627K, that enhances 
influenza polymerase activity in human or mice cells, also increased activity in pig cells. 
Introduction of 627K enhanced the polymerase activity of Bav and 50-92 to a level similar to 
that shown by Eng195, an influenza polymerase capable of replication in pigs. Moreover, 
the E627K mutation spontaneously occurred when a restricted reassortant virus was used to 
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infect pigs (Manzoor et al, 2009). It is not then clear why most porcine influenza viruses that 
derive directly from an avian source do not contain the 627K motif. Work presented in 
Chapter 2 suggests that a co-factor interacting with a lysine at position 627 of PB2 strongly 
increases the influenza polymerase activity in human cells (Moncorge et al, 2010). Results 
obtained in this study suggest that the same co-factor is present in pigs. Other mutations in 
PB2 such as D701N, 590S/591R, and T271A increased influenza polymerase function in pig 
cells as they did in human cells, and these are the ones that have been selected in nature 
when avian-origin viruses have crossed into swine. The D701N mutation might have 
contributed to pig adaptation of the avian H1N1 strain that crossed into pigs in 1979, and 
introduction of 701N in A/Duck/Bavaria/1/77 PB2 resulted in an increase, albeit a modest 
2.7 fold, of polymerase activity in pig cells (Figure 46). The SR and T271A mutations have 
also naturally appeared in swine in the generation of the TRIG cassette. Both these 
mutations enhanced activity of avian polymerase in pig cells (Figure 46) in line with their 
role in replication and virulence of influenza viruses in mice (Bussey et al, 2010; Liu et al, 
2012). The ability of these mutations to already adapt PB2 to pig cells might explain why 
engineering 627K into a swine virus with a TRIG cassette made little difference to replication 
in pigs whereas back mutating the same residue K627E in a classical swine influenza virus 
decreased replication in vivo (Ma et al, 2011). In conclusion, results of the polymerase 
assays suggest that from a polymerase point of view, pigs do not appear to be a more 
appropriate host for avian-origin influenza viruses than humans. 
 
Interestingly, HPAI H5N1 influenza A viruses that are lethal or extremely virulent in 
chickens and mammalian models such as ferret or mice barely induce any symptoms in pigs. 
HPAI H5N1 viruses killed so far 361 humans worldwide with a death rate of around 60% 
following WHO laboratory confirmed infections (source WHO, April 2012). In contrast, HPAI 
H5N1 infections result in only mild to moderate infection in pigs (Choi et al, 2005; Isoda et 
al, 2006; Lipatov et al, 2008; Shortridge et al, 1998). Although HPAI H5N1 strains can 
replicate in pigs, this species is known to show a very low susceptibility to this subtype. 
Conclusion from the polymerase assay is that the limited replication of HPAI H5N1 in pigs is 
not explained by a deficient polymerase activity 
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Similarly to HPAI H5N1 or H9N2 viruses, influenza type B virus does not naturally 
spread and persist among pigs. Close contact between human and pigs are frequent and 
would facilitate transmission of influenza B from human to pigs. However, sera collected 
from 2000 sows between 1991 and 1992 in Great Britain showed that only seven samples 
specifically reacted with influenza B epitopes (Brown et al, 1995). Seropositive pigs in 
haemagglutination-inhibition have also been reported in Hungary immediately after a 
human epidemic (Takatsy et al, 1967) and in Japan (Kawano et al, 1978). A single report 
suggests that in experimental conditions, domestic pigs can easily be infected with influenza 
B and that the virus seems to transmit between pigs (Takatsy et al, 1969). The animals 
remained clinically healthy, showing no or very mild illness. However, the absence of 
influenza type B viruses isolated from swine and the extremely low seroprevalence for 
influenza type B in pigs suggest that this virus is not adapted to pigs. 
Polymerase assays indicated that influenza B polymerase is highly active in pig cells 
(Figure 49) and that viral entry and nuclear import of influenza B vRNPs are not restricted 
(Figure 50 B). However, in the two pig cell lines tested (NPTr and NSK), influenza B failed to 
form plaques (Figure 50 A), suggesting that in pig cells, the restriction occurs at a later stage 
of the viral replication cycle. It is important to mention that the porcine lung epithelial cell 
line designated St. Jude porcine lung cells (SJPL) which was demonstrated to support 
influenza B replication (Seo et al, 2001) is indeed, according to a recent publication, not of 
porcine origin but is more likely of monkey origin (Silversides et al, 2010). 
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Chapter 6.  Identification of new residues involved in influenza 
polymerase adaptation to mammals 
 
6.1 Introduction 
As described in introduction (paragraph 1.6.2, page - 64 -), human infection due to 
H9N2 avian influenza viruses occurred occasionally in South-East Asia (Butt et al, 2005; Gou 
et al, 2000; Guo et al, 1999; Guo et al, 2002; Peiris et al, 1999). In 1999, H9N2 viruses were 
responsible for two cases of children presenting influenza-like illness. In 2003, influenza A 
virus of the H9N2 subtype were responsible for a children infection in Hong Kong. Recently, 
more cases were reported and a review of the literature identified more human infection 
events, suggesting that human infection with avian H9N2 is indeed more frequent than 
initially thought (Cheng et al, 2011). There are multiple lineages of H9N2 viruses circulating 
in chicken, ducks, quail and pigeons. One of the main prevalent lineages is the H9N2/G1-like 
lineage which is circulating predominantly in quail and chicken in Southern China (Dong et 
al, 2011). This lineage is represented by A/Quail/Hong Kong/G1/97 (H9N2 G1) and viruses 
from the G1 lineage were responsible for the two human cases of infection in 1999. The 
lethal H5N1 viruses responsible for the outbreak in humans in 1997 in Hong Kong acquired 
their six internal genes from H9N2 A/Quail/Hong Kong/G1/97 or one of its precursors. The 
two strains showed high similarity at the nucleotide and amino acid level (98% - 99%) (Guan 
et al, 1999). Thus, internal genes from G1 H9N2 must contain determinant(s) of interspecies 
transmission and mammalian adaptation. In a polymerase assay performed in human and 
swine cells, G1 H9N2 polymerase showed a robust polymerase activity (see Chapter 
5,paragraph 5.2.2, page - 156 -) confirming previous experimental infection of mammalian 
models and observations made by Lee et al. that H9N2 G1 can replicate in vitro in human 
cells at similar levels as a circulating human adapted strain (Lee et al, 2010). However, H9N2 
G1 polymerase and NP genes have none of the known mammalian signatures presented in 
Chapter 9: Appendix, (page - 224 -). Thus H9N2 G1 polymerase and NP genes represent a 
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good model to discover new residues or motifs involved in mammalian adaptation of avian-
origin influenza viruses.  
 
6.2 Results 
6.2.1 H9N2 G1 polymerase genes and NP sequences analysis  
In addition to its high level of activity in chicken cells, H9N2 G1 polymerase is also 
active in human and pig cells (Figure 45, page - 158 -). However, none of the known 
mammalian adaptation reported so far are present in H9N2 G1 PB1, PB2, PA or NP 
sequences. Amino-acid comparison of those sequences with polymerase and NP proteins 
from typical avian strains (A/Turkey/England/50-92/91 (50-92) and A/Duck/Bavaria/1/77 
(Bav)), less typical avian strain A/turkey/Turkey/1/05 (Ty05), or human-adapted strains 
(A/Victoria/3/75 (Vic) and A/England/195/09 (Eng195)) was performed. Particular attention 
was paid to differences of charge (i.e. E to K) because this is a characteristic of other well 
known PB2 E627K or Q591R mammalian adaptive mutations. 
Sequence comparison revealed that H9N2 G1 NP possesses a basic residue at 
position 430 which is not present in the five other isolates (Figure 51 A). Residue 430 is 
considered hypervariable and is exposed at the surface of NP in a flexible linker between the 
“tail lop/linker” region and the “head” domain (Figure 51 B). Residue 430 seems distant 
from the RNA binding groove represented by the cluster of basic residues shown in blue in 
Figure 51 B (Ng et al, 2009; Ng et al, 2008; Ye et al, 2006). Thus, residue 430 might be 
involved in interaction with PB2 or with a host cell factor. 430K is also present in the 1997 
H5N1 strains isolated from humans, whose internal genes origin is common with H9N2 G1.  
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Figure 51: NP residue K430 is characteristic of H9N2 G1 sequence. A. Alignment of H9N2 G1 
with avian or human adapted influenza strains around position 430. The consensus 
sequence shown is based on the 6 sequences analysed (G1, 50-92, Bav, Vic, Eng195, and 
Ty05). Alignment was performed using Geneious software. The green color indicates a 
conserved residue in all sequences. The yellow color indicates a mismatch in one or more 
sequences compared to the consensus. B. Tridimensional structure of NP adapted from (Ng 
et al, 2009). Exposed basic residues are coloured in blue (note that residue 430 is a K in the 
H5N1 A/HK/483/97 sequence). Exposed acidic charged residues are shown in red. 
 
Comparison of all the known PB2 sequences revealed three interesting difference 
between G1 PB2 and other avian virus genes. First, the motif composed of residues K194-
N195-N197 is only found in viruses of the H9N2 and H5N1 subtypes of clade 0 or strains 
derived by reassortment from 1997 H5N1 viruses such as some avian H6N1 strains (Chin et 
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al, 2002). PB2 residues 194 to 197 are located between the PB1 binding site and the cap-
binding domain (Figure 52 B), in a region with no attributed function. 
A lysine is present at position 334 of H9N2 G1 PB2. This residue is in the PB2 cap-
binding domain (Guilligay et al, 2008), and is close to the PB2 bound m7GTP molecule 
(Figure 52 B). Residues in that region of PB2 are otherwise quite conserved among the 6 
sequences presented in Figure 52 A. Thus, the presence of a lysine at position 334 of H9N2 
G1 might have a role in its polymerase activity. Other viruses circulating in avian, swine or 
human usually have a serine at this position. 
Interestingly, H9N2 G1 PB2 possesses only “half” of the 590-591 “SR” polymorphism 
present in the 2009 pH1N1 virus and the TRIG cassette which is thought to compensate for 
the lack of 627K (Mehle & Doudna, 2009). H9N2 G1 PB2 contains S at position 590 but 
retains the classical Q at position 591 rather than showing R or K as has been reported for 
other mammalian or ostrich adapted viruses (Yamada et al, 2010). 
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Figure 52: Comparison of H9N2 G1 PB2 sequence with avian or human-adapted PB2 
sequences. A. The consensus sequence shown is based on the 6 sequences analysed (G1, 
50-92, Bav, Vic, Eng195, and Ty05). Alignment was performed using Geneious software. The 
green color indicates a conserved residue in all sequences. The yellow color indicates a 
mismatch in one or more sequences compared to the consensus. Some motifs or residues 
specific for H9N2 G1 PB2 are located at position 194 to 197, 334, and 590. B: View of PB2 
cap-binding domain structure (residues 320 - 483, ref PDB 2VQZ, (Guilligay et al, 2008)) 
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showing that residue 334 is located close to the cap binding site and to the PB2 bound 
m7GTP. PyMOL software was used to visualise the structure. C. Linear representation of PB2 
showing the location of sequence polymorphisms and domains with structural or functional 
information.  
 
Two residues were identified as host adapting candidates in the G1 PA subunit: A85 
and K237. Position 85 was shown by Bussey et al. to increase the activity of an avian 
polymerase in human cells when mutated from the normal consensus T to an I (Bussey et al, 
2011). H9N2 G1 PA does not possess T or I but A at position 85. Interestingly, this residue is 
close to PA endonuclease active site and is on the same side as the known host-specific 
residues 55, 57 and 65 (Allen et al, 2009; Chen et al, 2006; Finkelstein et al, 2007; Shinya et 
al, 2007) (Figure 53 B), suggesting a potential interaction with factor(s). H9N2 G1 PA residue 
237 is a K whereas an E is commonly found in avian or human adapted PA. Apart from the 
N-terminal domain of PA (amino acids 1 – 209), which is involved in endonuclease cleavage 
of the cellular capped mRNA primer during the cap snatching reaction, (Dias et al, 2009; 
Yuan et al, 2009), and the C-terminal part involved in interaction with PB1 (Gonzalez et al, 
1996; Ohtsu et al, 2002), little is known about the rest of the protein. 
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Figure 53: Interesting residues on H9N2 G1 PA sequence. A: Alignment of avian or human-
adapted PA sequences (residues 61 to 95 and 223 to 251). The consensus sequence shown 
is based on the 6 sequences analysed (G1, 50-92, Bav, Vic, Eng195, and Ty05). Alignment 
was performed using Geneious software. The green color indicates a conserved residue in 
all sequences. The yellow color indicates a mismatch in one or more sequences compared to 
the consensus. B: View of PA N-terminal domain structure containing the endonuclease site 
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(residues 1 - 209, ref PDB 2W69, (Dias et al, 2009)) showing that residue 85 is located near 
the PA active site. Residues 55, 57 and 65 are known host signatures (see Chapter 9: 
Appendix). PyMOL software was used to visualise the structure. C. Linear representation of 
PA showing the location of sequence polymorphisms and domains with structural and 
functional information. 
 
6.2.2 Effect of NP K430T, PB2 KNN194-5-7QDK, K334S, S590G, and PA A85T, K237E 
mutations on H9N2 G1 polymerase function in human cells 
Mutations K430T on NP, KNN194-195-197QDK, K334S, S590G on PB2 or A85T, K237E 
on PA were introduced into H9N2 G1 coding sequences in the expression plasmid pCAGGS. 
Consequences of each of these mutations engineered alone on H9N2 G1 polymerase 
function were investigated in human 293T cells in a minigenome assay. If one of the 
mutated residues is essential for H9N2 G1 polymerase function in mammalian cells, a 
reduction of the firefly reporter expression was expected. PB2 mutations Q591R and E627K 
were also tested. Introduction of Q591R in H9N2 G1 restores the “SR” polymorphism 
(whereas the S590G mutation restores the normal “GQ” consensus sequence present in 
avian or human strains of influenza, except 2009 pH1N1 and TRIG containing viruses). The 
already described E627K mutation was used as a control. Another control used was 
influenza polymerase complex derived from A/Turkey/England/50-92/91 (50-92), as an 
example of a typical avian-origin influenza strain that replicates poorly in mammalian cells. 
Results of the polymerase assay are presented in Figure 54. 
- 179 - 
 
 
Figure 54: Activity of H9N2 G1 vRNP mutants. H9N2 vRNPs were reconstituted in 293T cells 
with the indicated NP, PB2 or PA mutations together with the firefly minigenome plasmid 
pHPOM-1-Firefly. 20 hours post-transfection, cells were lysed and firefly activity was 
measured. H9N2 G1 wt polymerase is represented as a black column, H9N2 G1 NP, PB2 and 
PA mutants are in white and the controls in grey. 50-92 (A/Turkey/England/50-92/91) is a 
typical avian-origin influenza strain that replicates poorly in mammalian cells. Results are 
normalised to mock (cells transfected with the reporter plasmid only). Results are from one 
experiment run in triplicate, representative of two independent experiments. Student’s t-
test was performed between values obtained for G1 wt and mutant polymerases to 
determine the p-values (*, P<0.05; **, P<0.01). 
 
NP K430T and PA A85T mutations reduced H9N2 G1 activity by around 10%. 20% 
reduction of activity was observed with the PB2 K334S mutant. However, these variations 
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were not stastically significant. PB2 mutation KNN194-5-7QDK was responsible for the 
strongest decrease of H9N2 G1 polymerase with a reduction of activity of 40% (P-value = 
0.12). However, the residual polymerase activity was still superior of that of 50-92 
polymerase.  
Changing residues PB2 S590 or PA K237 to the residues commonly found in avian 
adapted PB2 genes (G and E respectively) did not reduce firefly expression, but actually they 
caused a slight enhancement of the polymerase function. However, these variations were 
not stastically significant. Results with the PB2 S590G mutant suggests that it is the basic 
amino acid (arginine) in position 591 of the “SR” polymorphism which can compensate for 
the lack of 627K. A recent publication by Yamada et al. came to the same conclusion when 
591K or 591R mutants were naturally selected in ostrich cells and these authors also argue 
against a critical role of PB2 S590 (Yamada et al, 2010).  
Reconstitution of the “SR” polymorphism by introduction of 591R slightly increased 
H9N2 G1 polymerase function, in agreement with Mok et al. who showed that the Q591K 
mutation increased polymerase activity and viral replication of H9N2 G1 virus (Mok et al, 
2011). Finally, the E627K substitution significantly increased H9N2 G1 polymerase activity. 
So, the high level of H9N2 G1 polymerase activity in mammalian cells does not 
strongly rely on only one of the NP, PB2 or PA residues mutated. 
 
6.2.3 Restricted 50-92 and Bav polymerase complexes are more active in human cells with 
H9N2 G1 PA subunit 
A complementary approach was used to identify which viral protein(s) are involved 
in the replication capacity of H9N2 G1 vRNPs in mammalian cells. The activity of 16 vRNP 
combinations of PB1, PB2, PA and NP from either H9N2 G1 or the typical avian strain 50-92 
was determined in a polymerase assay in human 293T cells (Figure 55). 
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Figure 55: Polymerase activity of 16 vRNP combinations between H9N2 G1 and 50-92 
viruses. 293T cells were transfected with plasmids expressing PB1, PB2, PA and NP from 
either H9N2 G1 (blue) or 50-92 (purple) viruses together with the firefly minigenome 
plasmid pHPOM-1-Firefly. 20 hours post transfection, cells were lysed and firefly activities 
were measured. Results are normalised to mock (cells transfected with the reporter plasmid 
only). Results are from one experiment run in triplicate, AU: arbitrary units. 
 
As shown in Figure 55, activities of the heterogeneous vRNP complexes varied 
substantially. Introduction of 50-92 NP or PB1 in H9N2 G1 background only slightly reduced 
the vRNP activity (column 2 and 3 respectively), suggesting that H9N2 G1 NP and PB1 do not 
contain any mammalian adaptive motifs. However, introduction of 50-92 PB2 or PA in H9N2 
G1 background caused a dramatic reduction in the polymerase activity relative to the all 
H9N2 complex. In particular, the introduction of 50-92 PA caused the greatest reduction 
(column 5). Conversely, introduction of H9N2 PA in a 50-92 polymerase background 
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dramatically enhanced 50-92 polymerase activity (compare column 9 and column 16), and 
for every heterogeneous vRNP containing H9N2 G1 PA, a robust firefly expression was 
observed (columns 9, 12, 14, and 15). Introduction of H9N2 NP in a 50-92 background also 
enhanced 50-92 polymerase activity (column 6). More surprisingly, introduction of H9N2 
PB2 in a 50-92 polymerase background reduced 50-92 polymerase activity (columns 8 and 
13), but not if associated with H9N2 G1 NP (column 11) or PA (column 15). 
In conclusion, it seemed from this “mix and match” vRNP reconstitution assay that 
the high level of H9N2 G1 polymerase activity in human cells is mainly due to its PA subunit. 
In addition, H9N2 G1 PB2 subunit also has some effect (column 4), but in association with 
other H9N2 G1 polymerase, in particular PA (column 15). 
The capacity of H9N2 G1 PA to enhance influenza polymerase activity of another typical 
avian-origin influenza polymerase was tested. Activities of the heterogeneous vRNP 
complexes formed between H9N2 PA and A/Duck/Bavaria/1/77 (Bav) PB1, PB2, and NP was 
performed. As a control, PA from human adapted H3N2 A/Victoria/3/75 (Vic) strain was 
tested. In addition, the same heterogeneous vRNPs were tested with the mammalian 
adaptive mutation E627K introduced in Bav PB2 protein (Figure 56). 
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Figure 57: H9N2 G1 PA enhanced polymerase activity of A/Duck/Bavaria/1/77 (Bav). 293T 
cells were transfected with plasmids expressing Bav NP, PB1, PB2 wt (white bars) or E627K 
(grey bars), and PA from Bav, H9N2 G1 or Vic, together with the firefly minigenome plasmid 
pHPOM-1-Firefly. The control H9N2 G1 is represented as a black bar. 20 hours post 
transfection, cells were lysed and firefly activities were measured. Results are normalised to 
mock (cells transfected with the reporter plasmid only). 
 
vRNPs constituted by PA from H9N2 G1 in Bav background resulted in a stasticaly 
significant increase of the polymerase activity (P value = 0.008), to a level similar to what 
was seen when the E627K mutation was introduced in Bav PB2. Surprisingly, when the 
human adapted PA subunit from Victoria strain was introduced in Bav background, 
expression of the firefly reporter was drastically affected and was only just above the mock 
control. Even in the presence of PB2 627K residue, activity of this heterogenous vRNP was 
very low. This suggests a strong incompatibility between Vic PA and Bav vRNP components. 
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Similar observations were made with Vic PA and 50-92 PB1, PB2 and NP (data not shown). 
Finally, the enhancing effect of H9N2 G1 PA was also observed when 627K was present on 
Bav PB2 protein. Thus, the two effects (introduction of H9N2 G1 PA subunit and 
introduction of E627K mutation in Bav PB2 subunit) were cumulative. 
In conclusion, H9N2 G1 PA polymerase subunit seems particularly adapted to 
enhance influenza polymerase activity, compared to PA from typical avian-origin influenza 
strains.  
 
6.3 Conclusion 
The aim of this Chapter was to identify on polymerase and NP proteins new residues 
involved in mammalian adaptation of influenza virus. H9N2 G1 polymerase is already 
adapted to the mammalian environment despite having none of the known mammalian 
signatures identified so far. H9N2 G1 PB1, PB2, PA and NP sequences were compared with 
avian and human-origin influenza strains. Six mutants were made (NP K430T, PB2 KNN194-
5-7QDK, K334S, S590G, and PA A85T, K237E) but none of them dramatically reduced H9N2 
G1 activity. Only mutation of the KNN194-5-7QDK motif present on the PB2 subunit reduced 
significantly (40%) H9N2 G1 polymerase function. But the remaining activity was still well 
above that of a typical avian influenza strain.  
A “mix and match” assay between polymerase and NP genes from H9N2 G1 and the 
typical avian influenza strains 50-92 or Bav revealed that H9N2 G1 PA subunit was a key 
element to the high polymerase activity in mammalian cells. A role of some PA proteins in 
mammalian influenza adaptation has been put forward in an increasing number of 
publications, especially since 2009 pH1N1 virus emerged, but also when some purely avian 
strains were studied (Bussey et al, 2011; Kashiwagi et al, 2009; Leung et al, 2010; Mehle et 
al, 2012; Song et al, 2009b; Song et al, 2011; Sun et al, 2011). Sun et al. and Mehle et al. 
both showed that reassortant viruses containing 2009 pH1N1 PA had increased polymerase 
activity and higher pathogenicity compared to the original avian-origin virus (Mehle et al, 
2012; Sun et al, 2011). Similarly, Bussey et al. reported that 2009 pH1N1 PA contribute to 
the enhancement of activity of an avian-origin polymerase in human cells, and identified 3 
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residues in 2009 pH1N1 PA involved in this augmentation (85I, 186S, and 336M). When a 
“mix and match” experiment between Bav PB1, PB2 NP and 2009 pH1N1 Eng195 PA was 
performed, an increase similar to the one observed with H9N2 G1 PA was observed (data 
not shown). The 2009 pH1N1 virus replicates and transmits well in mammalian species, 
despite its avian-origin PB2 and PA. H9N2 G1 PA and 2009 pH1N1 PA might share some 
characteristics. The C-terminal part of PA is very well conserved. The N-terminal part, which 
contains the endonuclease domain, is also involved in cap binding, and promoter binding 
(Hara et al, 2006). It shows more sequence variation than the C-terminal domain. One might 
then speculate that H9N2 G1 PA and pH1N1 PA mammalian adapted motifs reside in the N-
terminal part of their sequence. A detailed characterisation of H9N2 G1 PA subunit would 
be of a great interest and might lead to the identification of new residues or motifs involved 
in mammalian adaptation. Chimera between fragments of H9N2 G1 and 50-92 PA can be 
made and tested in a polymerase assay. More mutagenesis can then be performed. In 
conclusion, the high polymerase activity of H9N2 G1 polymerase is mainly due to its PA 
subunit. The specific residues involved remain to be discovered. 
 
The H9N2 subtype highlights the potential for avian-origin influenza viruses to cross 
the species barrier and infect humans without prior reassortment in an intermediate host. 
H9N2 subtypes are endemic in many avian species, creating countless opportunities for this 
subtype to cross into humans or pigs. However, isolation of H9N2 viruses from mammals is 
rare and no H9N2 transmission between swine and humans and between humans have 
been reported (Uyeki et al, 2002). The presence of H9N2 viruses in chickens, ducks, quails, 
pigeons, pheasant, shorebirds, its global dissemination, and the replicative ability in 
mammalian cells of H9N2 viruses such as those from the G1 lineage are making this subtype 
a pandemic threat if adaptive mutations occur. So far, human infections caused by H9N2 
viruses resulted in only mild disease (Butt et al, 2005; Cheng et al, 2011; Gou et al, 2000; 
Guo et al, 1999; Guo et al, 2002; Lin et al, 2000; Peiris et al, 1999). However, enhanced 
polymerase activity was previously shown to increase virus replication, transmission, and in 
certain cases, pathogenicity and mortality in mammals. As shown in this Chapter and by 
Mok et al. (Mok et al, 2011), H9N2 G1 polymerase can be even more active with the E627K 
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mutation or the Q591R/K mutation. Indeed during the 1997 outbreak caused by HPAI H5N1 
virus, which shared the same internal gene constellation, some of the isolates had 627K and 
this was associated with increased virulence (Shinya et al, 2004). Repeated infection of 
mammals may lead to further adaptation of H9N2 viruses, thus monitoring H9N2 
transmission to humans or pigs is essential. Since its detection in China in 1994, H9N2 
viruses underwent extensive reassortment (Dong et al, 2011; Sun et al, 2010). This work 
indicates that reassortment of H9N2 G1-like PA segment in other avian influenza virus A 
strains might help mammalian adaptation of such reassortants. A continuous surveillance, 
especially in China, is necessary. 
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Chapter 7. Discussion 
 
7.1 Advances in understanding of avian influenza polymerase restriction in 
human cells 
It is widely documented that in human cells, typical avian-derived influenza A viral 
polymerase is poorly active but despite extensive study, the reason for this blockade is not 
known. Intracellular events of the replication cycle such as transcription, replication, gene 
expression, or intracellular trafficking of vRNP components, are probably performed sub 
optimally by avian influenza viruses in mammalian cells. It is also unknown how adaptive 
mutations on the polymerase components, such as PB2 E627K mutation, increase avian 
influenza polymerase replication in the human cell environment. 
Using heterokaryons between avian and human cells (Chapter 2), this study allowed 
the discrimination between the presence or absence in human cells of a dominant 
restriction factor for avian-derived viruses containing the PB2 627E signature. Interestingly, 
using a similar approach, Mehle and Doudna came to a different conclusion: their 
publication (Mehle & Doudna, 2008) attests to the presence of a dominant restriction factor 
in human cells that inhibited the avian virus polymerase. The authors compared activities of 
the laboratory-adapted WSN strain in its wild type form or mutated in PB2 (K627E) and 
concluded that the activity of the K627E PB2 polymerase did not approach that of wild type 
polymerase in fused 293T-DF1 cells because of an inhibitor present in human cells. Although 
the approach was very similar, there were a number of technical differences between the 
two studies such as the influenza strains, the non-coding viral sequences flanking the 
minigenome reporters, or the methods used to fuse the cells. In their study, Mehle and 
Doudna only used one minigenome reporter (luciferase) in one cell type, whereas the other 
cell type was expressing the polymerase subunits and NP. A high background (more than 
30%) was sometimes observed in absence of PB2, which suggests that cell fusion or 
transfection were performed sub-optimally. The authors have not used fluorescent 
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minigenomes to directly visualise influenza polymerase activity, but only analysed luciferase 
signals.  
Interpretation of the results was different. Mehle and Doudna directly compared in 
fused human and avian cells the activities of polymerases harbouring a lysine or a glutamic 
acid in position 627 in PB2. Since the 627E polymerase was never as efficient even in avian 
cells as the 627K polymerase, it is not surprising that a PB2 627E-containing polymerase did 
not reach the same absolute level of activity as a 627K-containing polymerase in fused 293T-
DF1 cells. Instead, Chapter 2 reports the comparison of polymerase activity between fused 
cells of the same or different origin (293T-293T or 293T-DF-1). 
Figure 24 page - 101 - clearly shows that supply of human factors does not inhibit an 
avian-origin polymerase. In addition, the use of fluorescent reporters confirmed that an 
avian-origin influenza polymerase can function in presence of human factors. 
In addition, transfection of excess plasmids encoding the 50-92 polymerase complex 
or 50-92 PB2 wild type protein alone failed to saturate any restriction activity (data not 
shown). Similar results were obtained by Mehle and Doudna (personal communication). 
In conclusion, results in Chapter 2 indicate that in heterokaryons with a mixture of 
human and avian components, a dominant factor supports rather than restricts avian 
influenza polymerase activity. This work also gives an explanation for the natural selection 
of the adaptive mutation E627K in PB2 by implying the presence of a human specific positive 
cell factor that enhances replication of polymerases only when the PB2 627K motif is 
present. 
 
7.2 Does PB2 play a role in viral mRNA translation? 
Due to their limiting coding capacity, Influenza viruses have to extensively use and 
manipulate host cell functions. This includes multiple interactions between viral proteins 
and cellular proteins. Over the last ten years, an increasing amount of information about the 
identity of the cellular factors that are involved in viral transcription and replication has 
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accumulated. However, cellular factors and mechanisms involved in restriction of avian-
origin influenza polymerases in mammalian cells are still not understood. 
A functional assay was developed to screen for avian cofactors for avian-origin 
influenza virus polymerase. A similar screen was successfully used by Kawaoka and co-
workers to identify RuvB-Like protein 2 as an avian-host encoded inhibitor of influenza 
polymerase (Kakugawa et al, 2009). The reason why an inhibitor of polymerase was 
discovered in this study rather than a factor that enhanced polymerase function is because a 
truncated version of the avian gene, which, acted as a dominant negative mutant and 
overcame the negative effect of the full length protein, was initially selected in the screen. 
A sample of avian cDNAs obtained after a single round of selection based on FACS 
sorting was sequenced. Several ribosomal protein encoding genes were represented (4 out 
of 8 full lengh cDNAs). Several reasons can explain that relative enrichment. First of all, 
ribosomal mRNAs might be more represented in the chicken cDNA library. However, when 
clones were randomly picked from the initial library in pDONR222 and sequenced 
(paragraph 3.2.2, page - 111 -), ribosomal coding sequences were present in only 1 out of 24 
plasmids. Secondly, it was expected that chicken proteins that can enhance protein 
expression would be selected in the screen, irrespectively of a specific role in influenza 
polymerase activity. It remains to be tested if the chicken ribosomal proteins obtained (40S 
ribosomal protein S13, S15 and S16, and 60S ribosomal protein L8) enhance general protein 
expression when overexpressed in human cells. Finally, those genes may have been selected 
because they act as co-factor(s) for avian-origin influenza polymerase. Interestingly, 
ribosomal proteins of the 60S and 40S subunits have previously been found to be associated 
with reconstituted vRNPs (Mayer et al, 2007) or with influenza polymerase alone (no vRNA 
nor NP) (Jorba et al, 2008). In addition, a gene ontology (GO) term enrichment analysis 
performed with the primary hits of a large scale RNAi screen revealed a specific enrichment 
in genes coding for the small ribosomal subunit (Karlas et al, 2010), an observation also 
made by Hao et al. in a previous RNAi screen for influenza co-factors performed in 
Drosophila cells (Hao et al, 2008). In addition, a comparison of the genes that are over-
represented in the five large scale RNAi screens for co-factors for influenza virus ranked 
those associated with the ribosome in first position (Shaw, 2011). Enrichment for ribosomal 
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subunits was not seen in RNAi screens against other viruses such as HIV-1, West Nile virus or 
dengue virus (Brass et al, 2008; Konig et al, 2008; Krishnan et al, 2008; Sessions et al, 2009). 
Dependency on ribosomes is not unexpected for a virus that replicates fast and must 
express its proteins rapidly. Very interestingly, the 40S ribosomal protein S16, whose coding 
sequence was isolated in the chicken cDNA screen, was also identified as influenza co-factor 
in three out of the five large scale RNAi screens published so far (Brass et al, 2009; Hao et al, 
2008; Karlas et al, 2010; Shapira et al, 2009).  
However, a proper characterisation of each candidate obtained in Chapter 3 will be 
required and more importantly, new rounds of selection must be performed with the sub-
library obtained after this first screen. Nonetheless, it is intriguing that ribosomal proteins 
were also identified using the proteomic-based approach presented in Chapter 4. The aim of 
this project was to identify human factor(s) that specifically interact with a lysine at position 
627 of influenza polymerase subunit PB2. Although it is premature to draw some conclusion 
from results obtained in Chapter 3 (chicken cDNA screen) and Chapter 4 (tap-tag approach) 
as more work needs to be done, it is tempting to associate those two observations.  
In order to efficiently translate its mRNAs, influenza virus has developed strategies to 
discriminate and favour the translation of its own mRNAs. However, the exact mechanisms 
involved are not known (see 1.5.5.3, page - 48 - in Introduction for more details). The cap 
structure of cellular mRNAs is bound in the nucleus by the cap-binding complex (CBC). After 
nuclear export, the CBC must be replaced by eIF4E in order for the mRNA to be translated. 
Translation of influenza virus mRNAs is not affected in eIF4E-silenced cells or when eIF4E 
function is inhibited (Burgui et al, 2007) indicating that influenza mRNAs translation does 
not require eIF4E. It has been shown that the three subunits of influenza polymerase can 
specifically interact with the eIF4GI protein independently of the presence of the viral 
protein NS1 or viral mRNAs (Burgui et al, 2007). eIF4G is responsible for the recruitment of 
the 40S ribosomal subunit to the mRNA to which it is bound. It was thus suggested that the 
viral polymerase can participate in viral mRNA translation probably by replacing eIF4E and 
directly associating with the cap structure and eIF4GI (Burgui et al, 2007; Yanguez et al, 
2012). It is the PB2 subunit which directly associates with eIF4GI through its C-terminal 
domain (Yanguez et al, 2012). Interestingly, Anna Cauldwell, a Master student I supervised, 
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mapped the stimulatory effect observed for avian-origin polymerase in the heterokaryon 
assay to the C-terminus of PB2 (unpublished results). Thus, we can speculate that the C-
terminal domain of PB2 might play a role in viral mRNA translation by recruiting eIF4GI and 
that PB2 C-terminal domain has to adapt to a new host.  
Cellular mRNAs, and probably influenza viral mRNAs, form large mRNP (messenger 
ribonucleoprotein) complexes containing proteins required for maturation, nucleo-
cytoplasmic transport and translation of mRNAs. Apart from LYAR, all the proteins identified 
by tap tag as potential vRNP binding partners partners that associate more with polymerase 
with PB2 627K than PB2 627E (Chapter 4) are involved in protein synthesis (including 
ribosomal proteins), and mRNA-binding proteins such as NSEBP1/YBX1, PABP2, La 
autoantigen, HRNH1, and DDX48, implying that functional influenza polymerase might 
associate with polysomes. It is striking that La autoantigen, NSEBP1/YBX1, DDX48, PABPs, 
HRNHI and many ribosomal proteins (including 60S ribosomal protein P0, L3 and L4) have 
also been identified in an RNP complex containing the anti‐HIV‐1 editing enzyme APOBEC3G 
which is known to shuttle between polysomes and stress granules (Kozak et al, 2006). This 
RNP complex also contains Staufen1 (a known NS1 binding partner) and CBP80. CBP80 
forms with CBP20 the cap binding complex (CBC). It is thus tempting to speculate that 
influenza polymerase (or PB2 alone) is attached to mRNAs associated with polysomes (or 
dormant storage complexes). 
Although premature, those observations support the model established by Yanguez 
and Nieto (Yanguez & Nieto, 2011). After initiation of viral mRNA transcription, the viral 
polymerase stays bound to the viral mRNA through interaction with the cap structure and 
the conserved AGCAAAGCAGG sequence (Shih & Krug, 1996b). This interaction would 
prevent the binding of CBC to the cap of the viral mRNA. The viral mRNA-polymerase 
complex then exits the nucleus. PB2 would then participate in the selective translation 
initiation of viral mRNAs by interaction with eIF4GI and by efficiently recruiting the large 
ribosomal subunit 60S. PB2, PB1 and PA then go back to the nucleus to initiate a new round 
of transcription. The model proposed by Yanguez and Nieto is presented in Figure 58. 
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Figure 58: Model that supports a role of influenza polymerase and in particular the PB2 
subunit in selective translation of viral mRNA from (Yanguez & Nieto, 2011). The authors 
latter found that it is PB2 that associates with eIF4G (Yanguez et al, 2012). 
 
In this model, the role of PB2 in viral translation would not necessarily rely on the 
nature of residue 627 and the factors identified by tap-tag in Chapter 4 might simply reflect 
the fact that more viral mRNAs are produced by PB2 627K containing polymerase. As a 
consequence, more viral mRNAs (associated with PB2 and cellular proteins) are pull-down in 
the case of 50-92 PB2 627K than in the case of 50-92 WT polymerase (Figure 42, page - 141 -
). Actually, it was demonstrated very recently that the low level of vRNA, cRNA or mRNA 
synthetised in human cells by avian-origin polymerases is the consequence of the 
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production of defective cRNA molecules. This defect can be overcome by PB2 E627K 
mutation (Manz et al, 2012). Thus it seems that the PB2 627K mutation affects the viral 
replication step, in particular the replication of cRNA into vRNA, rather than the 
transcription or translation step. 
 
A role of influenza polymerase in viral mRNA translation was not supported by Bier 
et al. (Bier et al, 2011). In this study, the authors did not detect any interaction between the 
influenza polymerase and viral mRNAs. Instead, viral mRNAs were found to be associated 
with CBC, REF/Aly, and eIF4E, some of the factors used by cellular mRNAs. Those conflicting 
results are difficult to explain and might be due to technical procedures. Interestingly, Bier 
et al. looked at NA, M or NP viral mRNAs whereas the work presented in this study and the 
data presented by Yanguez et al. (2012) where obtained with minigenomes containg NS1 
non-coding sequences.  
A role of influenza polymerase complex, and PB2 in particular, in viral mRNAs 
translation is an exciting topic that remains to be clarified. Further studies are required to 
understand the mechanisms involved in viral mRNAs’ selective translation and to determine 
if the influenza polymerase complex is involved in this process. 
 
 The work presented in Chapter 4 aimed to identify the PB2 627K cellular co-factor 
responsible for the dramatic enhancement of polymerase in mammalian cells. Some 
candidates identified by tap-tag will be investigated. So far, and to my knowledge, there is 
no report of human cell lines or human cell types in which the PB2 mutation E627K has not a 
dramatic effect on the ability of polymerase to function. Human cell lines 293T, Hela, but 
also U87MG (brain) or BxPC3 (pancreatic cancer cells) (unpublished observations), mouse 
cell line NIH 3T3, and the two swine cell lines used in this study (NPTr and NSK), show the 
627 E to K phenotype. Thus, the factor or the mechanism responsible for PB2 627K activity 
seems ubiquitous in mammalian cells.  
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7.3 Are pigs really a better “mixing vessel” than humans for influenza 
viruses? 
Pigs are thought to play an important role in influenza transmission between birds 
and humans. They have been proposed to be an intermediate host for the adaptation of 
avian influenza viruses to humans and the generation of reassortant viruses with pandemic 
potential (reviewed in (Brown, 2000)). Pigs are naturally susceptible to infection with at 
least some avian influenza viruses and avian-origin viruses have been isolated from pigs 
worldwide (reviewed in (Brown, 2008; Van Reeth, 2007)). Thus, one might anticipate that 
pig cells would be more permissive to avian-origin influenza polymerase than human cells 
are. Moreover it may be that pigs express co-factors for avian influenza polymerase that are 
not present in other mammalian species such as humans. 
Surprisingly, results from polymerase assays indicated that pig and human cells have 
similar restrictions in supporting the function of influenza polymerases from different 
origins. Low activity was observed in pig cells for polymerase from the two classical avian 
strains A/Turkey/England/50-92/91 (50-92) and A/Duck/Bavaria/1/77 (Bav). Although pigs 
seem to support growth of many typical avian influenza viruses, Kida et al. showed that not 
all strains replicated nor induced a serological response in pigs experimentally infected. In 
addition, the large majority of avian viruses replicated in pigs to a lower level compared to a 
swine adapted virus (Kida et al, 1994). In the field, only a minority of avian influenza strains 
seem to naturally spread among the pig population. This suggests that avian influenza 
viruses that have the potential to naturally and efficiently replicate and transmit in pigs are 
indeed rare.  
The results of the polymerase assays in pig cells indicate that mutations (or 
reassortment) are required for efficient replication of avian influenza in pigs, as they are 
required in humans. In fact, several reports recently challenged the notion that pigs readily 
replicate avian influenza viruses. In an experimental transmission study, avian influenza 
viruses failed to transmit among pigs (De Vleeschauwer et al, 2009b). Infection of pigs with a 
low pathogenic avian influenza virus resulted in only low titres shed (De Vleeschauwer et al, 
2009a). It is likely that the poor polymerase activity in pig cells is in part responsible for the 
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low viral titres usually obtained from swine infected with avian influenza (De Vleeschauwer 
et al, 2009b; Kida et al, 1994; Trebbien et al, 2011) and as a consequence could also be a 
contributing factor to inefficient virus spread. Several recent reports could not confirm the 
study from Ito et al. (Ito et al, 1998) and indicated instead that sialic acid distribution in 
respiratory tract of pigs and humans is indeed similar (Nelli et al, 2010; Trebbien et al, 2011; 
Van Poucke et al, 2010), challenging the theory of the pig as a mixing vessel for influenza 
reassortants. The avian-influenza receptor (NeuAcα2,3Gal) was found only in bronchioli and 
alveoli but not in trachea. Those observations and the results of the polymerase assays are 
both emphasising the resemblance between the two species and suggest that pigs do not 
appear to be a more appropriate mixing vessel for influenza viruses than humans. One can 
speculate that the reason more genetic reassortments are observed in pigs might simply be 
the consequence of swine husbandry and exposure of pigs to fecal contaminated material 
with high concentrations of influenza virus in farms (Van Poucke et al, 2010). 
Both influenza type B and type C viruses are normally exclusive to humans and likely 
to be well adapted to this host, whereas influenza A has its natural reservoir in aquatic 
wildfowl. Sequence comparisons between influenza A and B revealed that the polymerase 
genes show the highest level of homology (Webster et al, 1992). Chapter 5 indicates that an 
influenza B polymerase can replicate in pig cells and that the virus can successfully perform 
all the steps from attachment to the cell surface to viral proteins expression. It would be of 
interest to investigate which one of the late stages of the viral life cycle (i.e. vRNPs nuclear 
export, virion formation, or budding) is restricted in pig cells to explain the lack of influenza 
B virus circulating in pigs. 
 
7.4 Polymerase subunit PA can also be a major determining factor in 
overcoming the host range barrier 
During the course of this PhD a new human influenza pandemic strain emerged. The 
presence of PB2 627E on 2009 pH1N1 virus came as a surprise. PB2 627K was thought to be 
essential for influenza replication and transmission in humans. However, human infection 
with influenza viruses containing PB2 627E residue repeatedly occurred over the last 15 
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years. The majority (74%) of H5N1 viruses isolated from human cases, the huge majority of 
the viruses responsible for the HPAI H7N7 outbreak in The Netherland in 2003, and H9N2 
viruses responsible for human infections had an E at position 627. 
All the human pandemic strains from 1918 and until the emergence of the 2009 
pH1N1 lineage (H1N1, H2N2, H3N2) had a PB2 gene from the same origin: the 1918 H1N1 
“Spanish flu” virus. This PB2 segment encodes 627K and this residue has been conserved. It 
now appears that PB2 627K is not necessarily required for influenza replication and 
transmission in humans. PB2 627E has been maintained in pH1N1 viruses for 4 years now. 
There is no doubt E627K is a very potent mammalian adaptive mutation that allows most (if 
not all) avian-origin influenza polymerase to replicate better in human cells. In fact, the only 
exceptions are influenza strains containing the SR polymorphism at positions 590 and 591 
such as seen in swine triple reassortant viruses and also the descendant 2009 pH1N1 viruses 
(Mehle & Doudna, 2009). Other mutations on PB2 (i.e. 158, 271, 591, 701) and PA (i.e. 85, 
97, 186, 336) can have a role in overcoming the host range barrier and more residues 
involved in mammalian adaptation will likely be discovered on polymerase and NP proteins. 
In Chapter 6, H9N2 G1 strain was used as a prototype of an atypical avian-origin 
influenza polymerase with the ability of replicating in mammalian cells. This characteristic of 
H9N2 G1 polymerase seems to largely reside in polymerase subunit PA. Until recently, little 
was known about PA. Ser 624 is part of an active site for the protease activity of PA but this 
function is not fully understood (Hara et al, 2001). Influenza polymerase endonuclease 
activity has only recently been located on PA N-terminus (Dias et al, 2009; Yuan et al, 2009). 
PA N-terminus is also involved in viral promoter binding, in protein stability and cap binding 
(Hara et al, 2006) and it was reported that high influenza polymerase activity can be 
correlated with enhanced promoter binding though the N-terminal region of PA (Kashiwagi 
et al, 2009). C-terminal region of PA interacts with PB1 and with the minichromosome 
maintenance (MCM) complex which stabilizes replication elongation complexes through 
scaffolding between nascent cRNA and viral RNA polymerase (Kawaguchi & Nagata, 2007). 
Regions 493-512 and 557-574 of PA are involved in interaction with the host factor hCLE 
(Huarte et al, 2001). In a yeast two-hybrid screen, PA was found to interact with the cellular 
RNA polymerase II CTD domain (Tafforeau et al, 2011), an interaction probably essential for 
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influenza virus transcription and replication. All those interactions and functions will have to 
be investigated using H9N2 G1 PA in order to understand its contribution to the robust 
activity in mammalian cells of H9N2 G1 polymerase. It also remains to be investigated if 
differences in the recently discovered PA-X protein, which is translated by ribosomal 
frameshifting of the PA mRNA and contains the endonuclease domain of PA but not the PB1 
binding domain, plays a role. The effects of the mammalian adaptive mutation PB2 E627K 
and H9N2 G1 PA protein on A/Duck/Bavaria/1/77 polymerase activity were cumulative 
(Figure 57, page - 183 -), indicating that mammalian adaptation of avian-origin influenza 
polymerase can be achieved by a number of distinct mechanisms. 
Finally, this work and other reports suggest that H9N2 G1 polymerase is already 
capable of efficient replication in pig and human cells. So far, isolation of H9N2 viruses from 
pigs or human is rare, and no H9N2 documented transmission occurred between swine and 
humans and between humans (Uyeki et al, 2002). However, both human and pigs might 
create a suitable environment for H9N2 viruses to acquire adaptive mammalian mutations 
and generate a mammalian-transmissible strain.  
 
7.5 General conclusion 
Viruses require host cell factors to complete their replication cycles. The host factors 
that limit the interspecies transmission of influenza viruses are not well characterised or not 
all known. This work gave some insight into the restriction of avian-origin influenza 
polymerase in human cells but also in pig cells, questioning the role of pigs as “mixing 
vessel” for influenza A. 
There is no doubt 627K has a key role in mammalian adaptation of avian-origin 
influenza viruses but it is now clear that some strains that retain 627E are capable of 
efficient replication in mammalian cells (i.e. pH1N1, H9N2 G1). An increasing number of 
studies are highlighting the role of PA in mammalian adaptation. In addition, the two 
products of RNA segment 8, NS1 and NEP also affect polymerase function (de la Luna et al, 
1995; Enami et al, 1994; Manz et al, 2012; Robb et al, 2009). Finally, once the interferon 
response is activated, the viral protein NP determines the Mx sensitivity. Thus, influenza 
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virus polymerase adaptation to a new host is multigenic and can be achived by some rare 
specific constellations of gene segments encoding not only for the polymerase and NP but 
also NS. 
Defining specific interactions between host cell factors and viral proteins is essential 
in understanding how influenza exploits cellular functions and adapt from avian to human 
intracellular microenvironment. It also offers new solutions to develop new therapeutic 
strategies and new drugs. If a cellular factor that is required for influenza virus to replicate 
efficiently is targeted by a drug, the virus is virtually unable to overcome these with 
mutations. In the meantime, influenza will continue to be a serious threat to humans and 
animal species. 
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Chapter 8. Materials and Methods 
 
8.1 Materials 
8.1.1 Cell lines 
Table 10: Cell lines used in this study 
Cell line Comments Source 
293T Human kidney cells expressing large T-antigen of 
SV40  
ATCC 
DF-1 chicken fibroblast cell line ATCC 
CEF primary chicken embryo fibroblasts cells M. Mura (Barclay Lab) 
NPTr Newborn Pig Trachea cells I. Brown, AHVLA 
NSK Newborn Swine Kidney cells I. Brown, AHVLA 
MDCK Madin Darby Canine Kidney cells  ATCC 
 
8.1.2 Virus strains 
Table 11: Viruses used in this study 
Virus Comments Source 
B/Florida/04/06 Influenza B. Reverse genetic derived J. Ascroft (Barclay Lab) 
A/England/195/200
9 (H1N1) 
Influenza A H1N1. Reverse genetic derived R. Elderfield (Barclay 
Lab) 
Ty05 (6:2)  Recombinant virus. Segments 4 (HA) and 6 (NA) are from 
PR8 and segments 1 (PB2), 2 (PB1), 3 (PA), 5 (NP), 7 (M), 
and 8 (NS) are from A/turkey/Turkey/1/2005 
J. Long (Barclay Lab) 
Eng195 (6:2) Recombinant virus. Segments 4 (HA) and 6 (NA) are from 
PR8 and segments 1 (PB2), 2 (PB1), 3 (PA), 5 (NP), 7 (M), 
and 8 (NS) are from A/England/195/09 
J. Long (Barclay Lab) 
 
8.1.3 Plasmid vectors 
All plasmids used in this study contain genetic antibiotic resistance to Ampicillin 
unless otherwise stated. 
Table 12: List of plasmid vectors used in this study 
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Plasmid Description Source 
pCK-PolI-Firefly Negative-sense firefly minigenome plasmid to use in avian cells L. Tiley 
pCK-PolI-Renilla Negative-sense Renilla minigenome plasmid to use in avian cells This study 
pCK-PolI-eGFP Negative-sense eGFP minigenome plasmid to use in avian cells This study 
pCK-PolI-DsRed Negative-sense DsRed minigenome plasmid to use in avian cells This study 
pHuman-PolI-Firefly Negative-sense firefly minigenome plasmid to use in human cells This study 
pHuman-PolI-Renilla Negative-sense Renilla minigenome plasmid to use in human cells This study 
pHuman-PolI-eGFP Negative-sense eGFP minigenome plasmid to use in human cells This study 
pHuman-PolI-DsRed Negative-sense DsRed minigenome plasmid to use in human cells This study 
Measles F expression 
plasmid 
Express the measles virus fusion protein (F) M. Pizzato 
Measles H expression 
plasmid 
Express the measles virus heamagglutinin protein (H) M. Pizzato 
pCAGGS-5092-NP Express avian influenza 5092 NP protein Barclay Lab 
pCAGGS-5092-PB1 Express avian influenza 5092 PB1 protein Barclay Lab 
pCAGGS-5092-PB2 Express avian influenza 5092 PB2 protein Barclay Lab 
pCAGGS-5092-PB2 627K Express avian influenza 5092 PB2 protein mutated E627K This study 
pCAGGS-5092-PA Express avian influenza 5092 PA protein Barclay Lab 
pCMV-Victoria-NP Express human influenza Victoria NP protein Barclay Lab 
pCMV-Victoria-PB1 Express human influenza Victoria PB1 protein Barclay Lab 
pCMV-Victoria-PB2 Express human influenza Victoria PB2 protein Barclay Lab 
pCMV-Victoria-PB2 627E Express human influenza Victoria PB2 protein mutated K627E Barclay Lab 
pCMV-Victoria-PA Express human influenza Victoria PA protein Barclay Lab 
pDONR222 and 
pDONR221 
Gateway entry vector (Kanamycin resistance). Invitrogen 
pDONR222-Ck-Lib5-6 Chicken cDNA library “5+6” in universal Gateway entry plasmid 
pDONR222 (Kanamycin resistance). 
This study 
pDONR222-Ck-Lib7 Chicken cDNA library “5+6” in universal Gateway entry plasmid 
pDONR222 (Kanamycin resistance). 
This study 
pCAGGS-5092NP-IRES-
PB2 
Express avian influenza 5092 NP and PB2 proteins This study 
pCAGGS-5092NP-IRES-
PB2 627K 
Express avian influenza 5092 NP and PB2 mutated E627K proteins This study 
pCAGGS-5092PB1-IRES-
PA 
Express avian influenza 5092 PB1 and PA proteins This study 
pCH-GFPW HIV-1 derived lentiviral vector expressing eGFP protein P. Cherepanov 
pCH-cassetteA HIV-1 derived lentiviral containing the Gateway
 
AttR recombination sites This study 
pCH-5092-PB2 Lentiviral vector expressing 50-92 PB2 protein. Used as a negative control 
in chicken cDNA screen 
This study 
pCH-5092-PB2 627K Lentiviral vector expressing 50-92 PB2 protein mutated E627K. Used as a 
positive control in chicken cDNA screen 
This study 
pCH-Lib 5+6 Lentiviral vector expressing the chicken cDNA library “5+6” This study 
pCMV Delta 8.91 Plasmid expressing HIV-1 packaging proteins Gag and Pol C. Goujon 
VSV-G Plasmid expressing the G protein envelope from VSV C. Goujon 
pCAGGS-5092-NP-IRES-
PB2-Strep-Flag tag 
Express avian influenza 5092 NP and PB2 fused with the Strep-Flag tap-tag 
sequence 
This study 
pCAGGS-5092-NP-IRES-
PB2 627K-Strep-Flag tag 
Express avian influenza 5092 NP and PB2 E627K fused with the Strep-Flag 
tap-tag sequence 
This study 
pCAGGS-5092-NP-IRES-
PB2-SBP-ProtG tag 
Express avian influenza 5092 NP and PB2 fused with the SBP-ProtG tap-tag 
sequence 
This study 
pCAGGS-5092-NP-IRES-
PB2 627K-SBP-ProtG tag 
Express avian influenza 5092 NP and PB2 E627K fused with the SBP-ProtG 
tap-tag sequence 
This study 
pCAGGS-eGFP-Strep-Flag 
tag 
Express eGFP fused with the Strep-Flag tap-tag sequence This study 
pHPOM1-Firefly Human Pol I minigenome reporter plasmid containing the negative-sense 
firefly coding sequence and a mouse Pol I terminator 
This study 
pHPOM1-Renilla Human Pol I minigenome reporter plasmid containing the negative-sense 
Renilla coding sequence and a mouse Pol I terminator 
This study 
pHPOM1-GFP Human Pol I minigenome reporter plasmid containing the negative-sense 
eGFP coding sequence and a mouse Pol I terminator 
This study 
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pHPOM1-DsRed Human Pol I minigenome reporter plasmid containing the negative-sense 
DsRed coding sequence and a mouse Pol I terminator 
This study 
pHPOM1-NLS-DsRed Human Pol I minigenome reporter plasmid containing the negative-sense 
DsRed coding sequence fused to the SV40 NLS sequence and a mouse Pol I 
terminator 
This study 
pSPOM1-Firefly Swine Pol I minigenome reporter plasmid containing the swine Pol I 
promoter (-472 - +1), the negative-sense firefly coding sequence, and a 
mouse Pol I terminator 
This study 
pSPOM2-Firefly Swine Pol I minigenome reporter plasmid containing the swine Pol I 
promoter (-387 - +1), the negative-sense firefly coding sequence, and a 
mouse Pol I terminator 
This study 
pSPOM3-Firefly Swine Pol I minigenome reporter plasmid containing the swine Pol I 
promoter (-173 - +1), the negative-sense firefly coding sequence, and a 
mouse Pol I terminator 
This study 
pSPOM2-Renilla Swine Pol I minigenome reporter plasmid containing the swine Pol I 
promoter (-387 - +1), the negative-sense Renilla coding sequence, and a 
mouse Pol I terminator 
This study 
pSPOM2-eGFP Swine Pol I minigenome reporter plasmid containing the swine Pol I 
promoter (-387 - +1), the negative-sense eGFP coding sequence, and a 
mouse Pol I terminator 
This study 
pSPOM2-DsRed Swine Pol I minigenome reporter plasmid containing the swine Pol I 
promoter (-387 - +1), the negative-sense DsRed coding sequence, and a 
mouse Pol I terminator 
This study 
pFLUB1 Intermediate construct containing the human Pol I promoter, influenza B 
HA non coding sequences and the mouse Pol I terminator sequence 
This study 
pFLUB1-Firefly Human influenza B Pol I minigenome reporter plasmid containing the 
human Pol I promoter, the negative-sense firefly coding sequence, and a 
mouse Pol I terminator 
This study 
pFLUB1-Renilla Human influenza B Pol I minigenome reporter plasmid containing the 
human Pol I promoter, the negative-sense Renilla coding sequence, and a 
mouse Pol I terminator 
This study 
pFLUB1-GFP Human influenza B Pol I minigenome reporter plasmid containing the 
human Pol I promoter, the negative-sense eGFP coding sequence, and a 
mouse Pol I terminator 
This study 
pFLUB1-DsRed Human influenza B Pol I minigenome reporter plasmid containing the 
human Pol I promoter, the negative-sense DsRed coding sequence, and a 
mouse Pol I terminator 
This study 
pSFLUB1-Firefly Influenza B Pol I minigenome reporter plasmid containing the swine Pol I 
promoter, the negative-sense firefly coding sequence, and a mouse Pol I 
terminator 
This study 
polI-FluB-HA-GFP Human pol I reporter plasmid expressing a FluB HA-GFP fusion fusion. HA 
gene is from B/Beijin/1/87. Used in this study to amplify FluB HA non-
coding sequences. 
R. Elderfield 
pCIPA-Lee NP Express influenza B/Lee/40 NP protein Barclay Lab 
pCIPA-Panama PB1 Express influenza B/Panama/45/90 PB1 protein Barclay Lab 
pCIPA-Panama PB2 Express influenza B/Panama/45/90 PB2 protein Barclay Lab 
pCIPA-Panama PA Express influenza B/Panama/45/90 PA protein Barclay Lab 
pCAGGS-Bav NP Express avian influenza H1N1 Bavaria NP This study 
pCAGGS-Bav PB1 Express avian influenza H1N1 Bavaria PB1 This study 
pCAGGS-Bav PB2 Express avian influenza H1N1 Bavaria PB2 This study 
pCAGGS-Bav PA Express avian influenza H1N1 Bavaria PA This study 
pCAGGS-Bav PB2 E627K Express avian influenza H1N1 Bavaria PB2 mutated E627K This study 
pCAGGS-Bav PB2 D701N Express avian influenza H1N1 Bavaria PB2 mutated D701N This study 
pCAGGS-G1 NP Express avian influenza H9N2 G1 NP This study 
pCAGGS-G1 PB1 Express avian influenza H9N2 G1 PB1 This study 
pCAGGS-G1 PB2 Express avian influenza H9N2 G1 PB2 This study 
pCAGGS-G1 PA Express avian influenza H9N2 G1 PA This study 
pCAGGS-Vic NP Express human origin H3N2 Victoria NP A. Cauldwell 
pCAGGS-Vic PB1 Express human origin H3N2 Victoria PB1 A. Cauldwell 
pCAGGS-Vic PB2 Express human origin H3N2 Victoria PB2 A. Cauldwell 
pCAGGS-Vic PA Express human origin H3N2 Victoria PA A. Cauldwell 
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pCAGGS-Ty05 NP Express avian origin HPAI H5N1 Turkey05 NP J. Long 
pCAGGS-Ty05 PB1 Express avian origin HPAI H5N1 Turkey05 NP J. Long 
pCAGGS-Ty05 PB2 Express avian origin HPAI H5N1 Turkey05 NP J. Long 
pCAGGS-Ty05 PA Express avian origin HPAI H5N1 Turkey05 NP J. Long 
pCPOM1-Firefly Avian Pol I minigenome reporter plasmid containing the negative-sense 
firefly coding sequence and a mouse Pol I terminator 
A. Cauldwell 
pCAGGS-5092 PB2 
D701N 
Express avian influenza H5N1 50-92 PB2 mutated D701N M. Mura 
pCAGGS-5092 PB2 SR Express avian influenza H5N1 50-92 PB2 mutated G590S and Q591R A. Cauldwell 
pCAGGS-5092 PB2 T271A Express avian influenza H5N1 50-92 PB2 mutated T271A A. Cauldwell 
pCAGGS-Eng195 NP Express human origin pH1N1 Eng1295 NP M. Mura 
pCAGGS-Eng195 PB1 Express human origin pH1N1 Eng1295 PB1 M. Mura 
pCAGGS-Eng195 PB2 Express human origin pH1N1 Eng1295 PB2 M. Mura 
pCAGGS-Eng195 PA Express human origin pH1N1 Eng1295 PA M. Mura 
pCAGGS-H9N2 G1 NP 
K430T 
Express avian influenza H9N2 G1 NP mutated K430T This study 
pCAGGS-H9N2 G1 PB2 
KNN194-5-7QDK 
Express avian influenza H9N2 G1 PB2 mutated K194Q, N195D and N197K This study 
pCAGGS-H9N2 G1 PB2 
K334S 
Express avian influenza H9N2 G1 PB2 mutated K334S This study 
pCAGGS-H9N2 G1 PB2 
S590G 
Express avian influenza H9N2 G1 PB2 mutated S590G This study 
pCAGGS-H9N2 G1 PB2 
Q591R 
Express avian influenza H9N2 G1 PB2 mutated Q591R This study 
pCAGGS-H9N2 G1 PB2 
E627K 
Express avian influenza H9N2 G1 PB2 mutated E627K This study 
pCAGGS-H9N2 G1 PA 
A85T 
Express avian influenza H9N2 G1 PA mutated A85T This study 
pCAGGS-H9N2 G1 PA 
K237E 
Express avian influenza H9N2 G1 PA mutated K237E This study 
 
8.1.4 Antibodies 
Table 13: List of antibodies used in this study 
Antibody Comments Source 
Mouse anti-Flag Primary M2 monoclonal antibody used to 
probe for FLAG tag (diluted 1:2000 for 
western-blot)  
Sigma (F3165)  
 
Mouse IgG HRP-linked 
(from sheep) 
Secondary antibody conjugated to HR 
(diluted 1:10 000 for western-blot) 
GE Healthcare (NXA931) 
FluA NP Primary influenza A NP antibody (diluted 
1:300 for blue cell assay) 
AbD Serotec (MCA400) 
FluB NP Primary influenza B NP antibody (diluted 
1:300 for blue cell assay) 
AbD Serotec (MCA403) 
Goat α-mouse IgG- β-
galactosidase  
 
Secondary antibody conjugated to β-
galactosidase for use in blue cell assay.  
(Diluted 1:400 for blue cell assay)  
AbD Serotec (103006) 
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8.1.5 Oligonucleotides 
Table 14: List of the main oligonucleotides used in this report. Oligonucleotide 
primers were synthesised by MWG Eurofins and stock solutions of 100 pmol/μl were made 
using sterile water. 
Name of primer Sequence Use 
4715fw2 CTGCTAACCATGTTCATGCCTTC Sequencing primer of pCAGGS 
(forward) 
85rev GGTATTTGTGAGCCAGGGCATTG Sequencing primer of pCAGGS (reverse) 
M13(-20)fw GTAAAACGACGGCCAGT Sequencing primer of Pol I plasmids 
(forward) 
M13rev GGAAACAGCTATGACCATG Sequencing primer of Pol I plasmids 
(reverse) 
humanpolIpHinDrev1 TTAATATATAAAGCTTATTTAATGATAAAAAACACCCTTGTTTCTACTA
ATAACCCGG 
To clone the human Pol I promoter 
humanpolIpXhofw1 TTATTAATACTCGAGACGGGCCGGCCCCTGC To clone the human Pol I promoter 
RenEcoKozstartr1 ATAAGATAGAATTCGCCACCATGACTTCGAAAGTTTATGATCCAGAAC To clone the Renilla gene into Pol I 
plasmids 
RenHinDendsens1 TTACTTTAAAGCTTTTATTGTTCATTTTTGAGAACTCGCTCAACG To clone the Renilla gene into Pol I 
plasmids 
GFPEcoKozstartr1 ATAAGATAGAATTCTAGCCACCATGGTGAGCAAGGGCGAGG To clone the eGFP gene into Pol I 
plasmids 
GFPHinDendsens1 TTACTTTAAAGCTTACTTGTACAGCTCGTCCATGC To clone the eGFP gene into Pol I 
plasmids 
DsREDEcoKozstartr1 ATAAGATAGAATTCTAGCCACCATGGCCTCCTCCGAGGAC To clone the DsRed gene into Pol I 
plasmids 
DsREDHinDendsens1 TTACTTTAAAGCTTCTACAGGAACAGGTGGTGGCG To clone the DsRed gene into Pol I 
plasmids 
HumanpolIpfw1 GTGTGTGGCTGCGATGGT Sequencing primer for human Pol I 
reporter plasmids 
PB2endXhorev1 AATATGAAACTCGAGCTAATTGATGGCCATCCGAATTCTTTTG To clone 50-92 PB2 gene into pCHW 
plasmids 
PB2startBamKozs1 TATTAAATAGGATCCACCATGGAGAGAATAAAAGAACTAAGAGATTT
AATGTCG 
To clone 50-92 PB2 gene into pCHW 
plasmids 
CMV2 GTAGGCGTGTACGGTGG Used to amplify chicken cDNA from 
transduced 293T cells genomic DNA 
WPREstartseqrev2 CGTAAAAGGAGCAACATAGTTAAGAATACC 
 
Used to amplify chicken cDNA from 
transduced 293T cells genomic DNA 
5092PB2(MluI)rev GGCTTTCCACGCGTCGACACTAATTGATGGC Used to made the bicistronic plasmid 
pCAGGS-5092NP-IRES-PB2 
IRES-5092PB2fw GATTATATGGCCATGGAGAGAATAAAAGAACTAAG Used to made the bicistronic plasmid 
pCAGGS-5092NP-IRES-PB2 
IRES-PB15092fw2 CGATGATTATATGGCCATGGATGTCAATCCGACTTTACTTTTC Used to made the bicistronic plasmid 
pCAGGS-5092PB1-IRES-PA 
IRES-PB15092rev2 GTCGGATTGACATCCATGGCCATATAATCATCGTGTTTTTCAAAGG Used to made the bicistronic plasmid 
pCAGGS-5092PB1-IRES-PA 
IRESPAfw1 CGATGATTATATGGCCATGGAAGACTTTGTGCGACAATGCTTCAATC Used to made the bicistronic plasmid 
pCAGGS-5092PB1-IRES-PA 
IRESMluIfw1 TATTTATGTTTACGCGTTCCCCTCTCCCTCCCCCTAAC Used to made the bicistronic plasmid 
pCAGGS-5092NP-IRES-PB2 
XhoKozStrepsens1 TTATTATTCTCGAGGCCACCATGGCCGCGTGGTCTCATCCTC To clone the Strep-Flag tag into pCAGGS 
plasmid 
FlagendMluSal AATATATAAGTCGACGCGTGCCTCTAGACGCGGTTACTTGTC To clone the Strep-Flag tag into pCAGGS 
plasmid 
XhoKozSBPsens1 TTATTATTCTCGAGGCCACCATGGACGAGAAGACCACCGG To clone the SBP-ProtG tag into 
pCAGGS plasmid 
ProtGendMluSalr1 AATATATAAGTCGACGCGTCTACTATTCAGTGACAGTGAAAGTCTTTG To clone the SBP-ProtG tag into 
pCAGGS plasmid 
PB2startXhoKozs1 TATTAAATACTCGAGCCACCATGGAGAGAATAAAAGAACTAAGAGAT
TTAATGTCG 
To clone 5092 PB2 gene into tap-tag 
plasmids 
5092PB2endNOSTOPXh
oR1 
AATATGAAACTCGAGATTGATGGCCATCCGAATTCTTTTG To clone 5092 PB2 gene into tap-tag 
plasmids 
- 204 - 
 
GFPNostopXhorev1 AATTAATAACTCGAGGCCCCCCTTGTACAGCTCGTCCATGCC To clone the eGFP gene into pCAGGS-
Strep-Flag tag plasmid 
NLSDsREDs1 CCAAAGAAAAAGCGTAAAGTTGGAGGGGCCTCCTCCGAGGACG To clone SV40 NLS fused with the DsRed 
gene into pHPOM1 
SV40NLSEcos1 TTTAATTTGAATTCTAGCCACCATGGCTCCAAAGAAAAAGCGTAAAGT
TGGAGGG 
To clone SV40 NLS fused with the DsRed 
gene into pHPOM1 
mouseters1 CCCTGCTTTTGCTCCCCCCCAACTTCGGAGG To amplify the mouse polymerase I 
terminator sequence 
mousetermrev1 GGTCGACCTAAAGGTTCCAGG To amplify the mouse polymerase I 
terminator sequence 
NSmouseterms1 TTATTATATTGAATTCTATGACTTTGTCACCCTGCTTTTGCTCCCC To clone the mouse polymerase I 
terminator sequence in Pol I plasmid 
mousetermrev2 ATTTTATTTTGGATCCATCGATTAAGGTCGACCTAAAGGTTCCAG To clone the mouse polymerase I 
terminator sequence in Pol I plasmid 
PigPolIfw1 CTGGGCCTGAGGCGTGC To clone swine Pol I promoter 
(fragment – 472 to +1) into Pol I 
reporter plasmid (1rst PCR) 
PigPolIfw2 GGAGTGTTTCCCTGTCGGTCG To clone swine Pol I promoter 
(fragment – 387 to +1) into Pol I 
reporter plasmid (1rst PCR) 
PigPolIfw3 GGGTCGACCAGATGGCTCTG To clone swine Pol I promoter 
(fragment – 173 to +1) into Pol I 
reporter plasmid (1rst PCR) 
PigPolIendrev1 ATCTACCTGGTGACAGAAAAGGCG To clone swine Pol I promoter into Pol I 
reporter plasmid (1rst PCR) 
PigPolIfw1Xho TTATTTATACTCGAGCTGGGCCTGAGGCGTGC To clone swine Pol I promoter 
(fragment – 472 to +1) into Pol I 
reporter plasmid (2nd PCR) 
PigPolIfw2Xho TTATTTATACTCGAGGGAGTGTTTCCCTGTCGGTCG To clone swine Pol I promoter 
(fragment – 387 to +1) into Pol I 
reporter plasmid (2nd PCR) 
PigPolIfw3Xho TTATTTATACTCGAGGGTCGACCAGATGGCTCTG To clone swine Pol I promoter 
(fragment – 173 to +1) into Pol I 
reporter plasmid (2nd PCR) 
PigPolIendNSr1 ATATAAATAAAGCTTATTTAATGATAAAAAACACCCTTGTTTCTACTAT
CTACCTGGTGACAGAAAAGGCG 
 
To clone swine Pol I promoter into Pol I 
reporter plasmid (2nd PCR) 
SwinePolIFluBf1 CACCAGGTAGATAGTAGTAACAAGAGCATTTTTCAATAACG To clone influenza B non-coding 
sequences into swine PolI reporter 
plasmid 
Fireflyinternfw1 GCAAGATGGATTCCAATTCAGCG To clone influenza B non-coding 
sequences into swine PolI reporter 
plasmid 
humanpolIpXhofw1 TTATTAATACTCGAGACGGGCCGGCCCCTGC To clone influenza B non-coding 
sequences into human PolI reporter 
plasmid 
FluBHinDrev1 GCACTACAATAAAGGAAAATACAGGGCTTAATTTTCCAAGCTTTTTCAT
ATGTAACGAATTCTTTGTGG 
To clone influenza B non-coding 
sequences into human PolI reporter 
plasmid 
pBlueseqfw1 CTCTTCGCTATTACGCCAGCTG To clone influenza B non-coding 
sequences into swine PolI reporter 
plasmid 
endswinePolIFluBr1 GCCTTTTCTGTCACCAGGTAGATAGTAGTAACAAGAGC To clone influenza B non-coding 
sequences into swine PolI reporter 
plasmid 
FluBmouseterms1 GCTTTTTCATATGTAACGAATTCTTTGTGGATATTAGAAAATGCTCTGC
TTCTGCTCCCCCCCAACTTCGG 
To clone influenza B non-coding 
sequences into human PolI reporter 
plasmid 
BAVNPEcoKozs1 ATAAGATAGAATTCGCCACCATGGCGTCTCAAGGCACC To clone A/Duck/Bavaria/1/77 NP into 
pCAGGS 
BAVNPXhor1 TATATAAACTCGAGTTAATTGTCATACTCCTCTGCATTGTC To clone A/Duck/Bavaria/1/77 NP into 
pCAGGS 
BAVPAXhor1 TATATAAACTCGAGCTATTTCAGTGCATGTGTGAGGAAG To clone A/Duck/Bavaria/1/77 PA into 
pCAGGS 
BAVPANots1 ATAAGATAGCGGCCGCATGGAAGACTTTGTGCGACAATGC To clone A/Duck/Bavaria/1/77 PA into 
pCAGGS 
BAVPB1NotKozf1 ATAAGATAGCGGCCGCCACCATGGATGTCAATCCGACTTTACTTTTC To clone A/Duck/Bavaria/1/77 PB1 into 
pCAGGS 
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BAVPB1Xhor1 TATATAAACTCGAGCTATTTTTGCCGTCTGAGCTCTTC To clone A/Duck/Bavaria/1/77 PB1 into 
pCAGGS 
BAVPB2NotKozf1 ATAAGATAGCGGCCGCCACCATGGAGAGAATAAAAGAATTAAGAGAT
CTAATG 
To clone A/Duck/Bavaria/1/77 PB2 into 
pCAGGS 
BAVPB2Xhor1 TATATAAACTCGAGCTAATTGATGGCCATCCGAATCC To clone A/Duck/Bavaria/1/77 PB2 into 
pCAGGS 
G1NPEcoKozs1 ATAAGATAGAATTCGCCACCATGGCGTCTCAAGGCACC To clone A/Quail/Hong Kong/G1/97 NP 
into pCAGGS 
G1NPXhorev1 GACAATGCAGAGGAATATGACAATTGACTCGAGTTTATATA To clone A/Quail/Hong Kong/G1/97 NP 
into pCAGGS 
G1PANots1 ATAAGATAGCGGCCGCATGGAAGACTTTGTGCGACAATGC To clone A/Quail/Hong Kong/G1/97 PA 
into pCAGGS 
G1PAXhorev1 TATATAAACTCGAGCTATTTTAGTGCATGTGTGAGGAAGG To clone A/Quail/Hong Kong/G1/97 PA 
into pCAGGS 
G1PB1EcoKozs1 ATAAGATAGAATTCGCCACCATGGATGTCAATCCGACTTTACTTTTC To clone A/Quail/Hong Kong/G1/97 PB1 
into pCAGGS 
G1PB1Xhorev1 TATATAAACTCGAGTCACTTCCCTTGCCGTCCG To clone A/Quail/Hong Kong/G1/97 PB1 
into pCAGGS 
G1PB2NotKozs1 ATAAGATAGCGGCCGCCACCATGGAGAGAATAAAAGAACTAAGAGAT
TTGATG 
To clone A/Quail/Hong Kong/G1/97 PB2 
into pCAGGS 
G1PB2Xhorev1 TATATAAACTCGAGCTAATTGATGGCCATCCGAATTCTTTTGG To clone A/Quail/Hong Kong/G1/97 PB2 
into pCAGGS 
G1NP430Tfw1 GCTGCGTTTACGGGGAATACCGAGGGCAG Mutagenic primer to introduce K430T 
mutation into A/Quail/Hong 
Kong/G1/97 NP 
G1NP430Trev1 GGTATTCCCCGTAAACGCAGCCATAATGGTCGATC Mutagenic primer to introduce K430T 
mutation into A/Quail/Hong 
Kong/G1/97 NP 
G1PB219457f1 GAACTCCAGGATTGTAAAATTGCTCCTTTAATGGTGGCATATATG Mutagenic primer to introduce 
KNN194-5-7QDK mutations into 
A/Quail/Hong Kong/G1/97 PB2 
G1PB219457r1 GGAGCAATTTTACAATCCTGGAGTTCCTCCCTCTTTTCCTTTG Mutagenic primer to introduce 
KNN194-5-7QDK mutations into 
A/Quail/Hong Kong/G1/97 PB2 
G1PB2334Sfw1 CTTTCAAAAGAACATCGGGGTCTTCTGTCAAAAGAGAGG Mutagenic primer to introduce K334S 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1PB2334Srev1 CAGAAGACCCCGATGTTCTTTTGAAAGTGAACCCTCC Mutagenic primer to introduce K334S 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1PB2627Kf1 CCCACCTAAACAGAGTAGGATGCAATTTTCTTCTCTG Mutagenic primer to introduce E627K 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1PB2627Kr1 GCATCCTACTCTGTTTAGGTGGGGCTGCTGCAAATGG Mutagenic primer to introduce E627K 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1590Gfw1 GGCTGCCAGAGGCCAATATAGTGGATTTGTGAGAACG Mutagenic primer to introduce S590G 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1590Grev1 CTATATTGGCCTCTGGCAGCCTTTGGTACTAAAG Mutagenic primer to introduce S590G 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1591Rfw1 CCAGAAGCCGATATAGTGGATTTGTGAGAACGCTATTCC Mutagenic primer to introduce Q591R 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1591Rrev1 CACAAATCCACTATATCGGCTTCTGGCAGCCTTTGG Mutagenic primer to introduce Q591R 
mutation into A/Quail/Hong 
Kong/G1/97 PB2 
G1PAmut85fw2 GAAGGAAGAGACCGAACAATGGCCTGGACAGTGGTGAATAGC Mutagenic primer to introduce A85T 
mutation into A/Quail/Hong 
Kong/G1/97 PA 
G1PAmut85rev1 GGCCATTGTTCGGTCTCTTCCTTCAATTATTTCAAACC Mutagenic primer to introduce A85T 
mutation into A/Quail/Hong 
Kong/G1/97 PA 
G1PA237Efw1 GGATGGATTCGAACCGAACGGCTGCATTGAGG Mutagenic primer to introduce K237E 
mutation into A/Quail/Hong 
Kong/G1/97 PA 
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G1PA237Erev1 GCCGTTCGGTTCGAATCCATCCACATAGGCTCTAAAG Mutagenic primer to introduce K237E 
mutation into A/Quail/Hong 
Kong/G1/97 PA 
 
 
8.1.6 Buffers and culture media 
Table 15: List of Buffers and culture media used in this study 
Solution Recipe Uses 
TAE Buffer 40mM Tris-acetate pH 8  
1mM EDTA  
DNA gel electrophoresis  
Lysogeny Broth (LB) 1% Oxoid tryptone  
0.5% Oxoid yeast extract  
0.5% NaCl  
0.1% glucose  
Culturing transformed bacterial 
cells  
 
LB Agar LB + 1.5% (w/v) Difco Agar  
Supplemented with 1% Ampicilin 
or 2% Kanamycin  
Culturing transformed bacterial 
cells  
 
SOC Medium 2% Oxoid tryptone  
0.5% Oxoid yeast extract  
10mM NaCl  
2.5mM KCl  
10mM MgCl2  
10mM MgSO4  
20mM glucose  
Recovery medium used during 
transformation of Escherichia coli 
DH10B cells 
 
6X DNA loading dye 0.25% Bromophenol blue  
40% (w/v) sucrose.  
DNA gel electrophoresis 
6X protein loading dye 375 mM Tris-HCl pH 6.8, 6% SDS, 
30% glycerol, 9% 2-
Mercaptoethanol, and 0.03% 
bromophenol blue 
Protein gel electrophoresis 
Tap-tag lysis buffer 50 mM potassium phosphate pH 
7.4,  
200 mM NaCl, 
0.5% IGEPAL,  
1 mM DTT,  
2 mM EDTA,  
30 u/ml RNAsine,  
15% glycerol 
Lysing cells 
Tap-tag washing buffer 50 mM potassium phosphate pH 
7.4,  
200 mM NaCl,  
0.1% IGEPAL,  
1 mM DTT,  
2 mM EDTA,  
30 u/ml RNAsine 
Washing buffer for Tap-tag study 
LacZ Buffer 60mM Na2HPO4.7H2O  
40mM NaH2PO4.H2O  
10mM KCl  
1mM MgSO4  
Developing β-galactosidase assays  
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10X CN Buffer 30mM Ferricyanide  
30mM Ferrocyanide  
10mM MgCl2  
Blue cell assays  
 
X-Gal substrate Prepared to 2% in 
Dimethylformamide (DMF)  
Blue cell assays  
 
Phosphate Buffered Saline (PBS) 155 mM NaCl 
1 mM KH2PO4 
3 mM Na2HPO4 
Used for cell washes 
Plaque assay overlay  100 ml 10 x Earle’s minimal 
essential medium (EMEM)  
28 ml 7.5% BSA  
1% glutamine (200mM)  
20 ml 7.5% NaHCO3  
10 ml 1M HEPES  
5 ml 1% DEAE Dextran (Sigma)  
1% penicillin-streptomycin 
(5000IU/ml)  
2% Agarose (Oxoid)  
Plaque assays 
Crystal violet solution 100 ml Crystal violet stock solution 
300 ml ethanol 
1.6 l water 
Crystal violet staining 
 
 
8.2 Methods 
 
8.2.1 Molecular biology 
8.2.1.1. Standard polymerase chain reaction conditions 
PCR reactions were carried out in a total volume of 50 μl. Reaction mixtures 
contained 50 ng of plasmid DNA, 50 pmol of sense and anti-sense oligonucleotide primers, 5 
μl of 10X Thermo Pol buffer (New England Biolabs), 1 μl of dNTP mix (10 mM each of dATP, 
dCTP, dGTP and dTTP), and 1 μl of Vent polymerase (New England Biolabs). 
Standard PCR conditions are presented in Table 16. Following PCR reaction, 5 μl of 
the product was run on an agarose gel. 
- 208 - 
 
Table 16: Standard PCR thermal cycling conditions 
 Temperature Time Step 
1 96⁰C 3 min Initial denaturation 
2 96⁰C 30 sec Denaturation 
3 55⁰C 30 sec Annealing 
4 72⁰C 1 min/Kb Elongation 
5 Go to step 2, repeat 25 times   
6 72⁰C 4 min Final extension 
7 4⁰C hold  
 
8.2.1.2. Agarose gel electrophoresis 
DNA fragments were separated on 0.8% (or 1.5% for smaller DNA fragments) 
agarose gels diluted with 0.5x TAE buffer and supplemented with 1 μg/ml Gel Red 
(Cambridge Bioscience). Gels were submerged in TAE buffer. Samples were run 
simultaneously with a commercially available DNA size marker at 80-100V until the bands 
had separated. DNA was visualised using a UV transilluminator.  
 
8.2.1.3. DNA product purification 
Slices containing the required DNA fragments were excised, and DNA extracted using 
the SV Gel and PCR Clean-Up system (Promega) following manufacturer’s instructions. 
Similarly, PCR product or digestion products were purified using the same kit. DNA 
fragments were eluted with 35 µl of warm (37⁰C) sterile water and 2 µl of eluted product 
were run on a control agarose gel. 
 
8.2.1.4. Site directed mutagenesis by overlapping PCR 
For site directed mutagenesis, the first round of PCR was performed as described in 
section 8.2.1.1, generating fragments of the insert containing the desired mutation(s) and 
an overlapping region. For the second round of PCR, equal amounts of the purified DNA 
fragments were used as templates for the DNA reaction. 10 cycles of PCR were first 
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performed without primers, to allow annealing of the DNA templates. PCR was then 
performed as outlined in Table 16. 
 
8.2.1.5. DNA digestion by restriction endonucleases 
For cloning digests, reactions were performed in 40 μl total volume. 30 μl of PCR 
purified DNA (or 3 μg of purified plasmid DNA in 30 μl of water) was digested with 1 μl of 
each restriction enzyme (10 U, supplied by NEB), 4 μl of the appropriate 10X buffer and 0.5 
μl of 100 μg/ml bovine serum albumin (BSA), where recommended (NEB). For analytical 
digests, reactions were performed in 20 μl total volume. 1 μg of DNA was digested with 1 μl 
of each restriction enzyme, 2 μl of the appropriate 10X buffer and 0.15 μl of BSA, where 
recommended. All reactions were carried out at 37°C for 2 - 3 hours, unless recommended 
otherwise by manufacturer’s instructions. 
 
8.2.1.6. DNA ligation 
Ligation reactions were carried out in a total volume of 10 μl. Typically 2 to 7 μl of 
the digested insert and 1 μl of the digested vector was ligated with 1 μl of T4 DNA ligase 
buffer and 1 μl of T4 DNA ligase (both supplied by NEB). The reaction mixture was incubated 
at room temperature from 1 hour minimum and used to transform competent bacterial 
cells. 
 
8.2.1.7. Transformation of competent bacterial cells 
50 μl of high efficiency electro-competent bacterial cells (E.coli strain ElectroMAX 
DH10B T1 phage resistant, Invitrogen) diluted 10X in 10% sterile glycerol were incubated 
with 5 μl of ligated DNA or 2 ng of plasmid stocks for 10 minutes on ice in an 0.1 cm 
electroporation cuvette (BioRad). Cells were electroporated (MicroPulser, BioRad) and 150 
μl ml of sterile LB was then added to the suspension. Cells were then allowed to recover for 
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1 hour at 37°C. Reaction mixtures were plated onto LB-Agar plates containing the 
appropriate antibiotic and incubated at 37°C overnight.  
For the transformation of the chicken cDNA library in pDONR222 (BP reaction 
product), "BP" reactions were divided into 6 aliquots of 1.5 l each into 6 chilled sterile 
Eppendorf tubes. 70 l of ElectroMAX DH10B cells were added into the BP containing tubes 
and the mixes were transfered into chilled 0.1 cm elecroporation cuvettes and incubated on 
ice for 10 minutes before electroporation. 430 l of warm SOC media (Invitrogen) was 
added into each electroporation cuvette. Cells were pooled in a 50 ml tube. Each cuvette 
was washed with 500 l of warm SOC which was added into the same 50 ml tube. This 
procedure was repeated. Bacteria suspension was incubated for 1 hour at 37°C under 
shaking to allow expression of the kanamycin resistance protein. An aliquot from the 
suspension was harvested for titre determination by plating serial 10 fold dilutions on LB 
plates containing 50 g/ml kanamycin. 54 ml of LB media containing kanamycin (50g/ml 
final) was inoculated with the bacterial suspension (final volume: 60 ml), which was then 
incubated for 6 hours at 37°C at 225-250 rpm for library amplification. An aliquot from the 
culture was harvested and plated to determine the number of cell divisions. 10% of the 
bacteria suspension (6 ml) was mixed with 1.5 ml of sterile 80% glycerol and stored at -80°C 
as a backup and the rest of the culture was centrifuged and the pellet stored at -80°C for 
plasmid extraction and purification. 
 
8.2.1.8. Small scale plasmid purification 
A single bacterial colony was picked from agar plates containing a selection antibiotic 
(ampicillin or kanamycin) and grown overnight in 5 ml LB containing the same antibiotic at 
37°C, with shaking. 250 µl of the bacteria suspension was mixed with 850 µl of sterile 80% 
glycerol and stored at -80°C as a glycerol stock. The rest of bacteria were pelleted using a 
centrifuge at 3000xg for 5 minutes. The supernatant was discarded. Plasmid DNA was 
purified using the QIAprep spin miniprep kit (QIAGEN) following the manufacturer’s 
protocol. This involves alkaline lysis of bacterial cells followed by neutralisation and binding 
of plasmid DNA to a silica membrane. The membrane was washed and plasmids eluted with 
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50 µl of warm (37°C) sterile water in a 1.5ml Eppendorf tube. Plasmids were stored at -20°C 
to prevent DNA degradation.  
 
8.2.1.9. Large scale plasmid purification  
A 100 µl sample from a glycerol stock or a single colony was inoculated into 250 ml 
of LB containing selection antibiotic at the appropriate concentration, and grown overnight 
at 37°C with shaking. Plasmids were recovered using the high-speed plasmid purification 
maxi kit (QIAGEN) according to the manufacturer’s instructions. Briefly, bacterial cells were 
pelleted by centrifugation at 3000xg for 30 minutes at 4°C. The supernatant was discarded 
and cells resuspended in 10 ml of resuspension buffer containing RNaseA. Alkaline lysis 
buffer containing SDS was added to lyse the cells and denature the genomic DNA. The 
suspension was neutralised, precipitating contaminants, centrifugated at 3000xg for 5 
minutes and the supernatant was passed through a resin containing column that binds 
plasmid DNA. The columns were washed and plasmid DNA eluted. Isopropanol was added to 
desalt and precipitate plasmid DNA, which was then ethanol washed and eluted in 500 μl of 
TE (elution) buffer (QIAGEN). Plasmid preparations were stored at -20°C. 
 
8.2.1.10. DNA Concentration Determination 
DNA concentrations were determined using a spectrophotometer (BioPhotometer, 
Eppendorf), with optical density measurements at 260 nm with the assumption that 1 OD260 
unit corresponds to 50 μg/ml of double stranded (ds) DNA. 
 
8.2.1.11. DNA sequencing 
Constructs were sequenced using the MRC sequencing service (MRC Clinical Sciences 
Centre, Hammersmith Campus, Du Cane Road, London, W12 0NN). Samples were subjected 
to automated fluorescent DNA sequencing using the ABI3730xl instrument. The reaction 
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mixture was dispatched as a 10μl solution containing 3.2pmol primer, 400 – 600 ng DNA and 
water. 
 
8.2.1.12. Genomic DNA extraction 
Genomic DNA was extracted using the Wizard genomic DNA purification kit 
(Promega) according to the manufacturer’s instructions. Briefly, 106 cells were centrifugated 
13,000xg for 10 seconds to pellet the cells. Supernatant was removed and cells were 
washed with 200 µL of PBS. 600 µL of lysis buffer was used to resuspend the cells and 
mixture was incubated for 30 minutes at 37°C in presence of 3 µL of RNase Solution. 200 µL 
of Protein Precipitation Solution was added to the room temperature mixture, vortexed and 
incubated on ice 5 minutes. After centrifugation (4 minutes at 13,000xg) the supernatant 
was transferred into an Eppendorf tube containing 600 µL of isopropanol. DNA was pelleted 
by centrifugation (1 minute at 13,000xg) and washed with 70% ethanol. The pellet is air-
dried for 15 minutes and resuspended with 100 µL of Resuspension buffer by incubation at 
65⁰C for 1 hour. 
 
8.2.1.13. Plasmids made in this study 
Influenza minigenome reporter plasmids (Pol I plasmids) 
New set of PolI reporter plasmids (pHumanPolI and pCkPolI) were made from pCk-
PolI-Firefly (from L. Tiley) which is a minigenome plasmid containing the firefly luciferase 
gene flanked by the influenza A virus NS gene noncoding regions, a chicken RNA polymerase 
I promoter and the hepatitis delta virus (HDV) ribozyme. The chicken RNA polymerase I 
promoter sequence was removed with XhoI and HindIII, and replaced by the human RNA 
polymerase I promoter (amplified with primers humanpolIpXhofw1 and 
humanpolIHinDrev1), generating pHuman-PolI-Firefly. Then, the firefly coding sequence was 
replaced by Renilla luciferase, eGFP and DsRed coding sequences in pCk-PolI and pHuman-
PolI backgrounds to generate pCK-PolI-Renilla, pCK-PolI-GFP, pCK-PolI-DsRed, pHuman-PolI-
Renilla, pHuman-PolI-GFP and pHuman-PolI-DsRed respectively. Primers used: 
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RenEcoKozstartr1 and RenHinDendsens1 for Renilla, GFPEcoKozstartr1 and 
GFPHinDendsens1 for eGFP, and DsREDEcoKozstartr1 and DsREDHinDendsens1 for DsRed. 
In order to replace the HDV ribozyme sequence by the mouse RNA polymerase I 
terminator (Grummt et al, 1985), mouse genomic DNA was extracted from NIH3T3 cells and 
cloned between EcoRI and BamHI sites of pHuman-PolI-Firefly to generate pHPOM1-Firefly. 
Briefly, the mouse RNA polymerase I terminator sequence was first amplified using primers 
mouseters1 and mousetermrev1. The purified PCR product was then amplified with primer 
NSmouseterms1 which brings the influenza A segment 8 3’ non coding sequence and primer 
mousetermrev2 and cloned between EcoRI and BamHI sites of pHuman-PolI-Firefly to 
generate pHPOM1-Firefly. Then, the firefly coding sequence was replaced by Renilla 
luciferase, eGFP and DsRed coding sequences in pHPOM1 background to generate pHPOM1-
Renilla, pHPOM1-GFP and pHPOM1-DsRed respectively. To generate pHPOM1-NLS DsRed, 
DsRed coding sequence was first amplified from pHPOM1-DsRED with primers NLSDsREDs1 
and M13(-20)fw and the purified PCR product was then amplified with primers 
SV40NLSEcos1 and M13(-20)fw. The PCR product was then cloned into pHPOM1 between 
EcoRI and HindIII restriction sites to create pHPOM1-NLS-DsRed plasmid. 
To generate the swine minigenome reporter plasmids, swine genomic DNA was 
extracted from NKS cells and the three regions of the swine RNA polymerase I promoter 
sequence (fragment –472 to +1, fragment –387 to +1, fragment –173 to +1, based on (Ling & 
Arnheim, 1994)) were introduced into pHPMO1-Firefly between XhoI and HindIII sites, 
replacing the human RNA PolI promoter sequence. Briefly, the three regions of the swine 
RNA polymerase I promoter sequence were amplified using the forward primer PigPolIfw1 
(fragment –472 to +1), PigPolIfw2 (fragment –387 to +1), PigPolIfw3 (fragment –173 to +1) 
together with the reverse primer PigPolIendrev1. Purified PCR products were then amplified 
with XhoI containing forwards primers PigPolIfw1Xho, PigPolIfw2Xho and PigPolIfw3Xho 
respectively, together with reverse primer PigPolIendNSr1 which brings the influenza A 
segment 8 5’ non coding sequence and HindIII restriction site. Digested PCR products were 
introduced into pHPMO1-Firefly between XhoI and HindIII sites, replacing the human RNA 
PolI promoter sequence and generating pSPOM1-Firefly, pSPOM2-Firefly and pSPOM3-
Firefly respectively. The firefly coding sequence present in pSPOM2-Firefly was then 
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replaced with the Renilla, GFP and DsRed coding sequence to generate the full set of swine 
Pol I reporter plasmids (pSPOM2-Firefly, pSPOM2-Renilla, pSPOM2-GFP, and pSPOM2-
DsRed). 
The set of influenza B minigenome reporter plasmids was obtained by overlapping 
PCR. Briefly, the human PolI promoter sequence and influenza B HA non coding sequence 
were amplified from a Pol I plasmid expressing B/Beijing/1/87 HA gene fused with GFP (polI-
FluB-HA-GFP) with humanPolIXhoI and FluBHinDrev1. The mouse terminator was amplified 
with FluBmouseterms1 and M13rev2 from pHPOM1-Firefly. Purified PCR products were 
mixed and amplified with humanPolIXhoI and M13rev2. The product was cloned into 
pHPOM1-Firefly opened with XhoI and BamHI to create the intermediate construct pFLUB. 
Firefly, Renilla, GFP and DsRed coding sequences were introduced into pFLUB between 
HindIII and EcoRI to generate pFLUB1-Firefly, pFLUB1-Renilla, pFLUB1-GFP and pFLUB1-
DsRed respectively. The influenza B firefly minigenome reporter under control of the swine 
polymerase I promoter was made as follow: influenza B HA non coding sequence and the 
end of the firefly gene was amplified from pFLUB1-Firefly plasmid with SwinePolIfluBf1 and 
Fireflyinternfw1 primers. The swine PolI promoter sequence was amplified from pSPOM2-
Firefly with pBlueseqfw1 and endswinePolIFluBr1. The two purified PCR products were 
mixed and amplified with pBlueseqfw1 and Fireflyinternfw1. The product was digested with 
XhoI and HindIII and cloned into pFLUB1-Firefly to generate pSFLUB1-Firefly plasmid. 
 
Bicistronic expression plasmids 
The bicistronic plasmids were generated as follow. EMCV IRES-5092 PB2 chimera 
was produced by overlapping PCR and introduced into the expression plasmid pCAGGS-
5092NP to generate pCAGGS-5092NP-IRES-PB2. Briefly, 50-92 PB2 coding sequence and 
EMCV IRES sequence were amplified with primers IRES-5092PB2fw/5092PB2(MluI)rev and 
IRES(MluI)fw/IRES-5092PB2rev respectively. pCAGGS-5092 NP plasmid was digested with 
MluI, dephosphorylated with the alkaline phosphatase (CIP) (New England Biolabs) and 
ligated with the IRES EMCV-5092 PB2 insert, previously digested with MluI. The same 
strategy was used to generate pCAGGS-5092NP-IRES-PB2 627K.  
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The same strategy was used to generate pCAGGS-5092 PB1-IRES-PA. EMCV IRES-
5092 PA chimera was also produced by overlapping PCR and cloned into pCAGGS-5092-PB1. 
The primers used to amplify 5092 PA were IRESPAfw1 and 5092PArev; and IRES(MluI)fw and 
EMCVend-PArev1 were used to amplify EMCV IRES. 
 
Lentivirus plasmids 
The eGFP coding sequence present in the lentiviral genomic plasmid pCH-GFPW was 
removed after digestion with BamHI and XhoI, extremities were treated with the DNA 
polymerase I large fragment (Klenow) (Promega) to obtain blunt ends, then 
dephosphorylated and ligated with the CassetteA insert (Invitrogen). 50-92 PB2 wild type or 
5092 PB2 E627K were amplified by PCR using PB2startBamKozs1 and PB2endXhorev1 
primers, digested by BamHI and XhoI and cloned into pCH-GFPW digested with BamHI and 
XhoI. 
 
 Tap-tag expression plasmids 
The Tap-tag sequences were amplified by PCR respectively from pCG C-terminal-
StrepFlag with XhoKozStrepsens1/FlagendMluSal and from pcDNA4-TO\CTAP (SBP-ProtG) 
with XhoKozSBPsens1/ProtGendMluSalr1 and cloned into pCAGGS between XhoI and MluI. 
The eGFP coding sequence was amplified by PCR from pHumanPolI-GFP with M13rev and 
GFPnostopXhorev1 and cloned into pCAGGS-StrepFlag tag plasmid between EcoRI and XhoI 
to generate pCAGGS-GFP-StrepFlag tag. 
 
H1N1 Bav and H9N2 G1 expression plasmids 
A/Duck/Bavaria/1/77 and A/Quail/Hong Kong/G1/97 PB1, PB2, PA and NP genes 
were amplified from Pol I/Pol II pHW2000 plasmids and introduced into pCAGGS expression 
plasmid. 
All the mutagenesis reactions were performed by overlapping PCR. The correct 
sequence of all the reporter plasmids was verified by sequencing. 
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Measles F and H expression plasmid were kindly provided by Dr Massimo Pizzato 
(Imperial College London), pCH-GFPW by Dr Peter Cherepanov (Imperial College London), 
pCMV-Delta 8.91 (Gag-Pol) and VSV-G plasmids were from Dr Caroline Goujon (King’s 
College London). Tap tag plasmids pCG C-terminal (StrepFlag) and pcDNA4-TO\CTAP (SBP-
ProtG) were a gift from N. Peters (Imperial College London) and Dalan Bailey (Imperial 
College London) respectively. Plasmids encoding PB1, PB2, PA and NP genes from 
A/Duck/Bavaria/1/77 were provided by J. Stech (Friedrich Loeffler Institut, Greifswald–Insel 
Riems, Germany), and A/Quail/Hong Kong/G1/97 PolI/II plasmids were provided from M. 
Peiris (The University of Hong Kong SAR, China). 
 
 
8.2.2 Cell lines and cell culture techniques 
8.2.2.1. Cell lines, media and maintenance 
293T, DF-1, CEF, NPTr, NSK and MDCK cells were cultivated in Dulbecco's Modified 
Eagle Medium (DMEM) with pyruvate and L-Glutamine (Invitrogen) supplemented with 1% 
penicillin and streptomycin, and 10% (v/v) heat inactivated foetal Calf serum (Biosera). Cells 
were kept at 37°C in a 5% CO2 atmosphere except DF-1 and CEF cells which were maintained 
at 39°C in a 5% CO2 atmosphere. 
 
8.2.2.2. Freezing and thawing 
Long-term frozen stocks of all cell lines were kept in liquid nitrogen. Cells from a 
semi-confluent T75 cm2 flask were pelleted by centrifugation at 1,200 rpm for 5 minutes. 
Cell pellets were then re-suspended in freezing medium containing 30% foetal calf serum 
plus 20% DMSO in DMEM. Cells were immediately slow cooled at -80°C before being 
transferred to liquid nitrogen the following day. 
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Frozen vials of cells were thawed at 37°C for approximately 1 minute before being 
rapidly transferred to 10ml of pre-warmed media. Cells were centrifuged at 1,200 rpm for 5 
minutes before re-suspension of the pellet in 12 ml of media and transfer to a T75 cm2 
tissue culture flask. 
 
8.2.2.3. Transfections 
All transfections were performed on sub-confluent monolayers of cells plated 24 
hours beforehand. 
Cells were transfected with Lipofectamine 2000 (Invitrogen). For transfections in a 
12 well cell culture plate, 5 μl of Lipofectamine 2000 transfection reagent was mixed with 95 
μl of Optimem (Invitrogen). Separately, plasmid DNA was mixed with 100 μl of Optimem, 
before the two mixtures were combined and incubated at room temperature for 20 
minutes. The transfection mixture was the added dropwise to cells and the cell culture 
media was replaced 3 hours post transfection. 
Quantities were increased or decreased as appropriate for larger or smaller scale 
transfections. 
 
8.2.2.4. Minigenome assays 
Typically, cells were transfected in 12 well plates with plasmids encoding PB1, PB2, 
PA and NP proteins (NP: 320 ng, PB1 and PB2: 160 ng, PA: 40 ng) together with a minus-
sense reporter expressing plasmid (160 ng) were transfected as described in paragraph 
8.2.2.3. When DF1 cells were used, twice the normal amount of DNA was transfected. When 
firefly or Renilla luciferase reporters were used, cells were lysed with 300 l of Passive lysis 
buffer (Promega) and luciferase activity was measured using an Autolumat Plus LB 953 
(Berthold) or a FLUOstar Omega plate reader (BMG Labtech). 
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8.2.2.5. Fusion assay between 293T and DF1 cells 
293T and DF1 cells were transfected in 6 well plates with PEI transfection reagent 
with 1 g eGFP expression plasmid (pCH-GFPW), or 0.2 g of each Measles F and H 
expression plasmids (Schwarz strain, kindly provided by Dr M. Pizzato). 3 hours after 
transfection, cells were washed once with PBS, detached with 300 l of 0.01% trypsin 0.04 
g/L EDTA. After 5 minutes incubation at 37°C, trypsin was neutralised with 300 l of DMEM 
10% serum. Cells were collected, centrifuged 5 minutes at 60xg at room temperature, 
resuspended with DMEM 10% serum with antibiotics, counted, and mixed in a 12 well plate 
(ratio 1:1). Cells were incubated at 37°C with 5% CO2 for 24 hours. 
 
8.2.2.6. Minigenome assay in fused 293T and DF1 cells  
293T cells were transfected in 6 well plates using Lipofectamine 2000 transfection 
reagent (Invitrogen) with avian or human-derived polymerase and NP expression plasmids 
and a firefly minigenome reporter plasmid (NP: 0.8 g, PB1 and PB2: 0.4 g, PA: 0.1 g, 
pHuman-PolI-Firefly: 0.4 g) as described in paragraph 8.2.2.3 with adapted volumes. Those 
293T cells expressing a polymerase complex were named 293T-Pol. In parallel, DF1 and 293T 
cells were transfected with the two Measles protein F and H expression plasmids (DF1: 0.4 
g each, 293T 0.2 g each) and a Renilla minigenome reporter plasmid (0.8 g of pCk-PolI-
Renilla or 0.4 g of pHuman-PolI-Renilla respectively). Those cells expressing the fusogenic 
proteins and a species-specific Renilla minigenome were named DF1-R and 293T-R. 3 hours 
after transfection, cells were washed once with PBS, detached as described above, and 
counted. 2.5 105 293T-Pol cells were seeded in a 24 well plate and DF1-R or 293T-R cells 
were added (ratio 293T-Pol : DF1-R or 293T-R were 60:1 ; 30:1 ; 15:1 and 7.5:1). Cells were 
incubated at 37°C with 5% CO2 for 20 hours and lysed with 200 L of Passive lysis buffer 
(Promega) for measure of firefly and Renilla activities. When the fluorescent reporters were 
used, 293T and DF1 cells were transfected as described above, detached and counted. 293T 
cells expressing the DsRed minigenome and 293T or DF1 cells expressing 50-92 polymerase 
complex (PB1, PB2 and PA), 50-92 NP, an eGFP minigenome and the Measles F and H 
fusogenic proteins were mixed in a 6 well plate (7.5 105 of each cell type). Cells were 
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incubated at 37°C with 5% CO2 for 20 hours, washed with PBS, and fixed for 30 minutes at 
room temperature with 4% paraformaldehyde. Cells were stained with DAPI (0.5 μg/ml) and 
analysed for eGFP and DsRed expression. 
 
8.2.2.7. Microscopy 
Pictures from fluorescent cells were acquired with Axiovert 200M microscope (Zeiss) 
and an Axiocam HRC camera (Zeiss) and were treated with AxioVision Rel 4.7 program. 
 
8.2.2.8. Lentivectors (LV) production 
293T cells were transfected in 10 cm plates plates using Lipofectamine 2000 
transfection reagent with a mix of 3 plasmids (pCMV-Delta 8.91 (Gag-Pol): 8 g, VSV-G 
(Env): 4 g, pCH vector (genomic construct): 8 g) as described in paragraph 8.2.2.3 with 
adapted volumes. Cells were incubated at 37°C with 5% CO2 for 36 hours, and supernatants 
were collected, filtered through 0.45 µm, aliquotted and stored at -80⁰C. 
 
8.2.2.9. GFP lentivectors titration 
293T cells seeded in a 12 well plate were transduced with 0, 2, 4, 6, 8, 10, or 12 µl of 
GFL lentivectors (LV) in a total of 500 µl of DMEM plus 10% FCS and 1% antibiotics for 2 
hours. Inoculums were removed and 1 ml of media was added to the cells. 24 hours after 
incubation at 37°C, cells were detached, fixed and percentage of GFP expressing cells was 
analysed by FACS. 
 
8.2.2.10. FACS analysis 
Medium from transfected or transduced cells in a 12 well plate was removed and 
cells were washed with 1 ml of PBS and detached using 400 µL of 5 times diluted trypsin. 
Trypsin was neutralised with 400 µl of PBS containing 10% FCS. Cells were then centrifuged 
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at 2000xg for 5 minutes in Eppendorf tubes, before being resuspended with 600 µL of 1% 
paraformaldehyde in PBS and fixed for 15 minutes at room temperature. Cells were 
centrifuged again and resuspended with 700 µL of PBS and filtrated through cell strainer 70 
µm (BD Falcon) just before analysis. A CyAn ADP (Beckman Coulter) FACS machine was used. 
Data were analysed using Summit Software. 
 
8.2.2.11. Chicken cDNA screen 
A total of 3 x 10 cm plates were transduced at an MOI of 1 with the chicken cDNA 
library lentivectors. Controls were transduced in 6 well plates. 24h later, cells were splitted 1 
in 3. The next day, cells were transfected with 50-92 polymerase complex (i.e. for 1 x 10 cm 
plate: pCAGGS-NP-IRES-PB2: 4.8 µg, pCAGGS-5092-PB1-IRES-PA: 4.8 µg, pHumanPolI-GFP: 
2.4 µg). 20 hours later, cells were washed with PBS, detached and resuspended with PBS + 
5% serum. Cells are centrifugated 5 min at 450xg and resuspended with PBS + 0.5% serum 
and filtred before cell sorting. Selected cells were collected in media containing 20% serum. 
Cells were sorted using a BD FACS Aria Ill (Becton Dickinson) at the St Mary's Flow 
Cytometry Facility, Imperial College London, by Robert Sampson. 
 
 
8.2.2.12. Blue cell assay 
Infected cells were incubated at 37°C overnight. Blue cell assays were performed by 
removing the overlaying supernatant and fixing the monolayer with 1:1 methanol:acetone 
for 5 minutes. The methanol:acetone was then aspirated from the cells and the cells washed 
three times with PBS. A primary mouse α-NP antibody was diluted 1:300 in antibody diluent 
(PBS containing 0.35% BSA and 0.2% sodium azide) and 200μl added to individual wells of a 
12-well plate. The plates were incubated at room temperature with shaking for 1 hour. 
Primary antibody was then removed from the plates and the plates washed twice with PBS. 
A secondary goat-αmouse antibody, conjugated to β-galactosidase, was then used to probe 
the cells at a 1:400 dilution for 1 hour, with shaking, at room temperature. The secondary 
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antibody was then removed from the cells, and the plates washed twice with PBS. A 
developing solution was then prepared containing 0.25 ml 2% 5-bromo-4-chloro-3-indolyl- 
beta-D-galactopyranoside (X-gal) in Dimethylformamide (DMF), 1 ml 10x cyanide (CN) buffer 
(30 mM Ferricyanide, 30 mM Ferrocyanide and 10 mM MgCl2 in water) and 9.75 ml PBS. 
This developing solution was added to cells in 400 μl volumes overnight at 37°C. The X-Gal 
buffer was removed and blue can be observed in the cells positive for virus. 
 
8.2.2.13. Plaque assays 
Plaque assays were performed in 12 well plates by incubating 200 μl of 10-fold serial 
dilutions of samples onto NPTr or MDCK monolayers for 1 hour at 37°C and 5% CO2. 
Medium was then removed and 2% agarose overlay medium containing 1 µg/ml trypsin was 
added to the wells. Cells were incubated at 37°C and 5% CO2 for 3 days and then visualised 
by crystal violet staining. 
 
 
8.2.3 Protein manipulation 
8.2.3.1. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Commercial SDS-PAGE gels were used to separate proteins according to size (Ready 
gel Tris HCl 4-15% linear gradient). Samples were diluted in 6X gel loading dye (375 mM Tris-
HCl pH 6.8, 6% SDS, 30% glycerol, 9% 2-Mercaptoethanol, and 0.03% bromophenol blue). 
Before loading, samples were boiled for 10 minutes. Gels were run at 100V for 
approximately 2 hours in running buffer (0.1% SDS, 27.6 mM Tris base, 0.2 M glycine, pH 
8.8). Protein sizes were determined by comparison to the Novex sharp pre-stained protein 
standard (Invitrogen). 
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8.2.3.2. Immunoblot analysis 
Proteins were transferred onto 0.45 μm nitrocellulose (Anachem). Transfers were 
carried out at 16V overnight in transfer buffer (0.1% SDS, 27.6 mM Tris Base, 0.2 M glycine, 
20% methanol, pH 8.8). Following transfer, membranes were first blocked in 5% milk 
solution (milk powder, 0.1% tween, dissolved in PBS) for 1 hour at room temperature. 
Membranes were then incubated with the primary antibody, diluted in milk solution, for 
approximately 2 hours at room temperature, followed by 4 washes for 5 minutes in wash 
buffer (0.1% tween in PBS). Membranes were then incubated for 1 hour with horseradish 
peroxidise (HRP) conjugated secondary antibodies for detection by enhanced 
chemiluminescence (ECL). Subsequently, blots were washed 4 times for 10 minutes in wash 
buffer, as before. HRP-conjugated antibodies were detected by incubation of the membrane 
for 5 minutes with ECL Plus Western Blotting Detection System (Amersham) as per 
manufacturer’s instructions.  
 
8.2.3.3. Tap-tag purification of vRNP complexes 
Six 10 cm dishes of 80% confluent 293T cells were transfected as described in 
paragraph 8.2.2.3 with 2.4 µg of pCAGGS-5092-PB1-IRES-PA, 4.8 µg of pCAGGS-5092-NP-
IRES-PB2 WT or E627K Strep-Flag tag, and 2.4 µg pHPOM1-NLS-DsRed per plate. Fourty 
hours after transfection, culture medium was removed from the plates and the cells were 
washed with 15 mL of sterile 1X PBS per dish and detached by pipetting up and down with 3 
mL of chilled 1X PBS, and harvested. Dishes were rinsed with a total of 7 ml of chilled 1X PBS 
and cells were centrifuged at 500xg for 5 minutes at 4°C. The supernatant was removed and 
cells were lysed in 1.25 mL of lysis buffer (50 mM potassium phosphate pH 7.4; 200 mM 
NaCl, 0.5% IGEPAL, 1 mM DTT, 2 mM EDTA, 30 U/ml RNAsine, 15% glycerol supplemented 
with protease inhibitors (One Complete EDTA-free protease inhibitor cocktail, Roche)). Cells 
were incubated for 30 minutes on ice and lysates were then cleared by centrifugation at 
16,000xg for 25 minutes. Supernatants were loaded on 500 μl of Strep-tactin Superflow 
beads (IBA) that had been previously loaded in an empty column (Bio-spin chromatography 
columns empty, Bio-Rad) and washed twice with 500 μl of lysis buffer. Flowthrough was 
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loaded once on the beads and the Strep-tactin beads were washed 4 times with 500 μl of 
washing buffer (50 mM potassium phosphate pH 7.4; 200 mM NaCl, 0.1% IGEPAL, 1 mM 
DTT, 2 mM EDTA, 30 U/ml RNAsin, and complete protease inhibitor cocktail). Protein 
complexes were eluted with 500 µL of elution buffer 1 (wash buffer containing 1X STREP-tag 
elution buffer containing Desthiobiotin (IBA)): columns were incubated on a rotational 
tumbler at 4°C for 1 hour. The recovered elution fraction was then loaded on 200 µl of flag 
beads (Sigma) previously washed twice with 200 μl of wash buffer. Flowthrough was loaded 
once on the beads. After six washes with 500 µL mL of wash buffer, protein complexes were 
eluted twice with 400 µL of elution buffer 2 (wash buffer containing 250 µg/ml of Flag 
peptide (Sigma, F3290). Beads were incubated on a rotational tumbler at 4°C for 30 
minutes. At every step, a sample of 10 to 30 μl of was taken and mixed with 6X loading dye 
for immunoblot analysis to check for the presence of the tagged protein. 
 
Single-step purification (anti-Flag M2 affinity gel) 
Single-step purification on anti-Flag M2 affinity gel was preformed as described 
above. Anti-Flag M2 affinity gel were washed 5 times and protein complexes were eluted 
twice with 500 µL of elution buffer 2. Beads were incubated on a rotational tumbler at 4°C 
for 30 minutes. 
 
The final eluates were concentrated down to a lower volume using Centrifugal filter 
unit with ultracel-3 membrane (Millipore) to a final volume of approximately 80 µl. 
 
8.2.3.4. Mass spectrometric analysis 
Gel slices were isolated from the gel using a clean razor blade under a cell hood and 
gel fragments were transferred into sterile Eppendorf tubes. Samples processing and mass 
spectrometric protein identification was performed by the Mass Spectrometry core facility 
(Centre for Integrative Systems Biology and Bioinformatics, Imperial College London) by Dr 
Paul Hitchen. Results were visualised using Scaffold2 software. 
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Chapter 9. Appendix 
 
List of host signatures or host adaptive mutations on influenza proteins PB1, PB2, PA 
and NP. Only the main avian and human host signatures are listed (present twice or more in 
a selection of bioinformatic studies). Also listed are adaptive mutations obtained in animal 
models. PB1-F2 is not encoded by all influenza A viruses and thus was not included. 
 
NP 
Residue Observations References Comments 
16 Persistent host marker: avian: G, 
human: D 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Allen et al, 2009) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
33 Persistent host marker: avian: V, 
human: I 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
61 Persistent host marker: avian: I, 
human: L 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
100 Persistent host marker: avian: R, 
human: V 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
136 Persistent host marker: avian: L, 
human: I/M 
(Tamuri et al, 2009) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
214 Persistent host marker: avian: R, 
human: K 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
283 Persistent host marker: avian: L, 
human: P 
(Chen et al, 2006) 
(Allen et al, 2009) 
(Miotto et al, 2010) 
(Tamuri et al, 2009) 
(Hu, 2010) 
 
305 Persistent host marker: avian: R, 
human: K 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Tamuri et al, 2009) 
(Hu, 2010) 
 
313 Persistent host marker: avian: F, 
human: Y 
(Finkelstein et al, 2007) 
(Allen et al, 2009) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Tamuri et al, 2009) 
(Hu, 2010) 
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319 Lys  (K) correlates with high 
pathogenicity, increase nuclear import 
(Gabriel et al, 2005) 
(Gabriel et al, 2008) 
Situated on the surface of the body 
domain, mediating interactions with 
PB1 and PB2 
357 Persistent host marker: avian: Q, 
human: K 
(Finkelstein et al, 2007) 
(Allen et al, 2009) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Hu, 2010) 
 
375 Persistent host marker: avian: D/N, 
human: G 
(Miotto et al, 2010) 
(Tamuri et al, 2009) 
(Hu, 2010) 
 
422 Persistent host marker: avian: R, 
human: K 
(Chen et al, 2006) 
(Hu, 2010) 
 
442 Persistent host marker: avian: T, 
human: A 
(Chen et al, 2006) 
(Hu, 2010) 
 
455 Persistent host marker: avian: D, 
human: E 
(Chen et al, 2006) 
(Hu, 2010) 
 
 
 
PB2 
Residue Observations References Comments 
9 Persistent host marker: avian: D/E, 
human: N/T 
(Graef et al, 2010) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
Asn (N) or a Tyr (Y) correlates with 
mitochondrial localisation. Asp (D) 
reduces mitochondrial association. 
44 Persistent host marker: avian: A, 
human: S 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Hu, 2010) 
 
64 Persistent host marker: avian: M, 
human: T 
(Finkelstein et al, 2007) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
 
105 Persistent host marker: avian: T/A, 
human: V/M 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Hu, 2010) 
 
158 E to G mutation increases polymerase 
activity, virus titres, morbidity and 
mortality in mice model. 
(Zhou et al, 2011)  Obtained by passage of 2009 pH1N1 
virus in mice.  
199 Persistent host marker: avian: A, 
human: S 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Allen et al, 2009) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Bussey et al, 2010) 
(Hu, 2010) 
 
256 D to G mutation Increases influenza 
polymerase activity 
(Manzoor et al, 2009) Obtained in pigs experimentally 
infected. 
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271 Persistent host marker: avian: T, 
human: A 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
(Bussey et al, 2010) 
T271A mutation enhances function of 
an avian-origin influenza polymerase 
in human cells but not in avian cells, 
increases virus growth in human cells 
292 Persistent host marker: avian: I/V, 
human: T 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
 
368 Persistent host marker: avian: R, 
human: K 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
 
475 Persistent host marker: avian: L, 
human: M 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Allen et al, 2009) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Bussey et al, 2010) 
(Hu, 2010) 
 
567 Persistent host marker: avian: D, 
human: N 
(Finkelstein et al, 2007) 
(Allen et al, 2009) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
(Bussey et al, 2010) 
 
588 Persistent host marker: avian: A, 
human: I 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Hu, 2010) 
(Bussey et al, 2010) 
 
613 Persistent host marker: avian: V, 
human: T 
(Chen et al, 2006) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Hu, 2010) 
(Bussey et al, 2010) 
Exposed at the surface 
627 Persistent host marker: avian: E, 
human: K  
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Allen et al, 2009) 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Hu, 2010) 
(Bussey et al, 2010) 
Exposed at the surface. Lys (K) forms a 
basic patch, which is disrupted by the 
substitution K627E. See paragraph 
1.7.2.1 
 
636 L to F mutation increases influenza 
polymerase activity 
(Foeglein et al, 2011)  
661 Persistent host marker: avian: A, 
human: T 
(Miotto et al, 2010) 
(Miotto et al, 2008) 
(Tamuri et al, 2009) 
(Hu, 2010) 
 
Exposed at the surface 
674 Persistent host marker: avian: A, 
human: T 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Bussey et al, 2010) 
 
701 Asn (N) correlates with high 
pathogenicity, increases influenza 
polymerase activity in mammalian 
cells.  
(Gabriel et al, 2005) 
(Gabriel et al, 2008) 
(Tarendeau et al, 2007) 
(Yao et al, 2001) 
Asn (N) changes the specificity for α 
importins (see paragraph 1.7.2.2) 
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702 Persistent host marker: avian: K, 
human: R  
(Finkelstein et al, 2007) 
(Tarendeau et al, 2007) 
(Tamuri et al, 2009) 
(Bussey et al, 2010) 
Exposed to solvent: interaction with 
importin α 
714 Arg (R) correlates with high 
pathogenicity 
 
(Gabriel et al, 2005) 
(Tarendeau et al, 2007) 
Exposed to solvent: interaction with 
importin α 
 
 
PA 
Residue Observations References Comments 
28 Persistent host marker: avian: P, 
human: L 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
 
55 Persistent host marker: avian: D, 
human: N 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Allen et al, 2009) 
 
57 Persistent host marker: avian: R, 
human: Q 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
 
65 S to Y mutation observed in Equine 
H7N7 during mouse adaptation 
(Shinya et al, 2007) Adaptation to mice 
85 Usually T. I in pH1N1. I enhances 
polymerase activity of an avian strain. 
A is present in H9N2 G1 
(Bussey et al, 2011)  
97 I increases polymerase activity and 
virulence in mice 
(Song et al, 2009b) 
(Song et al, 2011) 
T97I was obtained by passage in mice 
lungs 
186 S present in 2009 pH1N1 enhances 
influenza polymerase activity 
(Bussey et al, 2011)  
225 Persistent host marker: avian: S, 
human: C.  
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
 
268 Persistent host marker: avian: L, 
human: I 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
 
336 M present in pH1N1 enhances 
influenza polymerase activity and 
morbidity in mice 
(Bussey et al, 2011)  
356 Persistent host marker: avian: K, 
human: R 
(Chen et al, 2006) 
(Tamuri et al, 2009) 
 
404 Persistent host marker: avian: A, 
human: S 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
 
409 Persistent host marker: avian: S, 
human: N 
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
 
515 T to A attenuates H5N1 pathogenicity 
in duck 
(Hulse-Post et al, 2007)  
552 Persistent host marker: avian: T, 
human: S.  
(Finkelstein et al, 2007) 
(Chen et al, 2006) 
(Tamuri et al, 2009) 
S enhances polymerase activity in 
human cells, not in avian cells (Mehle 
et al, 2012) 
615 Arg correlates with high pathogenicity (Gabriel et al, 2005)  
666 L increases polymerase activity of 
H7N7 in human cells, but not in quail 
cells. 
(de Wit et al, 2010)  
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PB1 
Residue Observations References Comments 
13 L to P correlates with high 
pathogenicity 
(Gabriel et al, 2005) Obtained in mice 
327 Persistent host marker: Avian: R, 
human: K 
(Chen et al, 2006) 
 
 
336 Persistent host marker: Avian: V, 
human: I 
(Chen et al, 2006) 
 
 
436 Y to H attenuates H5N1 pathogenicity 
in duck 
(Hulse-Post et al, 2007)  
578 K to Q mutation observed in Equine 
H7N7 during mouse adaptation 
(Shinya et al, 2007) Adaptation to mice 
614 R to G mutation observed in Equine 
H7N7 during mouse adaptation 
(Shinya et al, 2007) Adaptation to mice 
678 S to N correlates with high 
pathogenicity 
(Gabriel et al, 2005) Adaptation to mice 
 
- 229 - 
 
 
Chapter 10. References 
 
Air GM, Gibbs AJ, Laver WG, Webster RG (1990) Evolutionary changes in influenza B are not 
primarily governed by antibody selection. Proc Natl Acad Sci U S A 87: 3884-3888 
 
Alexander DJ (2000) A review of avian influenza in different bird species. Vet Microbiol 74: 3-
13 
 
Alexander DJ (2007) An overview of the epidemiology of avian influenza. Vaccine 25: 5637-
5644 
 
Ali N, Siddiqui A (1997) The La antigen binds 5' noncoding region of the hepatitis C virus RNA 
in the context of the initiator AUG codon and stimulates internal ribosome entry site-
mediated translation. Proc Natl Acad Sci U S A 94: 2249-2254 
 
Allen JE, Gardner SN, Vitalis EA, Slezak TR (2009) Conserved amino acid markers from past 
influenza pandemic strains. BMC Microbiol 9: 77 
 
Almond JW (1977) A single gene determines the host range of influenza virus. Nature 270: 
617-618 
 
Amonsin A, Payungporn S, Theamboonlers A, Thanawongnuwech R, Suradhat S, Pariyothorn 
N, Tantilertcharoen R, Damrongwantanapokin S, Buranathai C, Chaisingh A, Songserm T, 
Poovorawan Y (2006) Genetic characterization of H5N1 influenza A viruses isolated from zoo 
tigers in Thailand. Virology 344: 480-491 
 
Amorim MJ, Read EK, Dalton RM, Medcalf L, Digard P (2007) Nuclear export of influenza A 
virus mRNAs requires ongoing RNA polymerase II activity. Traffic 8: 1-11 
 
Area E, Martin-Benito J, Gastaminza P, Torreira E, Valpuesta JM, Carrascosa JL, Ortin J (2004) 
3D structure of the influenza virus polymerase complex: localization of subunit domains. 
Proc Natl Acad Sci U S A 101: 308-313 
 
- 230 - 
 
Argos P (1988) A sequence motif in many polymerases. Nucleic Acids Res 16: 9909-9916 
 
Avalos RT, Yu Z, Nayak DP (1997) Association of influenza virus NP and M1 proteins with 
cellular cytoskeletal elements in influenza virus-infected cells. J Virol 71: 2947-2958 
 
Azzeh M, Flick R, Hobom G (2001) Functional analysis of the influenza A virus cRNA 
promoter and construction of an ambisense transcription system. Virology 289: 400-410 
 
Bae SH, Cheong HK, Lee JH, Cheong C, Kainosho M, Choi BS (2001) Structural features of an 
influenza virus promoter and their implications for viral RNA synthesis. Proc Natl Acad Sci U 
S A 98: 10602-10607 
 
Barman S, Ali A, Hui EK, Adhikary L, Nayak DP (2001) Transport of viral proteins to the apical 
membranes and interaction of matrix protein with glycoproteins in the assembly of 
influenza viruses. Virus Res 77: 61-69 
 
Barrett T, Wolstenholme AJ, Mahy BW (1979) Transcription and replication of influenza virus 
RNA. Virology 98: 211-225 
 
Baudin F, Bach C, Cusack S, Ruigrok RW (1994) Structure of influenza virus RNP. I. Influenza 
virus nucleoprotein melts secondary structure in panhandle RNA and exposes the bases to 
the solvent. EMBO J 13: 3158-3165 
 
Baum LG, Paulson JC (1990) Sialyloligosaccharides of the respiratory epithelium in the 
selection of human influenza virus receptor specificity. Acta Histochem Suppl 40: 35-38 
 
Beare AS, Webster RG (1991) Replication of avian influenza viruses in humans. Arch Virol 
119: 37-42 
 
Beaton AR, Krug RM (1986) Transcription antitermination during influenza viral template 
RNA synthesis requires the nucleocapsid protein and the absence of a 5' capped end. Proc 
Natl Acad Sci U S A 83: 6282-6286 
 
Bentley DL (2005) Rules of engagement: co-transcriptional recruitment of pre-mRNA 
processing factors. Curr Opin Cell Biol 17: 251-256 
 
- 231 - 
 
Bier K, York A, Fodor E (2011) Cellular cap-binding proteins associate with influenza virus 
mRNAs. J Gen Virol 92: 1627-1634 
 
Biswas SK, Nayak DP (1994) Mutational analysis of the conserved motifs of influenza A virus 
polymerase basic protein 1. J Virol 68: 1819-1826 
 
Blaas D, Patzelt E, Kuechler E (1982) Identification of the cap binding protein of influenza 
virus. Nucleic Acids Res 10: 4803-4812 
 
Boivin S, Cusack S, Ruigrok RW, Hart DJ (2010) Influenza A virus polymerase: structural 
insights into replication and host adaptation mechanisms. J Biol Chem 285: 28411-28417 
 
Bortz E, Westera L, Maamary J, Steel J, Albrecht RA, Manicassamy B, Chase G, Martinez-
Sobrido L, Schwemmle M, Garcia-Sastre A (2011) Host- and strain-specific regulation of 
influenza virus polymerase activity by interacting cellular proteins. MBio 2 
 
Bose S, Mathur M, Bates P, Joshi N, Banerjee AK (2003) Requirement for cyclophilin A for 
the replication of vesicular stomatitis virus New Jersey serotype. J Gen Virol 84: 1687-1699 
 
Boulo S, Akarsu H, Ruigrok RW, Baudin F (2007) Nuclear traffic of influenza virus proteins 
and ribonucleoprotein complexes. Virus Res 124: 12-21 
 
Braam J, Ulmanen I, Krug RM (1983) Molecular model of a eucaryotic transcription complex: 
functions and movements of influenza P proteins during capped RNA-primed transcription. 
Cell 34: 609-618 
 
Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, Elledge SJ 
(2008) Identification of host proteins required for HIV infection through a functional 
genomic screen. Science 319: 921-926 
 
Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der 
Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ (2009) The IFITM proteins 
mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 
139: 1243-1254 
 
Brookes SM, Nunez A, Choudhury B, Matrosovich M, Essen SC, Clifford D, Slomka MJ, Kuntz-
Simon G, Garcon F, Nash B, Hanna A, Heegaard PM, Queguiner S, Chiapponi C, Bublot M, 
- 232 - 
 
Garcia JM, Gardner R, Foni E, Loeffen W, Larsen L, Van Reeth K, Banks J, Irvine RM, Brown IH 
(2010) Replication, pathogenesis and transmission of pandemic (H1N1) 2009 virus in non-
immune pigs. PLoS One 5: e9068 
 
Brown EG, Liu H, Kit LC, Baird S, Nesrallah M (2001) Pattern of mutation in the genome of 
influenza A virus on adaptation to increased virulence in the mouse lung: identification of 
functional themes. Proc Natl Acad Sci U S A 98: 6883-6888 
 
Brown IH (2000) The epidemiology and evolution of influenza viruses in pigs. Vet Microbiol 
74: 29-46 
 
Brown IH (2008) The role of pigs in interspecies transmission. Klenk H-D, Matrosovich MN, 
Stech J (eds): Avian Influenza 27: 88-100 
 
Brown IH (2012) History and Epidemiology of Swine Influenza in Europe. Curr Top Microbiol 
Immunol 
 
Brown IH, Alexander DJ, Chakraverty P, Harris PA, Manvell RJ (1994) Isolation of an influenza 
A virus of unusual subtype (H1N7) from pigs in England, and the subsequent experimental 
transmission from pig to pig. Vet Microbiol 39: 125-134 
 
Brown IH, Harris PA, Alexander DJ (1995) Serological studies of influenza viruses in pigs in 
Great Britain 1991-2. Epidemiol Infect 114: 511-520 
 
Brown IH, Harris PA, McCauley JW, Alexander DJ (1998) Multiple genetic reassortment of 
avian and human influenza A viruses in European pigs, resulting in the emergence of an 
H1N2 virus of novel genotype. J Gen Virol 79 ( Pt 12): 2947-2955 
 
Bruce EA, Digard P, Stuart AD (2010) The Rab11 pathway is required for influenza A virus 
budding and filament formation. J Virol 84: 5848-5859 
 
Bucher D, Popple S, Baer M, Mikhail A, Gong YF, Whitaker C, Paoletti E, Judd A (1989) M 
protein (M1) of influenza virus: antigenic analysis and intracellular localization with 
monoclonal antibodies. J Virol 63: 3622-3633 
 
- 233 - 
 
Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM (1986) Evolution of 
human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene. Science 
232: 980-982 
 
Burgui I, Yanguez E, Sonenberg N, Nieto A (2007) Influenza virus mRNA translation revisited: 
is the eIF4E cap-binding factor required for viral mRNA translation? J Virol 81: 12427-12438 
 
Bussey KA, Bousse TL, Desmet EA, Kim B, Takimoto T (2010) PB2 residue 271 plays a key role 
in enhanced polymerase activity of influenza A viruses in mammalian host cells. J Virol 84: 
4395-4406 
 
Bussey KA, Desmet EA, Mattiacio JL, Hamilton A, Bradel-Tretheway B, Bussey HE, Kim B, 
Dewhurst S, Takimoto T (2011) PA residues in the 2009 H1N1 pandemic influenza virus 
enhance avian influenza virus polymerase activity in mammalian cells. J Virol 85: 7020-7028 
 
Butler D (2006) Family tragedy spotlights flu mutations. Nature 442: 114-115 
 
Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris 
JS, Guan Y (2005) Human infection with an avian H9N2 influenza A virus in Hong Kong in 
2003. J Clin Microbiol 43: 5760-5767 
 
Campitelli L, Donatelli I, Foni E, Castrucci MR, Fabiani C, Kawaoka Y, Krauss S, Webster RG 
(1997) Continued evolution of H1N1 and H3N2 influenza viruses in pigs in Italy. Virology 
232: 310-318 
 
Castrucci MR, Donatelli I, Sidoli L, Barigazzi G, Kawaoka Y, Webster RG (1993) Genetic 
reassortment between avian and human influenza A viruses in Italian pigs. Virology 193: 
503-506 
 
Chan AY, Vreede FT, Smith M, Engelhardt OG, Fodor E (2006) Influenza virus inhibits RNA 
polymerase II elongation. Virology 351: 210-217 
 
Chan CC, Dostie J, Diem MD, Feng W, Mann M, Rappsilber J, Dreyfuss G (2004) eIF4A3 is a 
novel component of the exon junction complex. RNA 10: 200-209 
 
Chang YN, Kenan DJ, Keene JD, Gatignol A, Jeang KT (1994) Direct interactions between 
autoantigen La and human immunodeficiency virus leader RNA. J Virol 68: 7008-7020 
- 234 - 
 
 
Chase G, Deng T, Fodor E, Leung BW, Mayer D, Schwemmle M, Brownlee G (2008) Hsp90 
inhibitors reduce influenza virus replication in cell culture. Virology 377: 431-439 
 
Chatel-Chaix L, Melancon P, Racine ME, Baril M, Lamarre D (2011) Y-box-binding protein 1 
interacts with hepatitis C virus NS3/4A and influences the equilibrium between viral RNA 
replication and infectious particle production. J Virol 85: 11022-11037 
 
Chen BJ, Leser GP, Morita E, Lamb RA (2007) Influenza virus hemagglutinin and 
neuraminidase, but not the matrix protein, are required for assembly and budding of 
plasmid-derived virus-like particles. J Virol 81: 7111-7123 
 
Chen CD, Kobayashi R, Helfman DM (1999) Binding of hnRNP H to an exonic splicing silencer 
is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene. Genes 
Dev 13: 593-606 
 
Chen GW, Chang SC, Mok CK, Lo YL, Kung YN, Huang JH, Shih YH, Wang JY, Chiang C, Chen 
CJ, Shih SR (2006) Genomic signatures of human versus avian influenza A viruses. Emerg 
Infect Dis 12: 1353-1360 
 
Chen H, Smith GJ, Zhang SY, Qin K, Wang J, Li KS, Webster RG, Peiris JS, Guan Y (2005) Avian 
flu: H5N1 virus outbreak in migratory waterfowl. Nature 436: 191-192 
 
Chen J, Huang S, Chen Z (2010) Human cellular protein nucleoporin hNup98 interacts with 
influenza A virus NS2/nuclear export protein and overexpression of its GLFG repeat domain 
can inhibit virus propagation. J Gen Virol 91: 2474-2484 
 
Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S, O'Neill R, Schickli J, Palese 
P, Henklein P, Bennink JR, Yewdell JW (2001) A novel influenza A virus mitochondrial protein 
that induces cell death. Nat Med 7: 1306-1312 
 
Cheng VC, Chan JF, Wen X, Wu WL, Que TL, Chen H, Chan KH, Yuen KY (2011) Infection of 
immunocompromised patients by avian H9N2 influenza A virus. J Infect 62: 394-399 
 
Chin PS, Hoffmann E, Webby R, Webster RG, Guan Y, Peiris M, Shortridge KF (2002) 
Molecular evolution of H6 influenza viruses from poultry in Southeastern China: prevalence 
of H6N1 influenza viruses possessing seven A/Hong Kong/156/97 (H5N1)-like genes in 
poultry. J Virol 76: 507-516 
- 235 - 
 
 
Choi YK, Lee JH, Erickson G, Goyal SM, Joo HS, Webster RG, Webby RJ (2004) H3N2 influenza 
virus transmission from swine to turkeys, United States. Emerg Infect Dis 10: 2156-2160 
 
Choi YK, Nguyen TD, Ozaki H, Webby RJ, Puthavathana P, Buranathal C, Chaisingh A, 
Auewarakul P, Hanh NT, Ma SK, Hui PY, Guan Y, Peiris JS, Webster RG (2005) Studies of 
H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 
2004. J Virol 79: 10821-10825 
 
Chou MY, Rooke N, Turck CW, Black DL (1999) hnRNP H is a component of a splicing 
enhancer complex that activates a c-src alternative exon in neuronal cells. Mol Cell Biol 19: 
69-77 
 
Chun J (1919) Influenza including its infection among pigs. Natl Med J China 5: 34-44 
 
Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, 
Shortridge KF, Webster RG (1998) Human influenza A H5N1 virus related to a highly 
pathogenic avian influenza virus. Lancet 351: 472-477 
 
Clements ML, Subbarao EK, Fries LF, Karron RA, London WT, Murphy BR (1992) Use of 
single-gene reassortant viruses to study the role of avian influenza A virus genes in 
attenuation of wild-type human influenza A virus for squirrel monkeys and adult human 
volunteers. J Clin Microbiol 30: 655-662 
 
Coloma R, Valpuesta JM, Arranz R, Carrascosa JL, Ortin J, Martin-Benito J (2009) The 
structure of a biologically active influenza virus ribonucleoprotein complex. PLoS Pathog 5: 
e1000491 
 
Cong YL, Pu J, Liu QF, Wang S, Zhang GZ, Zhang XL, Fan WX, Brown EG, Liu JH (2007) 
Antigenic and genetic characterization of H9N2 swine influenza viruses in China. J Gen Virol 
88: 2035-2041 
 
Costa-Mattioli M, Svitkin Y, Sonenberg N (2004) La autoantigen is necessary for optimal 
function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in 
vitro. Mol Cell Biol 24: 6861-6870 
 
- 236 - 
 
Crawford PC, Dubovi EJ, Castleman WL, Stephenson I, Gibbs EP, Chen L, Smith C, Hill RC, 
Ferro P, Pompey J, Bright RA, Medina MJ, Johnson CM, Olsen CW, Cox NJ, Klimov AI, Katz 
JM, Donis RO (2005) Transmission of equine influenza virus to dogs. Science 310: 482-485 
 
Cros JF, Garcia-Sastre A, Palese P (2005) An unconventional NLS is critical for the nuclear 
import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic 6: 205-213 
 
Cros JF, Palese P (2003) Trafficking of viral genomic RNA into and out of the nucleus: 
influenza, Thogoto and Borna disease viruses. Virus Res 95: 3-12 
 
Crosby AW (1989) America's forgotten pandemic, the influenza of 1918.  Cambridge 
University Press, New York 
 
Crow M, Deng T, Addley M, Brownlee GG (2004) Mutational analysis of the influenza virus 
cRNA promoter and identification of nucleotides critical for replication. J Virol 78: 6263-6270 
 
Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges 
CB, Uyeki TM (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. 
N Engl J Med 360: 2605-2615 
 
de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, 
Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J 
(2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and 
hypercytokinemia. Nat Med 12: 1203-1207 
 
de la Luna S, Fortes P, Beloso A, Ortin J (1995) Influenza virus NS1 protein enhances the rate 
of translation initiation of viral mRNAs. J Virol 69: 2427-2433 
 
de la Luna S, Martin J, Portela A, Ortin J (1993) Influenza virus naked RNA can be expressed 
upon transfection into cells co-expressing the three subunits of the polymerase and the 
nucleoprotein from simian virus 40 recombinant viruses. J Gen Virol 74 ( Pt 3): 535-539 
 
De Vleeschauwer A, Atanasova K, Van Borm S, van den Berg T, Rasmussen TB, Uttenthal A, 
Van Reeth K (2009a) Comparative pathogenesis of an avian H5N2 and a swine H1N1 
influenza virus in pigs. PLoS One 4: e6662 
 
- 237 - 
 
De Vleeschauwer A, Van Poucke S, Braeckmans D, Van Doorsselaere J, Van Reeth K (2009b) 
Efficient transmission of swine-adapted but not wholly avian influenza viruses among pigs 
and from pigs to ferrets. J Infect Dis 200: 1884-1892 
 
de Wit E, Munster VJ, van Riel D, Beyer WE, Rimmelzwaan GF, Kuiken T, Osterhaus AD, 
Fouchier RA (2010) Molecular determinants of adaptation of highly pathogenic avian 
influenza H7N7 viruses to efficient replication in the human host. J Virol 84: 1597-1606 
 
Demirov D, Gabriel G, Schneider C, Hohenberg H, Ludwig S (2012) Interaction of influenza A 
virus matrix protein with RACK1 is required for virus release. Cell Microbiol 
 
Deng T, Engelhardt OG, Thomas B, Akoulitchev AV, Brownlee GG, Fodor E (2006a) Role of 
ran binding protein 5 in nuclear import and assembly of the influenza virus RNA polymerase 
complex. J Virol 80: 11911-11919 
 
Deng T, Vreede FT, Brownlee GG (2006b) Different de novo initiation strategies are used by 
influenza virus RNA polymerase on its cRNA and viral RNA promoters during viral RNA 
replication. J Virol 80: 2337-2348 
 
Desselberger U, Racaniello VR, Zazra JJ, Palese P (1980) The 3' and 5'-terminal sequences of 
influenza A, B and C virus RNA segments are highly conserved and show partial inverted 
complementarity. Gene 8: 315-328 
 
Detjen BM, St Angelo C, Katze MG, Krug RM (1987) The three influenza virus polymerase (P) 
proteins not associated with viral nucleocapsids in the infected cell are in the form of a 
complex. J Virol 61: 16-22 
 
Dias A, Bouvier D, Crepin T, McCarthy AA, Hart DJ, Baudin F, Cusack S, Ruigrok RW (2009) 
The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. 
Nature 458: 914-918 
 
Digard P, Elton D, Bishop K, Medcalf E, Weeds A, Pope B (1999) Modulation of nuclear 
localization of the influenza virus nucleoprotein through interaction with actin filaments. J 
Virol 73: 2222-2231 
 
Dittmann J, Stertz S, Grimm D, Steel J, Garcia-Sastre A, Haller O, Kochs G (2008) Influenza A 
virus strains differ in sensitivity to the antiviral action of Mx-GTPase. J Virol 82: 3624-3631 
 
- 238 - 
 
Dong G, Luo J, Zhang H, Wang C, Duan M, Deliberto TJ, Nolte DL, Ji G, He H (2011) 
Phylogenetic diversity and genotypical complexity of H9N2 influenza A viruses revealed by 
genomic sequence analysis. PLoS One 6: e17212 
 
Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S 
A 90: 4171-4175 
 
Duhaut SD, Dimmock NJ (2002) Defective segment 1 RNAs that interfere with production of 
infectious influenza A virus require at least 150 nucleotides of 5' sequence: evidence from a 
plasmid-driven system. J Gen Virol 83: 403-411 
 
Duhaut SD, McCauley JW (1996) Defective RNAs inhibit the assembly of influenza virus 
genome segments in a segment-specific manner. Virology 216: 326-337 
 
Easterday BC (2003) Swine influenza: Historical perspectives. 4th International Symposium 
on Emerging and Re-emerging Pig Diseases - Rome June 29th - July 2nd, 2003 
 
Eisfeld AJ, Kawakami E, Watanabe T, Neumann G, Kawaoka Y (2011a) RAB11A is essential for 
transport of the influenza virus genome to the plasma membrane. J Virol 85: 6117-6126 
 
Eisfeld AJ, Neumann G, Kawaoka Y (2011b) Human immunodeficiency virus rev-binding 
protein is essential for influenza a virus replication and promotes genome trafficking in late-
stage infection. J Virol 85: 9588-9598 
 
Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN (2011) Y-box-binding protein 1 
(YB-1) and its functions. Biochemistry (Mosc) 76: 1402-1433 
 
Elleman CJ, Barclay WS (2004) The M1 matrix protein controls the filamentous phenotype of 
influenza A virus. Virology 321: 144-153 
 
Elton D, Simpson-Holley M, Archer K, Medcalf L, Hallam R, McCauley J, Digard P (2001) 
Interaction of the influenza virus nucleoprotein with the cellular CRM1-mediated nuclear 
export pathway. J Virol 75: 408-419 
 
Enami K, Sato TA, Nakada S, Enami M (1994) Influenza virus NS1 protein stimulates 
translation of the M1 protein. J Virol 68: 1432-1437 
 
- 239 - 
 
Engelhardt OG, Smith M, Fodor E (2005) Association of the influenza A virus RNA-dependent 
RNA polymerase with cellular RNA polymerase II. J Virol 79: 5812-5818 
 
Enserink M (2004) Infectious diseases. Bird flu infected 1000, Dutch researchers say. Science 
306: 590 
 
Escoffier C, Gerlier D (1999) Infection of chicken embryonic fibroblasts by measles virus: 
adaptation at the virus entry level. J Virol 73: 5220-5224 
 
Evdokimova VM, Ovchinnikov LP (1999) Translational regulation by Y-box transcription 
factor: involvement of the major mRNA-associated protein, p50. Int J Biochem Cell Biol 31: 
139-149 
 
Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams 
DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie 
A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, Smyth RL, Openshaw PJ, Dougan 
G, Brass AL, Kellam P (2012) IFITM3 restricts the morbidity and mortality associated with 
influenza. Nature 484: 519-523 
 
Feigenblum D, Schneider RJ (1993) Modification of eukaryotic initiation factor 4F during 
infection by influenza virus. J Virol 67: 3027-3035 
 
Feng L, Li F, Zheng X, Pan W, Zhou K, Liu Y, He H, Chen L (2009) The mouse Pol I terminator is 
more efficient than the hepatitis delta virus ribozyme in generating influenza-virus-like RNAs 
with precise 3' ends in a plasmid-only-based virus rescue system. Arch Virol 154: 1151-1156 
 
Ferraiuolo MA, Lee CS, Ler LW, Hsu JL, Costa-Mattioli M, Luo MJ, Reed R, Sonenberg N 
(2004) A nuclear translation-like factor eIF4AIII is recruited to the mRNA during splicing and 
functions in nonsense-mediated decay. Proc Natl Acad Sci U S A 101: 4118-4123 
 
Ferrari M, Scalvini A, Losio MN, Corradi A, Soncini M, Bignotti E, Milanesi E, Ajmone-Marsan 
P, Barlati S, Bellotti D, Tonelli M (2003) Establishment and characterization of two new pig 
cell lines for use in virological diagnostic laboratories. J Virol Methods 107: 205-212 
 
Finkelstein DB, Mukatira S, Mehta PK, Obenauer JC, Su X, Webster RG, Naeve CW (2007) 
Persistent host markers in pandemic and H5N1 influenza viruses. J Virol 81: 10292-10299 
 
- 240 - 
 
Fislova T, Thomas B, Graef KM, Fodor E (2010) Association of the influenza virus RNA 
polymerase subunit PB2 with the host chaperonin CCT. J Virol 84: 8691-8699 
 
Flick R, Hobom G (1999) Interaction of influenza virus polymerase with viral RNA in the 
'corkscrew' conformation. J Gen Virol 80 ( Pt 10): 2565-2572 
 
Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A (1999) Rescue 
of influenza A virus from recombinant DNA. J Virol 73: 9679-9682 
 
Fodor E, Mingay LJ, Crow M, Deng T, Brownlee GG (2003) A single amino acid mutation in 
the PA subunit of the influenza virus RNA polymerase promotes the generation of defective 
interfering RNAs. J Virol 77: 5017-5020 
 
Fodor E, Pritlove DC, Brownlee GG (1994) The influenza virus panhandle is involved in the 
initiation of transcription. J Virol 68: 4092-4096 
 
Fodor E, Seong BL, Brownlee GG (1993) Photochemical cross-linking of influenza A 
polymerase to its virion RNA promoter defines a polymerase binding site at residues 9 to 12 
of the promoter. J Gen Virol 74 ( Pt 7): 1327-1333 
 
Fodor E, Smith M (2004) The PA subunit is required for efficient nuclear accumulation of the 
PB1 subunit of the influenza A virus RNA polymerase complex. J Virol 78: 9144-9153 
 
Foeglein A, Loucaides EM, Mura M, Wise HM, Barclay WS, Digard P (2011) Influence of PB2 
host-range determinants on the intranuclear mobility of the influenza A virus polymerase. J 
Gen Virol 92: 1650-1661 
 
Fornek JL, Gillim-Ross L, Santos C, Carter V, Ward JM, Cheng LI, Proll S, Katze MG, Subbarao 
K (2009) A single-amino-acid substitution in a polymerase protein of an H5N1 influenza virus 
is associated with systemic infection and impaired T-cell activation in mice. J Virol 83: 
11102-11115 
 
Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, 
Olsen B, Osterhaus AD (2005) Characterization of a novel influenza A virus hemagglutinin 
subtype (H16) obtained from black-headed gulls. J Virol 79: 2814-2822 
 
- 241 - 
 
Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, 
Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, 
Osterhaus AD (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis 
and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 101: 1356-
1361 
 
Fournier E, Moules V, Essere B, Paillart JC, Sirbat JD, Isel C, Cavalier A, Rolland JP, Thomas D, 
Lina B, Marquet R (2012) A supramolecular assembly formed by influenza A virus genomic 
RNA segments. Nucleic Acids Res 40: 2197-2209 
 
Franke EK, Yuan HE, Luban J (1994) Specific incorporation of cyclophilin A into HIV-1 virions. 
Nature 372: 359-362 
 
Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, 
Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, 
Ghani AC, Ferguson NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, 
Chapela IB, Zavala EP, Guevara DM, Checchi F, Garcia E, Hugonnet S, Roth C (2009) 
Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324: 1557-1561 
 
Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, 
Minami S, Watanabe Y, Narita H, Shiraki K (2002) In vitro and in vivo activities of anti-
influenza virus compound T-705. Antimicrob Agents Chemother 46: 977-981 
 
Gabriel G, Abram M, Keiner B, Wagner R, Klenk HD, Stech J (2007) Differential polymerase 
activity in avian and mammalian cells determines host range of influenza virus. J Virol 81: 
9601-9604 
 
Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J (2005) The viral polymerase 
mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci U S 
A 102: 18590-18595 
 
Gabriel G, Herwig A, Klenk HD (2008) Interaction of polymerase subunit PB2 and NP with 
importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog 4: e11 
 
Gabriel G, Klingel K, Otte A, Thiele S, Hudjetz B, Arman-Kalcek G, Sauter M, Shmidt T, Rother 
F, Baumgarte S, Keiner B, Hartmann E, Bader M, Brownlee GG, Fodor E, Klenk HD (2011) 
Differential use of importin-alpha isoforms governs cell tropism and host adaptation of 
influenza virus. Nat Commun 2: 156 
- 242 - 
 
 
Gagneux P, Cheriyan M, Hurtado-Ziola N, van der Linden EC, Anderson D, McClure H, Varki 
A, Varki NM (2003) Human-specific regulation of alpha 2-6-linked sialic acids. J Biol Chem 
278: 48245-48250 
 
Gammelin M, Mandler J, Scholtissek C (1989) Two subtypes of nucleoproteins (NP) of 
influenza A viruses. Virology 170: 71-80 
 
Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, Cooley AJ, Kawaoka Y (1999) 
Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus 
isolates from humans in Hong Kong. J Virol 73: 3184-3189 
 
Gao Y, Zhang Y, Shinya K, Deng G, Jiang Y, Li Z, Guan Y, Tian G, Li Y, Shi J, Liu L, Zeng X, Bu Z, 
Xia X, Kawaoka Y, Chen H (2009) Identification of amino acids in HA and PB2 critical for the 
transmission of H5N1 avian influenza viruses in a mammalian host. PLoS Pathog 5: 
e1000709 
 
Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T 
(1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. 
Virology 252: 324-330 
 
Garfinkel MS, Katze MG (1993) Translational control by influenza virus. Selective translation 
is mediated by sequences within the viral mRNA 5'-untranslated region. J Biol Chem 268: 
22223-22226 
 
Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, 
Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, 
Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, 
Lopez-Gatell H, Olivera H, Lopez I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD, Jr., 
Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, 
Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, 
Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, 
Smith DJ, Klimov AI, Cox NJ (2009) Antigenic and genetic characteristics of swine-origin 2009 
A(H1N1) influenza viruses circulating in humans. Science 325: 197-201 
 
Garten W, Klenk HD (1999) Understanding influenza virus pathogenicity. Trends Microbiol 7: 
99-100 
 
- 243 - 
 
Gatherer D (2010) Tempo and mode in the molecular evolution of influenza C. PLoS Curr 2: 
RRN1199 
 
Gaydos JC, Top FH, Jr., Hodder RA, Russell PK (2006) Swine influenza a outbreak, Fort Dix, 
New Jersey, 1976. Emerg Infect Dis 12: 23-28 
 
Gibbs EP, Anderson TC (2010) Equine and canine influenza: a review of current events. Anim 
Health Res Rev 11: 43-51 
 
Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A (2000) Influenza virus matrix 
protein is the major driving force in virus budding. J Virol 74: 11538-11547 
 
Gonzalez S, Zurcher T, Ortin J (1996) Identification of two separate domains in the influenza 
virus PB1 protein involved in the interaction with the PB2 and PA subunits: a model for the 
viral RNA polymerase structure. Nucleic Acids Res 24: 4456-4463 
 
Gorman OT, Bean WJ, Kawaoka Y, Donatelli I, Guo YJ, Webster RG (1991) Evolution of 
influenza A virus nucleoprotein genes: implications for the origins of H1N1 human and 
classical swine viruses. J Virol 65: 3704-3714 
 
Gorman OT, Donis RO, Kawaoka Y, Webster RG (1990) Evolution of influenza A virus PB2 
genes: implications for evolution of the ribonucleoprotein complex and origin of human 
influenza A virus. J Virol 64: 4893-4902 
 
Gottlieb E, Steitz JA (1989) The RNA binding protein La influences both the accuracy and the 
efficiency of RNA polymerase III transcription in vitro. EMBO J 8: 841-850 
 
Gottschalk A (1959) On the mechanism underlying initiation of influenza virus infection. 
Ergeb Mikrobiol Immunitatsforsch Exp Ther 32: 1-22 
 
Gou Y, Xie J, Wang M (2000) [A strain of influenza A H9N2 virus repeatedly isolated from 
human population in China]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 14: 209-
212 
 
Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, 
Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, Hoffmann E (2005) Lethality to 
- 244 - 
 
ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79: 2191-
2198 
 
Graef KM, Vreede FT, Lau YF, McCall AW, Carr SM, Subbarao K, Fodor E (2010) The PB2 
subunit of the influenza virus RNA polymerase affects virulence by interacting with the 
mitochondrial antiviral signaling protein and inhibiting expression of beta interferon. J Virol 
84: 8433-8445 
 
Grummt I, Maier U, Ohrlein A, Hassouna N, Bachellerie JP (1985) Transcription of mouse 
rDNA terminates downstream of the 3' end of 28S RNA and involves interaction of factors 
with repeated sequences in the 3' spacer. Cell 43: 801-810 
 
Guan Y, Shortridge KF, Krauss S, Li PH, Kawaoka Y, Webster RG (1996) Emergence of avian 
H1N1 influenza viruses in pigs in China. J Virol 70: 8041-8046 
 
Guan Y, Shortridge KF, Krauss S, Webster RG (1999) Molecular characterization of H9N2 
influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong 
Kong? Proc Natl Acad Sci U S A 96: 9363-9367 
 
Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 
355: 827-835 
 
Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, Sehr P, Lewis J, Ruigrok RW, 
Ortin J, Hart DJ, Cusack S (2008) The structural basis for cap binding by influenza virus 
polymerase subunit PB2. Nat Struct Mol Biol 15: 500-506 
 
Guo Y, Li J, Cheng X (1999) [Discovery of men infected by avian influenza A (H9N2) virus]. 
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 13: 105-108 
 
Guo Y, Xie J, Wu K, Dong J, Wang M, Zhang Y, Guo J, Chen J, Chen Z, Li Z (2002) 
[Characterization of genome of A/Guangzhou/333/99(H9N2) virus]. Zhonghua Shi Yan He Lin 
Chuang Bing Du Xue Za Zhi 16: 142-145 
 
Hale BG, Randall RE, Ortin J, Jackson D (2008) The multifunctional NS1 protein of influenza A 
viruses. J Gen Virol 89: 2359-2376 
 
- 245 - 
 
Haller O, Staeheli P, Kochs G (2007) Interferon-induced Mx proteins in antiviral host 
defense. Biochimie 89: 812-818 
 
Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y 
(2008) Drosophila RNAi screen identifies host genes important for influenza virus 
replication. Nature 454: 890-893 
 
Hara K, Schmidt FI, Crow M, Brownlee GG (2006) Amino acid residues in the N-terminal 
region of the PA subunit of influenza A virus RNA polymerase play a critical role in protein 
stability, endonuclease activity, cap binding, and virion RNA promoter binding. J Virol 80: 
7789-7798 
 
Hara K, Shiota M, Kido H, Ohtsu Y, Kashiwagi T, Iwahashi J, Hamada N, Mizoue K, Tsumura N, 
Kato H, Toyoda T (2001) Influenza virus RNA polymerase PA subunit is a novel serine 
protease with Ser624 at the active site. Genes Cells 6: 87-97 
 
Harris D, Zhang Z, Chaubey B, Pandey VN (2006) Identification of cellular factors associated 
with the 3'-nontranslated region of the hepatitis C virus genome. Mol Cell Proteomics 5: 
1006-1018 
 
Hatada E, Hasegawa M, Mukaigawa J, Shimizu K, Fukuda R (1989) Control of influenza virus 
gene expression: quantitative analysis of each viral RNA species in infected cells. J Biochem 
105: 537-546 
 
Hatta M, Gao P, Halfmann P, Kawaoka Y (2001) Molecular basis for high virulence of Hong 
Kong H5N1 influenza A viruses. Science 293: 1840-1842 
 
Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y 
(2007) Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS 
Pathog 3: 1374-1379 
 
Hayman A, Comely S, Lackenby A, Hartgroves LC, Goodbourn S, McCauley JW, Barclay WS 
(2007) NS1 proteins of avian influenza A viruses can act as antagonists of the human 
alpha/beta interferon response. J Virol 81: 2318-2327 
 
He X, Zhou J, Bartlam M, Zhang R, Ma J, Lou Z, Li X, Li J, Joachimiak A, Zeng Z, Ge R, Rao Z, Liu 
Y (2008) Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza 
H5N1 virus. Nature 454: 1123-1126 
- 246 - 
 
 
Helenius A (1992) Unpacking the incoming influenza virus. Cell 69: 577-578 
 
Herfst S, Chutinimitkul S, Ye J, de Wit E, Munster VJ, Schrauwen EJ, Bestebroer TM, Jonges 
M, Meijer A, Koopmans M, Rimmelzwaan GF, Osterhaus AD, Perez DR, Fouchier RA (2010) 
Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not 
result in enhanced virulence or transmission. J Virol 84: 3752-3758 
 
Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, 
Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA (2012) 
Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541 
 
Hernandez G, Vazquez-Pianzola P (2005) Functional diversity of the eukaryotic translation 
initiation factors belonging to eIF4 families. Mech Dev 122: 865-876 
 
Hillier LW, Miller W, Birney E, Warren W, Hardison RC, Ponting CP, Bork P, Burt DW, 
Groenen MAM, Delany ME, Dodgson JB (2004) Sequence and comparative analysis of the 
chicken genome provide unique perspectives on vertebrate evolution. Nature 432: 695-716 
 
Hinshaw VS, Alexander DJ, Aymard M, Bachmann PA, Easterday BC, Hannoun C, Kida H, 
Lipkind M, MacKenzie JS, Nerome K, et al. (1984) Antigenic comparisons of swine-influenza-
like H1N1 isolates from pigs, birds and humans: an international collaborative study. Bull 
World Health Organ 62: 871-878 
 
Hinshaw VS, Webster RG, Easterday BC, Bean WJ, Jr. (1981) Replication of avian influenza A 
viruses in mammals. Infect Immun 34: 354-361 
 
Hirayama E, Atagi H, Hiraki A, Kim J (2004) Heat shock protein 70 is related to thermal 
inhibition of nuclear export of the influenza virus ribonucleoprotein complex. J Virol 78: 
1263-1270 
 
Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G (2002) Rescue of 
influenza B virus from eight plasmids. Proc Natl Acad Sci U S A 99: 11411-11416 
 
Honda A (2008) Role of host protein Ebp1 in influenza virus growth: intracellular localization 
of Ebp1 in virus-infected and uninfected cells. J Biotechnol 133: 208-212 
 
- 247 - 
 
Honda A, Okamoto T, Ishihama A (2007) Host factor Ebp1: selective inhibitor of influenza 
virus transcriptase. Genes Cells 12: 133-142 
 
Honda A, Ueda K, Nagata K, Ishihama A (1988) RNA polymerase of influenza virus: role of NP 
in RNA chain elongation. J Biochem 104: 1021-1026 
 
Honore B, Vorum H, Baandrup U (1999) hnRNPs H, H' and F behave differently with respect 
to posttranslational cleavage and subcellular localization. FEBS Lett 456: 274-280 
 
Hopp TP, Prickett KS, Price VL, Libby RT, March CJ, Pat Cerretti D, Urdal DL, Conlon PJ (1988) 
A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and 
Purification. Nat Biotech 6: 1204-1210 
 
Horisberger MA (1980) The large P proteins of influenza A viruses are composed of one 
acidic and two basic polypeptides. Virology 107: 302-305 
 
Horisberger MA, Staeheli P, Haller O (1983) Interferon induces a unique protein in mouse 
cells bearing a gene for resistance to influenza virus. Proc Natl Acad Sci U S A 80: 1910-1914 
 
Hossain MJ, Hickman D, Perez DR (2008) Evidence of expanded host range and mammalian-
associated genetic changes in a duck H9N2 influenza virus following adaptation in quail and 
chickens. PLoS One 3: e3170 
 
Howard W, Hayman A, Lackenby A, Whiteley A, Londt B, Banks J, McCauley J, Barclay W 
(2007) Development of a reverse genetics system enabling the rescue of recombinant avian 
influenza virus A/Turkey/England/50-92/91 (H5N1). Avian Dis 51: 393-395 
 
Hsu JT, Yeh JY, Lin TJ, Li ML, Wu MS, Hsieh CF, Chou YC, Tang WF, Lau KS, Hung HC, Fang MY, 
Ko S, Hsieh HP, Horng JT (2011) Identification of BPR3P0128 as an Inhibitor of Cap-Snatching 
Activities of Influenza Virus. Antimicrob Agents Chemother 
 
Hsu MT, Parvin JD, Gupta S, Krystal M, Palese P (1987) Genomic RNAs of influenza viruses 
are held in a circular conformation in virions and in infected cells by a terminal panhandle. 
Proc Natl Acad Sci U S A 84: 8140-8144 
 
Hu W (2010) Novel host markers in the 2009 pandemic H1N1 influenza A virus. J Biomedical 
Science and Engineering 3: 584-601 
- 248 - 
 
 
Huang TS, Palese P, Krystal M (1990) Determination of influenza virus proteins required for 
genome replication. J Virol 64: 5669-5673 
 
Huarte M, Sanz-Ezquerro JJ, Roncal F, Ortin J, Nieto A (2001) PA subunit from influenza virus 
polymerase complex interacts with a cellular protein with homology to a family of 
transcriptional activators. J Virol 75: 8597-8604 
 
Hulse-Post DJ, Franks J, Boyd K, Salomon R, Hoffmann E, Yen HL, Webby RJ, Walker D, 
Nguyen TD, Webster RG (2007) Molecular changes in the polymerase genes (PA and PB1) 
associated with high pathogenicity of H5N1 influenza virus in mallard ducks. J Virol 81: 8515-
8524 
 
Hutchinson EC, von Kirchbach JC, Gog JR, Digard P (2010) Genome packaging in influenza A 
virus. J Gen Virol 91: 313-328 
 
Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, 
Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka 
Y (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet 
transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428 
 
Inglis SC, Mahy BW (1979) Polypeptides specified by the influenza virus genome. 3. Control 
of synthesis in infected cells. Virology 95: 154-164 
 
Ishigaki Y, Li X, Serin G, Maquat LE (2001) Evidence for a pioneer round of mRNA translation: 
mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and 
CBP20. Cell 106: 607-617 
 
Isoda N, Sakoda Y, Kishida N, Bai GR, Matsuda K, Umemura T, Kida H (2006) Pathogenicity of 
a highly pathogenic avian influenza virus, A/chicken/Yamaguchi/7/04 (H5N1) in different 
species of birds and mammals. Arch Virol 151: 1267-1279 
 
Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, Kida H, Paulson JC, 
Webster RG, Kawaoka Y (1998) Molecular basis for the generation in pigs of influenza A 
viruses with pandemic potential. J Virol 72: 7367-7373 
 
Ito T, Kawaoka Y (2000) Host-range barrier of influenza A viruses. Vet Microbiol 74: 71-75 
- 249 - 
 
 
Ito T, Okazaki K, Kawaoka Y, Takada A, Webster RG, Kida H (1995) Perpetuation of influenza 
A viruses in Alaskan waterfowl reservoirs. Arch Virol 140: 1163-1172 
 
Jackson D, Cadman A, Zurcher T, Barclay WS (2002) A reverse genetics approach for 
recovery of recombinant influenza B viruses entirely from cDNA. J Virol 76: 11744-11747 
 
Jagger BW, Memoli MJ, Sheng ZM, Qi L, Hrabal RJ, Allen GL, Dugan VG, Wang R, Digard P, 
Kash JC, Taubenberger JK (2010) The PB2-E627K mutation attenuates viruses containing the 
2009 H1N1 influenza pandemic polymerase. MBio 1 
 
Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, Dunfee RL, Schwartzman LM, 
Ozinsky A, Bell GL, Dalton RM, Lo A, Efstathiou S, Atkins JF, Firth AE, Taubenberger JK, Digard 
P (2012) An Overlapping Protein-Coding Region in Influenza A Virus Segment 3 Modulates 
the Host Response. Science 
 
Jia N, de Vlas SJ, Liu YX, Zhang JS, Zhan L, Dang RL, Ma YH, Wang XJ, Liu T, Yang GP, Wen QL, 
Richardus JH, Lu S, Cao WC (2009) Serological reports of human infections of H7 and H9 
avian influenza viruses in northern China. J Clin Virol 44: 225-229 
 
Jorba N, Coloma R, Ortin J (2009) Genetic trans-complementation establishes a new model 
for influenza virus RNA transcription and replication. PLoS Pathog 5: e1000462 
 
Jorba N, Juarez S, Torreira E, Gastaminza P, Zamarreno N, Albar JP, Ortin J (2008) Analysis of 
the interaction of influenza virus polymerase complex with human cell factors. Proteomics 8: 
2077-2088 
 
Jung K, Song DS, Kang BK, Oh JS, Park BK (2007) Serologic surveillance of swine H1 and H3 
and avian H5 and H9 influenza A virus infections in swine population in Korea. Prev Vet Med 
79: 294-303 
 
Kakugawa S, Shimojima M, Neumann G, Goto H, Kawaoka Y (2009) RuvB-like protein 2 is a 
suppressor of influenza A virus polymerases. J Virol 83: 6429-6434 
 
Kanegae Y, Sugita S, Shortridge KF, Yoshioka Y, Nerome K (1994) Origin and evolutionary 
pathways of the H1 hemagglutinin gene of avian, swine and human influenza viruses: 
cocirculation of two distinct lineages of swine virus. Arch Virol 134: 17-28 
- 250 - 
 
 
Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, 
Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY (2010) Identification of influenza A 
nucleoprotein as an antiviral target. Nat Biotechnol 28: 600-605 
 
Karasin AI, Schutten MM, Cooper LA, Smith CB, Subbarao K, Anderson GA, Carman S, Olsen 
CW (2000) Genetic characterization of H3N2 influenza viruses isolated from pigs in North 
America, 1977-1999: evidence for wholly human and reassortant virus genotypes. Virus Res 
68: 71-85 
 
Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, Becker D, Khalil H, Ogilvie LA, 
Hess S, Maurer AP, Muller E, Wolff T, Rudel T, Meyer TF (2010) Genome-wide RNAi screen 
identifies human host factors crucial for influenza virus replication. Nature 463: 818-822 
 
Kash JC, Cunningham DM, Smit MW, Park Y, Fritz D, Wilusz J, Katze MG (2002) Selective 
translation of eukaryotic mRNAs: functional molecular analysis of GRSF-1, a positive 
regulator of influenza virus protein synthesis. J Virol 76: 10417-10426 
 
Kashiwagi T, Leung BW, Deng T, Chen H, Brownlee GG (2009) The N-terminal region of the 
PA subunit of the RNA polymerase of influenza A/HongKong/156/97 (H5N1) influences 
promoter binding. PLoS One 4: e5473 
 
Katagiri S, Ohizumi A, Homma M (1983) An outbreak of type C influenza in a children's 
home. J Infect Dis 148: 51-56 
 
Katz JM, Lu X, Tumpey TM, Smith CB, Shaw MW, Subbarao K (2000) Molecular correlates of 
influenza A H5N1 virus pathogenesis in mice. J Virol 74: 10807-10810 
 
Katze MG, DeCorato D, Krug RM (1986) Cellular mRNA translation is blocked at both 
initiation and elongation after infection by influenza virus or adenovirus. J Virol 60: 1027-
1039 
 
Katze MG, Krug RM (1984) Metabolism and expression of RNA polymerase II transcripts in 
influenza virus-infected cells. Mol Cell Biol 4: 2198-2206 
 
Kawaguchi A, Momose F, Nagata K (2011) Replication-coupled and host factor-mediated 
encapsidation of the influenza virus genome by viral nucleoprotein. J Virol 85: 6197-6204 
- 251 - 
 
 
Kawaguchi A, Nagata K (2007) De novo replication of the influenza virus RNA genome is 
regulated by DNA replicative helicase, MCM. EMBO J 26: 4566-4575 
 
Kawano J, Onta T, Kida H, Yanagawa R (1978) Distribution of antibodies in animals against 
influenza B and C viruses. Jpn J Vet Res 26: 74-80 
 
Kawaoka Y, Krauss S, Webster RG (1989) Avian-to-human transmission of the PB1 gene of 
influenza A viruses in the 1957 and 1968 pandemics. J Virol 63: 4603-4608 
 
Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, 
Noppornpanth S, Wattanodorn S, Theambooniers A, Tantilertcharoen R, Pattanarangsan R, 
Arya N, Ratanakorn P, Osterhaus DM, Poovorawan Y (2004) Avian influenza H5N1 in tigers 
and leopards. Emerg Infect Dis 10: 2189-2191 
 
Kedersha N, Anderson P (2007) Mammalian stress granules and processing bodies. Methods 
Enzymol 431: 61-81 
 
Kida H, Ito T, Yasuda J, Shimizu Y, Itakura C, Shortridge KF, Kawaoka Y, Webster RG (1994) 
Potential for transmission of avian influenza viruses to pigs. J Gen Virol 75 ( Pt 9): 2183-2188 
 
Kida H, Shortridge KF, Webster RG (1988) Origin of the hemagglutinin gene of H3N2 
influenza viruses from pigs in China. Virology 162: 160-166 
 
Kilbourne ED (2006) Influenza pandemics of the 20th century. Emerg Infect Dis 12: 9-14 
 
Kim HJ, Fodor E, Brownlee GG, Seong BL (1997) Mutational analysis of the RNA-fork model 
of the influenza A virus vRNA promoter in vivo. J Gen Virol 78 ( Pt 2): 353-357 
 
Kimura N, Nishida M, Nagata K, Ishihama A, Oda K, Nakada S (1992) Transcription of a 
recombinant influenza virus RNA in cells that can express the influenza virus RNA 
polymerase and nucleoprotein genes. J Gen Virol 73 ( Pt 6): 1321-1328 
 
Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, Ozawa M, Furuta Y, 
Kawaoka Y (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc 
Natl Acad Sci U S A 107: 882-887 
- 252 - 
 
 
Koen JS (1919) A practical method for field diagnosis of swine diseases. American Journal of 
Veterinary Medicine 14: 468-470 
 
Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M (2003) The pleiotropic functions of the 
Y-box-binding protein, YB-1. Bioessays 25: 691-698 
 
Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne 
DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, 
Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, 
Chanda SK (2010) Human host factors required for influenza virus replication. Nature 463: 
813-817 
 
Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus 
PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, 
Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA, Chanda SK (2008) Global analysis of 
host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135: 49-60 
 
Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van 
Steenbergen J, Fouchier R, Osterhaus A, Bosman A (2004) Transmission of H7N7 avian 
influenza A virus to human beings during a large outbreak in commercial poultry farms in 
the Netherlands. Lancet 363: 587-593 
 
Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D (2006) The anti-HIV-1 editing enzyme 
APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and 
stress granules. J Biol Chem 281: 29105-29119 
 
Krishnan MN, Ng A, Sukumaran B, Gilfoy FD, Uchil PD, Sultana H, Brass AL, Adametz R, Tsui 
M, Qian F, Montgomery RR, Lev S, Mason PW, Koski RA, Elledge SJ, Xavier RJ, Agaisse H, 
Fikrig E (2008) RNA interference screen for human genes associated with West Nile virus 
infection. Nature 455: 242-245 
 
Kuhn U, Wahle E (2004) Structure and function of poly(A) binding proteins. Biochim Biophys 
Acta 1678: 67-84 
 
Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R, Osterhaus A 
(2004) Avian H5N1 influenza in cats. Science 306: 241 
 
- 253 - 
 
Kundin WD (1970) Hong Kong A-2 influenza virus infection among swine during a human 
epidemic in Taiwan. Nature 228: 857 
 
Kundin WD, Easterday BC (1972) Hong Kong influenza infection in swine: experimental and 
field observations. Bull World Health Organ 47: 489-491 
 
Kuzuhara T, Kise D, Yoshida H, Horita T, Murazaki Y, Nishimura A, Echigo N, Utsunomiya H, 
Tsuge H (2009) Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding 
domain containing the pathogenicity-determinant lysine 627 residue. J Biol Chem 284: 6855-
6860 
 
Labadie K, Dos Santos Afonso E, Rameix-Welti MA, van der Werf S, Naffakh N (2007) Host-
range determinants on the PB2 protein of influenza A viruses control the interaction 
between the viral polymerase and nucleoprotein in human cells. Virology 362: 271-282 
 
Lackenby A, Thompson CI, Democratis J (2008) The potential impact of neuraminidase 
inhibitor resistant influenza. Curr Opin Infect Dis 21: 626-638 
 
Lam TT, Zhu H, Wang J, Smith DK, Holmes EC, Webster RG, Webby R, Peiris JM, Guan Y 
(2011) Reassortment events among swine influenza A viruses in China: implications for the 
origin of the 2009 influenza pandemic. J Virol 85: 10279-10285 
 
Lamb RA, Choppin PW (1977) Synthesis of influenza virus polypeptides in cells resistant to 
alpha-amanitin: evidence for the involvement of cellular RNA polymerase II in virus 
replication. J Virol 23: 816-819 
 
Lamb RA, Krug RM (1996) Orthomyxoviridae: the viruses and their replication. Fields 
Virology: 1353-1445 
 
Landeras-Bueno S, Jorba N, Perez-Cidoncha M, Ortin J (2011) The Splicing Factor Proline-
Glutamine Rich (SFPQ/PSF) Is Involved in Influenza Virus Transcription. PLoS Pathog 7: 
e1002397 
 
Lange E, Kalthoff D, Blohm U, Teifke JP, Breithaupt A, Maresch C, Starick E, Fereidouni S, 
Hoffmann B, Mettenleiter TC, Beer M, Vahlenkamp TW (2009) Pathogenesis and 
transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection 
of pigs. J Gen Virol 90: 2119-2123 
 
- 254 - 
 
Lazarowitz SG, Choppin PW (1975) Enhancement of the infectivity of influenza A and B 
viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 68: 440-454 
 
Lee DC, Mok CK, Law AH, Peiris M, Lau AS (2010) Differential replication of avian influenza 
H9N2 viruses in human alveolar epithelial A549 cells. Virol J 7: 71 
 
Leung BW, Chen H, Brownlee GG (2010) Correlation between polymerase activity and 
pathogenicity in two duck H5N1 influenza viruses suggests that the polymerase contributes 
to pathogenicity. Virology 401: 96-106 
 
Li G, Zhang J, Tong X, Liu W, Ye X (2011) Heat shock protein 70 inhibits the activity of 
Influenza A virus ribonucleoprotein and blocks the replication of virus in vitro and in vivo. 
PLoS One 6: e16546 
 
Li J, Hawkins IC, Harvey CD, Jennings JL, Link AJ, Patton JG (2003) Regulation of alternative 
splicing by SRrp86 and its interacting proteins. Mol Cell Biol 23: 7437-7447 
 
Li J, Ishaq M, Prudence M, Xi X, Hu T, Liu Q, Guo D (2009) Single mutation at the amino acid 
position 627 of PB2 that leads to increased virulence of an H5N1 avian influenza virus during 
adaptation in mice can be compensated by multiple mutations at other sites of PB2. Virus 
Res 144: 123-129 
 
Li ML, Rao P, Krug RM (2001) The active sites of the influenza cap-dependent endonuclease 
are on different polymerase subunits. EMBO J 20: 2078-2086 
 
Li Z, Chen H, Jiao P, Deng G, Tian G, Li Y, Hoffmann E, Webster RG, Matsuoka Y, Yu K (2005) 
Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. 
J Virol 79: 12058-12064 
 
Lichty JJ, Malecki JL, Agnew HD, Michelson-Horowitz DJ, Tan S (2005) Comparison of affinity 
tags for protein purification. Protein Expr Purif 41: 98-105 
 
Lin-Marq N, Clarkson SG (1998) Efficient synthesis, termination and release of RNA 
polymerase III transcripts in Xenopus extracts depleted of La protein. EMBO J 17: 2033-2041 
 
Lin YP, Gregory V, Bennett M, Hay A (2004) Recent changes among human influenza viruses. 
Virus Res 103: 47-52 
- 255 - 
 
 
Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, 
Shortridge K, Webster R, Cox N, Hay A (2000) Avian-to-human transmission of H9N2 subtype 
influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad 
Sci U S A 97: 9654-9658 
 
Lindenmann J (1964) Inheritance of Resistance to Influenza Virus in Mice. Proc Soc Exp Biol 
Med 116: 506-509 
 
Ling X, Arnheim N (1994) Cloning and identification of the pig ribosomal gene promoter. 
Gene 150: 375-379 
 
Lipatov AS, Kwon YK, Sarmento LV, Lager KM, Spackman E, Suarez DL, Swayne DE (2008) 
Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. 
PLoS Pathog 4: e1000102 
 
Liu J, Xiao H, Lei F, Zhu Q, Qin K, Zhang XW, Zhang XL, Zhao D, Wang G, Feng Y, Ma J, Liu W, 
Wang J, Gao GF (2005) Highly pathogenic H5N1 influenza virus infection in migratory birds. 
Science 309: 1206 
 
Liu Q, Qiao C, Marjuki H, Bawa B, Ma J, Guillossou S, Webby RJ, Richt JA, Ma W (2012) 
Combination of PB2 271A and SR polymorphism at positions 590/591 is critical for viral 
replication and virulence of swine influenza virus in cultured cells and in vivo. J Virol 86: 
1233-1237 
 
Liu X, Sun L, Yu M, Wang Z, Xu C, Xue Q, Zhang K, Ye X, Kitamura Y, Liu W (2009) Cyclophilin 
A interacts with influenza A virus M1 protein and impairs the early stage of the viral 
replication. Cell Microbiol 11: 730-741 
 
Lu CY, Lu JH, Chen WQ, Jiang LF, Tan BY, Ling WH, Zheng BJ, Sui HY (2008) Potential 
infections of H5N1 and H9N2 avian influenza do exist in Guangdong populations of China. 
Chin Med J (Engl) 121: 2050-2053 
 
Lu H, Li W, Noble WS, Payan D, Anderson DC (2004) Riboproteomics of the hepatitis C virus 
internal ribosomal entry site. J Proteome Res 3: 949-957 
 
Luytjes W, Krystal M, Enami M, Parvin JD, Palese P (1989) Amplification, expression, and 
packaging of foreign gene by influenza virus. Cell 59: 1107-1113 
- 256 - 
 
 
Ma W, Kahn RE, Richt JA (2008) The pig as a mixing vessel for influenza viruses: Human and 
veterinary implications. J Mol Genet Med 3: 158-166 
 
Ma W, Lager KM, Li X, Janke BH, Mosier DA, Painter LE, Ulery ES, Ma J, Lekcharoensuk P, 
Webby RJ, Richt JA (2011) Pathogenicity of swine influenza viruses possessing an avian or 
swine-origin PB2 polymerase gene evaluated in mouse and pig models. Virology 410: 1-6 
 
Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus. Lab Anim 
(NY) 33: 50-53 
 
Maines TR, Chen LM, Matsuoka Y, Chen H, Rowe T, Ortin J, Falcon A, Nguyen TH, Mai le Q, 
Sedyaningsih ER, Harun S, Tumpey TM, Donis RO, Cox NJ, Subbarao K, Katz JM (2006) Lack of 
transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl 
Acad Sci U S A 103: 12121-12126 
 
Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen 
LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, 
Kim JH, Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM, Tumpey TM 
(2005) Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit 
increased virulence in mammals. J Virol 79: 11788-11800 
 
Mangus DA, Evans MC, Jacobson A (2003) Poly(A)-binding proteins: multifunctional scaffolds 
for the post-transcriptional control of gene expression. Genome Biol 4: 223 
 
Manz B, Brunotte L, Reuther P, Schwemmle M (2012) Adaptive mutations in NEP 
compensate for defective H5N1 RNA replication in cultured human cells. Nat Commun 3: 
802 
 
Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, Okamatsu M, Kida H (2009) PB2 protein 
of a highly pathogenic avian influenza virus strain A/chicken/Yamaguchi/7/2004 (H5N1) 
determines its replication potential in pigs. J Virol 83: 1572-1578 
 
Mark GE, Taylor JM, Broni B, Krug RM (1979) Nuclear accumulation of influenza viral RNA 
transcripts and the effects of cycloheximide, actinomycin D, and alpha-amanitin. J Virol 29: 
744-752 
 
- 257 - 
 
Marklund JK, Ye Q, Dong J, Tao YJ, Krug RM (2012) Sequence in the influenza A virus 
nucleoprotein required for viral polymerase binding and RNA synthesis. J Virol 86: 7292-
7297 
 
Martin-Benito J, Area E, Ortega J, Llorca O, Valpuesta JM, Carrascosa JL, Ortin J (2001) Three-
dimensional reconstruction of a recombinant influenza virus ribonucleoprotein particle. 
EMBO Rep 2: 313-317 
 
Martin K, Helenius A (1991) Nuclear transport of influenza virus ribonucleoproteins: the viral 
matrix protein (M1) promotes export and inhibits import. Cell 67: 117-130 
 
Mase M, Tanimura N, Imada T, Okamatsu M, Tsukamoto K, Yamaguchi S (2006) Recent 
H5N1 avian influenza A virus increases rapidly in virulence to mice after a single passage in 
mice. J Gen Virol 87: 3655-3659 
 
Massin P, Rodrigues P, Marasescu M, van der Werf S, Naffakh N (2005) Cloning of the 
chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in 
avian cells. J Virol 79: 13811-13816 
 
Massin P, van der Werf S, Naffakh N (2001) Residue 627 of PB2 is a determinant of cold 
sensitivity in RNA replication of avian influenza viruses. J Virol 75: 5398-5404 
 
Matlin KS, Reggio H, Helenius A, Simons K (1981) Infectious entry pathway of influenza virus 
in a canine kidney cell line. J Cell Biol 91: 601-613 
 
Matrosovich M, Zhou N, Kawaoka Y, Webster R (1999) The surface glycoproteins of H5 
influenza viruses isolated from humans, chickens, and wild aquatic birds have 
distinguishable properties. J Virol 73: 1146-1155 
 
Matrosovich MN, Gambaryan AS, Teneberg S, Piskarev VE, Yamnikova SS, Lvov DK, 
Robertson JS, Karlsson KA (1997) Avian influenza A viruses differ from human viruses by 
recognition of sialyloligosaccharides and gangliosides and by a higher conservation of the 
HA receptor-binding site. Virology 233: 224-234 
 
Matrosovich MN, Krauss S, Webster RG (2001) H9N2 influenza A viruses from poultry in Asia 
have human virus-like receptor specificity. Virology 281: 156-162 
 
- 258 - 
 
Matsumoto K, Bay BH (2005) Significance of the Y-box proteins in human cancers. J Mol 
Genet Med 1: 11-17 
 
Mayer D, Molawi K, Martinez-Sobrido L, Ghanem A, Thomas S, Baginsky S, Grossmann J, 
Garcia-Sastre A, Schwemmle M (2007) Identification of cellular interaction partners of the 
influenza virus ribonucleoprotein complex and polymerase complex using proteomic-based 
approaches. J Proteome Res 6: 672-682 
 
Meerovitch K, Svitkin YV, Lee HS, Lejbkowicz F, Kenan DJ, Chan EK, Agol VI, Keene JD, 
Sonenberg N (1993) La autoantigen enhances and corrects aberrant translation of poliovirus 
RNA in reticulocyte lysate. J Virol 67: 3798-3807 
 
Mehle A, Doudna JA (2008) An inhibitory activity in human cells restricts the function of an 
avian-like influenza virus polymerase. Cell Host Microbe 4: 111-122 
 
Mehle A, Doudna JA (2009) Adaptive strategies of the influenza virus polymerase for 
replication in humans. Proc Natl Acad Sci U S A 106: 21312-21316 
 
Mehle A, Dugan VG, Taubenberger JK, Doudna JA (2012) Reassortment and mutation of the 
avian influenza virus polymerase PA subunit overcome species barriers. J Virol 86: 1750-
1757 
 
Mena I, de la Luna S, Albo C, Martin J, Nieto A, Ortin J, Portela A (1994) Synthesis of 
biologically active influenza virus core proteins using a vaccinia virus-T7 RNA polymerase 
expression system. J Gen Virol 75 ( Pt 8): 2109-2114 
 
Miotto O, Heiny A, Tan TW, August JT, Brusic V (2008) Identification of human-to-human 
transmissibility factors in PB2 proteins of influenza A by large-scale mutual information 
analysis. BMC Bioinformatics 9 Suppl 1: S18 
 
Miotto O, Heiny AT, Albrecht R, Garcia-Sastre A, Tan TW, August JT, Brusic V (2010) 
Complete-proteome mapping of human influenza A adaptive mutations: implications for 
human transmissibility of zoonotic strains. PLoS One 5: e9025 
 
Mok CK, Yen HL, Yu MY, Yuen KM, Sia SF, Chan MC, Qin G, Tu WW, Peiris JS (2011) Amino 
acid residues 253 and 591 of the PB2 protein of avian influenza virus A H9N2 contribute to 
mammalian pathogenesis. J Virol 85: 9641-9645 
 
- 259 - 
 
Momose F, Basler CF, O'Neill RE, Iwamatsu A, Palese P, Nagata K (2001) Cellular splicing 
factor RAF-2p48/NPI-5/BAT1/UAP56 interacts with the influenza virus nucleoprotein and 
enhances viral RNA synthesis. J Virol 75: 1899-1908 
 
Momose F, Naito T, Yano K, Sugimoto S, Morikawa Y, Nagata K (2002) Identification of 
Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. J Biol Chem 
277: 45306-45314 
 
Moncorge O, Mura M, Barclay WS (2010) Evidence for avian and human host cell factors 
that affect the activity of influenza virus polymerase. J Virol 84: 9978-9986 
 
Morel C, Gander ES, Herzberg M, Dubochet J, Scherrer K (1973) The duck-globin messenger-
ribonucleoprotein complex. Resistance to high ionic strength, particle gel electrophoresis, 
composition and visualisation by dark-field electron microscopy. Eur J Biochem 36: 455-464 
 
Morens DM, Taubenberger JK, Fauci AS (2008) Predominant role of bacterial pneumonia as 
a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J 
Infect Dis 198: 962-970 
 
Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 
953-956 
 
Munster VJ, de Wit E, van Riel D, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Kuiken T, 
Fouchier RA (2007) The molecular basis of the pathogenicity of the Dutch highly pathogenic 
human influenza A H7N7 viruses. J Infect Dis 196: 258-265 
 
Muratore G, Goracci L, Mercorelli B, Foeglein A, Digard P, Cruciani G, Palu G, Loregian A 
(2012) Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit 
interactions of the viral polymerase. Proc Natl Acad Sci U S A 109: 6247-6252 
 
Myers KP, Olsen CW, Gray GC (2007) Cases of swine influenza in humans: a review of the 
literature. Clin Infect Dis 44: 1084-1088 
 
Naffakh N, Massin P, Escriou N, Crescenzo-Chaigne B, van der Werf S (2000) Genetic analysis 
of the compatibility between polymerase proteins from human and avian strains of 
influenza A viruses. J Gen Virol 81: 1283-1291 
 
- 260 - 
 
Naffakh N, Tomoiu A, Rameix-Welti MA, van der Werf S (2008) Host restriction of avian 
influenza viruses at the level of the ribonucleoproteins. Annu Rev Microbiol 62: 403-424 
 
Nagata K, Kawaguchi A, Naito T (2008) Host factors for replication and transcription of the 
influenza virus genome. Rev Med Virol 18: 247-260 
 
Naito T, Kiyasu Y, Sugiyama K, Kimura A, Nakano R, Matsukage A, Nagata K (2007a) An 
influenza virus replicon system in yeast identified Tat-SF1 as a stimulatory host factor for 
viral RNA synthesis. Proc Natl Acad Sci U S A 104: 18235-18240 
 
Naito T, Momose F, Kawaguchi A, Nagata K (2007b) Involvement of Hsp90 in assembly and 
nuclear import of influenza virus RNA polymerase subunits. J Virol 81: 1339-1349 
 
Nakajima K, Desselberger U, Palese P (1978) Recent human influenza A (H1N1) viruses are 
closely related genetically to strains isolated in 1950. Nature 274: 334-339 
 
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996) In vivo 
gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 
263-267 
 
Nelli RK, Kuchipudi SV, White GA, Perez BB, Dunham SP, Chang KC (2010) Comparative 
distribution of human and avian type sialic acid influenza receptors in the pig. BMC Vet Res 
6: 4 
 
Nemeth A, Krause S, Blank D, Jenny A, Jeno P, Lustig A, Wahle E (1995) Isolation of genomic 
and cDNA clones encoding bovine poly(A) binding protein II. Nucleic Acids Res 23: 4034-
4041 
 
Nerome K, Ishida M, Nakayama M, Oya A, Kanai C, Suwicha K (1981) Antigenic and genetic 
analysis of A/Hong Kong (H3N2) influenza viruses isolated from swine and man. J Gen Virol 
56: 441-445 
 
Neumann G, Hughes MT, Kawaoka Y (2000) Influenza A virus NS2 protein mediates vRNP 
nuclear export through NES-independent interaction with hCRM1. EMBO J 19: 6751-6758 
 
Neumann G, Kawaoka Y (2006) Host range restriction and pathogenicity in the context of 
influenza pandemic. Emerg Infect Dis 12: 881-886 
- 261 - 
 
 
Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin 
H1N1 influenza virus. Nature 459: 931-939 
 
Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, 
Hoffmann E, Hobom G, Kawaoka Y (1999) Generation of influenza A viruses entirely from 
cloned cDNAs. Proc Natl Acad Sci U S A 96: 9345-9350 
 
Ng AK, Wang JH, Shaw PC (2009) Structure and sequence analysis of influenza A virus 
nucleoprotein. Sci China C Life Sci 52: 439-449 
 
Ng AK, Zhang H, Tan K, Li Z, Liu JH, Chan PK, Li SM, Chan WY, Au SW, Joachimiak A, Walz T, 
Wang JH, Shaw PC (2008) Structure of the influenza virus A H5N1 nucleoprotein: 
implications for RNA binding, oligomerization, and vaccine design. FASEB J 22: 3638-3647 
 
Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, 
Shinya K, Iwatsuki-Horimoto K, Muramoto Y, Kawaoka Y (2010) Influenza A (H5N1) viruses 
from pigs, Indonesia. Emerg Infect Dis 16: 1515-1523 
 
Noda T, Sagara H, Yen A, Takada A, Kida H, Cheng RH, Kawaoka Y (2006) Architecture of 
ribonucleoprotein complexes in influenza A virus particles. Nature 439: 490-492 
 
Noda T, Sugita Y, Aoyama K, Hirase A, Kawakami E, Miyazawa A, Sagara H, Kawaoka Y (2012) 
Three-dimensional analysis of ribonucleoprotein complexes in influenza A virus. Nat 
Commun 3: 639 
 
O'Callaghan RJ, Gohd RS, Labat DD (1980) Human antibody to influenza C virus: its age-
related distribution and distinction from receptor analogs. Infect Immun 30: 500-505 
 
O'Neill RE, Jaskunas R, Blobel G, Palese P, Moroianu J (1995) Nuclear import of influenza 
virus RNA can be mediated by viral nucleoprotein and transport factors required for protein 
import. J Biol Chem 270: 22701-22704 
 
O'Neill RE, Palese P (1995) NPI-1, the human homolog of SRP-1, interacts with influenza 
virus nucleoprotein. Virology 206: 116-125 
 
- 262 - 
 
O'Neill RE, Talon J, Palese P (1998) The influenza virus NEP (NS2 protein) mediates the 
nuclear export of viral ribonucleoproteins. EMBO J 17: 288-296 
 
Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A, Nagata K, Tame JR, Park SY 
(2008) The structural basis for an essential subunit interaction in influenza virus RNA 
polymerase. Nature 454: 1127-1131 
 
Ohtsu Y, Honda Y, Sakata Y, Kato H, Toyoda T (2002) Fine mapping of the subunit binding 
sites of influenza virus RNA polymerase. Microbiol Immunol 46: 167-175 
 
Olofsson S, Kumlin U, Dimock K, Arnberg N (2005) Avian influenza and sialic acid receptors: 
more than meets the eye? Lancet Infect Dis 5: 184-188 
 
Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, Fouchier RA (2006a) 
Global patterns of influenza a virus in wild birds. Science 312: 384-388 
 
Olsen CW, Karasin AI, Carman S, Li Y, Bastien N, Ojkic D, Alves D, Charbonneau G, Henning 
BM, Low DE, Burton L, Broukhanski G (2006b) Triple reassortant H3N2 influenza A viruses, 
Canada, 2005. Emerg Infect Dis 12: 1132-1135 
 
Ortega J, Martin-Benito J, Zurcher T, Valpuesta JM, Carrascosa JL, Ortin J (2000) 
Ultrastructural and functional analyses of recombinant influenza virus ribonucleoproteins 
suggest dimerization of nucleoprotein during virus amplification. J Virol 74: 156-163 
 
Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA (2000) Influenza B 
virus in seals. Science 288: 1051-1053 
 
Ottis K, Bachmann PA (1980) Occurrence of Hsw 1 N 1 subtype influenza A viruses in wild 
ducks in Europe. Arch Virol 63: 185-190 
 
Palacios IM, Gatfield D, St Johnston D, Izaurralde E (2004) An eIF4AIII-containing complex 
required for mRNA localization and nonsense-mediated mRNA decay. Nature 427: 753-757 
 
Pannone BK, Xue D, Wolin SL (1998) A role for the yeast La protein in U6 snRNP assembly: 
evidence that the La protein is a molecular chaperone for RNA polymerase III transcripts. 
EMBO J 17: 7442-7453 
 
- 263 - 
 
Paranjape SM, Harris E (2007) Y box-binding protein-1 binds to the dengue virus 3'-
untranslated region and mediates antiviral effects. J Biol Chem 282: 30497-30508 
 
Park CJ, Bae SH, Lee MK, Varani G, Choi BS (2003) Solution structure of the influenza A virus 
cRNA promoter: implications for differential recognition of viral promoter structures by 
RNA-dependent RNA polymerase. Nucleic Acids Res 31: 2824-2832 
 
Park YW, Katze MG (1995) Translational control by influenza virus. Identification of cis-
acting sequences and trans-acting factors which may regulate selective viral mRNA 
translation. J Biol Chem 270: 28433-28439 
 
Park YW, Wilusz J, Katze MG (1999) Regulation of eukaryotic protein synthesis: selective 
influenza viral mRNA translation is mediated by the cellular RNA-binding protein GRSF-1. 
Proc Natl Acad Sci U S A 96: 6694-6699 
 
Pasma T, Joseph T (2010) Pandemic (H1N1) 2009 infection in swine herds, Manitoba, 
Canada. Emerg Infect Dis 16: 706-708 
 
Peiris JS, Guan Y, Markwell D, Ghose P, Webster RG, Shortridge KF (2001) Cocirculation of 
avian H9N2 and contemporary "human" H3N2 influenza A viruses in pigs in southeastern 
China: potential for genetic reassortment? J Virol 75: 9679-9686 
 
Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK, Shortridge KF (1999) Human 
infection with influenza H9N2. Lancet 354: 916-917 
 
Pensaert M, Ottis K, Vandeputte J, Kaplan MM, Bachmann PA (1981) Evidence for the 
natural transmission of influenza A virus from wild ducks to swine and its potential 
importance for man. Bull World Health Organ 59: 75-78 
 
Perales B, de la Luna S, Palacios I, Ortin J (1996) Mutational analysis identifies functional 
domains in the influenza A virus PB2 polymerase subunit. J Virol 70: 1678-1686 
 
Perez-Gonzalez A, Rodriguez A, Huarte M, Salanueva IJ, Nieto A (2006) hCLE/CGI-99, a 
human protein that interacts with the influenza virus polymerase, is a mRNA transcription 
modulator. J Mol Biol 362: 887-900 
 
- 264 - 
 
Perez JT, Varble A, Sachidanandam R, Zlatev I, Manoharan M, Garcia-Sastre A, tenOever BR 
(2010) Influenza A virus-generated small RNAs regulate the switch from transcription to 
replication. Proc Natl Acad Sci U S A 107: 11525-11530 
 
Ping J, Dankar SK, Forbes NE, Keleta L, Zhou Y, Tyler S, Brown EG (2010) PB2 and 
hemagglutinin mutations are major determinants of host range and virulence in mouse-
adapted influenza A virus. J Virol 84: 10606-10618 
 
Pinto LH, Lamb RA (1995) Understanding the mechanism of action of the anti-influenza virus 
drug amantadine. Trends Microbiol 3: 271 
 
Pleschka S, Jaskunas R, Engelhardt OG, Zurcher T, Palese P, Garcia-Sastre A (1996) A 
plasmid-based reverse genetics system for influenza A virus. J Virol 70: 4188-4192 
 
Poch O, Sauvaget I, Delarue M, Tordo N (1989) Identification of four conserved motifs 
among the RNA-dependent polymerase encoding elements. EMBO J 8: 3867-3874 
 
Portela A, Digard P (2002) The influenza virus nucleoprotein: a multifunctional RNA-binding 
protein pivotal to virus replication. J Gen Virol 83: 723-734 
 
Pringle CR (1996) Virus taxonomy 1996 - a bulletin from the Xth International Congress of 
Virology in Jerusalem. Arch Virol 141: 2251-2256 
 
Proudfoot NJ, Furger A, Dye MJ (2002) Integrating mRNA processing with transcription. Cell 
108: 501-512 
 
Pudi R, Abhiman S, Srinivasan N, Das S (2003) Hepatitis C virus internal ribosome entry site-
mediated translation is stimulated by specific interaction of independent regions of human 
La autoantigen. J Biol Chem 278: 12231-12240 
 
Puig O, Caspary F, Rigaut G, Rutz B, Bouveret E, Bragado-Nilsson E, Wilm M, Seraphin B 
(2001) The tandem affinity purification (TAP) method: a general procedure of protein 
complex purification. Methods 24: 218-229 
 
Punyadarsaniya D, Liang CH, Winter C, Petersen H, Rautenschlein S, Hennig-Pauka I, 
Schwegmann-Wessels C, Wu CY, Wong CH, Herrler G (2011) Infection of differentiated 
- 265 - 
 
porcine airway epithelial cells by influenza virus: differential susceptibility to infection by 
porcine and avian viruses. PLoS One 6: e28429 
 
Puthavathana P, Auewarakul P, Charoenying PC, Sangsiriwut K, Pooruk P, Boonnak K, 
Khanyok R, Thawachsupa P, Kijphati R, Sawanpanyalert P (2005) Molecular characterization 
of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 
86: 423-433 
 
Raffetseder U, Frye B, Rauen T, Jurchott K, Royer HD, Jansen PL, Mertens PR (2003) Splicing 
factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative 
splice site selection. J Biol Chem 278: 18241-18248 
 
Rameix-Welti MA, Tomoiu A, Dos Santos Afonso E, van der Werf S, Naffakh N (2009) Avian 
Influenza A virus polymerase association with nucleoprotein, but not polymerase assembly, 
is impaired in human cells during the course of infection. J Virol 83: 1320-1331 
 
Read EK, Digard P (2010) Individual influenza A virus mRNAs show differential dependence 
on cellular NXF1/TAP for their nuclear export. J Gen Virol 91: 1290-1301 
 
Regan JF, Liang Y, Parslow TG (2006) Defective assembly of influenza A virus due to a 
mutation in the polymerase subunit PA. J Virol 80: 252-261 
 
Regoes RR, Bonhoeffer S (2006) Emergence of drug-resistant influenza virus: population 
dynamical considerations. Science 312: 389-391 
 
Reid AH, Fanning TG, Hultin JV, Taubenberger JK (1999) Origin and evolution of the 1918 
"Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 96: 1651-1656 
 
Reid AH, Taubenberger JK, Fanning TG (2004) Evidence of an absence: the genetic origins of 
the 1918 pandemic influenza virus. Nat Rev Microbiol 2: 909-914 
 
Reinhardt J, Wolff T (2000) The influenza A virus M1 protein interacts with the cellular 
receptor of activated C kinase (RACK) 1 and can be phosphorylated by protein kinase C. Vet 
Microbiol 74: 87-100 
 
- 266 - 
 
Resa-Infante P, Jorba N, Zamarreno N, Fernandez Y, Juarez S, Ortin J (2008) The host-
dependent interaction of alpha-importins with influenza PB2 polymerase subunit is required 
for virus RNA replication. PLoS One 3: e3904 
 
Richardson JC, Akkina RK (1991) NS2 protein of influenza virus is found in purified virus and 
phosphorylated in infected cells. Arch Virol 116: 69-80 
 
Robb NC, Fodor E (2012) The accumulation of influenza A virus segment 7 spliced mRNAs is 
regulated by the NS1 protein. J Gen Virol 93: 113-118 
 
Robb NC, Smith M, Vreede FT, Fodor E (2009) NS2/NEP protein regulates transcription and 
replication of the influenza virus RNA genome. J Gen Virol 90: 1398-1407 
 
Robinson JL, Lee BE, Patel J, Bastien N, Grimsrud K, Seal RF, King R, Marshall F, Li Y (2007) 
Swine influenza (H3N2) infection in a child and possible community transmission, Canada. 
Emerg Infect Dis 13: 1865-1870 
 
Rodriguez A, Perez-Gonzalez A, Nieto A (2007) Influenza virus infection causes specific 
degradation of the largest subunit of cellular RNA polymerase II. J Virol 81: 5315-5324 
 
Rodriguez A, Perez-Gonzalez A, Nieto A (2011) Cellular human CLE/C14orf166 protein 
interacts with influenza virus polymerase and is required for viral replication. J Virol 85: 
12062-12066 
 
Rogers GN, Paulson JC (1983) Receptor determinants of human and animal influenza virus 
isolates: differences in receptor specificity of the H3 hemagglutinin based on species of 
origin. Virology 127: 361-373 
 
Rossman JS, Jing X, Leser GP, Lamb RA (2010) Influenza virus M2 protein mediates ESCRT-
independent membrane scission. Cell 142: 902-913 
 
Rossman JS, Lamb RA (2011) Influenza virus assembly and budding. Virology 411: 229-236 
 
Rota PA, Rocha EP, Harmon MW, Hinshaw VS, Sheerar MG, Kawaoka Y, Cox NJ, Smith TF 
(1989) Laboratory characterization of a swine influenza virus isolated from a fatal case of 
human influenza. J Clin Microbiol 27: 1413-1416 
 
- 267 - 
 
Rott R (1992) The pathogenic determinant of influenza virus. Vet Microbiol 33: 303-310 
 
Ruigrok RW, Crepin T, Hart DJ, Cusack S (2010) Towards an atomic resolution understanding 
of the influenza virus replication machinery. Curr Opin Struct Biol 20: 104-113 
 
Rust MJ, Lakadamyali M, Zhang F, Zhuang X (2004) Assembly of endocytic machinery around 
individual influenza viruses during viral entry. Nat Struct Mol Biol 11: 567-573 
 
Salmon P, Kindler V, Ducrey O, Chapuis B, Zubler RH, Trono D (2000) High-level transgene 
expression in human hematopoietic progenitors and differentiated blood lineages after 
transduction with improved lentiviral vectors. Blood 96: 3392-3398 
 
Salomon R, Franks J, Govorkova EA, Ilyushina NA, Yen HL, Hulse-Post DJ, Humberd J, Trichet 
M, Rehg JE, Webby RJ, Webster RG, Hoffmann E (2006) The polymerase complex genes 
contribute to the high virulence of the human H5N1 influenza virus isolate 
A/Vietnam/1203/04. J Exp Med 203: 689-697 
 
Salvatore M, Basler CF, Parisien JP, Horvath CM, Bourmakina S, Zheng H, Muster T, Palese P, 
Garcia-Sastre A (2002) Effects of influenza A virus NS1 protein on protein expression: the 
NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J 
Virol 76: 1206-1212 
 
Scheiffele P, Rietveld A, Wilk T, Simons K (1999) Influenza viruses select ordered lipid 
domains during budding from the plasma membrane. J Biol Chem 274: 2038-2044 
 
Schmitt AP, Lamb RA (2005) Influenza virus assembly and budding at the viral budozone. 
Adv Virus Res 64: 383-416 
 
Scholtissek C (1994) Source for influenza pandemics. Eur J Epidemiol 10: 455-458 
 
Scholtissek C, Burger H, Bachmann PA, Hannoun C (1983) Genetic relatedness of 
hemagglutinins of the H1 subtype of influenza A viruses isolated from swine and birds. 
Virology 129: 521-523 
 
Scholtissek C, Burger H, Kistner O, Shortridge KF (1985) The nucleoprotein as a possible 
major factor in determining host specificity of influenza H3N2 viruses. Virology 147: 287-294 
 
- 268 - 
 
Scholtissek C, Koennecke I, Rott R (1978a) Host range recombinants of fowl plague 
(influenza A) virus. Virology 91: 79-85 
 
Scholtissek C, Rohde W, Von Hoyningen V, Rott R (1978b) On the origin of the human 
influenza virus subtypes H2N2 and H3N2. Virology 87: 13-20 
 
Scholtissek C, Rott R (1970) Synthesis in vivo of influenza virus plus and minus strand RNA 
and its preferential inhibition by antibiotics. Virology 40: 989-996 
 
Schultz U, Fitch WM, Ludwig S, Mandler J, Scholtissek C (1991) Evolution of pig influenza 
viruses. Virology 183: 61-73 
 
Scull MA, Gillim-Ross L, Santos C, Roberts KL, Bordonali E, Subbarao K, Barclay WS, Pickles RJ 
(2009) Avian Influenza virus glycoproteins restrict virus replication and spread through 
human airway epithelium at temperatures of the proximal airways. PLoS Pathog 5: 
e1000424 
 
Seo SH, Goloubeva O, Webby R, Webster RG (2001) Characterization of a porcine lung 
epithelial cell line suitable for influenza virus studies. J Virol 75: 9517-9525 
 
Sessions OM, Barrows NJ, Souza-Neto JA, Robinson TJ, Hershey CL, Rodgers MA, Ramirez JL, 
Dimopoulos G, Yang PL, Pearson JL, Garcia-Blanco MA (2009) Discovery of insect and human 
dengue virus host factors. Nature 458: 1047-1050 
 
Shapira SD, Gat-Viks I, Shum BO, Dricot A, de Grace MM, Wu L, Gupta PB, Hao T, Silver SJ, 
Root DE, Hill DE, Regev A, Hacohen N (2009) A physical and regulatory map of host-influenza 
interactions reveals pathways in H1N1 infection. Cell 139: 1255-1267 
 
Shaw ML (2011) The host interactome of influenza virus presents new potential targets for 
antiviral drugs. Rev Med Virol 21: 358-369 
 
Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P (2008) Cellular proteins in influenza 
virus particles. PLoS Pathog 4: e1000085 
 
Sherer NM, Swanson CM, Hue S, Roberts RG, Bergeron JR, Malim MH (2011) Evolution of a 
species-specific determinant within human CRM1 that regulates the post-transcriptional 
phases of HIV-1 replication. PLoS Pathog 7: e1002395 
- 269 - 
 
 
Shi WF, Gibbs MJ, Zhang YZ, Zhang Z, Zhao XM, Jin X, Zhu CD, Yang MF, Yang NN, Cui YJ, Ji L 
(2008) Genetic analysis of four porcine avian influenza viruses isolated from Shandong, 
China. Arch Virol 153: 211-217 
 
Shibuya T, Tange TO, Sonenberg N, Moore MJ (2004) eIF4AIII binds spliced mRNA in the 
exon junction complex and is essential for nonsense-mediated decay. Nat Struct Mol Biol 11: 
346-351 
 
Shih SR, Chu TY, Reddy GR, Tseng SN, Chen HL, Tang WF, Wu MS, Yeh JY, Chao YS, Hsu JT, 
Hsieh HP, Horng JT (2010) Pyrazole compound BPR1P0034 with potent and selective anti-
influenza virus activity. J Biomed Sci 17: 13 
 
Shih SR, Krug RM (1996a) Novel exploitation of a nuclear function by influenza virus: the 
cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel 
protein in infected cells. EMBO J 15: 5415-5427 
 
Shih SR, Krug RM (1996b) Surprising function of the three influenza viral polymerase 
proteins: selective protection of viral mRNAs against the cap-snatching reaction catalyzed by 
the same polymerase proteins. Virology 226: 430-435 
 
Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: influenza virus 
receptors in the human airway. Nature 440: 435-436 
 
Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y (2004) PB2 amino acid at position 627 
affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in 
mice. Virology 320: 258-266 
 
Shinya K, Watanabe S, Ito T, Kasai N, Kawaoka Y (2007) Adaptation of an H7N7 equine 
influenza A virus in mice. J Gen Virol 88: 547-553 
 
Shope RE (1931) Swine Influenza : Iii. Filtration Experiments and Etiology. J Exp Med 54: 373-
385 
 
Shortridge K (1988) Pandemic influenza - a blueprint for control at source. Chin J Exp Clin 
Virol 3: 75-88 
 
- 270 - 
 
Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, Kodihalli S, Krauss S, Markwell D, 
Murti KG, Norwood M, Senne D, Sims L, Takada A, Webster RG (1998) Characterization of 
avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252: 331-342 
 
Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y 
(2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus 
infections in mice. Antimicrob Agents Chemother 51: 845-851 
 
Silversides DW, Music N, Jacques M, Gagnon CA, Webby R (2010) Investigation of the 
species origin of the St. Jude Porcine Lung epithelial cell line (SJPL) made available to 
researchers. J Virol 84: 5454-5455 
 
Skehel JJ (1972) Polypeptide synthesis in influenza virus-infected cells. Virology 49: 23-36 
 
Skehel JJ, Hay AJ (1978) Nucleotide sequences at the 5' termini of influenza virus RNAs and 
their transcripts. Nucleic Acids Res 5: 1207-1219 
 
Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the 
influenza hemagglutinin. Annu Rev Biochem 69: 531-569 
 
Smith FI, Palese P (1989) Variation in influenza virus genes. The influenza viruses, R M Krug 
(ed) Plenum Press, New York: 319-359 
 
Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, 
Raghwani J, Bhatt S, Peiris JS, Guan Y, Rambaut A (2009) Origins and evolutionary genomics 
of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459: 1122-1125 
 
Smith W, Andrewes CH, Laidlaw PP (1933) A virus obtained from influenza patients. Lancet 
222: 66-68 
 
Song D, Kang B, Lee C, Jung K, Ha G, Kang D, Park S, Park B, Oh J (2008) Transmission of avian 
influenza virus (H3N2) to dogs. Emerg Infect Dis 14: 741-746 
 
Song D, Lee C, Kang B, Jung K, Oh T, Kim H, Park B, Oh J (2009a) Experimental infection of 
dogs with avian-origin canine influenza A virus (H3N2). Emerg Infect Dis 15: 56-58 
 
- 271 - 
 
Song MS, Pascua PN, Lee JH, Baek YH, Lee OJ, Kim CJ, Kim H, Webby RJ, Webster RG, Choi YK 
(2009b) The polymerase acidic protein gene of influenza a virus contributes to pathogenicity 
in a mouse model. J Virol 83: 12325-12335 
 
Song MS, Pascua PN, Lee JH, Baek YH, Park KJ, Kwon HI, Park SJ, Kim CJ, Kim H, Webby RJ, 
Webster RG, Choi YK (2011) Virulence and genetic compatibility of polymerase reassortant 
viruses derived from the pandemic (H1N1) 2009 influenza virus and circulating influenza A 
viruses. J Virol 85: 6275-6286 
 
Sovinova O, Tumova B, Pouska F, Nemec J (1958) Isolation of a virus causing respiratory 
disease in horses. Acta Virol 2: 52-61 
 
Spackman E (2008) A brief introduction to the avian influenza virus. Methods Mol Biol 436: 
1-6 
 
Steel J, Lowen AC, Mubareka S, Palese P (2009) Transmission of influenza virus in a 
mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog 5: 
e1000252 
 
Stefano JE (1984) Purified lupus antigen La recognizes an oligouridylate stretch common to 
the 3' termini of RNA polymerase III transcripts. Cell 36: 145-154 
 
Stegmann T, White JM, Helenius A (1990) Intermediates in influenza induced membrane 
fusion. EMBO J 9: 4231-4241 
 
Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA (2001) The RNA binding 
protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative 
exon v4. EMBO J 20: 3821-3830 
 
Sturm-Ramirez KM, Ellis T, Bousfield B, Bissett L, Dyrting K, Rehg JE, Poon L, Guan Y, Peiris 
M, Webster RG (2004) Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly 
pathogenic to ducks. J Virol 78: 4892-4901 
 
Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, Lin-Chu SY, Chen YH, Wu CY, Lai MM, Cheng 
WC, Wu YT, Tsai MD, Cheng YS, Wong CH (2010) High-throughput identification of 
compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci 
U S A 107: 19151-19156 
 
- 272 - 
 
Su L, Hershberger RJ, Weissman IL (1993) LYAR, a novel nucleolar protein with zinc finger 
DNA-binding motifs, is involved in cell growth regulation. Genes Dev 7: 735-748 
 
Suarez DL, Perdue ML, Cox N, Rowe T, Bender C, Huang J, Swayne DE (1998) Comparisons of 
highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong 
Kong. J Virol 72: 6678-6688 
 
Suarez DL, Schultz-Cherry S (2000) Immunology of avian influenza virus: a review. Dev Comp 
Immunol 24: 269-283 
 
Subbarao EK, London W, Murphy BR (1993) A single amino acid in the PB2 gene of influenza 
A virus is a determinant of host range. J Virol 67: 1761-1764 
 
Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, 
Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N (1998) Characterization of an 
avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 
279: 393-396 
 
Sugimura T, Yonemochi H, Ogawa T, Tanaka Y, Kumagai T (1980) Isolation of a recombinant 
influenza virus (Hsw 1 N2) from swine in Japan. Arch Virol 66: 271-274 
 
Sugiyama K, Obayashi E, Kawaguchi A, Suzuki Y, Tame JR, Nagata K, Park SY (2009) Structural 
insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase. 
EMBO J 28: 1803-1811 
 
Sun Y, Pu J, Jiang Z, Guan T, Xia Y, Xu Q, Liu L, Ma B, Tian F, Brown EG, Liu J (2010) Genotypic 
evolution and antigenic drift of H9N2 influenza viruses in China from 1994 to 2008. Vet 
Microbiol 146: 215-225 
 
Sun Y, Qin K, Wang J, Pu J, Tang Q, Hu Y, Bi Y, Zhao X, Yang H, Shu Y, Liu J (2011) High genetic 
compatibility and increased pathogenicity of reassortants derived from avian H9N2 and 
pandemic H1N1/2009 influenza viruses. Proc Natl Acad Sci U S A 108: 4164-4169 
 
Svitkin YV, Pause A, Sonenberg N (1994) La autoantigen alleviates translational repression 
by the 5' leader sequence of the human immunodeficiency virus type 1 mRNA. J Virol 68: 
7001-7007 
 
- 273 - 
 
Tafforeau L, Chantier T, Pradezynski F, Pellet J, Mangeot PE, Vidalain PO, Andre P, 
Rabourdin-Combe C, Lotteau V (2011) Generation and comprehensive analysis of an 
influenza virus polymerase cellular interaction network. J Virol 85: 13010-13018 
 
Takatsy G, Farkas E, Romvary J (1969) Susceptibility of the domestic pig to influenza B virus. 
Nature 222: 184-185 
 
Takatsy G, Romvary J, Farkas E (1967) Susceptibility of the domestic swine to influenza B 
virus. Acta Microbiol Acad Sci Hung 14: 309-315 
 
Tamuri AU, Dos Reis M, Hay AJ, Goldstein RA (2009) Identifying changes in selective 
constraints: host shifts in influenza. PLoS Comput Biol 5: e1000564 
 
Tang Y, Lee CW, Zhang Y, Senne DA, Dearth R, Byrum B, Perez DR, Suarez DL, Saif YM (2005) 
Isolation and characterization of H3N2 influenza A virus from turkeys. Avian Dis 49: 207-213 
 
Tange TO, Nott A, Moore MJ (2004) The ever-increasing complexities of the exon junction 
complex. Curr Opin Cell Biol 16: 279-284 
 
Tarendeau F, Boudet J, Guilligay D, Mas PJ, Bougault CM, Boulo S, Baudin F, Ruigrok RW, 
Daigle N, Ellenberg J, Cusack S, Simorre JP, Hart DJ (2007) Structure and nuclear import 
function of the C-terminal domain of influenza virus polymerase PB2 subunit. Nat Struct Mol 
Biol 14: 229-233 
 
Tarendeau F, Crepin T, Guilligay D, Ruigrok RW, Cusack S, Hart DJ (2008) Host determinant 
residue lysine 627 lies on the surface of a discrete, folded domain of influenza virus 
polymerase PB2 subunit. PLoS Pathog 4: e1000136 
 
Taubenberger JK, Reid AH, Janczewski TA, Fanning TG (2001) Integrating historical, clinical 
and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish 
influenza virus. Philos Trans R Soc Lond B Biol Sci 356: 1829-1839 
 
Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG (2005) Characterization 
of the 1918 influenza virus polymerase genes. Nature 437: 889-893 
 
- 274 - 
 
Taylor JM, Illmensee R, Litwin S, Herring L, Broni B, Krug RM (1977) Use of specific 
radioactive probes to study transcription and replication of the influenza virus genome. J 
Virol 21: 530-540 
 
Thanawongnuwech R, Amonsin A, Tantilertcharoen R, Damrongwatanapokin S, 
Theamboonlers A, Payungporn S, Nanthapornphiphat K, Ratanamungklanon S, Tunak E, 
Songserm T, Vivatthanavanich V, Lekdumrongsak T, Kesdangsakonwut S, Tunhikorn S, 
Poovorawan Y (2005) Probable tiger-to-tiger transmission of avian influenza H5N1. Emerg 
Infect Dis 11: 699-701 
 
Thompson CI, Barclay WS, Zambon MC, Pickles RJ (2006) Infection of human airway 
epithelium by human and avian strains of influenza a virus. J Virol 80: 8060-8068 
 
Tiley LS, Hagen M, Matthews JT, Krystal M (1994) Sequence-specific binding of the influenza 
virus RNA polymerase to sequences located at the 5' ends of the viral RNAs. J Virol 68: 5108-
5116 
 
Trebbien R, Larsen LE, Viuff BM (2011) Distribution of sialic acid receptors and influenza A 
virus of avian and swine origin in experimentally infected pigs. Virol J 8: 434 
 
Tu J, Zhou H, Jiang T, Li C, Zhang A, Guo X, Zou W, Chen H, Jin M (2009) Isolation and 
molecular characterization of equine H3N8 influenza viruses from pigs in China. Arch Virol 
154: 887-890 
 
Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, 
Taubenberger JK, Palese P, Garcia-Sastre A (2005) Characterization of the reconstructed 
1918 Spanish influenza pandemic virus. Science 310: 77-80 
 
Tumpey TM, Maines TR, Van Hoeven N, Glaser L, Solorzano A, Pappas C, Cox NJ, Swayne DE, 
Palese P, Katz JM, Garcia-Sastre A (2007) A two-amino acid change in the hemagglutinin of 
the 1918 influenza virus abolishes transmission. Science 315: 655-659 
 
Ulmanen I, Broni BA, Krug RM (1981) Role of two of the influenza virus core P proteins in 
recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. 
Proc Natl Acad Sci U S A 78: 7355-7359 
 
Umbach JL, Yen HL, Poon LL, Cullen BR (2010) Influenza A virus expresses high levels of an 
unusual class of small viral leader RNAs in infected cells. MBio 1 
- 275 - 
 
 
Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul 
M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, 
Khontong R, Simmerman JM, Chunsutthiwat S (2005) Probable person-to-person 
transmission of avian influenza A (H5N1). N Engl J Med 352: 333-340 
 
Uyeki TM, Chong YH, Katz JM, Lim W, Ho YY, Wang SS, Tsang TH, Au WW, Chan SC, Rowe T, 
Hu-Primmer J, Bell JC, Thompson WW, Bridges CB, Cox NJ, Mak KH, Fukuda K (2002) Lack of 
evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong 
Kong, China 1999. Emerg Infect Dis 8: 154-159 
 
Van Poucke SG, Nicholls JM, Nauwynck HJ, Van Reeth K (2010) Replication of avian, human 
and swine influenza viruses in porcine respiratory explants and association with sialic acid 
distribution. Virol J 7: 38 
 
Van Reeth K (2007) Avian and swine influenza viruses: our current understanding of the 
zoonotic risk. Vet Res 38: 243-260 
 
Vreede FT, Brownlee GG (2007) Influenza virion-derived viral ribonucleoproteins synthesize 
both mRNA and cRNA in vitro. J Virol 81: 2196-2204 
 
Vreede FT, Chan AY, Sharps J, Fodor E (2010) Mechanisms and functional implications of the 
degradation of host RNA polymerase II in influenza virus infected cells. Virology 396: 125-
134 
 
Vreede FT, Fodor E (2010) The role of the influenza virus RNA polymerase in host shut-off. 
Virulence 1: 436-439 
 
Vreede FT, Jung TE, Brownlee GG (2004) Model suggesting that replication of influenza virus 
is regulated by stabilization of replicative intermediates. J Virol 78: 9568-9572 
 
Wahle E, Lustig A, Jeno P, Maurer P (1993) Mammalian poly(A)-binding protein II. Physical 
properties and binding to polynucleotides. J Biol Chem 268: 2937-2945 
 
Wan H, Sorrell EM, Song H, Hossain MJ, Ramirez-Nieto G, Monne I, Stevens J, Cattoli G, 
Capua I, Chen LM, Donis RO, Busch J, Paulson JC, Brockwell C, Webby R, Blanco J, Al-Natour 
MQ, Perez DR (2008) Replication and transmission of H9N2 influenza viruses in ferrets: 
evaluation of pandemic potential. PLoS One 3: e2923 
- 276 - 
 
 
Wang C, Takeuchi K, Pinto LH, Lamb RA (1993) Ion channel activity of influenza A virus M2 
protein: characterization of the amantadine block. J Virol 67: 5585-5594 
 
Wang M, Fu CX, Zheng BJ (2009a) Antibodies against H5 and H9 avian influenza among 
poultry workers in China. N Engl J Med 360: 2583-2584 
 
Wang P, Palese P, O'Neill RE (1997) The NPI-1/NPI-3 (karyopherin alpha) binding site on the 
influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal. J Virol 
71: 1850-1856 
 
Wang P, Song W, Mok BW, Zhao P, Qin K, Lai A, Smith GJ, Zhang J, Lin T, Guan Y, Chen H 
(2009b) Nuclear factor 90 negatively regulates influenza virus replication by interacting with 
viral nucleoprotein. J Virol 83: 7850-7861 
 
Wang Z, Duke GM (2007) Cloning of the canine RNA polymerase I promoter and 
establishment of reverse genetics for influenza A and B in MDCK cells. Virol J 4: 102 
 
Wang Z, Liu X, Zhao Z, Xu C, Zhang K, Chen C, Sun L, Gao GF, Ye X, Liu W (2011) Cyclophilin E 
functions as a negative regulator to influenza virus replication by impairing the formation of 
the viral ribonucleoprotein complex. PLoS One 6: e22625 
 
Webby RJ, Swenson SL, Krauss SL, Gerrish PJ, Goyal SM, Webster RG (2000) Evolution of 
swine H3N2 influenza viruses in the United States. J Virol 74: 8243-8251 
 
Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology 
of influenza A viruses. Microbiol Rev 56: 152-179 
 
Webster RG, Campbell CH, Granoff A (1971) The "in vivo" production of "new" influenza A 
viruses. I. Genetic recombination between avian and mammalian influenza viruses. Virology 
44: 317-328 
 
Webster RG, Yakhno M, Hinshaw VS, Bean WJ, Murti KG (1978) Intestinal influenza: 
replication and characterization of influenza viruses in ducks. Virology 84: 268-278 
 
- 277 - 
 
Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, Howard W, Anderson EC, Barclay WS, Digard 
P (2009) A complicated message: Identification of a novel PB1-related protein translated 
from influenza A virus segment 2 mRNA. J Virol 83: 8021-8031 
 
Wolffe AP (1994) Structural and functional properties of the evolutionarily ancient Y-box 
family of nucleic acid binding proteins. Bioessays 16: 245-251 
 
Wolin SL, Cedervall T (2002) The La protein. Annu Rev Biochem 71: 375-403 
 
Wood GW, Banks J, McCauley JW, Alexander DJ (1994) Deduced amino acid sequences of 
the haemagglutinin of H5N1 avian influenza virus isolates from an outbreak in turkeys in 
Norfolk, England. Arch Virol 134: 185-194 
 
Xu C, Fan W, Wei R, Zhao H (2004) Isolation and identification of swine influenza 
recombinant A/Swine/Shandong/1/2003(H9N2) virus. Microbes Infect 6: 919-925 
 
Yamada S, Hatta M, Staker BL, Watanabe S, Imai M, Shinya K, Sakai-Tagawa Y, Ito M, Ozawa 
M, Watanabe T, Sakabe S, Li C, Kim JH, Myler PJ, Phan I, Raymond A, Smith E, Stacy R, Nidom 
CA, Lank SM, Wiseman RW, Bimber BN, O'Connor DH, Neumann G, Stewart LJ, Kawaoka Y 
(2010) Biological and structural characterization of a host-adapting amino acid in influenza 
virus. PLoS Pathog 6: e1001034 
 
Yanguez E, Castello A, Welnowska E, Carrasco L, Goodfellow I, Nieto A (2011) Functional 
impairment of eIF4A and eIF4G factors correlates with inhibition of influenza virus mRNA 
translation. Virology 413: 93-102 
 
Yanguez E, Nieto A (2011) So similar, yet so different: selective translation of capped and 
polyadenylated viral mRNAs in the influenza virus infected cell. Virus Res 156: 1-12 
 
Yanguez E, Rodriguez P, Goodfellow I, Nieto A (2012) Influenza virus polymerase confers 
independence of the cellular cap-binding factor eIF4E for viral mRNA translation. Virology 
422: 297-307 
 
Yao Y, Mingay LJ, McCauley JW, Barclay WS (2001) Sequences in influenza A virus PB2 
protein that determine productive infection for an avian influenza virus in mouse and 
human cell lines. J Virol 75: 5410-5415 
 
- 278 - 
 
Yasuda J, Shortridge KF, Shimizu Y, Kida H (1991) Molecular evidence for a role of domestic 
ducks in the introduction of avian H3 influenza viruses to pigs in southern China, where the 
A/Hong Kong/68 (H3N2) strain emerged. J Gen Virol 72 ( Pt 8): 2007-2010 
 
Ye Q, Krug RM, Tao YJ (2006) The mechanism by which influenza A virus nucleoprotein 
forms oligomers and binds RNA. Nature 444: 1078-1082 
 
Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, Douglas A, Hay A, Krauss 
S, Rehg JE, Hoffmann E, Webster RG (2007) Inefficient transmission of H5N1 influenza 
viruses in a ferret contact model. J Virol 81: 6890-6898 
 
Yu H, Hua RH, Wei TC, Zhou YJ, Tian ZJ, Li GX, Liu TQ, Tong GZ (2008) Isolation and genetic 
characterization of avian origin H9N2 influenza viruses from pigs in China. Vet Microbiol 131: 
82-92 
 
Yuan P, Bartlam M, Lou Z, Chen S, Zhou J, He X, Lv Z, Ge R, Li X, Deng T, Fodor E, Rao Z, Liu Y 
(2009) Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease 
active site. Nature 458: 909-913 
 
Zhang J, Li G, Ye X (2010) Cyclin T1/CDK9 interacts with influenza A virus polymerase and 
facilitates its association with cellular RNA polymerase II. J Virol 84: 12619-12627 
 
Zhang S, Wang Q, Wang J, Mizumoto K, Toyoda T (2012) Two mutations in the C-terminal 
domain of influenza virus RNA polymerase PB2 enhance transcription by enhancing cap-1 
RNA binding activity. Biochim Biophys Acta 1819: 78-83 
 
Zhou B, Li Y, Halpin R, Hine E, Spiro DJ, Wentworth DE (2011) PB2 residue 158 is a 
pathogenic determinant of pandemic H1N1 and H5 influenza a viruses in mice. J Virol 85: 
357-365 
 
Zhou NN, Senne DA, Landgraf JS, Swenson SL, Erickson G, Rossow K, Liu L, Yoon K, Krauss S, 
Webster RG (1999) Genetic reassortment of avian, swine, and human influenza A viruses in 
American pigs. J Virol 73: 8851-8856 
 
Zhu H, Wang J, Wang P, Song W, Zheng Z, Chen R, Guo K, Zhang T, Peiris JS, Chen H, Guan Y 
(2010) Substitution of lysine at 627 position in PB2 protein does not change virulence of the 
2009 pandemic H1N1 virus in mice. Virology 401: 1-5 
 
- 279 - 
 
Zhu Q, Yang H, Chen W, Cao W, Zhong G, Jiao P, Deng G, Yu K, Yang C, Bu Z, Kawaoka Y, 
Chen H (2008) A naturally occurring deletion in its NS gene contributes to the attenuation of 
an H5N1 swine influenza virus in chickens. J Virol 82: 220-228 
 
Zimmermann P, Manz B, Haller O, Schwemmle M, Kochs G (2011) The viral nucleoprotein 
determines Mx sensitivity of influenza A viruses. J Virol 85: 8133-8140 
 
Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM (2002) Pathogenesis of avian 
influenza A (H5N1) viruses in ferrets. J Virol 76: 4420-4429 
 
Zobel A, Neumann G, Hobom G (1993) RNA polymerase I catalysed transcription of insert 
viral cDNA. Nucleic Acids Res 21: 3607-3614 
 
 
 
